

MASTOLOGY

Official Journal of the Brazilian Society of Mastology

Volume 31, 2021

ISSN 2594-5394



MASTOLOGY

Official Journal of the Brazilian Society of Mastology

Volume 31, 2021

EDITOR-IN-CHIEF

Gil Facina (São Paulo, SP, Brazil)

CO-EDITORS

Francisco Pimentel Cavalcante (Fortaleza, CE, Brazil)

Régis Resende Paulinelli (Goiânia, GO, Brazil)

Rene Aloisio da Costa Vieira (Barretos, SP, Brazil)

SPECIALTY EDITORS: MASTOLOGY

André Mattar (São Paulo, SP, Brazil)

Alfredo Carlos Simões Dornellas de Barros (São Paulo, SP, Brazil)

Antonio Luiz Frasson (Porto Alegre, RS, Brazil)

Benedito Borges da Silva (Teresina, PI, Brazil)

Cassio Cardoso Filho (Campinas, SP, Brazil)

César Cabello dos Santos (Campinas, SP, Brazil)

Cícero de Andrade Urban (Curitiba, PR, Brazil)

Daniel de Araújo Brito Buttros (Rio Claro, SP, Brazil)

Daniel Guimarães Tiezzi (Ribeirão Preto, SP, Brazil)

Délio Marques Conde (Goiania, GO, Brazil)

Eduardo Camargo Millen (Rio de Janeiro, RJ, Brazil)

Fabiana Baroni Makdissi (São Paulo, SP, Brazil)

Fábio Bagnoli (São Paulo, SP, Brazil)

Fabio Postiglione Mansani (Ponta Grossa, PR, Brazil)

Fabrizio Palermo Brenelli (Campinas, SP, Brazil)

Felipe Pereira Zerwes (Porto Alegre, RS, Brazil)

Gustavo Antonio de Souza (Campinas, SP, Brazil)

Gustavo Zucca-Matthes (Barretos, SP, Brazil)

José Luiz B Bevilacqua (São Paulo, SP, Brazil)

José Luiz Pedrini (Porto Alegre, RS, Brazil)

José Mauro Secco (Macapá, AP, Brazil)

José Roberto Filassi (São Paulo, SP, Brazil)

José Roberto Morales Piato (São Paulo, SP, Brazil)

Jurandyr Moreira de Andrade (Ribeirão Preto, SP, Brazil)

Luís Otávio Zanatta Sarian (Campinas, SP, Brazil)

Luiz Henrique Gebrim (São Paulo, SP, Brazil)

Marcelo Madeira (São Paulo, SP, Brazil)

Renato Zocchio Torresan (Campinas, SP, Brazil)

Roberto José S. Vieira (Rio de Janeiro, RJ, Brazil)

Rodrigo Gonçalves (São Paulo, SP, Brazil)

Rogério Fenile (São Paulo, SP, Brazil)

Rosemar Macedo Sousa Rahal (Goiania, GO, Brazil)

Ruffo de Freitas Júnior (Goiania, GO, Brazil)

Vinícius Milani Budel (Curitiba, PR, Brazil)

Vilmar Marques de Oliveira (São Paulo, SP, Brazil)

INTERNATIONAL ADVISORY BOARD

Marcelo Cruz (Chicago, USA)
Otto Metzger Filho (Boston, USA)
Bejnamin Anderson (Seattle, USA)
Eduardo González (Buenos Aires, Argentina)
Gail Lebovic (Dallas, USA)
Luciane Cavalli (Washington, USA)
Luiz Javier Gallón (Medellín, Colombia)
Jaime Letzkus Berríos (Santiago, Chile)
Juan Enrique Bargallo Rocha (Mexico City, Mexico)
Mahmoud El-Tamer (New York, USA)
Maria João Cardoso (Lisbon, Portugal)
Mario Rietjens (Milan, Italy)
Matthew Ellis (Houston, USA)
Melissa Bondy (Houston, USA)
Richard Raisbury (London, UK)
Rui Manuel Reis (Braga, Portugal)
Vesna Bjelic Radisic (Vienna, Austria)
Virgilio Sacchini (Milan, Italy)

SPECIALTY EDITORS: PATHOLOGY

Ângela Flávia Logullo Waitzberg (São Paulo, SP, Brazil)
Helenice Gobbi (Belo Horizonte, MG, Brazil)

SPECIALTY EDITOR: PHYSIOTHERAPY

Anke Bergmann (Rio de Janeiro, RJ, Brazil)
Samantha Karla Lopes de Almeida Rizzi (São Paulo, SP, Brazil)

SPECIALTY EDITOR: TRANSLATIONAL RESEARCH

Gustavo Arantes Rosa Maciel (São Paulo, SP, Brazil)
Tatiana Carvalho de Souza Bonetti (São Paulo, SP, Brazil)

SPECIALTY EDITORS: GENETICS

José Cláudio Casali da Rocha (Curitiba, PR, Brazil)
Maria Isabel Achatz (São Paulo, SP, Brazil)

SPECIALTY EDITORS: MEDICAL ONCOLOGY

Carlos Barrios (Porto Alegre, RS, Brazil)
Max Mano (São Paulo, SP, Brazil)
Sérgio Simon (São Paulo, SP, Brazil)

SPECIALTY EDITORS: RADIOTHERAPY

Nilceana Maya Aires Freitas (Goiânia GO Brazil)
Rodrigo Souza Dias (São Paulo, SP, Brazil)
Samir Abdallah Hanna (São Paulo, SP, Brazil)

SPECIALTY EDITORS: RADIOLOGY

Helio Amâncio Camargo (São Paulo, SP, Brazil)
Simone Elias Martinelli (São Paulo, SP, Brazil)

SPECIALTY EDITORS: EPIDEMIOLOGY AND PREVENTION

Edesio Martins (Goiânia, GO, Brazil)
Luiz Cláudio Santos Thuler (Rio de Janeiro, RJ, Brazil)

FORMER PRESIDENTS

Alberto Lima de Moraes Coutinho (1959–1961)
Jorge de Marsillac (1962–1963)
Eduardo Santos Machado (1964–1965)
Carlos A. M. Zanotta (1966–1967)
Alberto Lima de Moraes Coutinho (1968–1969)
Adayr Eiras de Araújo (1970–1971)
João Luiz Campos Soares (1972–1973)
Jorge de Marsillac (1974–1975)
Alberto Lima de Moraes Coutinho (1976–1977)
João Sampaio Góis Jr. (1978–1982)
Hiram Silveira Lucas (1983–1986)
José Antonio Ribeiro Filho (1987–1989)
Antônio S. S. Figueira Filho (1990–1992)
Marconi Menezes Luna (1993–1995)
Henrique Moraes Salvador Silva (1996–1998)
Alfredo Carlos S. D. Barros (1999–2001)
Ezio Novais Dias (2002–2004)
Diógenes Luiz Basegio (2005–2007)
Carlos Ricardo Chagas (2008–2010)
Carlos Alberto Ruiz (2011–2013)
Ruffo de Freitas Júnior (2014–2016)
Antonio Luiz Frasson (2017–2019)



BRAZILIAN SOCIETY OF MASTOLOGY

Praça Floriano, 55, sala 801, Centro – 20031-050 – Rio de Janeiro (RJ)
Phone numbers: (21) 2220-7711 / (21) 2220-7111
E-mail: contact@mastology.org

ABOUT

Mastology is a publication of the Brazilian Society of Mastology. The responsibility for concepts emitted in the articles is exclusive of its authors

The total or partial reproduction of the articles is allowed, provided the source is mentioned.

Founder: Antônio Figueira Filho

Submissions - mailing address: Praça Floriano, 55, sala 801, Centro – Rio de Janeiro (RJ) – 20031-050

National and international subscription and advertising: Brazilian Society of Mastology - Phone number: (21) 2220-7711 - Whatsapp (21) 98138-0034

NATIONAL BOARD OF DIRECTORS OF SOCIEDADE BRASILEIRA DE MASTOLOGIA

Triennium 2020-2022

Founder:

President	Alberto Lima de Moraes Coutinho
National Vice President	Vilmar Marques de Oliveira
North Region Vice President	Vinicius Milani Budel
Northeast Region Vice President	Francianne Silva Rocha
South Region Vice President	Darley de Lima Ferreira Filho
Southeast Region Vice President	Jorge Villanova Biazus
Midwest Region Vice President	César Cabello dos Santos
General secretary	Carlos Marino Cabral Calvano Filho
Assistant Secretary	Rosemar Macedo Sousa Rahal
General Treasurer	Sandra Marques Silva Gioia
Assistant Treasurer	Felipe Eduardo Martins de Andrade
Mastology Editor	Aleksandr Salamanca Miyahira
Escola Brasileira de Mastologia Director	Gil Facina
Deliberative Council President	Fabio Postiglione Mansani
TEMa Committee	Antonio Luiz Frasson
Ethics Committee	Eduardo Camargo Millen
Scientific Committee	Clécio Ênio Murta de Lucena
	Alfredo Carlos Simões Dornellas de Barros

PRODUÇÃO EDITORIAL



ZEPPELINI
PUBLISHERS

Analysis of bilateral breast carcinomas: a profile of patients at a reference service

Camila Vitola Pasetto^{1*} , Bruno Ribeiro Batista¹ , Lucas Roskamp Budel¹ ,
Mariana De Nadai Andreoli¹ , Vinicius Milani Budel¹ 

ABSTRACT

Objective: To select cases of bilateral breast carcinoma (BBC) of patients seen at Hospital de Clínicas of Paraná, besides recognizing clinical and family characteristics, histological and immunohistochemical pattern, and incidences of synchronic/metachronic tumor in these patients. **Method:** Observational and analytical study of BBC cases of patients treated at Hospital de Clínicas of Paraná, from 2003 to 2019, developed from the analysis of medical records. **Result:** A total of 42 patients with BBC were selected. The incidence of BBC was 3.64%. All patients were women, mostly of white skin color and postmenopausal, with an average age of 51.82 years. Half patients showed a positive family history for cancer, with breast cancer present in 46%, ovarian cancer in 16%, and other topographies in 68%. In this sample, the synchronous tumor was present in 55% of patients, and the metachronous tumor, in 45%. Regarding patients' initial clinical staging, 61% had a locally advanced tumor at diagnosis. Both in the group of synchronic and metachronic tumors, the ductal subtype was the most frequent. Regarding the immunohistochemical subtype, patients in both groups had Luminal B tumors more frequently. In the group of metachronic tumors, the average time between the diagnosis of the first tumor and the second tumor was 5.68 years. **Conclusion:** In this sample, BBC is associated with a relevant family history, with a synchronic presentation pattern, from histology to ductal and immunohistochemistry to Luminal B as the most frequent.

KEYWORDS: Breast neoplasms; Synchronous neoplasm; Metachronous neoplasm.

INTRODUCTION

Bilateral breast cancer (BBC) is a rare clinical entity. Its estimated incidence is between 0.3% and 12%.¹ This neoplasm pattern can be considered synchronous, when it occurs simultaneously, or metachronous, when it is diagnosed from one month to a year after the primary tumor is found.^{2,3}

The importance of studying BBC is due to the increased incidence of cases of breast carcinoma and its early diagnosis — which increases the survival time for these patients. However, the risk of developing contralateral breast cancer (CBC) is also increased. Patients who had early breast cancer treated have from two to six times greater chance of developing the contralateral neoplasia than the female population in general. The estimated risk is 0.4% to 0.8% per survival year.⁴

The relevance of BBC was first studied in 1956. The study showed that patients who treated breast cancer had from three to four times greater chance of developing bilateral cancer, which behaves as a primary tumor and not metastatic.⁵

There are several risk factors for bilateral breast cancer. Among them, the histological and immunohistochemical type,

family history of breast cancer, genetic mutations, and age at diagnosis of the first cancer are the most important.^{6,7}

The histological type most frequently associated with bilateral breast cancer is the lobular one. In the literature, the risk ranges from 1.42 to 6.55. According to the authors, this variation is due to the difference in biological behavior and tumor etiology.^{8,9}

Family history is relevant in the following situations: a first or second degree family member with breast cancer before the age of 45, or two or more of these family members with this type of cancer before the age of 50; a family member with two or more breast cancers; an individual with ovarian, fallopian tube, or primary peritoneal cancer; male breast cancer; or three or more family members with cancer in the following types and/or topographies (especially if diagnosed at the age of 50 or before that): breast, pancreas, prostate (metastatic Gleason score 7), melanoma, sarcoma, adrenocortical carcinoma, brain tumors, leukemia, colon, endometrium, thyroid, kidney, hamartomatous polyps of the gastrointestinal tract cancer, and an individual of Ashkenazi Jewish origin with breast, ovarian, or pancreas cancer at any age.¹⁰

¹Universidade Federal do Paraná – Curitiba (PR), Brazil.

*Corresponding author: camilavpmed@gmail.com

Conflict of interests: nothing to declare.

Received on: 05/31/2020. Accepted on: 06/11/2020.

As to family history, the relative risk (RR) of increase in BBC was 2.8, especially for first-degree family members.¹¹ A study by Reiner et al. from 2013 showed that the risk of contralateral breast cancer for a 30- to 34-year-old patient with breast cancer without BRCA1 and 2 mutations and no family history is 7% in 10 years. Patients without genetic mutations, but with a second-degree relative with breast cancer, are at 9% risk; those with an affected first-degree relative have a 14.7% risk of contralateral breast cancer. A bilaterally affected family member increases the risk of a patient without a genetic mutation for contralateral breast cancer to 23.7%.¹²

Bilaterality suggests genetic origin, that is, hereditary breast cancer. There are pathogenic mutations associated with this type of cancer, especially in BBC, which are: BRCA1 and BRCA2 (50%–85%), PALB2 (33%–58%), TP53 (Li-Fraumeni syndrome, 50%–90%), PTEN (Cowden syndrome/PTEN Hamartoma Tumor Syndrome, 25%–50%), STK11 (32–54%), and CDH1 (30%–50%).^{12,13} The most important mutation related to bilateral neoplasm is BRCA1 and BRCA2. A population study with 705 women with BBC — with a mutation in the BRCA 1 and 2 genes — showed that the risk of bilateral neoplasia was 4.5 and 3.4 in BRCA 1 and 2 mutations, respectively, and the estimated cumulative risk over 10 years was 18.4 with the mutation and 4.8 without it.¹³

The patient's age at diagnosis of the primary tumor is a significant factor for bilateral cancer, especially for patients under 50 years old.¹⁴ In a study carried out in Sweden with 1,351 cases, patients over 50 years old had an RR of 1, whereas those under 50 had an RR of 9.9.¹⁵

The objective of the present study was to assess the clinical, familial, histological, and immunohistochemical pattern of patients with bilateral breast cancer for a better understanding of this clinical entity, which, although rare, is of great importance.

METHODOLOGY

This is a cross-sectional, retrospective, observational, and analytical study. The target population analyzed is patients treated by the tocogynecology service of Hospital de Clínicas of Universidade Federal do Paraná, from January 2003 to December 2019. Patients with unilateral breast carcinoma, breast cancer whose histology did not confirm breast carcinoma, breast cancer resulting from metastasis from another primary site, and patients with information reported in their medical records in an incomplete, inconsistent, incomprehensible, or misplaced medical record were excluded.

Based on the analysis of medical records, data relating to clinical and family characteristics, histological and immunohistochemical pattern, time of diagnosis of contralateral neoplasia (synchronic/metachronic), and the type of treatment used in metachronic tumors were obtained and recorded. After that, data were grouped into spreadsheets in Microsoft Office Excel® (2016), with subsequent data analysis by the researchers.

Research waives the Free and Informed Consent Term because it is a project with simple analysis of medical record data, without direct or minimal interference in patients.

The present study was approved by the Research Ethics Committee of Hospital de Clínicas, Universidade Federal do Paraná, with Presentation Certificate for Ethical Appreciation (CAAE) No. 11701819.9.0000.0096.

RESULTS

A total of 42 patients with BBC was selected out of 1,523 patients seen at the tocogynecology service of Hospital de Clínicas of Universidade Federal do Paraná, of which four were excluded due to lost medical records or incomplete information on them. The incidence of BBC in the surveyed period was 3.64%. All patients are women with a mean age of 51.82 years. White skin color is the most prevalent (82%), followed by *parda* (11%), and black (8%). The mean menarche age of patients was 12.89, ranging from 10 to 18 years old. As to menopausal status, 42% are pre-menopausal and 58% post-menopausal, with an average age of menopause of 48, ranging from 39 to 56. Regarding pregnancy, 16% of the patients are nulligravida, 8% had one pregnancy, 32% had two pregnancies, and 45%, three or more. Half patients have a positive family history for neoplasm, with breast cancer present in 46%, ovarian cancer in 16%, and neoplasms of other topographies in 68%. Neoplasms of other topographies are distributed as follows: gastrointestinal tract with 21%, non-ovarian gynecological with 16%, urological with 16%, hematological with 11%, and head and neck with 5%. Smoking history was present in 29% of patients, with an average burden of tobacco-related conditions of 27.36. Patients' mean body mass index (BMI) was 28.08.

In this sample, the synchronous tumor was present in 55% of patients, whereas the metachronous tumor, in 45%. Regarding the patients' initial clinical staging, 61% presented with locally advanced tumor (stage IIb) at their first medical appointment.

Exclusively to the group of synchronous tumors, the mean age of patients was 52.14, distributed as follows: less than 40, 14%; between 40 and 49, 38%; between 50 and 59, 19%; older than 60, 29%. The ductal histological type was the most frequent (93%), followed by the lobular type (7%). Of the patients, 60% had moderately differentiated tumors. With respect to immunohistochemical subtype, most patients had luminal B tumors (43%), followed by HER2 (29%), triple negative (24%), and luminal A (5%). Comparing the histological and immunohistochemical profile of each breast, 62% agreed and 48% were not the same.

Exclusively to the group of synchronous tumors, the mean age of patients was 51.41, distributed as follows: less than 40, 24%; between 40 and 49, 12%; between 50 and 59, 47%; older than 60, 18%. The average time between the diagnosis of the first tumor and the appearance of the second was 5.68 years. The most common histological type was ductal carcinoma in 73%, followed by lobular carcinoma in 11%, medullary carcinoma in 9%, and metaplastic carcinoma in

7%. Regarding the immunohistochemical profile, the most prevalent was luminal B in 32%, luminal A in 29%, triple negative in 24%, and HER2 in 15%. The histological and immunohistochemical profile of each breast was equal in only 29% of patients, who had a triple negative in 60% and luminal B in the other 40%. When assessing treatment in the primary tumor, 41% of patients underwent neoadjuvant therapy (86% with standard chemotherapy and 14% hormone therapy), 53% underwent conservative surgery, and 73%, axillary lymphadenectomy. Of the patients, 67% had their tumors irradiated, and 87% performed adjuvant therapy according to their tumor profile.

DISCUSSION

Bilateral breast carcinomas (BBC) are rare cancer events. In the present study, despite the small sample, half patients have a positive family history from the oncological point of view, of which 46% are in breast topography and 16%, in ovarian topography, reiterating the importance of this risk factor, which has been well described in the literature.^{10,11}

In research, 55% are synchronous tumors. Upon diagnosis, neoplasm showed to be locally advanced, that is, above stage IIb. On the other hand, synchronic cancer represents 1% of the total, and metachronic cancer is seven times more frequent in the literature.¹⁶ This is probably due to the small sample size and the quality of the health system offered to this selected group.

Regarding patients' age, the trend in the two groups is different, although the average age is quite similar. In the synchronic ones, 52% of the sample is made up of women under 50 years old, whereas in the metachronic ones, 65% was above that age.

As for the histological subtype and the tumor grade, the study results were like those found in unilateral carcinomas. Both in the synchronous and metachronic groups, positive hormone receptor tumors were the most frequent. In the literature, the profile of the highest risk for bilateral breast cancer is that of negative hormone receptors, as in a study with 4,036 patients who presented that the risk of developing another tumor bilaterally was 10 times greater in negative receptors.¹⁷

Besides that, in the synchronic group, 52% of the patients had HER2 or triple negative tumors, that is, those potentially more aggressive tumors, whereas in the metachronic group the immunohistochemical profile was similar to the distribution of unilateral breast tumors. The aggressiveness and the worse prognosis of bilateral tumors is described in other articles. Bilateral tumors have lower survival disease-free, and high rates of lymphatic spread and distant metastasis.¹⁸ According to a study carried out with 1,705 patients, the rates of local recurrence in five and 10 years were 4.5% and 9.1%, respectively, for patients with bilateral cancer; *versus* 3.3% and 7.6%, respectively, for unilateral cancer. In 10 years, the rates of distant metastases were 26.9% and 50.7% for unilateral and bilateral cancer, respectively. Survival in five and 10 years was 82.1% and 41% in patients with bilateral cancer, respectively, and 91.4% and 84% for unilateral cases.¹⁶

When comparing the samples from each breast in the metachronous group, most were discordant in relation to the histological and immunohistochemical profile. This generates an interesting caveat which is that when treating a bilateral tumor, we must often approach it as a second primary tumor.

Although this is a rare pathology, there is a description of an important tool to prevent the development of BBC in the literature: contralateral risk-reducing mastectomy. However, this is beneficial only for high-risk patients regarding the development of BBC, which includes patients with known BRCA1, BRCA2, TP53, PTEN Gold mutations, and/or family history suggestive of the tumor's genetic origin,^{7,19,20} especially for young patients with triple negative tumors and with good response to neoadjuvant therapy.⁶

In a Mayo Clinic study, 214 women classified as high risk and 425 classified as moderate risk underwent bilateral mastectomy. During a 14-year follow-up period, seven breast cancers were diagnosed, which represented a 90% risk reduction compared to the expected number of neoplasms in this topography.²¹

A prospective analysis in the Netherlands evaluated 583 women with a BRCA mutation between 1980 and 2011, selected from a multicenter cohort. Of these, 242 (42%) underwent contralateral mastectomy and 341 (58%) were under observation. BBC was detected in four patients (2%) after contralateral mastectomy and in 64 patients, in the observation group (19%).²²

The largest prospective analysis of breast cancer after bilateral mastectomy, called the PROSE study and conducted in 2004, evaluated 2,484 women with BRCA1 and BRCA2 mutations and of 22 centers in the United States and Europe. No breast cancer was diagnosed in the 247 women who underwent bilateral mastectomy, whereas 98 breast cancers (7%) were diagnosed in the group of those under observation, during the three-year follow-up.²³

Further studies are needed to better clarify the clinical, familial, histological, and immunohistochemical pattern of bilateral breast carcinomas, which, although rare, are of great clinical importance.

CONCLUSION

BBC is rare and is associated with a relevant family history. The most frequent pattern was ductal carcinoma with luminal subtype B. In this sample, the synchronic type was the most common.

AUTHORS' CONTRIBUTIONS

C.V.P.: conceptualization, research, methodology; data acquisition; statistical analysis, data interpretation, article writing, article review; B.R.B.: data acquisition, data interpretation, article writing; L.R.B.: conceptualization, research and methodology, data interpretation, article review; M.N.A.: data acquisition, data interpretation; V.M.B.: conceptualization, investigation, methodology, data interpretation, article review.

REFERENCES

- Manea E, Munteanu A. Evolution of synchronous bilateral breast carcinoma in a young patient. *Rev Med Chir Soc Med Nat Iasi*. 2016;120(1):192-6. PMID: 27125095
- Vuoto HD, García AM, Candás GB, Zimmermann AG, Uriburu JL, Isetta JA, et al. Bilateral breast carcinoma: clinical characteristics and its impact on survival. *Breast J*. 2010;16(6):625-32. <https://doi.org/10.1111/j.1524-4741.2010.00976.x>
- Gollamudi SV, Gelman RS, Peiro G, Schneider LJ, Schnitt SJ, Recht A, et al. Breast-conserving therapy for stage I-II synchronous bilateral breast carcinoma. *Cancer*. 1997;79(7):1362-9. [https://doi.org/10.1002/\(SICI\)1097-0142\(19970401\)79:7<1362::AID-CNCR14>3.0.CO;2-Y](https://doi.org/10.1002/(SICI)1097-0142(19970401)79:7<1362::AID-CNCR14>3.0.CO;2-Y)
- Imyanitov EN, Hanson KP. Molecular pathogenesis of bilateral breast cancer. *Cancer Lett*. 2003;191(1):1-7. [https://doi.org/10.1016/s0304-3835\(02\)00523-2](https://doi.org/10.1016/s0304-3835(02)00523-2)
- Kilgore AR, Bell HG, Ahlquist Junior RE. Cancer in the second breast. *Am J Surg*. 1956;92(2):156-61. [https://doi.org/10.1016/s0002-9610\(56\)80055-x](https://doi.org/10.1016/s0002-9610(56)80055-x)
- Mau C, Untch M. Prophylactic surgery: for whom, when and how? *Breast Care (Basel)*. 2017;12(6):379-84. <https://doi.org/10.1159/000485830>
- Hunt KK, Euhus DM, Boughey JC, Chagpar AB, Feldman SM, Hansen NM, et al. Society of surgical oncology breast disease working group statement on prophylactic (risk-reducing) mastectomy. *Ann Surg Oncol*. 2017;24(2):375-97. <https://doi.org/10.1245/s10434-016-5688-z>
- Beckmann KR, Buckingham J, Craft P, Dahlstrom JE, Zhang Y, Roder D, et al. Clinical characteristics and outcomes of bilateral breast cancer in an Australian cohort. *Breast*. 2011;20(2):158-64. <https://doi.org/10.1016/j.breast.2010.10.004>
- Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. *Cancer Epidemiol Biomarkers Prev*. 1999;8(10):855-61. PMID: 10548312
- Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. *J Natl Compr Canc Netw*. 2017;15(1):9-20. <https://doi.org/10.6004/jnccn.2017.0003>
- Hemminki K, Ji J, Försti A. Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk. *Cancer Res*. 2007;67(3):868-70. <https://doi.org/10.1158/0008-5472.CAN-06-3854>
- Reiner AS, John EM, Brooks JD, Lynch CF, Bernstein L, Møllerhøj L, et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. *J Clin Oncol*. 2013;31(4):433-9. <https://doi.org/10.1200/JCO.2012.43.2013>
- Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. *J Clin Oncol*. 2010;28(14):2404-10. <https://doi.org/10.1200/JCO.2009.24.2495>
- Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. *Br J Cancer*. 2011;104(9):1384-92. <https://doi.org/10.1038/bjc.2011.120>
- Adami HO, Bergström R, Hansen J. Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based case-control study. *Cancer*. 1985;55(3):643-7. [https://doi.org/10.1002/1097-0142\(19850201\)55:3<643::aid-cnrcr2820550328>3.0.co;2-l](https://doi.org/10.1002/1097-0142(19850201)55:3<643::aid-cnrcr2820550328>3.0.co;2-l)
- Jobsen JJ, van der Palen J, Ong F, Riemersma S, Struikmans H. Bilateral breast cancer, synchronous and metachronous; differences and outcome. *Breast Cancer Res Treat*. 2015;153(2):277-83. <https://doi.org/10.1007/s10549-015-3538-5>
- Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Second primary breast cancer occurrence according to hormone receptor status. *J Natl Cancer Inst*. 2009;101(15):1058-65. <https://doi.org/10.1093/jnci/djp181>
- Kappikeri VK, Kriplani AM. Bilateral synchronous carcinoma breast- a rare case presentation. *Springerplus*. 2015;4:193. <https://doi.org/10.1186/s40064-015-0953-3>
- Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. *Cancer*. 2016;122(23):3673-81. <https://doi.org/10.1002/cncr.30248>
- Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer (Review). *Cochrane Database Syst Rev*. 2018;4(4):CD002748. <https://doi.org/10.1002/14651858.CD002748.pub4>
- Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. *N Engl J Med*. 1999;340(2):77-84. <https://doi.org/10.1056/NEJM199901143400201>
- Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, Ausems MG, Collée JM, Jansen L, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. *Int J Cancer*. 2015;136(3):668-77. <https://doi.org/10.1002/ijc.29032>
- Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *J Clin Oncol*. 2004;22(6):1055-62. <https://doi.org/10.1200/JCO.2004.04.188>



Tumor biological profile of patients up to 50 years of age in a countryside city of São Paulo

Mariana Rossi Corregliano^{1*} , Karine Angélica Cintra¹ , Barbara Mendes Kirchhoff¹ ,
Stella Souza Martins¹ , Rodrigo Tavares Silva¹ 

ABSTRACT

Introduction: In Brazil, breast cancer screening is not performed in young women. However, although less frequent, the disease is generally more aggressive in this age group, with worse prognosis and refractoriness to treatment. Thus, the identification of specific subtypes by immunohistochemistry can help improve the effectiveness of treatments. **Objectives:** To evaluate the biological characteristics of breast tumors in patients under 50 years. **Methods:** This is an observational, longitudinal, retrospective study, based on data collected from medical records of the Hospital do Câncer de Franca, from January 2015 to February 2018. **Results:** The most frequent biological subtype was luminal B (42.5%), and the mean age of the women was 43.6 years. The most prevalent clinical staging was IIA (31%). Mastectomy with axillary drainage was the most used surgical treatment. A positive correlation was found between biological profiles and sociodemographic data, with a predominance of the luminal B subtype in women under 40 years and luminal A in those between 41 and 50 years. The mean tumor size was 4.2 cm, being larger in older and white patients. In multiparous women, the subtypes HER2 and luminal A and B stood out. **Conclusion:** Luminal B and luminal A biological profiles, as well as staging II and III, were the most prevalent. Mastectomy and axillary drainage were the most common surgical treatments. The employment of these procedures should be reviewed by the service in order to improve the quality of life of the patients treated, favoring the expansion of primary conservative surgeries or post-neoadjuvant chemotherapy.

KEYWORDS: breast neoplasms; screening; immunohistochemistry.

INTRODUCTION

Currently, breast cancer is the subject of many scientific discussions about screening and treatment due to its high incidence and for being the main cause of cancer death among women in Brazil and worldwide¹. The worldwide incidence is approximately 1.7 million, representing the second most common type of cancer in women². In Brazil, according to the National Cancer Institute (*Instituto Nacional de Câncer* – INCA), the estimated incidence for 2020 is 66,280 new cases (61.61 cases for every 100,000 women), with the state of São Paulo having an estimated rate above the national, 81.06 cases for every 100,000 women².

This neoplasm is more prevalent in women over 50 years of age. However, when it affects younger women, it tends to have a more aggressive clinical presentation and a worse prognosis³⁻⁵, which may be associated with factors such as late diagnosis, since they do not fit the target population of screening programs, as well as the tumor molecular characteristics.

Although breast cancer is less prevalent in young women, the likelihood of its development increases with age. The incidence of invasive breast tumors published by the Surveillance, Epidemiology, and End Results (SEER) Program between 2013 and 2017 was 1.9% for individuals aged 20–34 years, 8.3% for 35–44 years, and 19.7% for 45–54 years⁶.

In Brazil, mammographic screening should be performed every 2 years in women aged 50 to 69 years, according to the Ministry of Health. Nonetheless, the American Cancer Society (ACS) recommends annual screening for individuals aged 45 to 54 years and biannual for those over 55 years. Women between 40 and 45 years of age are also free to have annual screenings if they so choose. In addition, ACS recommends bringing the screening forward for women at high risk of developing the disease, with mammography and breast magnetic resonance imaging (MRI) after the age of 30. This group includes women with mutations in the *BRCA1* and *BRCA2* genes; first-degree relatives with a known mutation in these genes; at 20% to 25% risk of developing

¹Universidade de Franca – Franca (SP), Brazil.

*Corresponding author: mari_corregliano@hotmail.com

Conflict of interests: nothing to declare.

Received on: 04/30/2020. Accepted on: 07/10/2020.

the disease, as estimated by specific models of risk calculation (BRCAPro, Claus, BOADICEA — Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm, and Tyrer-Cuzick); those with genetic diseases (Li-Fraumeni, Cowden, and others); or who had chest wall irradiation before the age of 30⁷.

The psychosocial issue is one of the most relevant after diagnostic confirmation in young patients, involving specific problems related to the preservation of fertility, pregnancy, and lactation, in addition to body image and sexuality. For this reason, these cases deserve a differential and individualized approach before the start of any therapeutic decision, since they can have long-term consequences, such as infertility and psychological disorders, such as anxiety and depression. This approach should be continuously discussed throughout the medical follow-up, in a multidisciplinary way^{4,8,9}.

Among the risk factors for disease recurrence directly related to prognosis, the following stand out: tumor size, lymph node involvement, proximity to surgical margins after resection, and classification of the tumor molecular subtype³. The immunohistochemical evaluation can identify four different groups of tumors related to the expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). They are luminal A, luminal B, triple-negative, and HER2^{10,11}.

The expression of estrogen and progesterone receptors characterizes the luminal A and B subtypes, which favor endocrine treatment, in general, and have a more favorable prognosis. The expression of epidermal growth factor receptor 2 may be present in the luminal B subtype and is the main characteristic of the HER2 subtype, which does not show hormone receptor expression, leading to greater biological aggressiveness. Triple-negative tumors do not express hormone receptors and epidermal receptor 2. The “baseline-like” type has an overexpression of cytokeratins (CK5, CK6, and CK14) and epidermal growth factor receptor (EGFR)¹².

The prevalence of each subtype varies according to age, ethnicity, and behavioral aspects. Biological behavior in young women tends to be more aggressive, with unfavorable clinical evolution, greater local recurrence and distance from the disease, in addition to being associated with several genomic instabilities related to molecular subtypes, especially triple-negative, basaloid, and HER2+¹³.

Thus, besides determining the classic prognostic and predictive factors, such as clinical and imaging staging to assess tumor size, lymph node involvement, and distant metastasis, the molecular classification of the disease must also be carried out in order to provide the most specific treatment for each case, seeking to control recurrences and overall disease-free survival¹³. Thus, this study aims to evaluate the tumor biological profiles of women aged outside the target population of mammographic screening practiced in Brazil, undergoing surgical treatment in an inland city of São Paulo.

MATERIALS AND METHODS

This is an observational, longitudinal, retrospective study, based on data collected from medical records of the Hospital do Câncer de Franca.

Inclusion criteria

Patients under 50 years of age who underwent surgical treatment at the Hospital do Câncer de Franca from January 2015 to January 2018 were included.

Exclusion criteria

Patients over 50 years of age who underwent surgical treatment and those under 50 years who were not submitted to surgical treatment were excluded.

Statistical analysis

The data obtained (demographic characteristics, initial staging, diagnostic approach, type of surgery, and adjuvant therapies) were entered into an Excel® spreadsheet and subsequently submitted to statistical analysis, represented descriptively in graphs and tables. A comparative analysis between tumor biological profiles, demographic data, and initial staging was also performed, with $p < 0.05$ being considered significant.

Ethical aspects

The project was submitted for consideration and approval to the Research Ethics Committee of Fundação Santa Casa de Misericórdia de Franca, following the guidelines and regulatory standards for research involving human beings established by resolution 4662012.3, and was approved under registration number 09441219.0.0000.5438.

RESULTS


The sample consisted of 34 women under 50 years of age diagnosed with breast cancer, treated at the Hospital do Câncer de Franca from January 2015 to February 2018.

The immunohistochemical analysis of the studied population revealed that the most frequent tumor subtype was luminal B (42.5%), followed by luminal A (33.5%), HER-2 (15%), and, finally, triple-negative (6%), as shown in Graph 1.

Demographic variables are described in Table 1, and the results of mammographic exams in the first appointment in Table 2.

The interval between the first appointment and the surgical treatment was 101 ± 79.5 days (standard deviation – SD). Graph 2 represents the complementary diagnostic tests performed in these patients in the service during this period. Those who only had a mammogram underwent a previous biopsy in another service; therefore, all patients submitted to surgery had a prior histopathological investigation.

Graph 3 presents the distribution of cases according to clinical staging.




Graph 1. Percentage of patients according to tumor subtype.

Table 1. Epidemiological characteristics.

Epidemiological characteristics of the sample		
Age (years)	Minimum	28
	Median	45
	Maximum	50
Ethnicity (%)	White	79
	Multiracial	15
	Black	6
Marital status (%)	Married	73
	Single	9
	Divorced	15
	Widow	3
Parity (%)	Nulliparous	3
	Multiparous	54.5
	Primiparous	9
	Not informed	33.5
Origin (%)	State of São Paulo	27.5
	Franca	39.5
	State of Minas Gerais	15
	Other states	18


Table 2. Mammographic BI-RADS in the first appointment.

Mammographic results in the first appointment (%)	
BI-RADS® 0	6
BI-RADS® 1 and 2	6
BI-RADS® 3	6
BI-RADS® 4	24.5
BI-RADS® 5	15
BI-RADS® 6	6
No data in the medical record or no previous exam	36.5



US: ultrasound.

Graph 2. Complementary diagnostic tests performed (%).



Clin. stag.: Clinical staging.

Graph 3. Clinical staging of patients (%).

After the histological diagnosis, the immediate procedures adopted were surgery (57.5% of cases), neoadjuvant chemotherapy (CT) (39.5%), and adjuvant CT (3%). Among the patients whose treatment was surgical, 73% were submitted to radical mastectomy and 27% to conservative procedures. Regarding the axillary approach, drainage was performed in 67% of women and sentinel lymph node biopsy in 18%. In 3% of them, there was no research on the lymph node chain, and in 12%, this information was not in the medical records. The high rate of mastectomy may be associated with the high percentage of locally advanced tumors (\geq IIB), the unfavorable relationship between tumor size and breast volume at the initial physical examination, and/or the option made by the patient, even after specialized guidance on the safety of conservative surgeries, which may also justify the low number of referrals for conservative procedures after neoadjuvant CT.

Despite the small sample size, multivariate analysis was performed between tumor characteristics and demographic data (age and ethnicity), as well as between tumor biological profiles and demographic data of the studied group.

Table 3. Relationship of biological subtypes with age group.

Age group (years)	Biological subtype (n)					Total
	Luminal A	Luminal B	HER2	Triple	Others	
≤40	0	6	1	0	1	8
41–50	11	7	4	2	1	25
Total	11	13	5	2	2	33

The mean tumor size was 4.2 ± 2.8 cm (SD). A positive relationship was found between this variable and age ($r=0.4$; $p=0.034$), that is, the older the woman, the larger the tumor. The same happened with ethnicity – the tumor size was larger in white women compared to multiracial and black women ($r=0.6$; $p=0.004$).

No significant association was detected between biological profiles and ethnicity ($\chi^2=1.83$; $p=0.40$) or origin ($\chi^2=1.40$; $p=0.706$). However, a positive relationship was identified with parity, namely, the prevalence of HER2, luminal A, and luminal B tumors was higher in multiparous women ($\chi^2=11.67$; $p=0.009$), and also with age ($\chi^2=9.49$; $p=0.08$), as shown in Table 3. The luminal A subtype was predominant in the age group 41 to 50 years ($p<0.02$). No statistical significance was found in the number of triple-negative cases among patients under 40 years of age.

DISCUSSION

The investigation of molecular subtypes in this sample demonstrated the predominance of luminal B (42.5%), followed by luminal A (33.5%). In a recent population study in the US, DeSantis et al. revealed that the number of triple-negative cases decreased by 1.5% to 2.6% in all ethnic groups and age groups in the period studied. The reason is unclear but may be related to the change in risk factors associated with different hormonal subtypes, such as parity, which has been decreasing in developed countries and is connected with triple-negative subtypes¹³. Conversely, in our multivariate analysis, multiparous women presented higher rates of tumors with receptor expression, which may be associated with the low sample size or the fact that they belong to a greater age range within this subgroup. The results of this study are compatible with the national survey carried out in 2014 by Carvalho et al., with more than 5,500 breast tumor samples from the 5 geographic regions. In the survey, they addressed the regional differences in the presentation of molecular subtypes of breast cancer, reporting a higher prevalence of luminal A and B subtypes in the Southeast and South regions of Brazil, even when analyzing age subgroups divided into older and younger than 50 years. They also found that the prevalence of triple-negative tumors was higher in the Northern region of the country. This difference in distribution can be explained by the diversity and heterogeneity of ethnic groups, eating habits, urbanization, climate, and access to health systems in Brazil¹⁴.

The prevalence data on the subtypes that express hormone receptors in this age group are also corroborated by the study by Olivieri et al., who analyzed histological samples from pre-menopausal Latin patients, using partial data from the PRECAMAMA study¹⁵, and also identified a higher incidence of the luminal A subtype (58%), followed by triple-negative (21%), luminal B (11%), and HER2 (5%). Despite the similarity of the subtypes found in the post-menopausal period, they detected a greater expression of Ki-67, even in the luminal A subtype, and specific gene mutations in oncogenes, as in the *TP53* gene, which could explain the differences in prognosis of these age groups¹⁶.

Regarding ethnicity, Clarke et al. analyzed the distribution of breast cancer subtypes in more than 90,000 patients in California and reported that black women had higher triple-negative rates at all ages¹⁷. This study found no significant differences between subtype distribution and ethnicity, which may be associated with the sample size and the ethnic diversity of our population.

We identified a low rate of patients in clinical staging I (12%) and 70% in staging II and III, with 39% being locally advanced (above IIB). We also observed that medical records lacked this information in 18% of cases, which will be used as a warning for the professionals responsible. Among the possible explanations, we highlight the failure to perform routine mammography in patients under 50 years of age. In this age group, mammographic screening is not recommended by the Brazilian Ministry of Health national guidelines. In a recent systematic review of the cost-effectiveness of breast screening programs, Mandrik et al. showed evidence of the benefits of screening individuals aged 50 to 69 years. However, before 50 and after 70 years, other factors should be considered, such as population characteristics of disease incidence and organizational structure of health systems¹⁸. In addition, European clinical trials on the subject also question the real effectiveness of screening in this age group in decreasing mortality from the disease, given the lower sensitivity and specificity and the higher proportion of false-positive results and biopsies performed unnecessarily¹⁹.

In 2013, a national study carried out with more than 12,000 breast cancer patients under 40 years of age (mean age 36 years) also found a higher prevalence of IIA staging¹. Similar data were presented by Stival et al., who detected a higher frequency of IIA and IIB tumors in patients aged between 40 and 50 years, with no significant differences in individuals over 50 years²⁰.

The time between visiting the service and surgical treatment was longer than that recommended by the Ministry of Health (60 days)²¹ and may be associated with the disproportion between the demand for care and the organizational structure of the service.

Concerning surgical treatment, some services still tend to perform a greater number of radical surgeries (mastectomies) in younger patients to the detriment of conservative procedures, as observed in this study, in which only 27% of patients were

submitted to conservative treatments. Moreover, the rate of patients referred to neoadjuvant CT was relatively low (39.5%), and these individuals are potential candidates for conservative surgery later. This finding can be explained by particular decisions between the staff physicians and their patients or by the lack of closer integration between the clinical oncology, mastology, and plastic surgery teams. No data were collected on the breast reconstructions performed, which, due to the structuring of the teams, are usually done late, in the second surgical period. Both conservative surgery and mastectomy are well-established local treatments for invasive breast carcinomas, and several randomized clinical trials with a follow-up of more than 20 years have shown that conservative surgery is safe and has outcomes equivalent to mastectomy as to overall disease-free survival in stages I and II²². In 2010, Veronesi et al. revealed that the cumulative risks of local recurrence after conservative surgery followed by radiotherapy would be acceptable in ten years (12%), and, therefore, age should not be a determining factor for surgical recommendation, which should be based on the oncological safety defined by the tumor/breast ratio and a favorable cosmetic result²³. In more recent studies, the recurrence after conservative surgery and subsequent adjuvant treatment decreased to 5.2% and 8.7%, according to protocols of the National Surgical Adjuvant Breast and Bowel Project (NSABP), in tumors without and with axillary involvement, respectively^{24,25}. In addition, several studies report that the recurrence rate is associated with different molecular subtypes, being higher in triple-negative tumors and those with overexpression of HER2²². We emphasize the importance of performing an appropriate preoperative screening with imaging tests (especially mammography and breast ultrasound, as well

as MRI when necessary) to rule out multicentric tumors, which would make conservative procedures contraindicated²⁵.

Thus, the immunohistochemical profile of this group of patients and the initial staging were similar to those of older age groups, according to the literature review. This finding also points to a worse prognosis of the disease at younger ages, possibly associated with complex factors of tumor genetic instability, whose knowledge is in progressive construction and will increasingly expand the individualization of therapeutic possibilities.

CONCLUSION

The most prevalent biological profiles in this sample of patients aged under 50 years were luminal B and luminal A subtypes and staging II and III. Mastectomy and axillary drainage were the most common surgical treatments. The employment of these procedures should be reviewed and rethought by the service in order to improve the quality of life of the patients treated, favoring the expansion of primary conservative surgeries or post-neoadjuvant chemotherapy.

AUTHORS' CONTRIBUTIONS

M.R.C.: data curation, formal analysis, investigation, writing – original draft; K.A.C.: conceptualization, investigation, methodology, investigation, project administration, supervision, validation, visualization, writing – review & editing; B.M.K.: data curation, formal analysis, investigation, writing – original draft; S.S.M.: data curation, formal analysis, investigation, writing – original draft; R.T.S.: methodology, validation, writing – review & editing.

REFERENCES

1. Pinheiro AB, Lauter DS, Medeiros GC, Cardozo IR, Menezes LM, Souza RMB, et al. Câncer de mama em mulheres jovens: análise de 12.689 casos. *Rev Bras Cancerol.* 2013;59(3):351-9. <https://doi.org/10.32635/2176-9745.RBC.2013v59n3.500>
2. Brazil. Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de câncer no Brasil [internet]. Rio de Janeiro: Inca; 2019. 120 p. [Accessed on Nov 11, 2020]. Available at: <https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2020-incidencia-de-cancer-no-brasil.pdf>
3. Cancelli G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, et al. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. *Ann Oncol.* 2010;21(10):1974-81. <https://doi.org/10.1093/annonc/mdq072>
4. Abdel-Razeq H, Almasri H, Abdel Rahman F, Abdulelah H, Abu Nasser M, Salam M, et al. Clinicopathological characteristics and treatment outcomes of breast cancer among adolescents and young adults in a developing country. *Cancer Manag Res.* 2019;11:9891-7. <https://doi.org/10.2147/CMAR.S229337>
5. Tang LC, Jin X, Yang HY, He M, Chang H, Shao ZM, et al. Luminal B subtype: a key factor for the worse prognosis of young breast cancer patients in China. *BMC Cancer.* 2015;15:201. <https://doi.org/10.1186/s12885-015-1207-z>
6. National cancer institute. Surveillance, epidemiology and end results program. Cancer stat facts: female breast cancer [internet]. [Accessed on Nov. 11, 2020]. Available at: <https://seer.cancer.gov/statfacts/html/breast.html>
7. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the united states, 2019: a review of current American cancer society guidelines and current issues in cancer screening. *CA Cancer J Clin.* 2019;69(3):184-210. <https://doi.org/10.3322/caac.21557>
8. Partridge AH, Pagani O, Abulkhair O, Aebi S, Amant F, Azim HA Jr, et al. First international consensus guidelines for breast cancer in young women (BCY1). *Breast.* 2014;23(3):209-20. <https://doi.org/10.1016/j.breast.2014.03.011>

9. Bártolo A, Santos IM, Valério E, Monteiro S. Depression and health-related quality of life among young adult breast cancer patients: the mediating role of reproductive concerns. *J Adolesc Young Adult Oncol*. 2020;9(3):431-435. <https://doi.org/10.1089/jayao.2019.0144>
10. Elias S, Facina G, Araujo Neto JT. *Mastologia: condutas atuais*. 1st ed. Nazário ACP, editor. São Paulo: Manole; 2015.
11. Alves HFBES; Viapiana PS; Silva KLT. Aspectos clínicos e patológicos do câncer de mama em mulheres jovens atendidas na FCEcon entre 2003 e 2013. *Rev Bras Cancerol*. 2017;63(2):103-9. <https://doi.org/10.32635/2176-9745.RBC.2017v63n2.145>
12. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. *Cancer*. 2009;115(21):4917-23. <https://doi.org/10.1002/cncr.24573>
13. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, et al. Breast cancer statistics, 2019. *CA Cancer J Clin*. 2019;69(6):438-51. <https://doi.org/10.3322/caac.21583>
14. Carvalho FM, Bacchi LM, Pincerato KM, Van de Rijn M, Bacchi CE. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil. *BMC Womens Health*. 2014;14:102. <https://doi.org/10.1186/1472-6874-14-102>
15. Olivier M, Bouaoun L, Villar S, Robitaille A, Cahais V, Heguy A, et al. Molecular features of premenopausal breast cancers in Latin American women: pilot results from the PRECAMA study. *PLoS One*. 2019;14(1):e0210372. <https://doi.org/10.1371/journal.pone.0210372>
16. Romieu I, Biessy C, Carayol M, His M, Torres-Mejía G, Ángeles-Llerenas A, et al. Reproductive factors and molecular subtypes of breast cancer among premenopausal women in Latin America: the PRECAMA study. *Sci Rep*. 2018;8(1):13109. <https://doi.org/10.1038/s41598-018-31393-7>
17. Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. *J Natl Cancer Inst*. 2012;104(14):1094-101. <https://doi.org/10.1093/jnci/djs264>
18. Mandrik O, Ekwunife OI, Meheus F, Severens JLH, Lhachimi S, Uyl-de Groot CA, et al. Systematic reviews as a "lens of evidence": determinants of cost-effectiveness of breast cancer screening. *Cancer Med*. 2019;8(18):7846-58. <https://doi.org/10.1002/cam4.2498>
19. Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L, et al. The European society of breast cancer specialists recommendations for the management of young women with breast cancer. *Eur J Cancer*. 2012 Dec;48(18):3355-77. <https://doi.org/10.1016/j.ejca.2012.10.004>
20. Stival RSM, Prestes ALO, Mansani FP. Câncer de mama em mulheres jovens: uma análise do estadiamento clínico inicial e dos subtipos moleculares dos tumores. *Rev Bras Mastologia*. 2014;24(1):17-22. <https://doi.org/10.5327/Z201400010004RBM>
21. Brasil. Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva. A situação do câncer de mama no Brasil: síntese de dados dos sistemas de informação [internet]. Rio de Janeiro: Inca; 2019. 85 p. [Accessed on Nov. 11, 2020]. Available at: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//a_situacao_ca_mama_brasil_2019.pdf
22. Moo TA, Sanford R, Dang C, Morrow M. Overview of breast cancer therapy. *PET Clin*. 2018;13(3):339-54. <https://doi.org/10.1016/j.cpet.2018.02.006>
23. Gentilini O, Botteri E, Rotmensz N, Toesca A, Oliveira H, Sangalli C, et al. Breast-conserving surgery in 201 very young patients (<35 years). *Breast*. 2010;19(1):55-8. <https://doi.org/10.1016/j.breast.2009.11.001>
24. Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. *J Clin Oncol*. 2009;27(15):2466-73. <https://doi.org/10.1200/JCO.2008.19.8424>
25. Katipamula R, Degnim AC, Hoskin T, Boughey JC, Loprinzi C, Grant CS, et al. Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. *J Clin Oncol*. 2009;27(25):4082-8. <https://doi.org/10.1200/JCO.2008.19.4225>



Postoperative complications following simultaneous therapeutic and contralateral prophylactic nipple-sparing mastectomy: a retrospective study

Marina Sonagli^{1*}, Eduardo Bertolli², Alexandre Katalinic Dutra³, Hirofumi Iyeyasu¹, Fabiana Baroni Alves Makdissi¹

ABSTRACT

Introduction: Nipple-Sparing Mastectomy (NSM) is increasingly indicated for therapeutic and prophylactic purposes due to better cosmetic results with nipple maintenance. Postoperative complications have not been compared among patients who have undergone simultaneous therapeutic and contralateral prophylactic NSM. The aim of the present study was to evaluate the incidence and risk factors for postoperative complications in bilateral/unilateral NSMs, and therapeutic and/or prophylactic NSMs. **Methods:** Retrospective study of patients who underwent NSM between 2007 and 2017 at A.C. Camargo Cancer Center. **Results:** Among 290 patients, 367 NSMs were performed, 64 simultaneous therapeutic and contralateral prophylactic NSM. The latter were associated with more postoperative complications (OR=3.42; p=0.002), mainly skin flap necrosis (OR=3.79; p=0.004), hematoma (OR=7.1; p=0.002), wound infection (OR=3.45; p=0.012), and nipple-areola complex (NAC) loss (OR=9.63; p=0.003). Of the 367 NSMs, 213 were unilateral NSMs, which were associated with lower rates of postoperative complications (OR=0.44; p=0.003), especially skin flap necrosis (OR=0.32; p=0.001), hematoma (OR=0.29; p=0.008), wound infection (OR=0.22; p=0.0001), and reoperation (OR=0.38; p=0.008). Obesity was related to more postoperative complications (OR=2.55; p=0.01), mainly hematoma (OR=3.54; p=0.016), reoperation (OR=2.68; p=0.023), and NAC loss (OR=3.54; p=0.016). Patients' age (p=0.169), their smoking status (p=0.138), breast ptosis (0.189), previous chest radiotherapy (p 1), or previous breast surgery (p=0.338) were not related to higher chances of postoperative complications. **Conclusions:** Results suggest that performing therapeutic and contralateral prophylactic NSM as separated procedures may represent a good strategy for minimizing postoperative complications.

KEYWORDS: subcutaneous mastectomy; postoperative complications; breast cancer; prophylactic mastectomy.

INTRODUCTION

Nipple-sparing mastectomy (NSM) consists of remove the mammary gland while preserving the skin envelope and the nipple-areola complex (NAC).¹ The main advantage of preserving the NAC during NSM is to achieve better cosmetic results.^{2,3} However, this approach has been associated with postoperative complications in 12.4% – 53.7% of cases.^{2,4-13} The main postoperative complications associated with NSM include skin flap necrosis, NAC necrosis, wound infection, wound dehiscence, implant removal due to infection or dehiscence, and hematoma which requires drainage.^{2,4-13}

NSM can be offered in different scenarios: bilateral risk-reducing (prophylactic) NSM for women who carry a genetic mutation which confers a higher risk of breast cancer; bilateral therapeutic NSM for patients with synchronous bilateral breast cancer; bilateral therapeutic NSM and contralateral prophylactic NSM for patients who carry a genetic mutation which can develop into breast cancer; unilateral therapeutic NSM; and unilateral prophylactic NSM. Previously, postoperative complications between bilateral and unilateral NSM,^{7,13} and between therapeutic and prophylactic NSM^{3,6,11} have been examined. However, to date, all of the scenarios listed above have not been compared. Therefore, the

¹Breast Cancer Department, A.C. Camargo Cancer Center – São Paulo (SP), Brazil

²Skin Cancer Department, A.C. Camargo Cancer Center – São Paulo (SP), Brazil

³Plastic and Reconstructive Surgery Department, A.C. Camargo Cancer Center – São Paulo (SP), Brazil

*Corresponding author: marina.sonagli@accamargo.org.br

Conflict of interests: nothing to declare.

Received on: 07/11/2020. Accepted on: 01/04/2021

aim of the present study was to compare postoperative complications of bilateral or unilateral NSM, and prophylactic and/or therapeutic NSM, and determine which risk factors are associated with NSM's postoperative complications.

MATERIALS AND METHODS

This retrospective study examined patients who underwent NSM at A.C. Camargo Cancer Center between January 2007 and December 2017. Male patients, patients treated at another institution, and patients whose data could not be retrieved from medical records were excluded. Prophylactic NSM was considered for patients without breast diseases or with a previous biopsy of Lobular Carcinoma *in situ*. Therapeutic NSM was considered for treatment of ductal carcinoma *in situ* and invasive carcinoma. Both sides of bilateral NSM were performed by the same team of surgeons. Postoperative complications considered were those that appeared within 90 days of surgery. Research was approved by the Research Ethics Committee of A.C. Camargo Cancer Center.

Statistical analyses were performed by using SPSS version 20.0 software for Windows (Chicago, IL, USA). Statistical significance was set at $p < 0.05$. Descriptive statistical methods were used to compare clinical characteristics of the patients and postoperative complications of NSM. Chi-square or Fisher's exact tests, Student's t-test, and the Mann-Whitney U test were used to evaluate associations between measures. Simple and multiple logistic regression were used to identify significant predictors of developing complications.

RESULTS

A total of 367 NSMs were performed in 290 patients for treatment of breast cancer or for risk-reduction between January 2007 and December 2017 at A.C. Camargo Cancer Center. Of these NSM procedures, 154 (42%) were bilateral, with 74/154 (48%) being prophylactic NSMs, 16/154 (10.4%) being therapeutic, and 64/154 (41.6%) being therapeutic and contralateral prophylactic NSMs (Figure 1).




Figure 1. Number of patients and nipple-sparing mastectomies (NSM) performed at A.C. Camargo Cancer Center between January 2007 and December 2017.

The mean age of the cohort examined was 47 years (range 26–74), 29 (10%) were smokers and 43 (14.8%) were former smokers, 35 (12.1%) were obese, and 172 (59.3%) were premenopausal. The most prevalent comorbidities included hypothyroidism (19.3%), systemic arterial hypertension (15.9%), dyslipidemia (9.3%), and diabetes (5.9%) ([Supplementary Table 1](#)).

The overall complication rate for the cohort was 40% ($n=116$). Among the 213 patients who underwent unilateral NSM, 74 (34.7%) developed postoperative complications. Meanwhile, 42/77 (54.5%) patients who underwent bilateral NSM presented postoperative complications. According to indication, postoperative complications were reported for: 32.7% (52/159) of patients undergoing prophylactic NSM, 44.4% (44/99) of patients undergoing therapeutic NSM, and 62.5% (20/32) of patients undergoing simultaneous therapeutic and contralateral prophylactic NSM. Among the 72 patients with a current or previous smoking habit, 44 (61.1%) developed postoperative complications. Among the 35 obese patients, 21 (60%) presented postoperative complications. Breast ptosis was also evaluated, and postoperative complications were observed in 26 (35.6%), 23 (41.1%), and 16 (57.1%) patients exhibiting mild, moderate, and accentuated breast ptosis, respectively. A total of 16 patients had a history of chest wall radiotherapy (RT), with six (37.5%) developing postoperative complications. Finally, among the 75 patients who previously underwent breast surgery, 34 (45.3%) presented postoperative complications. Overall, only bilateral/unilateral NSMs ($p=0.004$), therapeutic and/or prophylactic NSMs ($p=0.004$), and obesity ($p=0.015$) showed statistically significant differences for postoperative complications (Table 1).

A simple logistic regression analysis showed that unilateral NSM was associated with a lower chance of postoperative complications (OR=0.44; 95% confidence interval (95%CI) 0.26–0.75; $p=0.003$), whereas patients who underwent therapeutic and contralateral prophylactic NSM during the same surgery had three times higher chance of developing postoperative complications (OR=3.42; 95%CI 1.55–7.54; $p=0.002$). This association was further corroborated by multiple logistic regressions (OR=3.12; 95%CI 1.09–8.95; $p=0.03$). Both simple and multiple logistic regression analyses also demonstrated that obese patients had a greater chance of developing postoperative complications (OR=2.55; 95%CI 1.24–5.25; $p=0.01$; and OR=3.57; 95%CI 1.33–9.55; $p=0.01$, respectively) (Table 1). When evaluating if age contributed to postoperative complications, the mean age of women who developed postoperative complications *versus* those who did not was not significantly different ($p=0.169$), even when compared according to age groups ($p=0.131$) ([Supplementary Table 2](#)).

Complications were categorized as follows: partial or total NAC necrosis (21.7%), partial or total wound dehiscence (21.4%), partial or total skin flap necrosis (14.5%), wound infection

Table 1. Associations between risk factors and postoperative complications in patients who underwent nipple-sparing mastectomy (NSM).

Variables	Complications				Chi-square / Fisher's exact test	Simple logistic regression analysis			Multiple logistic regression analysis		
	No N(%)	Yes N(%)	No N(%)	Yes N(%)	p	p	OR	95%CI	p	OR	95%CI
Laterality											
Bilateral	35	45.5	42	54.5	0.004*		Ref			Ref	
Unilateral	139	65.3	74	34.7		0.003*	0.44	0.26–0.75	0.449	0.69	0.26–1.78
Indication											
Prophylactic	107	67.3	52	32.7	0.004*		Ref			Ref	
Therapeutic	55	55.6	44	44.4		0.059	1.64	0.98–2.76	0.62	1.18	0.60–2.35
1 Breast prophylactic and 1 Breast therapeutic	12	37.5	20	62.5		0.002*	3.42	1.55–7.54	0.03*	3.12	1.09–8.95
Smoking status											
Non-smoker	136	62.7	81	37.3	0.138		Ref				
Smoker	18	62.1	11	37.9		0.95	1	0.46–2.28			
Former Smoker	20	46.5	23	53.5		0.05	1,9	0.99–3.73			
Obesity											
No	160	63.0	94	37.0	0.015 *		Ref			Ref	
Yes	14	40.0	21	60.0		0.01*	2.55	1.24–5.25	0.01*	3.57	1.33–9.55
Breast ptosis											
No	10	71.4	4	28.6	0.189		Ref				
Mild	47	64.4	26	35.6		0.612	1.38	0.39–4.84			
Moderate	33	58.9	23	41.1		0.394	1.74	0.48–6.24			
Accentuated	12	42.9	16	57.1		0.087	3.33	0.83–13.25			
Previous chest Radiotherapy											
No	164	59.9	110	40.1	1		Ref				
Yes	10	62.5	6	37.5		0.834	0.89	0.31–2.53			
Previous breast surgery											
No	133	61.9	82	38.1	0.338		Ref				
Yes	41	54.7	34	45.3		0.274	1.34	0.79–2.28			

OR: odds ratio; CI: confidence interval; *p<0.05.

(10.3%), and hematoma (7.2%). A total of 38 (13.1%) women needed reoperations. The NAC was excised in 20 (6.9%) cases, 13 (4.5%) due to total necrosis, five (1.7%) due to the presence of invasive carcinoma in the retroareolar margin, and two (0.7%) due to the presence of carcinoma *in situ* in the retroareolar margin (Table 2).

The present data demonstrated that bilaterality, simultaneous therapeutic and contralateral prophylactic NSM, and obesity are factors associated with a higher risk of postoperative complications. Comparing to patients who underwent unilateral NSM,

those who underwent bilateral NSM presented a greater incidence of skin flap necrosis (26 *vs.* 10.3%, respectively; p=0.002), hematoma (14.3 *vs.* 4.7%, respectively; p=0.012), wound infection (22.1 *vs.* 6.1%, respectively; p=0.0001), and reoperation (22.1% *vs.* 9.9%, respectively; p=0.012) (Table 2). Logistic regression analysis identified unilateral NSM as a protective factor for skin flap necrosis (OR=0.32; 95%CI 0.16–0.64; p=0.001), hematoma (OR=0.29; 95%CI 0.12–0.72; p=0.008), wound infection (OR=0.22; 95%CI 0.10–0.49; p=0.0001), and reoperation (OR=0.38; 95%CI 0.19–0.77; p=0.008) (Table 3).

Table 2. Associations between risk factors and types of postoperative complications in patients who underwent nipple-sparing mastectomy (NSM).

No. patients who underwent NSM	NAC necrosis N%		Skin flap necrosis N%		Hematoma N%		Wound infection N%		Wound dehiscence N%		Reoperation N%		NAC Loss N%	
Overall (n=290)	63	21.7	42	14.5	21	7.2	30	10.3	62	21.4	38	13.1	20	6.9
Laterality	0.803		0.002*		0.012*		0.0001*		0.324		0.012*		0.532	
Bilateral (n=77)	18	23.4	20	26	11	14.3	17	22.1	20	26	17	12.1	7	9.1
Unilateral (n=213)	45	21.1	22	10.3	10	4.7	13	6.1	42	19.7	21	9.9	13	6.1
Indication	0.169		0.011*		0.003*		0.015*		0.435		0.280		0.001*	
Prophylactic (n=159)	28	17.6	17	10.7	5	3.1	14	8.8	30	18.9	20	12.6	3	1.9
Therapeutic (n=99)	26	26.3	15	15.2	10	10.1	8	8.1	23	23.2	11	11.1	12	12.1
1 Breast prophylactic +1 Breast therapeutic (n=32)	9	28.1	10	31.3	6	18.8	8	25	9	28.1	7	21.9	5	15.6
Obesity	0.382		0.217		0.022*		0.139		0.663		0.03*		0.022*	
No (n=254)	52	20.5	34	13.4	14	5.5	23	9	53	20.9	29	11.4	14	5.6
Yes (n=35)	10	28.6	8	22.8	6	17.1	6	17.1	9	25.7	9	25.7	6	17.1

NSM: nipple-sparing mastectomy, NAC: nipple-areola complex. Chi-square/Fisher's exact test *p<0.05.

Table 3. Associations between risk factors and postoperative complications of nipple-sparing mastectomy (NSM).

Risk Factors	Outcome	Simple Logistic Regression Analysis		
		OR	95%CI	p
Therapeutic	Skin flap necrosis	1.49	0.70–3.14	0.293
Prophylactic+therapeutic		3.79	1.54–9.34	0.004*
Unilateral		0.32	0.16–0.64	0.001*
Therapeutic	Hematoma	3.46	1.14–10.44	0.02*
Prophylactic+therapeutic		7.10	2.02–24.99	0.002*
Unilateral		0.29	0.12–0.72	0.008*
Obesity		3.54	1.26–9.94	0.016*
Therapeutic	Wound infection	0.91	0.36–2.25	0.84
Prophylactic+therapeutic		3.45	1.30–9.10	0.012*
Unilateral		0.22	0.10–0.49	0.0001*
Unilateral	Reoperation	0.38	0.19–0.77	0.008*
Obesity		2.68	1.14–6.29	0.023*
Therapeutic	NAC loss	7.17	1.97–26.1	0.003*
Prophylactic+therapeutic		9.63	2.17–42.6	0.003*
Obesity		3.54	1.26–9.94	0.016*

NAC: nipple-areola complex; OR: odds ratio; CI: confidence interval. *p <0.05

Women who underwent simultaneous therapeutic NSM and contralateral prophylactic NSM developed a greater number of complications than those who underwent therapeutic NSM or prophylactic NSM. For these three groups, significant differences in skin flap necrosis (31.3%, 15.2%, and 10.7%, respectively; p=0.011), hematoma (18.8%, 10.1%, and 3.1%, respectively; p=0.003),

wound infection (25, 18.8, and 10.1%, respectively; p=0.015), and NAC loss (15.6%, 12.1%, and 1.9%, respectively; p=0.001) were observed (Table 2). Furthermore, patients who underwent therapeutic NSM and contralateral prophylactic NSM during the same surgery had three times higher chance of developing skin flap necrosis (OR=3.79; 95%CI 1.54–9.34; p=0.004) and wound infection

(OR=3.45; 95%CI 1.3–9.1; $p=0.012$). However, this increased risk was not observed for patients who underwent therapeutic NSM. Regarding hematoma and NAC loss, a higher chance of developing these complications was associated with patients undergoing simultaneous therapeutic and contralateral prophylactic NSM or therapeutic NSM. Compared to women who underwent prophylactic NSM, the chance of developing a hematoma was higher for those who underwent therapeutic NSM (OR=3.46; 95%CI 1.14–10.44; $p=0.02$), and even higher for women who underwent simultaneous therapeutic NSM and contralateral prophylactic NSM (OR=7.1; 95%CI 2.02–24.99; $p=0.002$). A similar profile was observed regarding NAC loss, with seven times higher chance observed for patients who underwent therapeutic NSM (OR=7.17; 95%CI 1.9–26.1; $p=0.003$) and nine times higher chance for patients who underwent simultaneous therapeutic and contralateral prophylactic NSM (OR=9.63; 95%CI 2.1–42.6; $p=0.003$), compared to patients who underwent prophylactic NSM (Table 3).

Obese patients presented the greatest number of overall complications, although a statistically significant association with obesity was only observed for hematoma (17.1% *vs.* 5.5%, respectively; $p=0.02$), reoperation rate (25.7% *vs.* 11.4%, respectively; $p=0.03$), and loss (17.1% *vs.* 5.6%, respectively; $p=0.02$) (Table 2). Obese patients had three times higher chance of developing hematoma and NAC loss (OR=3.54; 95%CI 1.26–9.94; $p=0.016$) and two times higher chance of needing reoperation (OR=2.68; 95%CI 1.26–9.94; $p=0.016$) (Table 3).

Among the 13 patients treated with neoadjuvant chemotherapy (NCT), no postoperative complications were reported ($p=0.138$). Meanwhile, among 131 patients who underwent therapeutic NSM, 47 (35.9%) received adjuvant treatment with hormone therapy (HT) alone, eight (6%) received radiotherapy alone, three (2.3%) received chemotherapy (CT) alone, 21 (16%) received CT and HT, 17 (13%) received RT, CT, and HT, 14 (10.7%) did not receive any adjuvant treatment, and data for two patients were not available (Supplementary Table 3). Patients who received only adjuvant radiotherapy have been treated with NCT. The start of adjuvant treatment did not significantly differ among the patients who underwent unilateral or bilateral NSM ($p=0.078$), or among those who underwent therapeutic or simultaneous therapeutic and contralateral prophylactic NSM ($p=0.449$) (Table 4).

DISCUSSION

An increased demand for specialized breast cancer services has been reported worldwide, after the Angelina Jolie Effect.¹⁴ In addition, studies have shown a trend towards a progressive increase in bilateral risk-reducing NSM and contralateral NSM in patients who have already undergone mastectomy for cancer treatment.^{15,16} A recent study has further demonstrated a growth

trend in the indication of NSM, not only for risk-reduction, but also for treatment of larger tumors.¹⁷

Cosmetic contraindications of NSM include factors associated with postoperative complications which impact cosmetic results and the malposition of NAC. Both large breast size and breast ptosis are reported to be absolute cosmetic contraindications of NSM, due to the difficulties associated with managing a large skin envelope.¹⁸ Breasts heavier than 800 g also present two to five times greater chance of developing postoperative complications.^{19,20} In the present study, obesity (defined as body mass index (BMI) $>30 \text{ cm/m}^2$) was associated with two to three times higher chance of developing postoperative complications. In order to expand NSM indications, reconstruction of large and ptotic breasts can be managed by using a staged approach, with mastopexy or reduction performed prior to NSM in prophylactic surgery candidates.²¹

Increased BMI, diabetes mellitus, smoking, previous breast incisions, prior chest or breast radiotherapy, and NCT have been identified as relative contraindications for NSM.^{2,8,10,11,18,20,22} In the present study, no associations between patient's age, smoking status, breast ptosis, prior chest radiotherapy, or prior breast surgery were observed for NSM postoperative complications.

There are few studies which have compared postoperative complications between bilateral and unilateral NSMs, and none of them found statistical differences between laterality and the incidence of postoperative complications.^{7,13} In a study conducted by Wang et al., 51 unilateral and 166 bilateral NSMs were compared to 187 unilateral and 394 bilateral Skin-Sparing Mastectomy. Bilateral surgery was found to be associated with a longer hospital stay, yet it was not associated with higher complications rates.¹³ In contrast, cases of unilateral NSM examined in the present study were associated with a lower rate of postoperative complications.

Previously, NSM postoperative complication rates have been reported to range up to 53.7%.⁷ In the present study, the overall

Table 4. Time to start of chemotherapy and/or adjuvant radiotherapy in patients who underwent unilateral/bilateral therapeutic nipple-sparing mastectomy (NSM) and therapeutic/simultaneous therapeutic and contralateral prophylactic NSM.

Therapeutic NSM	Time to start of adjuvant treatment (months)	Mann-Whitney U test
	Mean \pm SD (range)	p
Bilateral	2.1 \pm 1.48 (0–5)	0.078
Unilateral	1.5 \pm 1.1 (0–4)	
Therapeutic Unilateral	1.64 \pm 1.2 (0–5)	0.449
1 Breast Prophylactic + 1 Breast Therapeutic	1.8 \pm 1.32 (0–5)	

NSM: nipple-sparing mastectomy, SD: standard deviation. * $p < 0.05$.

complication rate was 40%, consistent with the published literature. However, the relation between indications of NSM and postoperative complications remains controversial. Mitchell et al. compared 833 therapeutic NSM and 1,102 prophylactic NSM, and found that therapeutic NSM was associated with a greater incidence of flap infections.³ However, other studies have not found differences between indications (therapeutic/prophylactic) of NSM and postoperative complications.^{6,11} To the best of our knowledge, the present study is the first to include a third group for comparison: patients who undergo therapeutic and contralateral prophylactic NSM during the same operation. We observed that this third group presented a greater number of postoperative complications, followed by therapeutic NSM alone and prophylactic NSM alone. We also observed that patients who underwent therapeutic and contralateral prophylactic NSM presented three-fold greater chance of experiencing postoperative complications.

NAC necrosis is a significantly adverse postoperative complication of NSM. Rates of NAC necrosis have been reported to range from 0.8%–29.6%.^{2,4–11,13,16,17,20,23,24} However, not all cases of NAC necrosis require operation and NAC excision. Wagner et al. reported rates of NAC necrosis up to 29.6%,¹⁰ although most of these cases involved partial NAC necrosis (20.3%) and only 7.4% of the cases required NAC excision.⁷ Similarly, Garcia-Etienne et al. described a NAC necrosis rate of 48%, yet only 5% of these cases were removed due to total NAC necrosis.²⁵ In the present study, NAC desquamation was grouped with partial and total necrosis, resulting in a NAC necrosis rate of 21.7%. However, only 4.5% of the NACs needed to be excised due to total NAC necrosis. Smoking and obesity have also been described as risk factors for NAC necrosis.^{10,26} In the present study, NAC necrosis was not found to be related to these or other factors.

Skin flap necrosis is another relatively common postoperative complication of NSM, with incidence rates ranging from 1.5%–37.5%.^{2,4,6–11,23} Just like NAC necrosis, not all cases of skin flap necrosis require surgical debridement. In the present study, partial and total skin flap necrosis were grouped, resulting in a skin flap necrosis rate of 14.5%. Factors reported to be associated to skin flap necrosis in NSM are prior breast surgery, prior breast radiotherapy, duration of surgery, sharp dissection, and specimen size.^{10,27} In the present study, neither prior breast surgery nor prior breast radiotherapy were identified as risk factors. However, women who underwent therapeutic and contralateral prophylactic NSM had three-fold higher chance of developing skin flap necrosis. In contrast, women who underwent unilateral NSM had a 68% lower chance of developing skin flap necrosis.

Wound dehiscence rates after NSM have been reported to range from 1.9%–7.7%.^{7,10,13,23} In the present study, wound dehiscence rate was 21.4%. This higher rate may be due to our consideration of any wound dehiscence when calculating this rate, not only those which required a second operation. Besides that, no

risk factors associated with a higher risk of wound dehiscence were identified.

Regarding hematoma as a postoperative complication of NSM, we observed that patients who underwent unilateral NSM had a 71% lower chance for developing this complication. Furthermore, we observed that patients who underwent therapeutic NSM had three-fold higher chance of presenting hematoma, whereas patients undergoing therapeutic and contralateral prophylactic NSM during the same surgery increased the chance to seven-fold. To the best of our knowledge, we believe the present study is the first to demonstrate an association between laterality and indication (prophylactic/therapeutic) of NSM with hematoma. All patients who underwent NSM received the same thromboembolic prophylaxis.

Two studies have investigated an association between wound infection and indication of NSM. Whereas Spear et al. did not find differences between postoperative infections and therapeutic or prophylactic NSM,⁶ Mitchell et al. showed a higher infection rate after therapeutic NSM.³ In the present study, patients who underwent therapeutic and contralateral prophylactic NSM during the same surgery had a three-fold higher chance of wound infection. Conversely, unilateral NSM was found to be associated with a 78% lower chance of developing postoperative infection.

Reoperation rates of NSM to treat postoperative complications are reported to range from 4.2%–9.4%.^{8,13,17} The overall reoperation rate in the present study was 13.1%. Excluding patients who underwent reoperation to excise NAC due to involvement of the retroareolar margin with carcinoma, the reoperation rate found in this study to treat postoperative complications was 10.7%, which is close to the rates reported in other studies.^{8,13,17} We further observed that obese patients had two-fold higher chance of reoperation after NSM.

A delay in the start of adjuvant treatment of up to two months after surgery proved to be related to a worse overall survival (OS) in patients with disease stage III, triple-negative and HER2 positive tumors, and a worse disease-free survival (DFS) in patients with disease stage III.²⁸ Worse OS and DFS have also been reported for patients who received adjuvant radiotherapy 2.3 months and 3 months after surgery, respectively.²⁹ Riba et al. showed that patients older than 70 years old, with hospital readmission within 30 days after surgery, positive margins after conservative breast surgery, reconstruction with autologous flap, and mastectomy were factors associated with a beginning of adjuvant treatment three months after surgery. In this study, bilateral mastectomy was not associated with a greater chance of delaying systemic treatment;³⁰ patients who underwent bilateral NSM, therapeutic NSM, or simultaneous therapeutic and contralateral prophylactic NSM, despite having higher risks of postoperative complications, did not have a delay in adjuvant treatment.

Type of breast reconstruction, operative time, and type of dissection (sharp or electrocautery) were not evaluated and consist a limitation of this study. However, our results can be used to discuss with patients which moment is the best to perform the prophylactic NSM.

CONCLUSIONS

We conclude that therapeutic and contralateral prophylactic NSM performed in the same surgery is associated with more postoperative complications, mainly skin flap necrosis, hematoma, wound infection, and NAC loss. Obesity was also observed to be associated with an increased risk of hematoma, reoperation, and NAC loss. Despite major postoperative complications, we observed that laterality (bilateral/ unilateral) and purpose (prophylactic/therapeutic) were not associated with delay in starting adjuvant treatment. When analyzed together, these results suggest that performing therapeutic NSM and contralateral prophylactic NSM at different times as separate procedures

could minimize the incidence of postoperative complications, especially for obese patients.

ACKNOWLEDGMENTS

We thank A.C. Camargo Cancer Center for giving permission to use its database of medical records, Silvana Soares dos Santos for her support with the initial database research performed, and Barbara Bettim for her support with statistical analyses.

AUTHORS' CONTRIBUTIONS

M.S.: conceptualization, investigation, methodology, project administration, data curation, writing original draft, writing – review & editing; E.B.: formal analysis, visualization, writing – review & editing; A.K.D.: visualization, writing – review & editing; H.I.: writing – review & editing; F.B.A.M.: conceptualization, formal analysis, investigation, methodology, validation, writing – review & editing.





REFERENCES

- Freeman MD, Gopman JM, Salzberg CA. The evolution of mastectomy surgical technique: from mutilation to medicine. *Gland Surg.* 2018;7(3):308-15. <https://doi.org/10.21037/gs.2017.09.07>
- De Vita R, Zoccali G, Buccheri EM, Costantini M, Botti C, et al. Outcome evaluation after 2023 nipple-sparing mastectomies: our experience. *Plast Reconstr Surg.* 2017;139(2):345e-47e. <https://doi.org/10.1097/PRS.0000000000003027>
- Mitchell SD, Willey SC, Beitsch P, Feldman S. Evidence based outcomes of the american society of breast surgeons nipple sparing mastectomy registry. *Gland Surg.* 2018;7(3):247-57. <https://doi.org/10.21037/gs.2017.09.10>
- Sacchini V, Pinotti JA, Barros ACS, Luini A, Pluchinotta A, et al. Nipple-sparing mastectomy for breast cancer and risk reduction: oncologic or technical problem? *J Am Coll Surg.* 2006;203(5):704-14. <https://doi.org/10.1016/j.jamcollsurg.2006.07.015>
- Petit JY, Veronesi U, Orecchia R, Rey P, Martella S, et al. Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European institute of oncology of Milan (EIO). *Breast Cancer Res Treat.* 2009;117(2):333-8. <https://doi.org/10.1007/s10549-008-0304-y>
- Spear SL, Willey SC, Feldman ED, Cocilovo C, Sidawy M, et al. Nipple-sparing mastectomy for prophylactic and therapeutic indications. *Plast Reconstr Surg.* 2011;128(5):1005-14. <https://doi.org/10.1097/PRS.0b013e31822b6456>
- Wagner JL, Fearmonti R, Hunt KK, Hwang RF, Meric-Bernstam F, et al. Prospective evaluation of the nipple-areola complex sparing mastectomy for risk reduction and for early-stage breast cancer. *Ann Surg Oncol.* 2012;19(4):1137-44. <https://doi.org/10.1245/s10434-011-2099-z>
- Colwell AS, Tessler O, Lin AM, Liao E, Winograd J, et al. Breast reconstruction following nipple-sparing mastectomy: Predictors of complications, reconstruction outcomes, and 5-year trends. *Plast Reconstr Surg.* 2014;133(3):496-506. <https://doi.org/10.1097/01.prs.0000438056.67375.75>
- Manning AT, Sacchini VS. Conservative mastectomies for breast cancer and risk-reducing surgery: the Memorial Sloan Kettering Cancer Center experience. *Gland Surg.* 2016;5(1):55-62. <https://doi.org/10.3978/j.issn.2227-684X.2015.10.02>
- Orzalesi L, Casella D, Santi C, Cecconi L, Murgo R, et al. Nipple sparing mastectomy: surgical and oncological outcomes from a national multicentric registry with 913 patients (1006 cases) over a six year period. *Breast.* 2016;25:75-81. <https://doi.org/10.1016/j.breast.2015.10.010>
- Dull B, Conant L, Myckatyn T, Tenenbaum M, Cyr A, Margenthaler JA. Nipple-sparing mastectomies: clinical outcomes from a single academic institution. *Mol Clin Oncol.* 2017;6(5):737-42. <https://doi.org/10.3892/mco.2017.1208>
- Galimberti V, Vicini E, Corso G, Morigi C, Fontana S, et al. Nipple-sparing and skin-sparing mastectomy: review of aims, oncological safety and contraindications. *Breast.* 2017;34:S82-4. <https://doi.org/10.1016/j.breast.2017.06.034>
- Wang M, Huang J, Chagpar AB. Is nipple sparing mastectomy associated with increased complications, readmission and length of stay compared to skin sparing mastectomy? *Am J Surg.* 2020;219(6):1030-5. <https://doi.org/10.1016/j.amjsurg.2019.09.011>
- James PA, Mitchell G, Bogwitz M, Lindeman GJ. The Angelina Jolie effect. *Med J Aust.* 2013;199(10):646. <https://doi.org/10.5694/mja13.11218>
- Tuttle TM, Abbott A, Arrington A, Rueth N. The increasing use of prophylactic mastectomy in the prevention of breast cancer.

- Curr Oncol Rep. 2010;12(1):16-21. <https://doi.org/10.1007/s11912-009-0070-y>
16. Frasson AL, Lichtenfels M, Anton A, Souza AAB, Vollbrecht B. Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients. *Breast Cancer Res Treat.* 2020;181(1):69-75. <https://doi.org/10.1007/s10549-020-05582-w>
 17. Valero MG, Muhsen S, Moo TA, Zabor EC, Stempel M, et al. Increase in utilization of nipple-sparing mastectomy for breast cancer: indications, complications, and oncologic outcomes. *Ann Surg Oncol.* 2020;27(2):344-51. <https://doi.org/10.1245/s10434-019-07948-x>
 18. Kopkash K, Pesce C, Sisco M, Poli E, Seth A. The modern approach to the nipple-sparing mastectomy. *J Surg Oncol.* 2020;122(1):29-35. <https://doi.org/10.1002/jso.25909>
 19. Frey JD, Salibian AA, Karp NS, Choi M. The impact of mastectomy weight on reconstructive trends and outcomes in nipple-sparing mastectomy: progressively greater complications with larger breast size. *Plast Reconstr Surg.* 2018;141(6):795e-804e. <https://doi.org/10.1097/PRS.0000000000004404>
 20. Tang R, Coopey SB, Colwell AS, Specht MC, Gadd MA, Kansal K, et al. Nipple-sparing mastectomy in irradiated breasts: selecting patients to minimize complications. *Ann Surg Oncol.* 2015;22(10):3331-7. <https://doi.org/10.1245/s10434-015-4669-y>
 21. Spear SL, Rottman SJ, Seiboth LA, Hannan CM. Breast reconstruction using a staged nipple-sparing mastectomy following mastopexy or reduction. *Plast Reconstr Surg.* 2012;129(3):572-81. <https://doi.org/10.1097/PRS.0b013e318241285c>
 22. Bartholomew AJ, Dervishaj OA, Sosin M, Kerivan LT, Tung SS, et al. Neoadjuvant chemotherapy and nipple-sparing mastectomy: timing and postoperative complications. *Ann Surg Oncol.* 2019;26(9):2768-72. <https://doi.org/10.1245/s10434-019-07418-4>
 23. DellaCroce FJ, Blum CA, Sullivan SK, Stolier A, Trahan C, et al. Nipple-sparing mastectomy and ptosis: perforator flap breast reconstruction allows full secondary mastopexy with complete nipple areolar repositioning. *Plast Reconstr Surg.* 2015;136(1):1e-9e. <https://doi.org/10.1097/PRS.0000000000001325>
 24. Galimberti V, Morigi C, Bagnardi V, Corso G, Vicini E, et al. Oncological outcomes of nipple-sparing mastectomy: a single-center experience of 1989 patients. *Ann Surg Oncol.* 2018;25(13):3849-57. <https://doi.org/10.1245/s10434-018-6759-0>
 25. Garcia-Etienne CA, Cody III HS 3rd, Disa JJ, Cordeiro P, Sacchini V. Nipple-sparing mastectomy: initial experience at the Memorial Sloan-Kettering Cancer Center and a comprehensive review of literature. *Breast J.* 2009;15(4):440-9. <https://doi.org/10.1111/j.1524-4741.2009.00758.x>
 26. Webb C, Gupta N, Kosiorek H, Cronin PA, Pockaj BA, et al. The effects of body mass index on operative time and outcomes in nipple-sparing mastectomy. *Am J Surg.* 2020;220(2):395-400. <https://doi.org/10.1016/j.amjsurg.2019.12.011>
 27. Zheng Y, Zhong M, Ni C, Yuan H, Zhang J. Radiotherapy and nipple-areolar complex necrosis after nipple-sparing mastectomy: a systematic review and meta-analysis. *Radiol Med.* 2017;122(3):171-8. <https://doi.org/10.1007/s11547-016-0702-x>
 28. Gagliato DM, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, et al. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. *J Clin Oncol.* 2014;32(8):735-44. <https://doi.org/10.1200/JCO.2013.49.7693>
 29. Lesage M, Pilloy J, Fleurier C, Cirier J, Jourdan ML, et al. Impact pronostique du délai d'induction de la radiothérapie adjuvante dans le cancer du sein. [Prognosis impact of breast cancer adjuvant radiotherapy delay]. *Gynecol Obstet Fertil Senol.* 2019;47(6):516-21. French. <https://doi.org/10.1016/j.gofs.2019.03.001>
 30. Riba LA, Gruner RA, Fleishman A, James TA. Surgical risk factors for the delayed initiation of adjuvant chemotherapy in breast cancer. *Ann Surg Oncol.* 2018;25(7):1904-11. <https://doi.org/10.1245/s10434-018-6351-7>



Clinicopathologic profile of breast cancer patients treated with neoadjuvant chemotherapy at HUCFF/UFRJ

Luís Claudio Belo Amendola^{1,2*} , Maria de Fatima Dias Gauí¹ ,
Ana Helena Pereira Correia Carneiro¹ , Nathalie Henriques Silva Canedo¹ 

ABSTRACT

Introduction: The objective of this study is to describe the profile of patients from a public institution, submitted to neoadjuvant chemotherapy (NACT), comparing the verified pathological response with literature data. **Methods:** Observational retrospective cohort study on breast cancer patients diagnosed between September 2001 and October 2018 and treated with NACT at Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ), located in Rio de Janeiro, Brazil. The adopted neoadjuvant chemotherapy regimen was based on anthracycline and docetaxel. **Results:** A total of 133 patients were evaluated. The average age in this group was 54 years (28-86), 49 women (37%) were under 50 years old. The following distribution by molecular subtype was observed: overexpression or amplification of the human epidermal growth factor receptor 2 (HER2+) (13 women, 26.6%), Luminal (19 women, 38.8%), and Triple-negative (TN) (17 women, 34.6%). The HER2+ and TN subtypes had a higher incidence of cases between 40-49 years and 50-59 years. As for the initial staging, 34% were IIIA; 26%, IIB; and 19%, IIIB. Only one patient did not undergo surgery after NACT, 33 (24.8%) underwent conservative surgery, and 99 patients (74.4%) underwent mastectomy. Regarding the axillary approach, 41 (31%) underwent sentinel lymph node biopsy and 88 (66%) had an indication for lymphadenectomy. In the anatomopathological evaluation of the surgery, 12 (9.1%) patients obtained a pathologic complete response (pCR) and 113 (84.9%), partial or no response to chemotherapy. **Conclusion:** This research enabled the identification of clinicopathologic characteristics and outcome of patients who received neoadjuvant chemotherapy in a public university service. The predominance of advanced tumors was observed, stressing the need for public health policies for the screening of breast cancer as well as the guarantee of timely treatment for diagnosed cases. The data somewhat reflect the difficulty that the public sector encounters to carry out the most appropriate treatment. The authors expect that this article, by analyzing the profile and the adopted treatment in real-life cases and in a public university institution, can contribute to the improvement of breast cancer treatment in Brazil.

KEYWORDS: locally advanced breast cancer, neoadjuvant chemotherapy, pathological response.

INTRODUCTION

Breast cancer is the most common malignancy among women worldwide. In Brazil, 66,280 new cases of breast cancer are expected per year for the 2020-2022 triennium. This value corresponds to an estimated risk of 61.61 new cases per 100 thousand women¹.

The prognosis of breast cancer depends, among other data, on its extension (staging) and the molecular subtype. TNM (T – tumor; N – nearby lymph nodes; M – metastasis) is the international system for assessing the extent of neoplasia, whose last systematic review was carried out in January 2018 by the American Joint Committee On Cancer (AJCC); this is the

8th edition, incorporating biological factors into the anatomico-clinical data². Pathological staging (pTNM) is determined after surgery or neoadjuvant treatment (ypTNM), with greater accuracy than the clinical one (cTNM).

Neoadjuvant chemotherapy (NACT) was initially adopted for locally advanced tumors aiming at cytoreduction, in order to provide conservative surgeries to patients who are candidates for mastectomy or to make it operable. However, lately, NACT has been adopted with the purpose of evaluating the response to a new protocol or medication, taking advantage of the pathological response as an intermediate outcome, identifying predictive and

¹Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro – Rio de Janeiro (RJ), Brazil.

²Instituto Nacional da Saúde da mulher, da criança e do adolescente Fernandes Figueira, Fundação Oswaldo Cruz – Rio de Janeiro (RJ), Brazil.

*Corresponding author: lcamendola@globo.com

Conflict of interests: nothing to declare.

Received on: 11/10/2020. Accepted on: 01/04/2021

prognostic factors or indicating complementary adjuvant treatment according to the residual disease. The effectiveness of the NACT regimen can be assessed by the rate of objective clinical response, tumor reduction and operability or, preferably, by the pathologic complete response (pCR – absence of residual invasive tumor in the surgical specimen in the breast and axilla). The first studies based on anthracyclines showed rates of clinical responses (60% to 80%) and pCR (10% to 20%)^{3,4}. In the early 2000s, taxanes were incorporated into neoadjuvant breast cancer treatment regimens, either alone or combined with anthracyclines, doubling the rate of clinical and pathological response⁵⁻⁹. Randomized studies on amplified HER2 (human epidermal growth factor receptor 2) patients have shown a significant increase in pCR when combining chemotherapy with anti-HER2 therapy¹⁰⁻¹². pCR is the best indicator of response to neoadjuvant treatment, indicating an increase in survival (overall survival and disease-free survival), as initially demonstrated in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18 study¹³. This correlation is especially true for triple-negative (TN) and HER2-positive¹⁴ (HER2+) tumors.

The indications and protocols for neoadjuvant therapy in breast cancer are well established in the literature. Nevertheless, in Brazil, we find barriers, mainly in the public sector, due to the delay in diagnosis, the difficulty of infrastructure, and the incorporation of medicines. This study aims to analyze the profile and clinicopathological outcome (pathological response) of patients treated with neoadjuvant therapy, in a clinical oncology service at a university hospital in Rio de Janeiro, Brazil.

MATERIAL AND METHODS

Methodology

This is a retrospective observational cohort study, whose unit of analysis consisted in breast cancer cases diagnosed between 2001 and 2018 and treated with NACT at Hospital Universitário Clementino Fraga Filho/Universidade Federal do Rio de Janeiro (HUCFF/UFRJ), located in the city of Rio de Janeiro, state of Rio de Janeiro, Brazil. The patients included in the study were selected from the HUCFF/UFRJ hospital-based cancer registries. Clinical and pathological data were obtained by consulting physical and electronic medical records.

To assess tumor characteristics, we used the TNM Classification of the Union for International Cancer Control (UICC), 8th edition, considering the size of the tumor – T, the presence of axillary metastasis – N, and the presence of metastasis – M (locoregional or systemic), at the time of diagnosis (cTNM).

The subclassification of breast tumors by immunohistochemistry was performed based on results presented by the Pathological Anatomy of HUCFF/UFRJ based on the evaluation of hormone receptors for estrogen (ER) and progesterone (PR),

overexpression of c-erb2, or amplification of the human epidermal growth factor receptor 2 (HER2), and cell proliferation index (Ki67). According to these results, three immunohistochemical subgroups were defined: Luminal subtypes (ER+ and/or PR+/- and HER2-), HER2+ (c-erb2 3+ or 2+, confirmed by FISH [Fluorescence *in situ* hybridization] amplification test), and hormone receptor-positive or negative (HR+/-) and TN or basal-like (ER-, PR-, and HER2-). There is some controversy on the evaluation of Ki67 in the literature due to the difficulty in standardizing its results in different services. The 2011 St. Gallen Consensus considers values below 14% as low or negative and values above 15% as high. However, due to lack of inputs, some patients did not perform the Ki67 evaluation, and they cannot be properly classified into Luminal A and B. Ki67 was described, when possible, to demonstrate tumor aggressiveness.

All patients underwent routine exams for staging and exclusion of metastases before primary chemotherapy. The adopted chemotherapy treatment was the PACS 01 regimen¹⁵, which uses three cycles of FEC (5 fluorouracil 500 mg/m², epirubicin 100 mg/m², and cyclophosphamide 500 mg/m² with an interval of 21 days) followed by three cycles of docetaxel 100 mg/m² every 21 days. Trastuzumab, despite being incorporated into the Brazilian Unified Health System (SUS) since 2013, has not been associated with neoadjuvant chemotherapy in amplified HER2 patients due to logistical difficulties, delay in carrying out the FISH test, and unavailability of the drug to start the treatment (distribution centralized by the Brazilian Ministry of Health with delivery around three months after scheduling the patient). Trastuzumab was administered to these patients in adjuvant therapy for 12 months.

Data from surgical treatment on the breast (conservative or radical procedure) and axilla (lymphadenectomy or sentinel lymph node biopsy) were analyzed. The response to NACT was described as: pathologic complete response (pCR), in the absence of invasive neoplasia in the breast and lymph nodes, in which there may be ductal carcinoma *in situ* (DCIS) in the specimen or partial response in the existence of residual invasive tumor in the breast or lymph node.

Inclusion criteria

Female patients with infiltrating breast carcinoma treated at HUCFF/UFRJ between 2001 and 2018, with neoadjuvant chemotherapy based on anthracyclines and/or taxanes, were eligible for this study.

Exclusion criteria

Patients who abandoned chemotherapy treatment were excluded.

Statistical analysis

The results of this study are exploratory and descriptive. Analyses of quantitative variables are presented with the mean and standard

deviation; the qualitative variables are presented with their absolute and relative frequency. No statistical analysis was performed between the variables due to the small number of cases.

RESULTS

A total of 133 patients treated at HUCFF/UFRJ, diagnosed with breast cancer, and who underwent NACT followed by surgery from September 2001 to October 2018 were evaluated. The distribution of clinical characteristics according to breast cancer subtypes classified by immunohistochemistry is demonstrated in Table 1.

Regarding the age distribution at diagnosis, the average age in this group was 54 years (28–86), with no significant difference between the subgroups HER2+ 54 years old (32–86), Luminal 54 years old (28–86), and TN 52 years old (33–81). In this sample, 49 women (37%) were under 50 years old with the following distribution by molecular subtype: HER2+ (13 women, 26.6%), Luminal subtypes (19 women, 38.8%), and TN (17 women, 34.6%). The distribution by molecular subtype for 10 patients aged 70 years or older was: 5 (50%) Luminal subtypes; 4 (40%), HER2+; and 1 (10%), TN.

As for the HER2+ subgroup, 25 cases were diagnosed with 3+ in immunohistochemistry, whereas eight cases needed to perform the FISH test to confirm the diagnosis. When evaluating the Ki67 cell proliferation marker, a large percentage (69.6%) was found, which is deemed a high cell proliferation index (>14), and 10 cases did not perform the test.

In the Luminal subgroup, 52 cases were classified as HER2 negative (0 and 1+), whereas six cases were c-erbB-2 2+ and required FISH test to be performed. In the evaluation of ER and PR, the following were verified: ER+/PR+=45, ER+/PR-=10, and Rpx=3.

Concerning TN, 40 cases were classified as HER2 negative (c-erbB-2 0 and 1+), whereas two cases were c-erbB-2 2+ and required FISH test to be performed. In this population, no cases of low Ki67 were found.

At the time of diagnosis, 71% of the cases had a >5-cm tumor, and in 70% of the cases the armpits were clinically compromised. Almost half of the cases (43%) were classified as staging IIIA; 26%, as IIB; and 19%, as IIIB. Fifteen patients were classified into stage I and IIA, stages in which patients are not usually submitted to neoadjuvant therapy. However, all these patients were initially evaluated by the services of mastology and clinical oncology, and opted for starting treatment with chemotherapy due to the rapid clinical evolution and structural difficulties. Subsequently, it was verified that 10 of these patients had subtypes TN and amplified HER2. See Table 1.

After receiving NACT, patients were referred to surgical evaluation, with only one patient considered inoperable. Table 2 shows that conservative surgery was an infrequent practice, and only 33 patients (25%) underwent such a procedure. Other 99

Table 1. Distribution of clinical characteristics according to breast cancer subtypes.

	Total (%)	HER2 (%)	Luminal subtypes (%)	TN (%)
Age at diagnosis				
20–29	1 (1)	0 (0)	1 (100)	0 (0)
30–39	14 (10)	3 (21)	6 (42)	5 (37)
40–49	34 (26)	10 (30)	12 (35)	12 (35)
50–59	43 (32)	9 (21)	19 (44)	15 (35)
60–69	28 (21)	6 (21)	14 (50)	8 (29)
70–79	10 (7)	4 (40)	5 (50)	1 (10)
80–89	3 (3)	1 (33)	1 (33)	1 (33)
Tumor size				
cT1	2 (1)	1 (50)	1 (50)	0
cT2	37 (28)	12 (32)	16 (43)	9 (25)
cT3	66 (50)	15 (23)	24 (36)	27 (41)
cT4	28 (21)	5 (18)	17 (61)	6 (21)
Lymph node evaluation				
cN0	40 (30)	12 (30)	17 (42)	11 (28)
cN1	62 (47)	13 (21)	25 (40)	24 (39)
cN2	29 (22)	7 (24)	15 (52)	7 (24)
cN3	2 (1)	1 (50)	1 (50)	0 (0)
Distant metastasis				
M0	133 (97)	33 (25)	58 (43)	42 (32)
M1	0 (0)	0 (0)	0 (0)	0 (0)
Clinical Staging				
I	2 (1)	1 (50)	1 (50)	0 (0)
IIA	13 (10)	8 (62)	3 (23)	2 (15)
IIB	34 (26)	4 (12)	19 (56)	11 (32)
IIIA	57 (43)	15 (26)	17 (30)	25 (44)
IIIB	25 (19)	4 (16)	17 (68)	4 (16)
IIIC	2 (1)	1 (50)	1 (50)	0 (0)
TOTAL	133	33	58	42

HER2: human epidermal growth factor receptor 2; TN: triple-negative; cT: clinical stage of the tumor; cN: clinical stage of nearby lymph nodes; M: metastasis.

patients (74%) had an indication for radical surgery. Concerning axillary surgery, a total of 41 patients (31%) underwent sentinel lymph node biopsy (11 HER2 women, 17 Luminal, and 13 TN) and 88 patients (66%) had an indication for lymphadenectomy (21 HER2 women, 39 Luminal, and 28 TN). In this sample, seven cases (5%) did not undergo an axillary evaluation.

In the anatomopathological evaluation of post-NACT surgery, 12 patients (9%) obtained pCR (4 HER2 women, 2 Luminal, and 6 TN). In 113 (85%) patients, there was partial or no response to chemotherapy (26 HER2 women, 54 Luminal, and 33 TN).

Table 2. Surgical treatment of the breast and axilla.

	Total (%)	HER2 (%)	Luminal subtypes (%)	TN (%)
Surgical treatment of the breast				
Conservative surgery	33 (25)	10 (30)	12 (36)	11 (34)
Radical surgery	99 (74)	22 (22)	46 (46)	31 (32)
Not performed	1 (1)	1 (100)	0 (0)	0 (0)
Surgical treatment of the axilla				
Sentinel lymph node biopsy	41 (31)	11 (27)	17 (41)	13 (32)
Lymphadenectomy	88 (66)	21 (24)	39 (44)	28 (32)
Not performed	4 (3)	1 (25)	2 (50)	1 (25)
Histopathology of the axilla (SL and lymphadenectomy)				
Negative lymph node	52 (39)	15 (29)	16 (31)	21 (40)
Positive lymph node	74 (56)	17 (23)	38 (51)	19 (26)
Not evaluated	7 (5)	1 (14)	4 (57)	2 (29)
TOTAL	133	33	58	42
Pathologic complete response – pCR				
Yes	12 (9)	4 (33)	2 (17)	6 (50)
No	113 (85)	26 (23)	54 (48)	33 (29)
Not evaluated	8 (6)	3 (37)	2 (26)	3 (37)
TOTAL	133	33	58	42

HER2: human epidermal growth factor receptor 2; TN: triple-negative; SL: sentinel lymph node; pCR: pathologic complete response.

DISCUSSION

Locally advanced breast cancer remains an important public health issue in Brazil. About 32% of breast cancer patients diagnosed at the National Cancer Institute have locally advanced disease¹⁶. This study evaluates this universe of patients, reporting their profile, adopted treatment, and obtained results.

Patients treated at HUCFF from 2001 to 2018 who underwent NACT were selected for the analysis. The patients had a mean age of 54 years (28–86) and 49 women (37%) were under 50 years old. These data are similar to those described in a Brazilian observational study that included 4,912 patients, conducted in 28 public and private healthcare centers, and described an average age of 54 years and 44.3% of patients under 50 years of age¹⁷. According to the guidelines of the Brazilian Ministry of Health, this population would not be subjected to screening tests¹⁸.

At the time of diagnosis, 71% of cases had a >5-cm tumor, and 70% had a clinically compromised axilla. Almost half of the cases (43%) were classified as staging IIIA, followed by 26% IIB, and 19% IIIB, with NACT being adopted with purpose of operability and to increase conservative surgical procedures. These findings

demonstrate the delay in diagnosis, probably caused by the difficulty of access to screening tests and delay in diagnosis in the public sector. These findings are similar to those described in another oncological center of national reference¹⁹.

According to the immunohistochemical profile, a predominance of aggressive HER2+ (26.6%) and TN (34.6%) subtypes were observed, which differ from the normal distribution of the population with breast cancer described in other Brazilian series, according to which the Luminal subtypes predominate with 57.9%; overexpression of HER2 with 17.6%; and triple-negative with 24.2%²⁰. This fact can be justified by the selection of locally advanced breast cancer patients.

This is a retrospective study, conducted over a long period of time (17 years). This fact could arise a methodological difficulty due to changes in the protocols considered. Nevertheless, due to the difficulty in technological incorporation, there was no major change in the adopted regimen of neoadjuvant therapy.

A 9% pCR was observed, which is well below the value currently reported in the international literature, but compatible with the report of other Brazilian series^{21,22}. HER2+ tumors were not treated with neoadjuvant trastuzumab achieving a 12% response, whereas in the literature on dual inhibitor, a response of up to 60% was obtained^{11,12}. Thus, these patients shall also present a lower response of overall and disease-free survival, as pCR has been confirmed as an intermediate marker capable of predicting survival²³.

Currently, the evaluation of the residual tumor according to the methodology suggested by M. D. Anderson is considered the most employed method in the literature²⁴. However, considering that this is a long-term retrospective study, with difficulties in obtaining and reviewing the anatomopathological tests of the surgical specimens, the pathologic complete response was considered as the absence of an invasive tumor in the breast and lymph nodes.

Although the pCR is lower than that reported in the literature, most patients obtained a partial response and almost all patients were able to perform the surgery (99%). In 21 patients (15.7%), it was possible to perform conservative surgery and search for sentinel lymph nodes, avoiding axillary dissection. Unfortunately, the actual assessment of axillary downstaging was difficult to document, as patients did not perform histopathological or cytological analysis of the pre-NACT lymph node. Of 93 patients (69.9%) with clinically palpable axillary lymph nodes, at the beginning of the study, 52 (39%) had a negative axilla according to the histopathological examination.

HER2-positive patients (positive FISH or IHC [immunohistochemistry] 3+) have a proven benefit of combined chemotherapy treatment with anti-HER2 therapy. Studies evaluating the role of adding trastuzumab to chemotherapy have shown increased pCR and increased survival¹⁰. Subsequently, new inhibitors of the HER2 pathway, such as lapatinib, tyrosine kinase inhibitor

(NEO-ALTO)¹¹, and pertuzumab (NeoSphere)¹², were tested alone and combined with chemotherapy, and showed a pCR benefit in relation to HER2 dual inhibitor. Thus, most international guidelines recommend the use of trastuzumab and pertuzumab, preferably in an anthracycline-free regimen, to avoid cardiotoxicity^{25,26} as a neoadjuvant therapy for patients with HER2-positive tumors greater than 2 cm²⁷.

In TN and HER2 amplified patients, NACT has been early indicated, in tumors larger than 1 cm and 2 cm respectively, or positive axilla, as these tumors are quite aggressive and have good response to chemotherapy. In addition, the adoption of NACT to these patients is intended to guide adjuvant treatment, as recent randomized and prospective studies demonstrate the benefit of survival with the use of capecitabine in TN²⁸ and Trastuzumab emtansine (T-DM1) in HER2²⁹ in patients with residual disease.

The standard treatment of neoadjuvant chemotherapy for TN patients remains anthracyclines and taxanes, with the still controversial addition of platinum, antiangiogenic therapy, poly (ADP-ribose) polymerase inhibitors (PARP), and immunotherapy^{30,31}.

Neoadjuvant chemotherapy based on anthracyclines and taxanes remains the standard therapy adopted in SUS. Trastuzumab was approved by SUS in 2013 for use in initial breast cancer, in adjuvant and neoadjuvant treatments. However, to date, its use has not been adequately incorporated due to difficulties in the immunohistochemistry test of HER2 or in the acquisition of the drug.

CONCLUSION

This research enabled the identification of clinicopathologic characteristics and outcome of patients who received neoadjuvant chemotherapy in a public university service. A predominance of tumors larger than 5.0 cm and positive axilla was verified, reinforcing the need for public health policies aimed at consolidating the national breast cancer screening program as well as ensuring timely treatment for diagnosed cases.

The data somewhat reflect the difficulty that the public sector encounters to perform the appropriate treatment or that recommended by international guidelines. The authors expect that this article, by analyzing the profile and the adopted treatment, in real cases and in a public university institution, can contribute to the improvement of breast cancer treatment in Brazil.

AUTHORS' CONTRIBUTION

L.C.B.A.: conceptualization, data curation, formal analysis, investigation, methodology, project administration, supervision, validation, visualization, writing – original draft, writing – review & editing; M.F.D.G.: conceptualization, data curation, formal analysis, investigation, methodology, project administration, supervision, validation, visualization, writing – original draft, writing – review & editing; A.H.P.C.C.: formal analysis, supervision, visualization, writing – review & editing; N.H.S.C.: formal analysis, supervision, visualization, writing – review & editing




REFERENCES

1. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de câncer no Brasil / Instituto Nacional de Câncer José Alencar Gomes da Silva [internet]. [cited on Oct. 13, 2020]. Available at: <https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf>.
2. Amin MB, Edge SB, Greene FL, Compton CC, Gershengwald JE, et al (Eds.). AJCC Cancer Staging Manual. 8th ed. Chicago: Springer;2018.
3. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. *J Clin Oncol*. 1998;16(8):2672-85. <https://doi.org/10.1200/JCO.1998.16.8.2672>
4. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. *Cancer*. 1988;62(12):2507-16. [https://doi.org/10.1002/1097-0142\(19881215\)62:12<2507::AID-CNCR2820621210>3.0.CO;2-D](https://doi.org/10.1002/1097-0142(19881215)62:12<2507::AID-CNCR2820621210>3.0.CO;2-D)
5. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. *J Clin Oncol*. 1999;17(11):3412-7. <https://doi.org/10.1200/JCO.1999.17.11.3412>
6. Fumoleau P, Tubiana-Hulin M, Romieu G, Namer M, Delva R, et al. A randomized phase II study of 4 or 6 cycles of adriamycin/taxol®(paclitaxel) as neoadjuvant treatment of breast cancer. Abstracts of the 24th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas, USA. December 10-13, 2001. *Breast Cancer Res Treat*. 2001;69(3):209-325. PMID: 11762328.
7. Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. *J Clin Oncol*. 1999;17(10):3033-7. <https://doi.org/10.1200/JCO.1999.17.10.3033>
8. von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, et al. Doxorubicin with Cyclophosphamide followed by Docetaxel every 21 days Compared with Doxorubicin and Docetaxel every 14 days as preoperative treatment in operable breast cancer: The Geparduo Study of the German Breast Group. *J Clin Oncol*. 2005;23(12):2676-85. <https://doi.org/10.1200/JCO.2005.05.078>
9. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. *J Clin Oncol*. 2003;21(22):4165-74. <https://doi.org/10.1200/JCO.2003.12.005>

10. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials. *Anticancer Drugs*. 2011;22(2):128-35. <https://doi.org/10.1097/cad.0b013e32834120aa>
11. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, Aura C, et al. First results of the nealto trial (big 01-06 / egf 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with her2-positive primary breast cancer. *Cancer Res*. 2010;70(24):S3-3. <https://doi.org/10.1158/0008-5472.SABCS10-S3-3>
12. Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. *Lancet Oncol*. 2016;17(6):791-800. [https://doi.org/10.1016/S1470-2045\(16\)00163-7](https://doi.org/10.1016/S1470-2045(16)00163-7)
13. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. *J Clin Oncol*. 2008;26(5):778-85. <https://doi.org/10.1200/JCO.2007.15.0235>
14. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol*. 2012;30(15):1796-804. <https://doi.org/10.1200/JCO.2011.38.8595>
15. Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. *J Clin Oncol*. 2006;24(36):5664-71. <https://doi.org/10.1200/JCO.2006.07.3916>
16. Instituto Nacional de Câncer José Alencar Gomes da Silva. Informação dos registros hospitalares de câncer como estratégia de transformação: perfil do Instituto Nacional de Câncer José Alencar Gomes da Silva em 25 anos/Instituto Nacional de Câncer José Alencar Gomes da Silva. [internet]. [cited on Oct. 13, 2020]. Available at: <https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//informacao-dos-registros-hospitalares-de-cancer-como-estrategia-de-transformacao.pdf>
17. Simon SD, Bines J, Werutsky G, Nunes JS, Pacheco FC, et al. Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: the AMAZONA retrospective cohort study. *Breast*. 2019;44:113-9. <https://doi.org/10.1016/j.breast.2019.01.008>
18. Instituto Nacional de Câncer José Alencar Gomes da Silva. Confirma as recomendações do Ministério da Saúde para o rastreamento do câncer de mama: mamografia de rotina deve ser feita entre os 50 e os 69 anos, a cada dois anos. [internet]. [cited on Dec. 24, 2020]. Available at: <https://www.inca.gov.br/noticias/confirma-recomendacoes-do-ministerio-da-saude-para-o-rastreamento-do-cancer-de-mama>
19. Andrade DAP, Zucca-Matthes G, VIEIRA RAC, Andrade CTAE, Costa AM, et al. Quimioterapia neoadjuvante e resposta patológica: coorte retrospectiva. *Einstein*. 2013;11(4):446-50. <https://doi.org/10.1590/S1679-45082013000400007>
20. Cintra JRD, Teixeira MTB, Diniz RW, Gonçalves Junior H, Florentino TM, et al. Perfil imuno-histoquímico e variáveis clinicopatológicas no câncer de mama. *Rev Assoc Med Bras*. 2012;58(2):178-87. <https://doi.org/10.1590/S0104-42302012000200013>
21. Pessoa EC, Rodrigues JR, Michelin O, De Luca HV, Kamiya CP, et al. Avaliação da resposta à quimioterapia primária em amostra de mulheres brasileiras com tumores de mama localmente avançados. *Rev Bras Ginecol Obstet*. 2007;29(1):18-26. <https://doi.org/10.1590/S0100-72032007000100004>
22. Bines J, Small IA, Sarmiento R, Kestelman F, Silva S, et al. Does the Sequence of Anthracycline and Taxane Matter? The NeoSAMB Trial. *Oncologist*. 2020;25(9):758-64. <https://doi.org/10.1634/theoncologist.2019-0805>
23. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet*. 2014;384(9938):164-72. [https://doi.org/10.1016/S0140-6736\(13\)62422-8](https://doi.org/10.1016/S0140-6736(13)62422-8)
24. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. *J Clin Oncol*. 2007;25(28):4414-22. <https://doi.org/10.1200/JCO.2007.10.6823>
25. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHANA). *Ann Oncol*. 2013;24(9):2278-84. <https://doi.org/10.1093/annonc/mdl182>
26. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med*. 2011;365:1273-83. <https://doi.org/10.1056/NEJMoa0910383>
27. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, et al. Early breast cancer: esmo clinical practice guidelines. *Ann Oncol*. 2019;30(8):1194-1220. <https://doi.org/10.1093/annonc/mdz173>
28. Masuda N, Lee SJ, Ohtani S, Young-Hyuck I, Eun-Sook L, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. *N Engl J Med*. 2017;376(22):2147-59. <https://doi.org/10.1056/NEJMoa1612645>
29. von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, et al. Trastuzumab emtansine for residual invasive her2-positive breast cancer. *N Engl J Med*. 2019;380(7):617-28. <https://doi.org/10.1056/NEJMoa1814017>
30. Denduluri N, Somerfield MR, Chavez-MacGregor M, Comander AH, Dayao Z, et al. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. *J Clin Oncol*. 2020;38:1-11. <https://doi.org/10.1200/JCO.20.02510>
31. Amorim G, Tavares M, Sahade M, Reinert T. Mama: doença localizada -neoadjuvância. [internet]. [cited on Dec. 26, 2020]. Available at: <https://www.sboc.org.br/images/diretrizes/lote-8/Diretrizes%20SBoc%202020%20-%20Mama%20neoadjuvante%20p%C3%B3s-sugest%C3%B5es.pdf>



Comparative analysis: QOL in breast cancer patients before and during the COVID-19 pandemic

Letícia Araujo Pinholato¹ , Maria Clara Santos Pupim¹ ,
Ana Cristina da Silva do Amaral Herrera^{1*} , Carlos Eduardo Coral de Oliveira¹ 

ABSTRACT

Introduction: The 2019 outbreak of coronavirus disease (COVID-19) posed unprecedented challenges of emotional matter for women diagnosed with breast cancer. This research aimed to compare the quality of life of patients who were diagnosed with breast cancer from 2014 to 2019, and patients who were diagnosed during the COVID-19 pandemic, from January to August 2020. **Methods:** A cross-sectional study was performed, including patients with breast cancer, associated or not with chronic pathologies, with no psychiatric disorders, aged over 18 years. The questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC-C30) version 3.0 was used for the comparative analysis of quality of life. The study population consisted of 185 women, of which 43.2% (n = 80) were previously diagnosed and 56.7% (n = 105) were diagnosed during the pandemic, with a median age of 45 years (IQ = 15). **Results:** The EORTC-C30 quality of life score remained the same for both groups (33.33; 33.33). There was a decrease in the scores on the emotional (58; 50) and physical (60; 40) scales of patients diagnosed during the pandemic. **Conclusions:** Future longitudinal research should contribute to the understanding of the long-term effects of COVID-19 on the psychological health of patients with breast cancer.

KEYWORDS: breast neoplasms; coronavirus infections; quality of life.

INTRODUCTION

Cancer is considered one of the main causes of death worldwide, and, among the female population, the breast tumor is the most prevalent in Brazil and in the world¹. According to the literature, approximately 50% of cancer patients suffer from psychiatric disorders, in such a way that anxiety and depression are generally considered to be the most important and prevalent psychopathological comorbidities². This psychological morbidity is caused by changes in physical appearance after treatment, limitations in physical functioning and daily activities, limited functioning in previous roles, and the stigma of the disease, which compromise the patient's quality of life³.

All the emotional overload due to a cancer diagnosis was enhanced by the coronavirus pandemic (Sars-CoV-2) and the resulting disease, COVID-19, which emerged in December 2019. Initial reports suggested that patients with a history of or active malignancy may be at increased risk of contracting the disease and developing complications related to COVID-19, as it is an immunocompromised group due to the effects of antineoplastic therapy and supportive drugs, in addition to the immunosuppressive properties of cancer itself^{4,5}.

Among factors related to the outcome of breast cancer, the quality of life of patients is an important parameter, considering that it influences the prognosis of the disease and can be used to manage the condition and treatment of the patient, assist in taking medical decisions, control symptoms, and plan supportive care interventions⁶. Although previous studies address the issue of COVID-19 and cancer patients, the literature does not present studies that assess the quality of life of patients diagnosed with breast cancer during the pandemic. This study aimed to compare the quality of life of patients who were diagnosed between 2014 and 2019 and of patients who were diagnosed during the COVID-19 pandemic from January to August 2020.

MATERIAL AND METHODS

Study design

A cross-sectional and epidemiological study was developed for analyzing data on the periods from 2014 to 2019, and from January to August 2020, provided by participants of the *Centro de Apoio ao Paciente com Câncer de Londrina* [Londrina Cancer

¹Pontifícia Universidade Católica do Paraná – Londrina (PR), Brazil.

*Corresponding author: ana.proonco@gmail.com

Conflict of interests: nothing to declare.

Received on: 01/04/2021 Accepted on: 02/17/2021.

Support Center] (state of Paraná, Brazil) and by patients of the *Centro de Tratamento Oncológico Pro Onco* [Pro Onco Oncological Treatment Center].

Study population

The study population included a convenience sampling consisting of 185 women who were diagnosed with breast cancer and underwent treatment between 2014 and August 2020. The eligibility criteria included patients with breast neoplasms associated or not with chronic pathologies, with no psychiatric alterations, aged over 18 years. Patients who underwent treatment prior to 2014 were excluded from the research. The interviews took place remotely, through telephone calls or an online questionnaire. In both instruments, the participants were asked to answer a questionnaire with objective questions. The Informed Consent Form was sent by a message application for signature before starting the study.

Study questionnaire

Questions from the questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC-C30) version 3.0 were used to assess the quality of life of patients during the treatment of breast cancer. The EORTC-C30 is a multidimensional and self-administered questionnaire for patients with breast, esophageal, or lung cancer that includes a total of 30 questions addressing 5 functional scales (role, physical, emotional, social, and cognitive), 1 scale on overall quality of life, in addition to 3 symptom scales (fatigue, pain, and nausea/vomiting) and 6 additional items related to other symptoms (dyspnea, insomnia, loss of appetite, constipation, diarrhea, and financial impact). A final question was added to the EORTC-C30 for patients who underwent treatment during the year 2020 to assess the psychological impact of the pandemic on these women.

Ethical aspects

This study was carried out after approval by the Research Ethics Committee 35791720.0.0000.0020 by means of the participants' signed consent, after a detailed explanation of its development, in accordance with resolution No. 466/2012 of the National Health Council and the Declaration of Helsinki.

Statistical analysis

For data analysis, the Statistical Package for the Social Sciences (SPSS) program, version 22.0, was used, and the adopted level of significance was 5%. Data distribution was determined by Kolmogorov-Smirnov and Shapiro-Wilk tests. The median and interquartile range were used to indicate measures of central tendency and dispersion. Variables were submitted to Spearman's correlation analysis and were presented as correlation index and p-value. The EORTC-C30 Scoring Manual was used to calculate the medians of the questionnaire domains, which were

transformed into a linear scale from 0 to 100 points. The interpretation of the manual scores implies that the score of zero is related to a worse health condition, whereas the score of 100 represents patients with better functioning levels. The exception is for the scoring of the symptom scales, in which the highest score represents the worst symptomatology.

RESULTS

From August to October 2020, 185 women were interviewed. The group diagnosed before the pandemic corresponds to $n = 80$ patients, and the group diagnosed during the pandemic corresponds to $n = 105$ patients. Table 1 shows the patients' sociodemographic data. The median age of the patients was 45 years (IQ = 15). Among them, 54% of the patients ($n = 100$) were white, 37.8% ($n = 70$) were black, and only 8.1% ($n = 15$) were Asian. Regarding marital status, 49% of patients ($n = 92$) were married, 34% ($n = 63$) were divorced, 10.81% ($n = 20$) were widows, and only 5.4% ($n = 10$) were single.

The clinical characteristics related to the treatment are shown in Table 2. Of the total sample, 95.13% of patients ($n = 169$) underwent surgery, 91.35% ($n = 176$) underwent chemotherapy, and 65.40% ($n = 121$) underwent radiotherapy. However, most patients underwent more than one treatment modality, which justifies the overlapping percentage.

Table 1. Sociodemographic data and clinical characteristics of patients.

	n = 185 (%)
Age	Median = 45 years (IQ = 15)
Ethnicity	
White	100 (54)
Black	70 (37.8)
Asian	15 (8.1)
Religion	
Have a religion	163 (88.1)
Have no religion	22 (11.8)
Marital status	
Married	92 (49)
Single	10 (5.4)
Divorced	63 (34)
Widow	20 (10.81)

Table 2. Clinical characteristics of patients.

Type of treatment	n (%)
Chemotherapy	169 (91.35)
Radiotherapy	121 (65.40)
Surgery	176 (95.13)

Table 3 shows the median and interquartile range of the scales and symptoms addressed in the EORTC-C30. Although the median quality of life remained the same for both groups (33.33), the results show that patients diagnosed during the pandemic had the lowest physical scale median (40) in relation to the patients diagnosed before the pandemic (60). In addition, the emotional scale of the group diagnosed during the pandemic was lower (50) than that of patients diagnosed before the pandemic (58).

To assess whether the pandemic influenced the quality of life of patients with breast cancer, Spearman's correlation analysis

between the questionnaire variables was performed. The correlation analysis showed that there was no relationship with changes in quality of life among women treated before or during the pandemic ($r = -0.016$; $p = 0.83$). Nevertheless, there was a weak association between the treatment period and the patients' emotional function ($r = -0.146$; $p = 0.047$), demonstrating that the pandemic had a negative impact on the patients' emotional status. Chemotherapy is related to 11 of the 13 aspects analyzed by the EORTC-C30, which shows a worsening of the symptoms of women undergoing this treatment (Table 4).

Table 3. Median and interquartile range of the items of the functions and symptoms of the questionnaires of the European Organisation for Research and Treatment of Cancer.

Items	Period	Median	Interquartile range
Functions*			
Physical	Before the pandemic	60.00	60.00
	During the pandemic	40.00	60.00
Emotional	Before the pandemic	58.30	41.70
	During the pandemic	50.00	33.30
Cognitive	Before the pandemic	50.00	66.67
	During the pandemic	50.00	33.33
Financial impact	Before the pandemic	00.00	66.67
	During the pandemic	33.33	66.67
Role	Before the pandemic	50.00	100.00
	During the pandemic	50.00	37.50
Social	Before the pandemic	66.67	50.00
	During the pandemic	66.67	50.00
Quality of life	Before the pandemic	33.33	33.33
	During the pandemic	33.33	33.33
Symptoms**			
Insomnia	Before the pandemic	66.67	50.00
	During the pandemic	33.33	33.33
Loss of appetite	Before the pandemic	33.33	66.67
	During the pandemic	33.33	58.33
Constipation	Before the pandemic	33.33	66.67
	During the pandemic	33.33	66.67
Diarrhea	Before the pandemic	00.00	33.33
	During the pandemic	16.67	33.33
Fatigue	Before the pandemic	44.44	44.44
	During the pandemic	44.44	41.67
Pain	Before the pandemic	66.67	50.00
	During the pandemic	66.67	50.00
Nausea/vomiting	Before the pandemic	83.33	50.00
	During the pandemic	66.67	50.00

*The closer to one hundred, the better the Overall Quality of Life; **The closer to zero, the worse the Overall Quality of Life.

DISCUSSION

In this study, between January and August 2020, the impact of breast cancer diagnosis on the patients' quality of life, before the pandemic (2014–2019) and during the new coronavirus pandemic (from January to August 2020), was compared. Although the assessment of quality of life was the same in both groups, as it is a sample of young patients (median = 45 years), the literature pinpoints that women under 50 years of age are more likely to have a lower quality of life because they are in a very active age group, in which they need to reconcile motherhood, their occupation, and loving and social relationships, in comparison with older women⁷. Thus, age is directly related to greater concerns regarding self-image, sexuality, menopause, and loss of fertility⁸, which justifies the low score in the quality of life of both groups (33.33).

Previous studies have also associated faith and spirituality, characteristics of the Brazilian culture, as coping mechanisms that act in the perception of quality of life⁹. In addition to the age group and cultural aspects, another factor associated with quality of life and reported during the interviews is the disease itself, which requires distancing measures and hygiene care similar to those imposed by the pandemic, due to the immunosuppressive properties of cancer and the antineoplastic therapy^{4,5}. Thus, the limitations that the group diagnosed during the pandemic encountered did not differ from the restrictions experienced by previously diagnosed and treated patients.

Nevertheless, the analysis demonstrates a worsening in the emotional state of the patients who were diagnosed during the year 2020. Previous studies report that the population with breast cancer is at high risk of developing emotional disorders due to the disturbing nature of the diagnosis, treatments, and long-term adverse effects¹⁰. In addition to the already known risks, the result is also related to the fear of contracting the virus (Sars-CoV-2) and the subsequent impact on treatment, besides the concern with access to oncology services during the pandemic. As a result, patients carry the emotional burden of doubt about whether their treatments will be delayed and what would be the implications for their outcome. In addition to these uncertainties, there are measures of social distancing and the limitations of

Table 4. Correlations between the scales of the European Organisation for Research and Treatment of Cancer and quality of life, treatment period, and therapeutic modalities.

	Treatment period	QOL	Chemotherapy	Radiotherapy	Surgery
Physical					
Spearman	-0.032	-0.250**	-0.057	-0.145	-0.105
p	0.669	0.001*	0.43	0.04*	0.15
Emotional					
Spearman	-0.146	-0.049	-0.114	-0.123	-0.073
p	0.04*	0.504	0.124	0.095	0.324
Loss of appetite					
Spearman	-0.028	0.119	0.184*	0.177*	0.221**
p	0.701	0.106	0.012*	0.016*	0.002*
Dyspnea					
Spearman	0.007	0.148*	0.232	0.154*	0.015
p	0.925	0.044*	0.001*	0.036*	0.836
Insomnia					
Spearman	-0.117	0.011	0.173*	0.121	0.027
p	0.114	0.879	0.019*	0.101	0.714
Constipation					
Spearman	0.134	0.178*	0.190**	0.095	-0.090
p	0.069#	0.015*	0.010*	0.200	0.222
Diarrhea					
Spearman	0.067	-0.060	0.141	0.166*	0.060
p	0.363	0.420	0.056*	0.024	0.417
Role					
Spearman	-0.044	-0.152*	-0.203**	-0.195**	-0.033
p	0.553	0.039*	0.006*	0.008	0.654
Cognitive					
Spearman	0.038	-0.150*	-0.240**	-0.046	0.046
p	0.605	0.041*	0.001*	0.532	0.539
Social					
Spearman	-0.142	-0.175*	-0.229**	-0.193**	0.054
p	0.054	0.017*	0.002*	0.009*	0.468
Fatigue					
Spearman	0.062	-0.192**	-0.240**	-0.284**	-0.065
p	0.398	0.009*	0.001*	0.000*	0.376
Pain					
Spearman	0.040	-0.108	-0.150*	-0.293**	-0.079
p	0.592	0.142	0.041*	0.000*	0.286
Nausea/vomiting					
Spearman	-0.009	-0.167*	-0.262**	-0.160*	-0.090
p	0.906	0.023*	0.000	0.030*	0.224
Quality of life					
Spearman	-0.016	1.000	0.125	-0.154*	-0.027
p	0.831	-	0.089	0.037	0.717

*Significant results ($p < 0.05$); **Significant results ($p < 0.01$); #Tendency toward significance.

visitors, which weakens opportunities for family support, affecting an important sense of connection and a source of strength for patients with breast cancer¹¹.

There was also a deterioration in the physical scale of patients treated during the pandemic. A meta-analysis provided evidence that programs of physical exercises performed during or after breast cancer treatment have a small, but positive impact on physical functioning and cancer-related fatigue in patients with breast cancer compared with conventional care¹². However, the transmissibility of COVID-19 is greater in sports environments due to the viability of the virus as well as its incubation period and milder symptomatology¹³. The fear of being exposed to physical exercise outside their house and the consequent decrease in physical activity during the pandemic may be related to the worsening of the patients' physical scale.

The correlation analysis showed that chemotherapy significantly affects the domains analyzed by the EORTC-C30. This finding corroborates previous studies that point to chemotherapy as an emotional drainage experience, which can affect patients for a long time after the end of treatment. Patients who underwent chemotherapy may experience prolonged fatigue for up to three years after treatment¹⁴. Nonetheless, it is unclear whether the lower index of quality of life in patients who underwent chemotherapy is caused by the treatment itself or by a more aggressive neoplasm or a more advanced stage compared with those who did not need to undergo chemotherapy⁷.

Although previous studies have pointed out the social isolation resulting from the pandemic as an adverse factor in the mental health of patients¹⁵, some women considered quarantine to be a beneficial period, as they were able to keep the diagnosis and treatment of cancer confidential. Therefore, because they did not need to be exposed to work environments and social events, the patients reported feeling preserved from the concern and curiosity of others.

The present study has limitations. Due to social distancing, participants were recruited by means of a message application and by telephone calls, therefore, they may not be fully representative of the population with breast cancer in general. Furthermore, the study lacks information about socioeconomic data and possible comorbidities associated with breast cancer. Finally, individual differences between cancer patients and survivors play an important role in quality of life and present themselves as a limitation, considering that this perception is shaped by some personality traits, and not only by physical, sociodemographic, and oncological variables¹⁶.

CONCLUSION

Although the quality of life score remained the same in both groups, the results demonstrated that women who were diagnosed during the pandemic had a lower physical and emotional score compared with previously diagnosed patients. Further research should continue to monitor the long-term effects of COVID-19 on the psychological health and quality of life of patients with breast cancer.

AUTHORS' CONTRIBUTIONS:

A.C.S.A.H.: Conceptualization, data curation, methodology, investigation, project administration, resources, supervision, validation, writing – review & editing.

L.A.P.: Conceptualization, investigation, data curation, formal analysis, methodology, investigation, resources, visualization, writing – original draft.

M.C.S.P.: Conceptualization, investigation, data curation, formal analysis, methodology, investigation, resources, visualization, writing – original draft.

C.E.C.: Supervision, data curation, validation, software, writing – review & editing.

REFERENCES

1. Federação Brasileira de Instituições Filantrópicas de Apoio à Saúde da Mama. O câncer de mama em números [Internet]. FEMAMA; 2018 [accessed on May 28, 2020]. Available from: <https://www.femama.org.br/2018/br/noticia/o-cancer-de-mama-em-numeros>
2. Knopf, MT. Clinical update: psychosocial responses in breast cancer survivors. *Semin Oncol Nurs*. 2011 Aug;27(3):e1-14. <https://doi.org/10.1016/j.soncn.2011.05.001>
3. Leite MAC, Nogueira DA, Terra, FS. Avaliação da autoestima em pacientes oncológicos submetidos a tratamento quimioterápico. *Rev Latinoam Enferm*. 2015 Dec;23(6):1082-9. <https://doi.org/10.1590/0104-1169.0575.2652>
4. Janz NK, Mujahid M, Chung LK, Lantz PM, Hawley ST, Morrow M, et al. Symptom experience and quality of life of women following breast cancer treatment. *J Womens Health (Larchmt)*. 2007 Nov;16(9):1348-61. <https://doi.org/10.1089/jwh.2006.0255>
5. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol*. 2020 Mar;21(3):335-7. [https://doi.org/10.1016/s1470-2045\(20\)30096-6](https://doi.org/10.1016/s1470-2045(20)30096-6)
6. Rohani C, Abedi HA, Omranipour R, Langius-Eklöf A. Health-related quality of life and the predictive role of sense of coherence, spirituality and religious coping in a sample of Iranian women with breast cancer: a prospective study with comparative design. *Health Qual Life Outcomes*. 2015 Mar;13:40. <https://doi.org/10.1186/s12955-015-0229-1>

7. Cohen L, Hamer J, Helwig C, Fergus K, Kiss A, Mandel R, et al. Formal evaluation of PYNK: Breast Cancer Program for Young Women – the patient perspective. *Curr Oncol*. 2016 Apr;23(2):e102-8. <https://doi.org/10.3747/co.23.2773>
8. Avis NE, Crawford S, Manuel J. Quality of life among younger women with breast cancer. *J Clin Oncol*. 2005 May;23(15):3322-30. <https://doi.org/10.1200/jco.2005.05.130>
9. Mello ML, Oliveira SS. Saúde, religião e cultura: um diálogo a partir das práticas afro-brasileiras. *Saude Soc*. 2013 Dec;22(4):1024-35. <https://doi.org/10.1590/S0104-12902013000400006>
10. Carreira H, Williams R, Müller M, Harewood R, Stanway S, Bhaskaran K. Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review. *J Natl Cancer Inst*. 2018 Dec;110(12):1311-27. <https://doi.org/10.1093/jnci/djy177>
11. Al-Shamsi HO, Alhazzani W, Alhurairi A, Coomes EA, Chemaly RF, Almuhanna M et al. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. *Oncologist*. 2020 Jun;25(6):e936-45. <https://doi.org/10.1634/theoncologist.2020-0213>
12. Juvet LK, Thune I, Elvsaas IKØ, Fors EA, Lundgren S, Bertheussen G, et al. The effect of exercise on fatigue and physical functioning in breast cancer patients during and after treatment and at 6 months follow-up: A meta-analysis. *The Breast*. 2017 Jun;33:166-77. <https://doi.org/10.1016/j.breast.2017.04.003>
13. Wong AYY, Ling SKK, Louie LHT, Law GYK, So RCH, Lee DCW, et al. Impact of the COVID-19 pandemic on sports and exercise. *Asia Pac J Sports Med Arthrosc Rehabil Technol*. 2020 Jul;22:39-44. <https://doi.org/10.1016/j.asmart.2020.07.006>
14. Goedendorp MM, Andrykowski MA, Donovan KA, Jim HS, Phillips KM, Small BJ, et al. Prolonged impact of chemotherapy on fatigue in breast cancer survivors: a longitudinal comparison with radiotherapy-treated breast cancer survivors and noncancer controls. *Cancer*. 2012 Aug;118(15):3833-41. <https://doi.org/10.1002/cncr.26226>
15. Swainston J, Chapman B, Grunfeld EA, Derakshan N. COVID-19 Lockdown and Its Adverse Impact on Psychological Health in Breast Cancer. *Front Psychol*. 2020 Aug;11:2033. <https://doi.org/10.3389/fpsyg.2020.02033>
16. CARVER, CS. Enhancing adaptation during treatment and the role of individual differences. *Cancer*. 2005 Dec;104(11 Suppl):2602-7. <https://doi.org/10.1002/cncr.21247>



Burow's triangle advancement flap: a reliable tool on oncoplastic breast-conserving surgery

Jaime Letzkus^{1,2,3*} , Maria José Del Río^{1,2} , Carlos Rencoret³ ,
Alejandro Belmar¹ , Galina Ivanova^{1,2} , Daniela Hidalgo¹ , Jorge Gamboa^{1,2} 

ABSTRACT

Oncoplastic techniques in breast cancer treatment allow increasing indications of breast-conserving surgery and improving cosmetic results. Breast tumors located at the superior edge of the upper quadrant or at the upper inner quadrant represent a challenge for conservative surgery due to insufficient breast thickness and risk of skin involvement. We present a modified Burow's triangle advancement flap for breast-conserving surgery in patients with breast tumors at these locations. This retrospective observational study analyzed 8 out of 213 patients submitted to major oncoplastic breast procedures, who underwent breast-conserving surgery with matrix rotation mammoplasty, using a modified Burow's triangle advancement flap. All patients were treated in public and private health systems in Santiago, Chile. The median age at diagnosis was 47 years. The average initial tumor size was 5.9 cm, and the mean excised breast weight was 117 g. Patients required neither symmetrization nor displacement of the nipple-areola complex. Only one patient had a minor complication (wound dehiscence). During follow-up, no local recurrences were reported. We conclude that the modified Burow's triangle advancement flap is a safe and effective technique to manage tumors at this complex location. It provides adequate oncological margins, good cosmetic results, and contralateral symmetry, with complication rates similar to those of standard conservative surgery.

KEYWORDS: breast neoplasms; surgical flaps; mastectomy, segmental; mammoplasty.

INTRODUCTION

Breast-conserving surgery (BCS) including axillary treatment and radiotherapy has become the standard of care for most breast cancer patients, reaching long-term survival rates similar to those of radical mastectomy^{1,2}. However, in many cases, the cosmetic results are unsatisfactory given the percentage of breast volume to be resected or its location, leading to severe breast deformities, skin retraction, nipple-areola complex (NAC) distortion or deviation, and secondary contralateral breast asymmetry. Oncoplastic breast surgery (OBS) techniques were developed to offer an advantage over classical breast-conserving treatment in selected patients. OBS allows larger breast resection for cancer treatment with minimal deformities, larger free resection margins, and lower re-excision rates while maintaining equivalent oncological outcomes^{3,4}. According to a recently published volumetrically-based OBS classification system, volume displacement or replacement techniques can be used depending on the

proportion of breast volume resected⁵; for all of them, including different types of reduction mammoplasty with large breast reshaping, local advancement flaps have been described whenever the defect cannot be covered with the same breast⁶⁻¹⁰.

Even with many oncoplastic techniques, some patients will still need a total mastectomy to obtain satisfactory cosmetic or adequate oncological results. Tumors located at the superior edge of the upper quadrant or at the upper inner quadrant usually replace the whole breast thickness, compromising the anterior margin and making it difficult to preserve the skin. Tumors at these locations are a challenge for conservative surgery, whenever necessary to resect the entire breast thickness, as it might produce secondary glandular deformity, high risk of positive tumor margins, and upper NAC deviation¹¹.

We present a modified triangular advancement flap for breast cancer to preserve the breast in difficult cases.

The present study aimed to assess the reliability and safety of Burow's triangular advancement flap. This technique, usually described

¹Breast Surgery Department, Obstetrics and Gynecology Service, San Borja Arriarán Clinical Hospital – Santiago, Chile.

²Academic Obstetrics and Gynecology Department, University of Chile Medical School, Santiago, Chile.

³Private practice breast surgeon – Santiago, Chile.

*Corresponding author: jaime.letzkus@gmail.com

Conflict of interest: nothing to declare.

Received on: 01/06/2021. Accepted on: 03/07/2021.

for the correction of facial defects^{12–18}, can be applied to the breast so as to preserve it in difficult cases, with minimal effect on breast volume and mostly without need of contralateral breast symmetrization.

METHODS

This retrospective observational study analyzed a prospectively maintained database cohort of female patients with breast cancer diagnosed at the Breast Surgical Unit of San Borja Arriarán Clinical Hospital and private practices in Santiago, Chile, between August 2010 and November 2019. In the study period, 213 patients were treated with conservative surgery and major oncoplastic procedures. Among them, eight patients were diagnosed with tumors located at the high upper quadrant or at the upper inner quadrant. They were treated with BCS, using the triangular resection described below. The same senior breast surgeon, who was fully trained in oncologic and reconstructive breast surgery, performed both procedures and followed up the patients.

Descriptive statistics was carried out to analyze the results.

Selection criteria

All patients were diagnosed with breast cancer and managed by a multidisciplinary breast cancer team. They were submitted to conventional preoperative exams and had a previous percutaneous biopsy, with histological and immunohistochemical (IHC) analysis for hormone receptor status, HER2, and Ki67. Clinical evaluation was performed to determine the location of the tumor in the breast, distance to the skin, possible multicentricity, and potential axillary involvement. Patients fulfilling the inclusion criteria had tumors located closer than 16 cm from the sternal notch and/or less than 7 cm from the sternal midline.

Imaging studies included mammogram, ultrasound, computed tomography (CT) scan, and bone scan to identify local and distant involvement. The indication for primary conservative surgery was based on the tumor/breast ratio and IHC results. Patients with cT3 tumors received neoadjuvant chemotherapy. Other factors were taken into account for surgical planning, such as previous breast surgery that could hinder adequate local blood supply for advancement glandular flaps. Associated risk factors for local complications, such as diabetes, active smoking, and obesity, were recorded. Furthermore, contralateral breast shape was considered when evaluating the need for symmetrization surgery.

Surgical technique

Skin markings were made on patients in a standing position right before surgery. The inframammary fold, sternal midline, breast boundaries, and tumor location were marked. The nipple position was not changed. A curved line with inferior concavity was drawn from the mid-axillary line with the arm abducted 90°, extending medially parallel to the clavicle, 1–2 cm above the tumor location in the breast. Next, a triangle was drawn with the

upper base in this line. The base width depended on the tumor size and should have at least 1 cm of macroscopic safe surgical margins. The triangle vertex was drawn long down in relation to the lateral margin of the tumor toward the NAC in order to achieve posterior orderly and harmonic breast rotation without deformity of central breast projection. At the axillary region, a small upside-down triangle (Burow's triangle) was drawn to enable access to the axilla for either sentinel lymph node biopsy or axillary dissection, which later allowed skin compensation when the rotation advancement dermoglandular flap was done (Figure 1).

Under general anesthesia, a triangular incision was performed, with resection of the main triangle, including the whole breast thickness, the tumor, its overlaid skin, and the pectoral fascia. Histologic tumor margins were assessed by a pathologist contemporarily. Free margins were defined as no tumor cells at the inked margin of the specimen for invasive carcinoma and a 2 mm margin for ductal carcinoma *in situ*¹⁹. Tumor bed was marked with vascular clips. A simultaneous axillary study was carried out through the small triangular resection drawn before. The curved line incision was completed between both triangles straight to the pectoralis major muscle. Afterward, this lateral dermoglandular flap was raised from the muscle just enough to allow its advancement toward the medial border of the main triangle resected before (Figure 2). Accurate hemostasis was performed. If necessary, closed-suction drains were placed on the breast and axilla. The advancement flap was closed in 2 layers with 2-0 interrupted absorbable Vicryl® sutures (Vicryl®: Ethicon, J&J), 3-0 subcutaneous Vicryl®, and 3-0 or 4-0 absorbable monofilament (Monocryl®; Ethicon, J&J). Wounds were dressed with gauze. Patients were discharged the day after surgery. Drains were removed 2–7 days after surgery.

Postoperative assessment

Weekly clinical examinations were performed until the final histology was received. Oncological treatments were completed according to national protocols, with chemotherapy, radiotherapy, biological treatment, and hormonal blockade if needed.

Cosmetic evaluation

Cosmetic outcomes were assessed using photographic documentation of each patient taken preoperatively and 6–12 months post-surgery and radiotherapy. Seven surgeons independently analyzed each case and classified them into excellent, good, fair, or poor, according to the Harris Scale²⁰.

RESULTS

The median patient age at diagnosis was 47 years (range 26–71). The mean body mass index (BMI) was 25 (range 21–29). All patients were symptomatic at diagnosis (palpable tumor). Histological reports showed seven invasive ductal and one invasive lobular carcinoma. The IHC analysis revealed five luminal, one luminal

HER2+, and two triple-negative breast cancers. At diagnosis, one patient had stage I cancer, three patients had stage II, and four had stage III. The mean initial clinical tumor size was 5.9 cm (range 3–13). Three patients received neoadjuvant chemotherapy, one with pathological complete response, one with pathological partial response, and the last one with initial clinical response, but having a secondary progression during chemotherapy, forcing us to advance the surgery before completing neoadjuvant chemotherapy (Figure 3). No patient required contralateral breast symmetrization. The mean resected tumor size was 2.9 cm (range 0–7). The mean resected specimen weight was 117 g (range 53–257). All patients had adequate histological margins on final pathologic reports, and none required re-excision surgery before adjuvant radiotherapy. According to the Harris scale, the cosmetic result was considered excellent in 28.6% of cases, good in 51.8%, fair in 16.1%, and poor in 3.5%. No major complications were reported. One patient had minor wound dehiscence, requiring only outpatient management. Median follow-up was 59 months (range 1–129). To date, no patient has had local recurrence. A patient developed contralateral breast cancer 48 months after the first diagnosis and was diagnosed with distant metastasis at 93 months of follow-up. Among these patients, no deaths have been reported (Table 1).

DISCUSSION

Oncoplastic surgery increases the indication for BCS in case of large tumors or tumors at difficult locations of the breast, making it possible to obtain better cosmetic results and adequate

surgical margins^{1,2,7,10}. Tumors located at the upper quadrants can be excised and repaired by different oncoplastic techniques, including glandular reshaping or undermining, inferior pedicle mammaplasty²¹, round-block²², racket resection^{7,23}, batwing technique²⁴, among others. The main issues of all these techniques are repositioning the areola at the center of the new breast and avoiding a filling defect due to insufficient tissue after reshaping. However, in some areas, repairing partial mastectomy defects is extremely difficult, like in the site known as “no man's land”²⁵, which refers to tumors located closer than 16 cm from the sternal notch and/or less than 7 cm from the sternal midline.

Tumors in this area usually leave a significant filling defect, especially if the skin section must be excised. The solution comes with volume replacement techniques, such as the latissimus dorsi flap²⁶ and the more recently described immediate fat grafting, which shows promising results²⁷.

The application of Burow's triangle advancement flap — first described in the early 19th century¹² for facial defects — to the breast^{11,28} has become a fast and straightforward technique, allowing resecting the whole thickness of the affected breast quadrant, including its skin, and partial breast reconstruction with a volume displacement approach involving lateral dermoglandular rotation and advancement flap. Burow's triangle corresponds to a compensatory excision of redundant tissue at the proximal edge of any advancement flap in order to improve cosmesis and avoid standing cones¹⁴. The size of the Burow's triangle can be reduced by extending the length of the flap, especially useful when resecting breast tumors at the “no man's land




Figure 1. Schema of breast advancement flap after a triangular resection and a small upside-down “Burow” triangle to allow skin compensation in the axillary region.




Figure 2. 37-year-old patient. 3.5-cm luminal A invasive ductal carcinoma, located 10 cm from the sternal notch. Triangular quadrantectomy (90 g) with negative SLNB* (A–D). Lateral glandular matrix rotation to cover the breast defect (E–G). 4-year follow-up pictures (H and I) with symmetrical breast shape and scars that tend to fade after radiotherapy.

*SLNB: sentinel lymph node biopsy.




Figure 3. 34-year-old patient. 5-cm triple-negative invasive ductal carcinoma (IDC). (A, B) T3N2M0 neoadjuvant chemotherapy with adequate response to anthracycline regimen but progression with taxanes. (C–E) Large breast resection, including skin and a superficial layer of the pectoral muscle (65 g). Pathology report: 2.5-cm IDC, Elston III. Axillary dissection: 17 negative lymph nodes. (F–H) Lateral glandular matrix rotation. (I) 3-month follow-up pictures with acceptably symmetrical breast shape.

area” and when access to the axilla is necessary. The advantages of this flap include a wide, well-vascularized pedicle and the ability to place the compensatory triangle relatively far from the oncological defect, allowing good access to the axilla¹⁴⁻¹⁸. If the flap is judiciously planned, the breast shape can be preserved without major NAC displacement. Operative time does not increase significantly from a standard BCS. Since symmetrization surgery is not required, a second surgical team is not needed. The complication rate is low. In our cohort, only one partial wound dehiscence was described, requiring outpatient treatment. A disadvantage of this technique is the large scar, sometimes in a visible area; however, the cosmetic result was excellent or good in most patients, according to the postoperative photographic evaluation (80.4%). No patient required conversion to total mastectomy. This could be explained by the adequate preoperative breast assessment with images, the careful management of margins during surgery, and the concept that oncoplastic techniques are associated with lower incidence of positive margins and secondary reoperations^{29,30,31}.

By applying the oncoplastic partial breast reshaping technique described herein, we can avoid converting these surgeries

to total mastectomy and posterior breast reconstruction, reducing the high postoperative complication rate associated with breast reconstruction and posterior radiotherapy³². This technique allows performing wider excisions and, therefore, obtaining adequate surgical margins. The local breast recurrence rate should be as low or even lower than that of conventional partial mastectomy^{29,30}. In our cohort, only one patient developed contralateral breast cancer and distant metastasis, but, to date, none of them has had any local recurrence, showing the safety of this technique³³.

CONCLUSION

Local breast advancement flaps are an essential part of partial breast reconstruction tools, with which every breast surgeon should be familiar. The Burow's triangle advancement flap offers significant benefits, such as a straightforward and fast coverage of upper inner surgical breast defects. This flap allows an excellent matching of skin color, texture, thickness, shape, volume, and sensibility regarding the original breast and very close similarity to the contralateral one, often avoiding the need for a symmetrization surgery. The compensatory triangle can be hidden in the axillary region. Its main disadvantage is the evident geometrical scar outside the esthetic landmarks of the breast, which must be understood and accepted by the patient. Fortunately, most of the time, the scars partially fade after radiotherapy.

Modified Burow's triangle advancement flap is a technique that can be safely used in breast surgery, with adequate oncological and cosmetic outcomes, avoiding total mastectomy and giving more patients the opportunity to have a BCS.

AUTHORS' CONTRIBUTIONS

J.L.: Conceptualization, data curation, formal analysis, investigation, methodology, project administration, resources, software, supervision, validation, visualization, writing – original draft, writing – review & editing.

M.R.: Data curation, formal analysis, investigation, methodology, validation, surgical technique, visualization, writing – review & editing.

C.R.: Conceptualization, validation, visualization, writing – original draft, writing – review & editing.

A.B.: Validation, visualization, writing – original draft, writing – review & editing.

G.I.: Validation, visualization, writing – original draft, writing – review & editing.

D.H.: Validation, visualization, writing – original draft, writing – review & editing.

J.G.: Validation, visualization, writing – original draft, writing – review & editing.

Table 1. Characteristics of patients who underwent breast surgery with modified Burow's triangle technique (N=8).

Median age (year, range)	47 (26–71)
Mean initial tumor size (cm, range)	5.9 (3–13)
Mean pathological size (cm, range)	2.9 (0–7)
Mean excised breast volume (g, range)	117 (53–257)*
Mean BMI (range)	25 (21–29)
Histological type (core biopsy)	
Invasive ductal carcinoma	7
Invasive lobular carcinoma	1
Molecular subtype (according to IHC)	
Luminal	5
Luminal HER2+	1
Triple-negative	2
Stage at diagnosis	
Stage 0 (<i>in situ</i>)	0
Stage I	1
Stage II	3
Stage III	4
Stage IV	0
Median follow-up (range, months)	59 (1–129)
Local recurrence	0
Distant metastasis	1
Contralateral new breast cancer	1

*One patient had a pathological complete response after neoadjuvant chemotherapy, corresponding to the 0 value in range; BMI: body mass index; IHC: immunohistochemical analysis.

REFERENCES

1. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. *N Engl J Med*. 2002;347(16):1233-41. <https://doi.org/10.1056/NEJMoa022152>
2. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. *N Engl J Med*. 2002;347(16):1227-32. <https://doi.org/10.1056/NEJMoa020989>
3. Clough KB, Lewis JS, Couturaud B, Fitoussi A, Nos C, Falcou M-C. Oncoplastic techniques allow extensive resections for breast-conserving therapy of breast carcinomas. *Ann Surg*. 2003;237(1):26-34. <https://doi.org/10.1097/00000658-200301000-00005>
4. Munhoz AM, Montag E, Gemperli R. Oncoplastic breast surgery: indications, techniques and perspectives. *Gland Surg*. 2013;2(3):143-57. <https://doi.org/10.3978/j.issn.2227-684X.2013.08.02>
5. Chatterjee A, Gass J, Patel K, Holmes D, Kopkash K, Peiris L, et al. A Consensus Definition and Classification System of Oncoplastic Surgery Developed by the American Society of Breast Surgeons. *Ann Surg Oncol*. 2019;26(11):3436-44. <https://doi.org/10.1245/s10434-019-07345-4>
6. Youssif S, Hassan Y, Tohamy A, Eld S, Ashour T, Malahias M, et al. Pedicled local flaps: a reliable reconstructive tool for partial breast defects. *Gland Surg*. 2019;8(5):527-36. <https://doi.org/10.21037/gs.2019.09.06>
7. Clough KB, Kaufman GJ, Nos C, Buccimazza I, Sarfati IM. Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery. *Ann Surg Oncol*. 2010;17(5):1375-91. <https://doi.org/10.1245/s10434-009-0792-y>
8. Kronowitz SJ, Kuerer HM, Buchholz TA, Valero V, Hunt K. A management algorithm and practical oncoplastic surgical techniques for repairing partial mastectomy defects. *Plast Reconstr Surg*. 2008;122(6):1631-47. <https://doi.org/10.1097/PRS.0b013e31818cbf1b>
9. Petit J-Y, Rietjens M, Lohsiriwat V, Rey P, Garusi C, Lorenzi F, et al. Update on breast reconstruction techniques and indications. *World J Surg*. 2012;36(7):1486-97. <https://doi.org/10.1007/s00268-012-1486-3>
10. Kramer S, Darsow M, Kummel S, Kimmig R, Rezai M. Breast-conserving treatment of breast cancer--oncological and reconstructive aspects. *Gynakol Geburtshilfliche Rundsch*. 2008;48(2):56-62. <https://doi.org/10.1159/000118932>
11. Lin J, Chen D-R, Wang Y-F, Lai H-W. Oncoplastic Surgery for Upper/Upper Inner Quadrant Breast Cancer. *PLoS One*. 2016;11(12):e0168434. <https://doi.org/10.1371/journal.pone.0168434>
12. Gormley DE. A Brief Analysis of the Burow's Wedge/Triangle Principle. *The Journal of Dermatologic Surgery and Oncology*. 1985;11(2):121-3. <https://doi.org/10.1111/j.1524-4725.1985.tb02978.x>
13. Quatrano NA, Samie FH. Modification of Burow's Advancement Flap. *JAMA*. 2014;16(5):364-6. <https://doi.org/10.1001/jamafacial.2014.427>
14. Krishnan R, Garman M, Nunez-Gussman J, Orengo I. Advancement flaps: a basic theme with many variations. *Dermatol Surg*. 2005;31(S2):986-94. <https://doi.org/10.1111/j.1524-4725.2005.31823>
15. Quatrano NA, Dawli TB, Park AJ, Samie FH. Simplifying Forehead Reconstruction: A Review of More Than 200 Cases. *Facial Plast Surg*. 2016;32(3):309-14. <https://doi.org/10.1055/s-0036-1579780>
16. Wang SQ, Goldberg LH. Burow's Wedge Advancement Flap for Lateral Forehead Defects. *Dermatol Surg*. 2006;32(12):1505-8. <https://doi.org/10.1111/j.1524-4725.2006.32363.x>
17. Zivony D, Siegle RJ. Burow's Wedge Advancement Flaps for Reconstruction of Adjacent Surgical Defects. *Dermatol Surg*. 2002;28(12):1162-4. <https://doi.org/10.1097/00042728-200212000-00013>
18. Boggio P, Gattoni M, Zanetta R, Leigh G, Burow's Triangle Advancement Flaps for Excision of Two Closely Approximated Skin Lesions. *Dermatol Surg*. 1999;25(8):622-5. <https://doi.org/10.1046/j.1524-4725.1999.99053.x>
19. Pilewskie M, Morrow M. Margins in breast cancer: How much is enough? *Cancer*. 2018;124(7):1335-41. <https://doi.org/10.1002/cncr.31221>
20. Harris J, Levene M, Svensson G, Hellman S. Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. *Int J Radiation Oncology Biol Phys*. 1979;5(2):257-61. [https://doi.org/10.1016/0360-3016\(79\)90729-6](https://doi.org/10.1016/0360-3016(79)90729-6)
21. Munhoz AM, Montag E, Arruda E, Aldrighi C, Filassi JR, Barros AC, et al. Reliability of inferior dermoglandular pedicle reduction mammaplasty in reconstruction of partial mastectomy defects: surgical planning and outcome. *Breast*. 2007;16(6):577-89. <https://doi.org/10.1016/j.breast.2007.04.008>
22. Bramhall RJ, Lee J, Concepcion M, Westbroek D, Huf S, Mohammed K, et al. Central round block repair of large breast resection defects: oncologic and aesthetic outcomes. *Gland Surg*. 2017;6(6):689-97. <https://doi.org/10.21037/gs.2017.06.11>
23. Dogan L, Gulcelik MA, Karaman N, Camlibel M, Serdar GK, Ozaslan C. Intraglandular flap technique for tumors located in the upper outer quadrant of the breast. *Clin Breast Cancer*. 2012;12(3):194-8. <https://doi.org/10.1016/j.clbc.2012.03.010>
24. Anderson BO, Masetti R, Silverstein MJ. Oncoplastic approaches to partial mastectomy: an overview of volume-displacement techniques. *Lancet Oncol*. 2005;6(3):145-57. [https://doi.org/10.1016/S1470-2045\(05\)01765-1](https://doi.org/10.1016/S1470-2045(05)01765-1)
25. Grisotti A, Calabrese C. Conservative treatment of breast cancer: reconstructive Issues. In: Spear SL, Willey SC, editors. *Surgery of the Breast: Principles and Art*. 2^a ed. Lippincott: Williams & Wilkins; 2006. p.147-8.
26. Munhoz AM, Montag E, Fels KW, Arruda EG, Sturtz G, Aldrighi C, et al. Outcome analysis of breast-conservation surgery and immediate latissimus dorsi flap reconstruction in patients with T1 to T2 breast cancer. *Plast Reconstr Surg*. 2005;116(3):741-52. <https://doi.org/10.1097/01.prs.0000176251.15140.36>
27. Stumpf CC, Zucatto AE, Cavaleiro JAC, Melo MP, Cericato R, Damin APS, et al. Oncologic safety of immediate autologous fat grafting for reconstruction in breast-conserving surgery. Vol. 180, *Breast Cancer Research and Treatment*. 2020;180:301-9. <https://doi.org/10.1007/s10549-020-05554-0>

28. Lee J, Bae Y, Audretsch W. Combination of two local flaps for large defects after breast conserving surgery. *Breast*. 2012;21(2):194-8. <https://doi.org/10.1016/j.breast.2011.09.011>
29. De La Cruz L, Blankenship SA, Chatterjee A, Geha R, Nocera N, Czerniecki BJ, et al. Outcomes After Oncoplastic Breast-Conserving Surgery in Breast Cancer Patients: A Systematic Literature Review. *Ann Surg Oncol*. 2016;23(10):3247-58. <https://doi.org/10.1245/s10434-016-5313-1>
30. Losken A, Dugal CS, Styblo TM, Carlson GW. A meta-analysis comparing breast conservation therapy alone to the oncoplastic technique. *Ann Plast Surg*. 2014;72(2):145-9. <https://doi.org/10.1097/SAP.0b013e3182605598>
31. Clough KB, Gouveia PF, Benyahi D, Massey EJD, Russ E, Sarfati I, et al. Positive Margins After Oncoplastic Surgery for Breast Cancer. *Ann Surg Oncol*. 2015;22(13):4247-53. <https://doi.org/10.1245/s10434-015-4514-3>
32. Silverstein MJ, Savalia N, Khan S, Ryan J. Extreme oncoplasty: breast conservation for patients who need mastectomy. *Breast J*. 2015;21(1):52-9. <https://doi.org/10.1111/tbj.12356>
33. Kaur N, Petit J-Y, Rietjens M, Maffini F, Luini A, Gatti G, et al. Comparative study of surgical margins in oncoplastic surgery and quadrantectomy in breast cancer. *Ann Surg Oncol*. 2005;12(7):539-45. <https://doi.org/10.1245/ASO.2005.12.046>



Evaluation of clinical and pathological response factors to neoadjuvant chemotherapy in breast cancer patients

Rayane Ferreira^{1*} , Maximiliano Cassilha Kneubil^{1,2} , Janaina Brollo^{2,3} , Luiza Herdy Boechat Luz Tiago¹ , Karen Bazzo Goulart² , Isnard Elman Litvin³ , Mariana Roesch Ely² , João Antonio Pêgas Henriques² 

ABSTRACT

Objectives: To evaluate breast cancer (BC) patients treated with neoadjuvant chemotherapy (NACT) and to analyze clinicopathological features correlating with pathological complete response (PCR) and survival outcomes. **Methods:** Observational, descriptive, and retrospective study. The medical records of BC patients who underwent NACT were reviewed and analyzed using the Statistical Package for the Social Sciences (SPSS), version 20.0. **Results:** Of the 176 BC patients who underwent NACT, 62 patients (35.2%) achieved PCR. The PCR rate was 22% (n = 2) for luminal A, 15% (n = 9) for luminal B/HER2-negative, 45.5% (n = 15) for luminal B/HER2-positive, 50% (n = 14) for non-luminal/HER2-positive, and 47.8% (n = 22) for triple-negative (p = 0.01). Histological grade, estrogen receptor (ER) expression, progesterone receptor (PR) expression, and HER2 status were significantly associated with PCR (p = 0.022, p = 0.01, p = 0.01, and p = 0.02, respectively). The median follow-up was 35.9 months, the estimated 5-year disease-free survival (DFS) was 96.7% in the PCR group and 83.2% in the non-PCR group (p = 0.05). The estimated 5-year overall survival (OS) was 95.5% in the PCR group and 69.1% in the non-PCR group (p = 0.017). Overall, 11 patients (6.25%) presented with locoregional recurrence (LRR), one (1.6%) in the PCR group and 10 (8.8%) in the non-PCR group (p = 0.10). **Conclusion:** We observed higher PCR rates in triple-negative and HER2-positive molecular subtypes. DFS and OS were significantly better in patients who achieved PCR, regardless of clinicopathological features. We also observed lower rates of LRR in the population that reached PCR.

KEYWORDS: breast neoplasms; neoadjuvant therapy; molecular biology; residual volume.

INTRODUCTION

Breast cancer (BC) is a heterogeneous and complex disease¹. During the last decade, genomic analyzes using microarrays have revolutionized the field of BC research². Molecular subtypes were identified, outlining different risk factors^{3,4}, different prognoses⁵, as well as different natural histories, different survival rates and sensitivity to local and systemic treatments⁶⁻⁹.

Neoadjuvant chemotherapy (NACT) is equivalent in overall survival (OS) compared to adjuvant chemotherapy in the treatment of BC. Unlike adjuvant treatment, NACT has traditionally been relegated to patients with locally advanced, initially inoperable BC. However, NACT has played an increasingly important role in the treatment of early-stage disease¹⁰. NACT has benefits in several clinical strategies, including tumor size reduction

and remission of the involvement of the axillary lymph nodes by metastases (downstaging), aiming at a less mutilating surgery, with breast preservation and with resection only of the sentinel lymph nodes in case of negative axillary lymph nodes.

One of the main benefits of NACT is the prognostic information obtained by the pathological evaluation of the tumor bed and axillary lymph nodes after surgery. The complete pathological response is strongly associated with a better prognosis of patients undergoing NACT, as observed in clinical trials NSABP B-18 and B-27^{11,12}.

Given the arguments presented, we believe that it is extremely important to analyze our population of patients with BC who underwent NACT and understand the subpopulation of responders and non-responders to conventional treatments, as well as to assess survival outcomes.

¹General Hospital, Universidade de Caxias do Sul – Caxias do Sul (RS), Brazil.

²Biotechnology Institute, Universidade de Caxias do Sul – Caxias do Sul (RS), Brazil.

³School of Medicine, Universidade de Caxias do Sul – Caxias do Sul (RS), Brazil.

*Corresponding author: luuiza_bt@hotmail.com

Conflict of interests: nothing to declare.

Received on: 05/31/2020. Accepted on: 06/11/2020.

METHODS

All the medical records of patients who underwent NACT with a diagnosis of breast malignancy, between March 2012 and June 2020, in the oncology service (UNACON) of the General Hospital (HG) in Caxias do Sul and in the clinic practice were reviewed. The study included all patients who received NACT diagnosis through anatomopathological examination of invasive carcinoma, selecting cases of both non-special invasive breast carcinomas and special breast carcinomas, with histological grades from I to III and with stages from I to IIIC. Data were recorded on forms, as shown in Appendix 1.

The status of estrogen receptor (ER)/progesterone receptor (RP), epidermal growth factor receptor 2 (HER2) protein, and Ki-67 antigen with the following primary antibodies were assessed: monoclonal antibody (MAb) to ER (Dako, clone EP1, prediluted), MAb to RP (Dako, clone PgR, prediluted), MIB-1 MAb to Ki-67 antigen (Dako, clone MIB-1, prediluted) and polyclonal antiserum (Biogen, clone SP3, 1/1,100 dilution) in HER2 protein. Intense and complete membrane staining in at least 10% of tumor cells was qualified for immunohistochemical expression (IHC) of HER2 3+ and considered to be HER2 positive. For this analysis, HER2 scores of 0 and 1+ were considered negative. All HER 2+ tumors were tested for gene amplification by fluorescence in situ hybridization (FISH). The Ki-67 labeling index value was divided into low (< 14%) and high (\geq 14%). Tumors were stratified into subtypes¹³:

- luminal A: ER positive and/or PR positive, HER2 negative, and low Ki-67 (< 14%);
- luminal B/HER2 negative: ER positive, PR positive, HER2-negative, and Ki-67 high (\geq 14%);
- luminal B/HER2 positive: ER positive, PR positive, HER2 positive, and any Ki-67;
- non-luminal/HER2 positive: ER negative, PR negative, and HER2 positive;
- triple negative: ER negative, PR negative, and HER2 negative.
- Pathologic complete response (PCR) was defined as the absence of invasive carcinoma in the breast and ipsilateral axilla after NACT¹⁴.

Regarding the post-NACT pathological evaluation, the pieces were duly evaluated according to well-established international recommendations¹⁵. The piece was weighed and measured and the surgical margins were painted with India ink; subsequently, 0.5 cm slices were cut from anterosuperior to posterior inferior and each slice was labeled as 1, 2, 3, etc. and subdivided into letters A, B, C, etc. (from the upper to the lower axis), setting up a coordinate chart for the assessment of the tumor bed.

Data were entered into Excel and later exported to the Statistical Package for Social Sciences (SPSS), version 20.0, for statistical analysis. Categorical variables were described by frequencies and percentages. Symmetry of quantitative variables

was verified using the Kolmogorov-Smirnov test. Quantitative variables were described by mean and standard deviation. Categorical variables were associated using the chi-square test. Quantitative variables were compared between the group with and without PCR using the Student's *t* test for independent samples. OS and disease-free survival (DFS) were assessed using the Kaplan-Meier curve and compared between groups using the log rank test. Factors associated with PCR with a p-value of less than 0.05 in the bivariate analysis or those considered to be potential confounders were included in a multivariate Cox regression analysis. A significance level of 5% was considered for the established comparisons.

The OS was analyzed from the date of diagnosis to the date of death or last follow-up (patients who lost follow-up), and the DFS was analyzed from the date of diagnosis to the date of disease progression (locoregional recurrence and/or distant recurrence), date of death (patients who did not show disease progression and evolved to death) or date of last follow-up (patients who lost follow-up).

RESULTS

One hundred and seventy-six patients with BC were submitted to NACT at the UNACON of the GH and in the private practice from March 2012 to June 2020. All were included in this analysis. Table 1 shows the clinical characteristics of the population.

The patient population in this sample had a median age of 47.3 years (ranging 24 – 77). It was observed that approximately half of the patients (*n* = 94; 53.5%) were aged between 35 and 49 years. Regarding the body mass index (BMI), it was noticed that the majority (*n* = 116; 65.9%) had a BMI \geq 25. Furthermore, 86.4% (*n* = 152) had non-special invasive ductal carcinoma as histological subtype and 40.3% (*n* = 71) of the patients presented histological grade 3. The most frequent molecular subtypes were luminal B/HER2 negative (*n* = 60; 34.1%) and triple negative (*n* = 46; 26, 1%), and most patients were in clinical stage (CS) IIB (*n* = 56; 31.8%) and IIIA (*n* = 52; 29.5%). Of these patients, 145 (82.4%) received regimens based on anthracyclines and taxanes in NACT, 13 (7.38%) received anthracyclines, taxanes, and carboplatin in NACT, and 18 (10.22%) received other regimens. Fifty-eight (32.9%) patients received trastuzumab concomitantly with taxane in neoadjuvant therapy and only nine (5.11%) received pertuzumab concomitantly with taxane and trastuzumab. Only four HER2 positive patients did not receive trastuzumab in neoadjuvant therapy due to delayed delivery of the medication by the Unified Health System (*Sistema Único de Saúde* – SUS), but received it during adjuvant treatment.

Regarding the surgical modality, we observed that 84 patients underwent quadrantectomy, 36 adenomastectomy, 10 skin-sparing mastectomy, 39 modified radical mastectomy, and seven did not undergo surgery due to disease progression. According to

international recommendations, 162 (92%) patients underwent adjuvant radiotherapy after surgery.

After evaluating the surgical specimen, we observed that 62 patients (35.2%) had PCR and 114 (64.8%) did not have PCR.

Analyzing all clinical characteristics of patients who entered *versus* those who did not enter PCR, it was possible to observe a significant association between the molecular subtype and the presence of PCR ($P = 0.001$). By the adjusted analysis of previously standardized subcategories, it is possible to detect that patients with the triple negative and HER2 positive subtype had a statistically significant higher frequency of PCR, and that the luminal B/HER2 negative subtype had a significantly lower percentage of PCR ($p = 0.01$) (Table 2).

Table 1. Characteristics of the population.

Clinical characteristics	Categories	Number of patients	%
Total		176	100
Age (years)	< 35	15	8.5
	35–49	94	53.5
	50–64	59	33.5
	≥ 65	8	4.5
BMI	< 18.5	3	1.7
	18.5–24.9	57	32.4
	≥ 25	116	65.9
Histological Subtype	Lobular	3	1.7
	Ductal	152	86.4
	Medullary	14	8
Histological Grade	Others	7	3.9
	I	12	6.8
	II	57	32.4
	III	71	40.3
	Not rated	36	20.4
Molecular Subtype	Luminal A	9	5.1
	Luminal B/HER2 negative	60	34.1
	Luminal B/HER2 positive	33	18.8
	HER2 positive/non luminal	28	15.9
	Triple negative	46	26.1
Clinical Stage	I	4	2.3
	IIA	34	19.3
	IIB	56	31.8
	IIIA	52	29.5
	IIIB	24	13.6
	IIIC	6	3.4

BMI: body mass index.

Pathological characteristics such as histological grade, ER expression, RP expression, and HER2 status are associated with PCR with statistical significance, with $p = 0.022$, $p = 0.01$, $p = 0.01$, and $p = 0.02$, respectively. The other clinicopathological characteristics analyzed, such as age, clinical stage, and Ki-67, did not show a significant correlation with PCR, with $p = 0.92$, $p = 0.248$, and $p = 0.749$, respectively, which demonstrates that they did not influence the outcome of PCR of this sample (Table 3).

Multivariate analysis by Cox regression showed that patients who presented PCR had better OS regardless of clinical characteristics related to the molecular subtype, ER, PR, and Ki67 (hazard ratio — HR = 0.15; 95%CI 0.04 – 0.54) (Appendix 2).

The median follow-up was 35.9 months. The five-year DFS for the total sample was 88.8%, for the group with PCR it was 96.7% and, for the group without PCR, it was 83.2%, with a difference in the limit of statistical significance between groups ($p = 0.05$) (Figure 1).

The estimated five-year overall survival was 77.8%. When patients were categorized into two groups, with and without CPR, it was possible to observe a significant difference in the estimate of overall survival at five years, with 95.5% in the group with PCR and 69.1% in that without PCR ($p = 0.017$) (Figure 2).

Among the 176 patients in the total sample, 11 evolved with locoregional recurrence (LRR) (6.25%); one LRR in the group with PCR (1.6%) and 10 LRR were in the group without PCR (8.8%) ($p = 0.10$).

DISCUSSION

Among the 176 patients with BC who underwent NACT in our study, the PCR rate was 35.2%. Currently, one of the main benefits of NACT is the prognostic information obtained by the pathological evaluation of the tumor bed and axillary lymph nodes after surgery. The PCR is strongly associated with a better prognosis of patients undergoing NACT, as observed in the NSABP B-18 and B-27 clinical trials^{11,16}.

In our study, we observed a significant association between the molecular subtype and the presence of PCR ($p = 0.001$), with

Table 2. Association between molecular subtype and PCR.

Molecular Subtype	No. of patients	No. of patients who reached PCR (%)	p-value
Luminal A			$p = \text{wss}$
Luminal B/HER2 negative			$p = 0.01$
Luminal B/HER2 positive			$p = 0.01$
HER2 positive non luminal			$p = 0.01$
Triple negative			$p = 0.01$

wss: without statistical significance.

PCR rates ranging from 22 to 50% according to the molecular subtype. This finding is consistent with the literature, in which PCR rates are higher in patients with HER2 positive BC and triple negative BC (TN) when compared to patients with HER2 negative/hormone receptor positive BC^{14,17}.

In line with data from the world literature, we demonstrated that patients who achieved PCR had significantly higher survival rates compared to those with residual disease. In our study, the five-year DFS for the group with PCR was 96.7% *versus* 83.2% for the group without PCR ($p = 0.05$). The estimated five-year OS for the group with PCR was 95.5% *versus* 69.1% for the group without PCR ($p = 0.017$). Furthermore, among the patients in our total sample, 11 evolved with LRR (6.25%); one LRR in the group with PCR (1.6%) and 10 LRR were in the group without PCR (8.8%). In the NSABP B-18 study, patients who had post-NACT PCR had longer DFS and greater OS (HR = 0.47, $p = 0.0001$ and HR = 0.32, $p = 0.0001$, respectively)¹⁸.

A therapy based on the assessment of prognostic and predictive factors enables the application of different therapeutic modalities used in cancer treatment with the intensity and effectiveness that are adequate and individualized for each specific patient¹⁹. In our study, pathological characteristics such as histological grade, ER expression, PR expression, and HER2 status are associated with PCR with statistical significance, with $p = 0.022$, $p = 0.01$, $p = 0.01$, and $p = 0.02$, respectively. The other clinicopathological characteristics analyzed, such as age, clinical stage, and Ki-67, did not show a significant correlation with PCR, with $p = 0.92$, $p = 0.248$, and $p = 0.749$, respectively, demonstrating that they did not influence the outcome of PCR in this sample.

The population in our study consisted mostly of young patients; 53.5% of them were aged between 35 and 49 years and had tumors in more advanced stages, and 61.3% had clinical stage

Table 3. Clinicopathological characteristics according to complete pathological response (PCR).

Characteristics		All	PCR N (%)	Without PCR N (%)	P
Total		176	62	114	
Age (years), mean \pm SD		176	46.0 \pm 11.7	48.0 \pm 10.1	$p = 0.25$
Age (years)	< 35	15	9 (14.5)	6 (5.3)	$p = 0.92$
	35–49	94	32 (51.6)	62 (54.4)	
	50–64	59	18 (29.0)	41 (36.0)	
	≥ 65	8	3 (4.9)	5 (4.3)	
Histological grade	I	12	2 (3.2)	10 (8.7)	$p = 0.022$
	II	57	16 (25.8)	41 (36.0)	
	III	71	31 (50.0)	40 (35.1)	
	not available	36	13 (21.0)	23 (20.2)	
Clinical Stage	I	4	1 (1.6)	3 (2.6)	$p = 0.249$
	IIA	34	12 (19.4)	22 (19.3)	
	IIB	56	19 (30.6)	37 (32.5)	
	IIIA	52	17 (27.4)	35 (30.7)	
	IIIB	24	10 (16.1)	14 (12.3)	
	IIIC	6	3 (4.9)	3 (2.6)	
ER	0–9	73	36 (58.1)	41 (36.0)	$p = 0.01$
	10–49	15	6 (9.7)	9 (7.9)	
	≥ 50	84	20 (32.2)	64 (56.1)	
PR	0–9	89	43 (69.4)	51 (44.7)	$p = 0.01$
	10–49	30	8 (12.9)	22 (19.3)	
	≥ 50	52	11 (17.7)	41 (36.0)	
Ki-67	< 14	11	3 (4.8)	8 (7.0)	$p = 0.749$
	≥ 14	165	59 (95.2)	106 (93.0)	
HER2	Positivo	62	29 (46.8)	33 (28.9)	$p = 0.02$
	Negativo	114	33 (53.2)	81 (71.1)	

ER: estrogen receptor; PR: progesterone receptor.

IIB (31.8%) and IIIA (29.5%). However, clinical stage and age did not have a significant correlation with PCR, which shows that age and tumor size at diagnosis probably do not influence PCR rates in the neoadjuvant setting.

NACT is equivalent in OS compared to adjuvant chemotherapy in the treatment of BC. In contrast to adjuvant treatment, NACT has traditionally been relegated to patients with locally advanced, initially inoperable BC. However, NACT has played an increasingly important role in the treatment of early-stage

disease¹⁰, especially in patients with triple negative BC and HER2 positive, regardless of patient age, with benefits even in elderly patients in good clinical condition.

Another key point in the neoadjuvant scenario is the proper interaction between the pathologist and the surgeon, as the former needs adequate clinical and imaging information, such as tumor size and location, in addition to the presence or absence of a clip in the tumor bed for a careful evaluation of the residual tumor. This was a positive point of our work: the pathologist




Figure 1. Disease-free survival estimate of patients according to the PCR.




Figure 2. Estimate of overall survival in patients according to PCR.

presented this necessary and important information before the macroscopic examination of the surgical specimen, directing it to specific serial sections post-NACT according to well-established international recommendations and allowing the anatomicopathological result to mirror the extension of post-NACT residual tumor with high accuracy¹⁵.

Although our study has shown relevant and expected data according to the world literature, we understand that the limitations of this work are related to the small sample, the retrospective nature, and the short follow-up time. In addition, we also observed that a small sample of patients (5.11%) underwent double HER2 blockade in neoadjuvant therapy.

CONCLUSION

In our sample of patients with BC undergoing NACT, we observed higher rates of PCR in the triple negative and HER2 positive molecular subtypes. PFS and OS rates were significantly better in patients who achieved PCR, regardless of clinicopathological factors. We also observed lower LRR rates in the population that reached PCR. Thus, we increasingly

emphasize the importance of NACT in the approach of the initial BC.

ACKNOWLEDGMENTS

To the employees of the various intra- and extra-hospital sectors, who contribute to the comprehensive care and treatment of patients with BC.

AUTHORS' CONTRIBUTIONS

R.F.: Conceptualization, Data curation, Formal analysis, Writing — original draft.

Maximiliano Cassilha Kneubil: Conceptualization, Data curation, Formal analysis, Writing — original draft.

J.B.: Project administration, Methodology, Writing — review & editing.

L.H.B.L.T.: Investigation, Writing — review & editing.

K.B.G.: Methodology, Data curation, Formal analysis.

I.E.L.: Methodology, Project administration, Validation.

M.R.E.: Project administration, Writing — review & editing.

J.A.P.H.: Project administration, Writing — review & editing.

REFERENCES

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. *Nature*. 2000;406(6797):747-52. <https://doi.org/10.1038/35021093>
2. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci*. 2001;98(19):10869-74. <https://doi.org/10.1073/pnas.191367098>
3. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, et al. Epidemiology of basal-like breast cancer. *Breast Cancer Res Treat*. 2008;109(1):123-39. <https://doi.org/10.1007/s10549-007-9632-6>
4. Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, et al. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. *Cancer Causes Control*. 2011;22(3):399-405. <https://doi.org/10.1007/s10552-010-9709-0>
5. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Stefanick ML, Wactawaski-Wende J, et al. Body size, physical activity, and risk of triple negative and estrogen receptor-positive breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2011;20(3):454-63. <https://dx.doi.org/10.1158/2F1055-9965.EPI-10-0974>
6. Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. *Lancet*. 2005;365(9460):671-9. [https://doi.org/10.1016/s0140-6736\(05\)17947-1](https://doi.org/10.1016/s0140-6736(05)17947-1)
7. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*. 1987;235(4785):177-82. <https://doi.org/10.1126/science.3798106>
8. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science*. 1989;244(4905):707-12. <https://doi.org/10.1126/science.2470152>
9. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. *JAMA*. 2006;295(21):2492-502. <https://doi.org/10.1001/jama.295.21.2492>
10. Haddad TC, Goetz MP. Landscape of neoadjuvant therapy for breast cancer. *Ann Surg Oncol*. 2015;22(5):1408-15. <https://dx.doi.org/10.1245%2Fs10434-015-4405-7>
11. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. *J Clin Oncol*. 1997;15(7):2483-93. <https://doi.org/10.1200/jco.1997.15.7.2483>
12. Mamounas EP. NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. *Oncology (Williston Park)*. 1997;11(6 Suppl. 6):37-40.

13. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Ann Oncol.* 2013;24(9):2206-23. <https://doi.org/10.1093/annonc/mdt303>
14. Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol.* 2012;30(15):1796-804. <https://doi.org/10.1200/jco.2011.38.8595>
15. Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, et al. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. *Mod Pathol.* 2015;28(9):1185-201. <https://doi.org/10.1038/modpathol.2015.74>
16. Bear HD, Anderson S, Smith RE, Geyer CE Jr., Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. *J Clin Oncol.* 2006;24(13):2019-27. <https://doi.org/10.1200/jco.2005.04.1665>
17. Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. *Eur J Cancer.* 2012;48(18):3342-54. <https://doi.org/10.1016/j.ejca.2012.05.023>
18. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. *J Clin Oncol.* 2008;26(5):778-85. <https://doi.org/10.1200/jco.2007.15.0235>
19. Abreu E, Koifman, S. Prognostic factors in woman breast cancer. *Rev Bras Cancerol.* 2002;48(1):113-31.

Apêndice 1. Ficha de avaliação.

Nome: _____ Prontuário: _____
 Data de nascimento: ____/____/____ Idade ao diagnóstico: _____
 Sexo: ☐ 1. Feminino; 2. Masculino
 Etnia: ☐ 1. Branca; 2. Negra; 3. Asiática 4. Parda; 5. Outra.
 IMC: _____ Peso: _____ kg Estatura: _____ cm
 Performance status: ☐ 0. 0; 1. 1; 2. 2; 3. 3; 4. 4
 História prévia de tabagismo: ☐ 0. Não 1. < 20 maços/ano 2. > 20 maços/ano
 Status menopausal: ☐ 0. Pré-menopausa; 1. Pós-menopausa
 Data do diagnóstico: ____/____/____ Laboratório: _____
 Tipo histológico: ☐ 1. Lobular invasor; 2. Ductal invasor; 3. Outros _____
 Grau histológico (Nottingham): ☐ 1. G1; 2. G2; 3. G3 99. Não disponível
 Expressão ER: ☐ valor: _____ 0. Ausente (0%); 1. Baixa ($\geq 1\%$ e $< 10\%$); 2. Positiva ($\geq 10\%$ e $< 50\%$); 3. Fortemente positiva ($\geq 50\%$)
 Expressão PgR: ☐ valor: _____ 0. Ausente (0%); 1. Baixa ($\geq 1\%$ e $< 10\%$); 2. Positiva ($\geq 10\%$ e $< 50\%$); 3. Fortemente positiva ($\geq 50\%$)
 HER2: ☐ 0. 0+; 1. 1+; 2. 2+; 3. 3+; 99. Não disponível
 Se 2+: ☐ 0. FISH não amplificado; 1. FISH amplificado; 88. Não se aplica 99. Não disponível
 Ki67: ☐ valor: _____ 1. Baixo ($< 14\%$); 2. Alto; 3. Não disponível
 Subtipo Molecular: 1. Luminal A 2. Luminal B 3. Luminal-HER2 Positivo
 4. HER2 Puro 5. Tripló Negativo
 TNM inicial
 T: ☐ valor: _____ (cm) 0. T1mi; 1. T1a; 2. T1b; 3. T1c 4. T2; 5. T3; 6. T4a; 7. T4b; 8. T4c; 9. T4d
 T: ☐ Avaliado por: 0. Exame Físico; 1. Ecografia mamária bilateral; 2. Ambos
 N: ☐ 0. N0; 1. N1; 2. N2a; 3. N2b; 4. N3a; 5. N3b; 6. N3c
 M: ☐ 0. M0; 1. M1
 Estádio clínico: ☐ 1. IA; 2. IB; 3. IIA; 4. IIB; 5. IIIA; 6. IIIB; 7. IIIC; 8. IV
 Se 8 (EC IV), sítio metastático: ☐ 8a. Fígado; 8b. Pulmão, pleura ou derrame pleural; 8c. Osso; 8d. SNC;
 8e. Outros _____

TRATAMENTO SISTÊMICO NEOADJUVANTE

Quimioterapia neoadjuvante: ☐ 0. Não realizou; 1. Realizou

Se 1, protocolo ☐ (ver Anexo 1)

Data início: ____/____/____ Data término: ____/____/____ N° ciclos: _____

Progressão em vigência de quimioterapia neoadjuvante: 0. Não 1. Sim

Terapia de alvo molecular ☐ 0. Não realizou; 1. Trastuzumab; 2. Lapatinib; 3. Pertuzumab 4. Trastuzumab+Pertuzumab 5. Trastuzumab+Lapatinib 6. Outra

Data início: ____/____/____ Data término: ____/____/____ N° ciclos: _____

Resposta patológica completa: ☐ 0. Não 1. Sim 88. Não se aplica

Tumor residual ypT _____ valor: _____ (cm) ypN _____ (____/____)

TNM Patológico pós-quimioterapia neoadjuvante

yT: valor: _____ (cm) 0. T1mi; 1. T1a; 2. T1b; 3. T1c; 4. T2; 5. T3; 6. T4a; 7. T4b; 8. T4c; 9. T4d; 10. Carcinoma ductal *in situ* 88. Não se aplica

yN: ☐ 0. N0; 1. N1; 2. N2; 3. N3 88. Não se aplica

Laboratório AP Cirurgia: _____ ICR: _____

Se não houve resposta patológica completa, Tumor residual: ☐ 0. CDIS; 1. Carcinoma Invasor; 2. CDIS+Carcinoma invasor

Tipo histológico: ☐ 1. Lobular invasor; 2. Ductal invasor; 3. Outros _____ 88. Não se aplica
 99. Não disponível

Grau histológico (Nottingham): ☐ 1. G1; 2. G2; 3. G3 88. Não se aplica 99. Não disponível

Se não houve resposta patológica completa. ☐ 1. Doença estável; 2. Resposta parcial; 3. Progressão da doença

Em caso de progressão de doença. ☐ 0. Local; 1. Regional; 2. Locorregional

IMH do tumor residual 0. Não realizada; 1. Realizada

Se realizada:

Expressão ER: ☐ valor: _____ 0. Ausente (0%); 1. Baixa ($\geq 1\%$ e $< 10\%$); 2. Positiva ($\geq 10\%$ e $< 50\%$); 3. Fortemente positiva ($\geq 50\%$)

Expressão PgR: ☐ valor: _____ 0. Ausente (0%); 1. Baixa ($\geq 1\%$ e $< 10\%$); 2. Positiva ($\geq 10\%$ e $< 50\%$); 3. Fortemente positiva ($\geq 50\%$)

HER2: ☐ 0. 0+; 1. 1+; 2. 2+; 3. 3+; 4. Não disponível

Se 2+: ☐ 0. FISH não amplificado; 1. FISH amplificado; 2. Não disponível

Ki67: ☐ valor: _____ 1. Baixo ($< 14\%$); 2. Alto; 3. Não disponível

CIRURGIA

Cirurgia: ☐ 0. Não; 1. Sim Data: ____/____/____ 88. Não se aplica 99. Não disponívelSe sim: ☐ 1a. Setorectomia/Quadrantectomia; 1b. Adenomastectomia (*nipple sparing*); 1c. Mastectomia (*skin sparing*); 1d. Mastectomia radical modificadaLinfonodo sentinela: ☐ 0. Não realizado; 1. RealizadoSe 1: ☐ 1a. Negativo; 1b. Positivo (____/____)Se 1b: ☐ 1ba. Micrometástase (<2mm); 1bb. MacrometástaseEsvaziamento linfonodal: ☐ 0. Não; 1. Sim (____/____) Se 1, presença de extravasamento extracapsular: ☐ 1a. Não; 1b. Sim

RADIOTERAPIA ADJUVANTE

Radioterapia adjuvante: ☐ 0. Não; 1. Sim _____Gy _____sessõesSe sim: ☐ 1a. ELIOT; 1b. Mama; 1c. Mama + *boost* leito tumoral; 1d. Mama + áreas de drenagem; 1e. Plastrão 1f. Plastrão+áreas de drenagem
1g. outro _____

TRATAMENTO SISTÊMICO ADJUVANTE

Quimioterapia adjuvante: ☐ 0. Não realizou; 1. RealizouSe 1, protocolo ☐ (ver Anexo 1)

Data início: ____/____/____ Data término: ____/____/____ N° ciclos: _____

Terapia de alvo molecular adjuvante ☐ 0. Não realizou; 1. Trastuzumab; 2. Lapatinib; 3. Trastuzumab+Lapatinib 4. Outra

Data início: ____/____/____ Data término: ____/____/____ N° ciclos: _____

Hormonioterapia adjuvante ☐ 0. Não realizou; 1. Tamoxifeno; 2. Anastrozol; 3. Letrozol 4. Tamoxifeno+IA 5. IA+Tamoxifeno 6. Exemestane
7. Outro

Data início: ____/____/____ Data término: ____/____/____ N° meses: _____

Supressão ovariana: ☐ 0. Não; 1. Sim N° meses: _____Progressão de doença: ☐ 0. Não; 1. Sim Data da progressão: ____/____/____

Sítio de progressão: _____

Recidiva locorregional: ☐ 0. Não; 1. Plastrão; 2. Mama ipsilateral; 3. Axila ipsilateral; 4. Fossa supraclavicular; 5. Mama+axila ipsilateral 6. Outro

Data da recidiva: ____/____/____

Carcinoma mama contralateral: ☐ 0. Não; 1. Sim Data: ____/____/____Paciente vivo: ☐ 0. Não; 1. Sim Se não, data do óbito: ____/____/____Data do último *follow-up*: ____/____/____

Pesquisador responsável: _____

Data: ____/____/____

ANEXO 1

1. AC (Doxorrubicina+Ciclofosfamida);
2. DC (Docetaxel+Ciclofosfamida);
3. AT (Doxorrubicina+Docetaxel);
4. TAC (Docetaxel+Doxorrubicina+Ciclofosfamida);
5. AC-D* (Doxorrubicina+Ciclofosfamida+Docetaxel)
6. AC-T** (Doxorrubicina+Ciclofosfamida+Paclitaxel);
7. AC-T*** (Doxorrubicina+Ciclofosfamida+Paclitaxel dose densa);
8. T-AC (Paclitaxel+Doxorrubicina+Ciclofosfamida);
9. CMF (Ciclofosfamida+Metotrexato+5-FU);
10. FAC (Ciclofosfamida+Doxorrubicina+5-FU);
11. FAC-D (Ciclofosfamida+Doxorrubicina+5-FU+Docetaxel);
12. FEC100-T (Epirubicina+5-FU+Ciclofosfamida+Docetaxel);
13. FEC90-T (Epirubicina+5-FU+Ciclofosfamida+Paclitaxel)
14. Outro _____

Appendix 2. Cox regression tables of factors associated with overall survival.

Model 1

	P	HR	95.0%CI	
			Lower	Upper
PCR	0.003	0.153	0.045	0.524
Age at diagnosis	0.448	0.982	0.938	1.029
PRvalue	0.119	0.982	0.960	1.005
ERvalue	0.678	1.004	0.986	1.022
Ki67value	0.019	1.028	1.005	1.052




HR: *hazard ratio*; CI: confidence interval; PCR: pathologic complete response; PR: progesterone receptor; ER: estrogen receptor.

Model 2

	P	HR	95.0%CI	
			Lower	Upper
RPC	0.003	0.151	0.043	0.528
Molecular subtype	0.044			
Molecular subtype (1)	0.796	0.755	0.090	6.363
Molecular subtype (2)	0.693	1.583	0.162	15.496
Molecular subtype (3)	0.652	1.687	0.174	16.334
Molecular subtype (4)	0.196	3.913	0.494	30.989
Age at diagnosis	0.230	0.973	0.932	1.017

HR: *hazard ratio*; CI: confidence interval; PCR: pathologic complete response.

Epidemiological profile of women with breast cancer in a public hospital in the Federal District of Brazil

Jardeson Saraiva Jorge^{1*} , Fabio Siqueira² , Jessica Vick de Oliveira Leal¹ 

ABSTRACT

Introduction: In Brazil, for the 2020–2022 triennium, the estimated incidence of breast cancer in women was 66,280/year. It is the most incident type of cancer in all Brazilian regions. Several risk factors are associated with the probable etiology of breast cancer, though the complexity of the disease makes it difficult to define its main cause. **Objective:** To investigate the prevalence of factors associated with breast cancer in an outpatient population at a public hospital in the Federal District, and to verify the epidemiological profile of this population to compare the data obtained with data published in the literature. **Method:** This is a descriptive cross-sectional study, with 115 participants diagnosed with breast cancer undergoing treatment in a highly complex unit of oncology care in the Federal District between July and October 2020. Data collection was done through a questionnaire. The electronic medical record was consulted to complement the data. **Results:** The majority of women were brown, married, with an average age of 52. Hormone therapy was reported by 73.9%, early menarche by only 33.9% and late menopause by 25.2%. Most had children before the age of 30 and more than 80% breastfed. A family history of breast cancer was present in 30.4% of the sample. The consumption of alcoholic beverages was reported by more than half of the women, but the use of cigarettes was denied by the majority. The practice of some physical activity before the diagnosis of cancer was reported by 69.6%. Most were overweight or had some degree of obesity. Non-special invasive carcinoma was the most common type. **Conclusions:** This study showed that the main factors present in the sample were: advanced age, alcohol consumption, use of hormone therapy and overweight.

KEYWORDS: breast neoplasms; risk factors; health profile; women's health.

INTRODUCTION

Breast cancer represents the most common malignant neoplasm in women worldwide and is also one of the most important causes of death in this gender¹. In Brazil, the estimate of new cases of the disease in females for the triennium 2020-2022 is 66,280 per year, which places it as the most common type of cancer in all regions².

For the Federal District, the estimate for the year 2020 is 730 new cases of this neoplasm in women, the second most common, second only to prostate cancer².

Although this disease occurs in all parts of the world, the incidence, mortality, and survival rates vary considerably between different regions of the world. The justification for these variations may lie in the different specificities of each population, such as population structure, lifestyle, genetic factors, environment, and health care¹.

Several risk factors are associated with the probable etiology of breast cancer, though, due to the complexity of the

disease, it is not yet possible to specifically define the main cause. However, the genetic inheritance of the BRCA-1 and BRCA-2 genes, which are associated with high risk for the development of familial breast cancer, is a good predictor of the genetic cause of cancer³.

The best known factors that can increase the possibility of breast malignancy include: gender, advanced age, early menarche and late-onset menopause, nulliparity, late primiparity, non-breastfeeding, sedentary lifestyle, obesity, exposure to estrogen (contraceptives and hormone replacement therapy for menopause), family history, genetic mutation, smoking, and alcohol consumption^{4,5}.

The clinical stage presented by patients at the time of diagnosis is a determining factor in the design of the therapeutic management. Unfortunately, in developing countries, especially those where the majority of the population has low or middle income, most cases of breast cancer are diagnosed at advanced stages due to lack of knowledge or resources⁶.

¹Programa Multiprofissional em Atenção ao Câncer da Escola Superior de Ciências da Saúde – Brasília (DF), Brazil.

²Hospital Regional de Taguatinga, Secretaria de Saúde do Distrito Federal – Taguatinga (DF), Brazil.

*Corresponding author: jardesonsaraiva@gmail.com

Conflict of interests: nothing to declare.

Received on: 04/01/2021. Accepted on: 05/21/2021.

The objectives of this study were to investigate the prevalence of factors associated with breast cancer in women undergoing treatment at the outpatient clinic of clinical oncology of a tertiary hospital in the Federal District, to verify the epidemiological profile of this population and to compare the data obtained in this study with those in the literature.

METHOD

A descriptive cross-sectional study was carried out with 115 patients diagnosed with breast cancer who were undergoing treatment in a high-complexity oncology unit between July and October 2020.

Sample size was calculated using a tool available in the OpenEpi version 3.0 software. The 200 patients who underwent intravenous (IV) chemotherapy in 2019 at an outpatient level were considered, with a 95% confidence interval. Taking these values into account, the sample would need at least 110 patients in order to be representative.

For data collection, a questionnaire was applied in the form of an interview/anamnesis about socioeconomic aspects, risk, and protection factors that patients could or not have been exposed to during their lives. In order to have access to the histological type of breast cancer of the patient at the time of diagnosis and other information necessary for the study, the electronic medical record was consulted. Patients informed their consent to participate in the research by signing the Informed Consent.

The socioeconomic and epidemiological variables taken into account are: age, education, children, breastfeeding, weight and height (used to calculate the body mass index – BMI), family history, age at menarche, age at first pregnancy, use hormone therapy, physical activity, smoking, and alcohol consumption.

Inclusion criteria were: diagnosis of breast cancer, female patients, 18 years of age or more, having agreed to participate in the research, and signed informed consent. Patients disoriented in time and space, unaccompanied, who could not answer the questionnaire clearly, and patients with a history of a primary tumor other than breast cancer were excluded. In all, two patients were excluded by the first criterion.

Data were stored in Microsoft Office Excel® 2010 spreadsheets, in which a database was built for descriptive analysis through the distribution of absolute and relative frequencies, in order to generate the results in the form of graphics and tables.

This study was approved by the Research Ethics Committee of Centro Universitário do Distrito Federal (UDF) via Plataforma Brasil (approval number: 4.115.051/2020).

RESULTS

Of the total of 115 patients who participated in the survey, the mean age was 52.8 years (ranging from 28 to 80), most declared themselves

brown (55.7%), 52.1% had completed high school or high education degree, 38% were married, with a family nucleus composed of one to three people (67%), family income around one to three minimum wages (41.7%), and own housing conditions (61.7%) (Table 1).

Most had their menarche in the age group considered as normal or late, and the use of contraceptives and/or hormone replacement therapies was reported by 73.9% of them. Mean age at first pregnancy was 23.5 years. Most women had menopause in the normal age group (Table 2).

More than 80% breastfed. Of them, 63.5% reported that they did it for a period equal to or longer than one year. Family history of breast cancer in up to fourth degree relatives was reported by 30.4% of the women in the study (Table 2).

Regarding alcoholism, smoking, and physical activity, the former was prevalent in 61.7%. Smoking was prevalent in less than half of the participants (44.3%). The majority (69.6%) reported that they practiced some type of physical activity before the diagnosis of breast cancer.

To interpret the participants' BMI values, the World Health Organization (WHO) classification of nutritional status was used⁷.

Most patients were overweight or had some degree of obesity at the time of the interview (Figure 1). In addition to some incomplete medical records, some patients were unable to inform their weight and height. Thus, 10.4% of patients did not have their BMI calculated.

The most prevalent histological type of tumors among the study participants was non-special invasive carcinoma. This type corresponded to 96.5% of the total diagnoses. The other types of cancer identified in the sample were invasive carcinomas, special types (3.5%).

DISCUSSION

The worldwide incidence of breast cancer in black women traditionally used to be lower than in white ones, though the disease was more aggressive. From 2012 to the present day, this reality has been changing and new cases of breast cancer have an almost similar distribution between white and black women⁸.

More than 50% of the women were 50 years old or older, with a mean age of 52.8 years. According to *Instituto Nacional de Câncer José Alencar Gomes da Silva* (INCA), the risk of cancer is increased in women after the age of 50 due to cumulative exposure to risk factors and biological alterations⁹. A study carried out in Bahia also showed a greater predominance of people aged 50 years old or older¹⁰.

Of the 115 participants in the present study, 73.9% reported having used hormonal therapy with contraceptives and/or hormone replacement for menopause at some point in their lives, which emerged as an important common risk factor in the population studied. A similar study in South Africa did not associate the use of hormone therapy with breast cancer⁶. The same was observed in Özsoy et al.¹¹.

Table 1. Socioeconomic data of women assisted in a high-complex oncology care unit. Brasília, 2020.

Characteristic	N	%
Age range (years)		
< 30	1	0.9
30–39	10	8.7
40–49	30	26
50–59	46	40
60–69	25	21.8
> 70	3	2.6
Mean age	52.8 years	
Ethnicity		
Yellow	11	9.6
White	25	21.7
Black	13	11.3
Brown	64	55.7
Did not declare	2	1.7
Education		
Illiterate	4	3.5
Incomplete Elementary School	34	29.6
Complete Elementary School	10	8.7
Incomplete High School	7	6.1
Complete High School	32	27.8
Incomplete High Education	7	6.1
Complete High Education	16	13.9
Postgraduate studies	5	4.3
Marital Status		
Married	44	38
Single	19	17
Divorced	40	35
Widower	12	10
Family Nucleus		
Alone	10	8.7
1–3 people	77	67
4–7 people	28	24.3
Family Income		
Less than 1 salary	27	23.5
From 1 to 3 salaries	48	41.7
From 3 to 6 salaries	26	22.6
More than 6 salaries	10	8.7
Did not know	4	3.5
Housing Conditions		
Rent	41	35.7
Owner	71	61.7
Other	3	2.6

Table 2. Biological and behavioral factors involved in the genesis of breast cancer in women treated at a highly complex oncology care unit. Brasília, 2020.

Characteristics	N	%
Age of Menarche (years)		
≥ 9 and < 10	2	1.7
10–12	37	32.2
13–15	60	52.2
> 15	13	11.3
Did not remembe	3	2.6
Use of contraceptives and/or hormone replacement		
Yes	85	73.9
No	30	26.1
Age of first pregnancy (years)		
15–17	15	13.1
18–21	33	28.7
22–25	22	19.1
26–29	13	11.3
≥ 30	18	15.6
Nulliparas	13	11.3
Did not know	1	0.9
Breastfeeding		
Yes	96	83.5
> 1 year	61	63.5
< 1 year	35	36.5
No	19	16.5
Age of Menopause (years)		
45–49	57	49.6
50–60	29	25.2
Does not apply	29	25.2
Neoplasm in the Family		
Yes	79	68.7
Type of Cancer		
Breast	35	44.3
Ovary	2	2.5
Others	42	53.2
No	36	31.3
Alcoholism		
Former drinker	66	57.4
Yes	5	4.3
No	44	38.3
Smoking		
Former smoker	46	40
Yes	5	4.3
No	64	55.7
Practice of physical activity prior to diagnosis		
Yes	80	69.6
No	35	30.4

In the “AMAZONA III” study, both in the group of women undergoing treatment in the private network and in the group receiving care from the public network, it was observed that more than half had undergone hormonal therapy during their lifetime¹².

However, some studies claim that the risk of developing breast cancer influenced by contraceptive therapy and hormone replacement therapy can decrease or even zero over the years of its interruption. Sun et al. stated that after two years of discontinuation of contraceptives, the risk of developing cancer significantly decreases and, after 10 years, this correlation is null¹⁵.

Given this scenario, the best thing to be done is to guide patients who use hormone therapy to adopt preventive measures, to make periodic consultations with the mastologist, and to perform tests in the presence of any suspicious changes.

The Brazilian Society of Pediatrics considers, for women: precocious puberty those that start before the age of eight; late puberty as the ones that start after 13 years of age; and normal when it occurs between 8 and 13 years of age¹³. Rojas and Stuckey bring studies that showed early menarche as a risk factor for breast cancer, as this is the moment that starts ovulation cycles, which increase women's exposure to endogenous estrogen¹⁴.

None of the women in this study had menarche at an early age. Oliveira et al. observed most women with menarche in the normal age group¹⁵, corroborating the data found in the study by Santos et al.¹⁶.

Normal menopause occurs between the ages of 40 and 55 years. It is considered early when it occurs before 40 years of age and late after 55 years of age¹⁷.

The later the menopause occurs, the longer women are exposed to breast-stimulating hormones, estrogen and progesterone. A relative risk of two was found for developing breast cancer in women who went through menopause after age 55 compared to women who went through it before age 45^{14,18}.

In the present study, only 25.2% of women reported menopause in the age group that includes cases considered late. A study from Paraná and another from Minas Gerais also did not observe a relationship between late menopause and the consulted cases^{16,18}.




Figure 1. Classification of the participants' body mass index.

Primiparity after the age of 30 is associated with a higher risk of breast cancer, due to the likely cumulative exposure of these women to factors, cited in our study, which have the potential to change breast cells to a neoplastic configuration and which will be stimulated during pregnancy to proliferate. The relationship between nulliparity and the risk of malignant breast cancer is justified by the non-exposure to the benefits of breastfeeding, explained below¹⁹.

The majority of women in our study had their first pregnancy before the age of 30 years. A study from Pará showed a similar result¹⁷.

Breastfeeding is widely known for its protective potential against breast cancer due to the hypoestrogenic state during this period¹⁴. This protection is provided both in the pre- and post-menopause period⁹. Breastfeeding for at least a year reduces the risk of developing breast cancer by 48%²⁰.

In this study, 83.5% of the participating women reported having breastfed their children, most of them for a period equal to or longer than one year. Rosa et al.¹², as well as Rocha et al.¹⁸, also reported a high number of women who breastfed.

Regarding the family history of cancer as a risk factor, the literature states that having individuals diagnosed with breast and/or ovarian cancer in the family is related to a higher risk of developing the disease in the breast throughout life due to the hereditary nature of the disease. This risk triples for first-degree relatives¹⁴.

In our data, 30.4% of the women reported having a case of breast cancer in a relative up to the fourth degree in their family. Rocha et al.¹⁸ and Nunes et al.²¹ reported a prevalence of breast cancer in the participants' relatives of less than 30%, considering relatives up to the fourth and first degrees, respectively.

Alcohol consumption and its relationship with breast cancer is controversial, but most epidemiological studies demonstrate a consistent relationship between the daily consumption of at least 30 g of alcohol and breast cancer¹⁴. The consumption of this substance is related to the increase in the levels of hormones associated with estrogen, which trigger the pathway of its receptor⁵.

In our sample, alcohol consumption was reported by more than 60% of women, who reported no daily use, only social. Several similar studies did not show a correlation between alcohol consumption and the investigated cases^{10,12,18,19}. However, a Brazilian survey showed alcohol consumption in 57% of the sample²², similar to the data in our study.

Recent studies have associated active and passive smoking with an increased risk of breast cancer and worse survival outcomes¹⁴. Mutagenic compounds from cigarette smoke have already been found in the breast fluid of non-lactating women, showing the potential for activating oncogenes in the breast through this habit⁵.

In our data and in several other studies, it was observed that most women denied exposure to smoking, generating little association of cases in these studies with smoking^{10,12,18,19,22}.

The regular practice of physical activity is a factor that is related to the protection of women against breast cancer. It is believed that the mechanism that leads to this protection is due to the decrease in body fat, with a consequent reduction in the peripheral conversion of androgens to estrogens by the aromatase enzyme^{5,14}.

Most of the participants in our study reported doing some kind of physical activity before being diagnosed with cancer. However, 60.9% were overweight or had some degree of obesity at the time of the interview. Rocha et al.¹⁸, revealing data similar to those shown here, reported that more than 70% of the participants were overweight or had some degree of obesity, which shows that obesity is an important factor common to this population.

The most prevalent histological type of breast cancer in the population of this study was non-special type invasive carcinoma (96.5%), but in a smaller quantity there were also special type invasive carcinomas (3.5%). INCA estimates that invasive carcinoma of the non-special type corresponds to the most common type of breast cancer, representing between 70 and 80% of cases. Santos et al.¹⁶, Rocha et al.¹⁸, and Nunes et al.²¹ also showed a predominance of the non-special type in their studies.

CONCLUSION

This study showed that the main factors prevalent in the population with breast cancer studied were: advanced age, socially consuming alcohol, use of hormone therapy, and overweight.

The data emphasize the importance of medical follow-up with advancing age. Healthy routines and habits must also continue as breast cancer preventive practices, as well as the promotion of the rational use of hormonal therapies.

ACKNOWLEDGMENTS

To the hospital management and the director of the oncology clinic who authorized this study to be carried out.

AUTHORS' CONTRIBUTIONS

J.S.J.: Investigation, funding acquisition, investigation, data curation, methodology, project management, formal analysis, writing — review & editing.

F.S.: Administration, supervision, writing — review & editing.

J.V.O.L.: writing — review & editing.

REFERENCES

1. Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. *Breast Cancer*. 2019;11:151-64. <https://dx.doi.org/10.2147%2FBCCTT.S176070>
2. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2019.
3. Yanes T, Young MA, Meiser B, James PA. Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field. *Breast Cancer Res*. 2020;22(1). <https://doi.org/10.1186/s13058-020-01260-3>
4. Diniz CSG, Pellini ACG, Ribeiro AG, Tedardi MV, Miranda MJ, Touso MM, et al. Breast cancer mortality and associated factors in São Paulo State, Brazil: an ecological analysis. *BMJ Open*. 2017;7(8):016395. <https://doi.org/10.1136/bmjopen-2017-016395>
5. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk Factors and Preventions of Breast Cancer. *Int J Biol Sci*. 2017;13(11):1387-97. <https://doi.org/10.7150/ijbs.21635>
6. KakudjiBK, MwilaPK, BurgerJR, DuPlessisJM. Epidemiological, clinical and diagnostic profile of breast cancer patients treated at Potchefstroom regional hospital, South Africa, 2012-2018: an open-cohort study. *Pan African Med J*. 2020;36:9. <https://dx.doi.org/10.11604%2Fpamj.2020.36.9.21180>
7. Nascimento MM, Pereira LGD, Cordeiro PRN, Araújo LMG. Comparação e concordância de critérios à classificação do IMC de idosas fisicamente ativas, residentes no Sertão Nordestino. *J Hum Growth Dev*. 2017;27(3):342-9. <http://dx.doi.org/10.7322/jhgd.128227>
8. Yedjou CG, Sims JN, Miele L, Noubissi F, Lowe L, Fonseca DD, et al. Health and Racial Disparity in Breast Cancer. *Adv Exp Med Biol*. 2019;1152:31-49. https://doi.org/10.1007/978-3-030-20301-6_3
9. Instituto Nacional de Câncer José Alencar Gomes da Silva. Fatores de risco para o câncer de mama [Internet]. Rio de Janeiro: INCA; 2019 [cited on September 3, 2020]. Available at: <https://www.inca.gov.br/controlado-cancer-de-mama/fatores-de-risco>
10. Reis FP, Santos MEG, Sena WR, Santana R, Freitas TS, Silveira HF, et al. Perfil epidemiológico das pacientes com câncer de mama atendidas em uma unidade de saúde em São Francisco do Conde, Ba. *Rev Ciênc Méd Biol*. 2016;15(2):144-50.
11. Özsoy A, Barça N, Dölek BA, Aktas H, Elverice E, Araz L, et al. The Relationship Between Breast Cancer and Risk Factors: A Single-Center Study. *Eur J Breast Health*. 2017;13(3):145-9. <https://doi.org/10.5152/tjbh.2017.3180>
12. Rosa DD, Bines J, Werutsky G, Barrios CH, Cronemberger E, Queiroz GS, et al. The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115). *Breast Cancer Res Treat*. 2020;183(3):749-57. <https://doi.org/10.1007/s10549-020-05831-y>
13. PaulaLCC, PuñalesM. PuberdadePrecoce [Internet]. Brasil: Sociedade Brasileira de Pediatria, Departamento Científico de Endocrinologia; 2016 [cited on March 8, 2021]. Available at: https://www.sbp.com.br/fileadmin/user_upload/2016/09/Puberdade-Precoce.Leila_Ve4_.pdf
14. Rojas K, Stuckey A. Breast Cancer Epidemiology and Risk Factors. *Clin Obstet Gynecol*. 2016;59(4):651-72. <https://doi.org/10.1097/grf.0000000000000239>

15. Oliveira TSG, Neris RR, Santos LNT, Teixeira RG, Magnabosco P, Anjos ACY. Perfil de mulheres com câncer de mama tratadas com quimioterapia. *Rev Enferm UFPE On Line*. 2016;10(11):4097-103. <https://doi.org/10.5205/1981-8963-v10i11a11496p4097-4103-2016>
16. Santos JCM, Silva CM, Teixeira JJV, Peder LD. Perfil epidemiológico e clínico de mulheres com câncer de mama na região oeste do Paraná. *Rev Bras Ciên Saúde*. 2019;23(4):449-58. <https://doi.org/10.22478/ufpb.2317-6032.2019v23n4.44252>
17. Federação Brasileira de Ginecologia e Obstetrícia (Febrasgo). Manual de Orientação em Climatério. Climatério: Conceitos, Etiopatogenia, Endocrinologia e Epidemiologia [Internet]. Brasil: Febrasgo [cited on March 8, 2021]. Available at: https://edisciplinas.usp.br/pluginfile.php/4236559/mod_page/content/3/Climaterio.pdf
18. Rocha FS, Silva WS, Nascimento ER, Bacciotti AM. Epidemiological profile of breast cancer in a reference hospital in the north region. *Mastology*. 2018;28(3):169-75. <https://doi.org/10.29289/2594539420180000413>
19. Sousa MM, Figueredo SB, Fernandes RM. Perfil clínico-epidemiológico de mulheres com neoplasia de mama atendidas no hospital regional de referência no município de Araguaína-TO no período de 2000 a 2015. *Desafios*. 2016;2(2):283-306. <https://doi.org/10.20873/uft.2359-3652.2016v2n2p283>
20. Gradim CVC, Magalhães MC, Faria MCF, Arantes CIS. Aleitamento materno como fator de proteção para o câncer de mama. *Rev Rene*. 2011;12(2):358-64.
21. Nunes BAP, Siqueira SL, Pereira SM, Pacheco TJ, Pessanha TO, Mendonça SB. Perfil epidemiológico dos pacientes diagnosticados com câncer de mama em Campos dos Goytacazes (RJ), Brasil. *Rev Bras Mastologia*. 2012;22(4):117-23.
22. Souza NHA, Falcão LMN, Nour GFA, Brito JO, Castro MM, Oliveira MS. Câncer de mama em mulheres jovens: estudo epidemiológico no nordeste brasileiro. *SANARE*. 2017;16(2):60-7. <https://doi.org/10.36925/sanare.v16i2.1179>



Trends in bilateral mastectomy for cases of unilateral breast cancer in a Brazilian institute over a 10-year period

Francisco Pimentel Cavalcante^{1*} , Paulo Goberlâneo de Barros Silva² , Marcos Venicio Alves Lima² 

ABSTRACT

Introduction: There has been a substantial increase worldwide in the number of women with unilateral breast cancer who undergo bilateral mastectomy. Possible contributing factors include the advent of nipple-sparing mastectomy (NSM) and an improvement in breast reconstruction techniques. This study evaluated the trend in bilateral mastectomy at the Ceará Cancer Institute in Brazil. **Methods:** Patients with unilateral breast cancer who underwent mastectomy and immediate breast reconstruction were evaluated retrospectively between 2009 and 2018. Clinical, pathological and surgical factors were analyzed to determine their possible effects on the type of surgery performed. **Results:** Of 121 patients, 77 (63.6%) were submitted to unilateral mastectomy, while 44 (36.4%) underwent bilateral mastectomy. Most were treated with NSM ($n = 66$; 54.5%), with this technique being significantly associated with bilateral mastectomy ($p < 0.001$). Bilateral mastectomy increased significantly over the period ($p = 0.009$; $r^2 = 0.592$), but unilateral mastectomy did not ($p = 0.417$; $r^2 = 0.084$). Age < 45 years ($p = 0.007$) and negative axilla ($p = 0.003$) were also associated with bilateral mastectomy, while axillary dissection was associated with unilateral mastectomy ($p = 0.028$). Multivariate analysis showed the 2016-2018 period to be an independent factor associated with bilateral mastectomy. **Conclusions:** These results corroborate the international literature. From 2010 onwards, there was a trend towards an increase in bilateral mastectomy with breast reconstruction. These data may contribute to multidisciplinary debates, facilitating the establishment of guidelines. Further studies are required to improve understanding of this phenomenon in Brazil.

KEYWORDS: prophylactic mastectomy; unilateral breast neoplasms; mammoplasty.

INTRODUCTION

Breast-conserving surgery is the preferred treatment for early breast cancer. Survival rates after long periods of follow-up are comparable to those achieved with radical mastectomy.¹⁻⁶ Currently, the rates of local recurrence are low irrespective of the extent of the surgery;⁷ nevertheless, many patients will still undergo mastectomy.

Skin-sparing (SSM) and nipple-sparing mastectomy (NSM) facilitate breast reconstruction and, although no prospective controlled studies have been conducted to evaluate the oncologic safety of these techniques, retrospective studies show adequate local control when compared to radical mastectomy.^{8,9}

Recently, various countries have registered increased rates of bilateral mastectomy and a reduction in cases of unilateral mastectomy.¹⁰ Possible explanations include cancer phobia, the possibility of detecting genetic susceptibility to breast cancer,¹¹ and of immediate

breast reconstruction, particularly with the use of implants, following SSN or NSM, with the potential to achieve better breast symmetry,¹² and the greater attention given to the subject by the lay press. This trend, however, has yet to be evaluated in Brazil.

The purpose of the present study was to evaluate this trend in the surgical treatment of breast cancer, specifically bilateral mastectomy and its associated clinical factors, in a setting in which immediate breast reconstruction is available, in women with unilateral breast cancer who were to undergo mastectomy in a reference oncology institute in Brazil.

METHODS

This retrospective, longitudinal study included women with unilateral breast cancer. The internal review board of the Ceará Cancer Institute approved the study protocol under reference

¹Hospital Geral de Fortaleza – Fortaleza (CE), Brazil.

²Instituto do Câncer do Ceará – Fortaleza (CE), Brazil.

*Corresponding author: fpimentelcavalcante@gmail.com

Conflict of interests: nothing to declare.

Received on: 04/28/2021. Accepted on: 06/28/2021.

61,473. Medical records were reviewed and, between 2009 and 2018, patients submitted to mastectomy for the treatment of unilateral invasive breast cancer with recommendation for immediate breast reconstruction were selected. Patients with bilateral breast cancer, breast cancer recurrence or metastatic disease on an initial stage were excluded from the study. The factors evaluated were: whether mastectomy was SSM or NSM, unilateral or bilateral, and the year of the procedure. Data on age, tumor size (T), lymph nodes (N) and molecular subtypes were recorded. Hormone receptor (HR)-positive and HER2-negative tumors were considered luminal, while those expressing HER2 (or FISH/SISH-positive) were classified as HER2, and those that were HR-negative and HER2-negative were considered triple-negative (TN). The type of axillary surgery, adjuvant treatment (chemotherapy, hormone therapy and radiotherapy) and the presence of the inherited pathogenic mutations that predispose to cancer were also evaluated. Clinical outcomes were classified as local and/or regional recurrences, distant recurrences or death resulting from breast cancer. Follow-up of at least three months was required to determine any failure or major complications (skin necrosis, infection or hematoma that required reoperation) in breast reconstruction.

Data were expressed as absolute frequencies and percentages. Associations with the type of mastectomy were determined by using Fisher's exact test or Pearson's χ^2 test. To determine the

factors independently associated with unilateral or bilateral mastectomy, the variables with $p < 0.20$ were selected using a forward stepwise approach to build a multinomial logistic regression model.

Linear regression was performed to establish the rate profile of bilateral and unilateral mastectomies over the evaluation period. The SPSS statistical software package for the social sciences, version 20.0 for Windows, was used. A significance level of 95% was adopted throughout the analysis.

RESULTS

The medical records of 341 patients were reviewed and 121 met the inclusion criteria. Between 2009 and 2018, 77 patients (63.6%) underwent unilateral mastectomy, while 44 (36.4%) underwent bilateral mastectomy. Most were treated with NSM ($n = 66$; 54.5%), a method significantly more common among the patients undergoing bilateral mastectomy ($p < 0.001$) (Table 1).

Bilateral mastectomies were more common in patients < 45 years of age ($p = 0.007$). Of those undergoing bilateral mastectomy, only two had a pathogenic mutation, BRCA, in both cases. T1 ($n = 38$; 36.2%) and N0 ($n = 33$, 56.9%) were the most prevalent tumor stage and node status, respectively. Distant metastases were found in 7 patients (8.0%). Node status was significantly associated with bilateral mastectomy ($p = 0.003$) (Table 2).

Table 1. Profile of mastectomies performed between 2009 and 2018.

Total	Mastectomy			
	Total	Unilateral	Bilateral	p-value
	121 (100%)	77 (63.6%)	44 (36.4%)	-
Surgery				
Nipple-sparing mastectomy	66 (54.5%)	31 (40.3%)	35 (79.5%)*	< 0.001
Skin-sparing mastectomy	55 (45.5%)	46 (59.7%)*	9 (20.5%)	
Year				
2009	2 (1.7%)	2 (2.6%)	0 (0.0%)	< 0.001
2010	8 (6.6%)	8 (10.4%)	0 (0.0%)	
2011	4 (3.3%)	3 (3.9%)	1 (2.3%)	
2012	2 (1.7%)	2 (2.6%)	0 (0.0%)	
2013	7 (5.8%)	6 (7.8%)	1 (2.3%)	
2014	23 (19.0%)	22 (28.6%)*	1 (2.3%)	
2015	19 (15.7%)	16 (20.8%)*	3 (6.8%)	
2016	13 (10.7%)	5 (6.5%)	8 (18.2%)*	
2017	10 (8.3%)	3 (3.9%)	7 (15.9%)	
2018	33 (26.3%)	10 (13.0%)	23 (52.3%)*	
Period				
2009-2015	65 (53.7%)	59 (76.6%)*	6 (13.6%)	< 0.001
2016-2018	56 (46.3%)	18 (23.4%)	38 (86.4%)*	

* $p < 0.05$. Fisher's exact test or Pearson's χ^2 test (n; %).

Most tumors were HR-positive ($n = 63$, 78.8%) and HER-negative ($n = 70$, 87.5%). Only 9 tumors (11.3%) were TN. Tumor phenotype was similar in the two groups ($p > 0.05$) (Table 2).

Adjuvant radiotherapy was administered to 53 patients (51.0%) and was not associated with unilateral or bilateral mastectomy ($p = 0.116$). Ten patients (11.1%) developed postoperative complications and three patients (2.5%) suffered local recurrence, unassociated with the type of mastectomy performed in both cases ($p = 0.717$ and $p = 1.000$, respectively) (Table 3). Positive sentinel lymph nodes were found in 62 patients (59.0%), with no difference between the two groups ($p = 0.292$). Thirty-two patients (30.5%) underwent axillary dissection, which was significantly associated with unilateral mastectomy ($p = 0.028$). Most of the patients ($n = 71$; 71.7%) underwent chemotherapy, with no association with the type of mastectomy performed ($p = 0.102$). Chemotherapy was neoadjuvant in 53% of cases. Most women received hormone therapy ($n = 74$; 85.1%),

which was associated with unilateral mastectomy ($p = 0.013$). Six deaths occurred (7.5%), unassociated with the type of mastectomy performed ($p = 0.092$) (Table 3).

Bilateral mastectomy increased significantly ($p = 0.009$, $r^2 = 0.592$) over the period. Conversely, unilateral mastectomy did not ($p = 0.417$, $r^2 = 0.084$) (Figure 1). The number of bilateral mastectomies was significantly higher than unilateral mastectomies from 2016 onwards ($p < 0.001$) (Table 1). In the multivariate analysis, the 2016–2018 period was independently associated with bilateral mastectomy, with an odds ratio of 11.53 (95%CI 1.26–105.71) in relation to unilateral mastectomy ($p = 0.031$) (Table 4).

DISCUSSION

This study found increasing rates of bilateral mastectomy, particularly after 2016. Conversely, unilateral mastectomy did not increase significantly over this period. A study based on the Surveillance,

Table 2. Effect of age at diagnosis, clinical staging and tumor phenotype on the profile of the mastectomies performed.

	Mastectomy			p-value
	Total	Unilateral	Bilateral	
Age (years)				
< 45	39 (44.3%)	15 (31.3%)	24 (60.0%)*	0.007
≥ 45	49 (55.7%)	33 (68.8%)*	16 (40.0%)	
Tumor stage				
T1	38 (36.2%)	20 (32.8%)	18 (40.9%)	0.809
T2	52 (49.5%)	31 (50.8%)	21 (47.7%)	
T3	12 (11.4%)	8 (13.1%)	4 (9.1%)	
T4	3 (2.9%)	2 (3.3%)	1 (2.3%)	
Node status				
N0	33 (56.9%)	14 (40.0%)	19 (82.6%)*	0.003
N1	20 (34.5%)	18 (51.4%)*	2 (8.7%)	
N2	5 (8.6%)	3 (8.6%)	2 (8.7%)	
Metastases				
M0	80 (92.0%)	50 (89.3%)	30 (96.8%)	0.413
M1	7 (8.0%)	6 (10.7%)	1 (3.2%)	
Hormone receptor				
No	17 (21.3%)	6 (13.6%)	11 (30.6%)	0.066
Yes	63 (78.8%)	38 (86.4%)	25 (69.4%)	
HER2				
No	70 (87.5%)	41 (93.2%)	29 (80.6%)	0.104
Yes	10 (12.5%)	3 (6.8%)	7 (19.4%)	
Triple-negative				
No	71 (88.8%)	41 (93.2%)	30 (83.3%)	0.286
Yes	9 (11.3%)	3 (6.8%)	6 (16.7%)	

* $p < 0.05$. Fisher's exact test or Pearson's χ^2 test (n; %).

Table 3. Additional treatment and outcome according to the type of mastectomy performed.

	Mastectomy			
	Total	Unilateral	Bilateral	p-value
Radiotherapy				
No	51 (49.0%)	28 (43.1%)	23 (59.0%)	0.116
Yes	53 (51.0%)	37 (56.9%)	16 (41.0%)	
Complications				
No	80 (88.9%)	55 (87.3%)	25 (92.6%)	0.717
Yes	10 (11.1%)	8 (12.7%)	2 (7.4%)	
Local recurrence				
No	118 (97.5%)	75 (97.4%)	43 (97.7%)	1.000
Yes	3 (2.5%)	2 (2.6%)	1 (2.3%)	
Positive sentinel lymph node				
No	43 (41.0%)	28 (45.2%)	15 (34.9%)	0.292
Yes	62 (59.0%)	34 (54.8%)	28 (65.1%)	
Axillary dissection				
No	73 (69.5%)	38 (61.3%)	35 (81.4%)*	0.028
Yes	32 (30.5%)	24 (38.7%)*	8 (18.6%)	
Chemotherapy				
No	28 (28.3%)	17 (28.3%)	11 (28.2%)	0.102
Neoadjuvant	32 (32.3%)	15 (25.0%)	17 (43.6%)	
Adjuvant	39 (39.4%)	28 (46.7%)	11 (28.2%)	
Hormone therapy				
No	13 (14.9%)	4 (7.3%)	9 (28.1%)*	0.013
Yes	74 (85.1%)	51 (92.7%)*	23 (71.9%)	
Death				
No	74 (92.5%)	47 (88.7%)	27 (100.0%)	0.092
Yes	6 (7.5%)	6 (11.3%)	0 (0.0%)	

* $p < 0.05$. Fisher's exact test or Pearson's χ^2 test (n; %).

Epidemiology and End Results (SEER) program showed an increase in contralateral mastectomy in the United States from 1.8% in 1998 to 4.5% in 2003.¹³ Simultaneously, conservative treatment remained stable, indicating that the preference for contralateral mastectomy is especially for women undergoing major surgery.¹⁴

The present rate of bilateral mastectomy was higher compared to earlier studies,^{13,14} particularly in cases of NSM. Having selected patients for whom immediate breast reconstruction was available may have affected our results: preservation of the entire skin envelope of the breast facilitates reconstruction involves more discrete scars, and may affect the decision to perform bilateral surgery.¹⁵ A retrospective study by the American National Cancer Database (NCDB) showed that in women submitted to surgery between 1998 and 2011, contralateral surgery increased 7% for each percentage point of increase in reconstruction.¹⁶

More women have opted for bilateral mastectomy despite a paradoxical decline in the rates of contralateral disease in recent years. Following the introduction of systemic treatment, the annual risk of contralateral cancer fell from 0.5% to around 0.1% annually.¹⁷ Overestimation of the risk may have affected the planning of surgeries. Germline mutations such as the BRCA1/2 gene mutations are known to play a role in the appearance of new breast tumors, with bilateral surgery often being recommended in such cases.¹⁸ Nevertheless, in this study, only two patients were confirmed to have one of the inherited gene mutations.^{19,20} Most of the prophylactic surgeries were probably performed based on family history and on the patients' personal decisions. A survey showed that only 38.1% of the patients with unilateral breast cancer knew that the contralateral prophylactic surgery had no effect on survival.²¹

Age also affected the results, with 56% of the women under 50 years of age undergoing bilateral surgery compared to 27% of the

older patients, and a significant association being found between age < 45 years and bilateral surgeries. Likewise, data from the California Cancer Registry revealed that bilateral surgery was associated with younger age, with the rates increasing from 3.6% in 1998 to 33% in 2011, an increase of almost 10 times within little more than ten years.²²

Neoadjuvant chemotherapy (NACT), traditionally used in cases of locally advanced cancer, has recently been indicated to facilitate breast conservation also in operable tumors.²³ Paradoxically, its use in the present study was associated with bilateral mastectomy in 53% of cases. A recent NCDB-based study reported similar results following the evaluation of almost 60,000 women submitted to NACT between 2010 and 2014.²⁴ Despite the increase in full pathological response over the time period, the rates of breast conservation increased slightly from 37.0% to 40.8% ($p = 0.22$) and bilateral mastectomy rates with immediate breast reconstruction increased from 8% to 13.1%, with a reduction in unilateral mastectomy. In the present study, bilateral surgery increased for patients with aggressive chemosensitive disease (70% of HER2 and 67% of the TN cases), although they would normally be potential candidates for NACT and conservative surgeries. Conversely, in luminal tumors, the bilateral surgery rate was lower: 30% of the cases. Better understanding is required regarding the reason why many patients who are eligible for breast-conserving surgeries decide that mastectomy is necessary. One of the possibilities is the fear of recurrence of the disease and the false impression that mastectomy is a "safer" treatment.²⁵

In the present study, bilateral surgery was more closely associated with early-stage breast cancer. Patients with negative axilla were more likely to undergo bilateral surgery, whereas those who had undergone axillary dissection were more likely to have had a unilateral surgery. In general, the impact of a prophylactic surgery tends to be lower in the advanced stages of the disease, which may have affected these results.

Breast reconstruction failure, the most serious local complication in this procedure, was low in the present analysis, irrespective of laterality. In a cohort of 471 patients from Yale University, 58% underwent bilateral surgery, with complication rates being similar to those found with unilateral surgery (re-operation: 11.2% versus 10.8%).²⁶ Bilateral prophylactic mastectomy was associated with a longer hospitalization period, a factor that was not evaluated in the present study. Most cases of breast reconstruction today are performed with the use of implants, minimizing surgical complications. Women undergoing reconstruction with autologous flaps,²⁷ which prolongs surgery and increases associated morbidity, were not included in the present study.

CONCLUSION

In conclusion, these results corroborate the international literature. From 2010 onwards, there was a trend towards an increase in bilateral mastectomy with breast reconstruction. These data may contribute to multidisciplinary debates, facilitating the

Table 4. Multinomial logistic regression for predictive factors of bilateral mastectomy.

	p-value	Adjusted OR (95%CI)
Bilateral mastectomy		
Surgery (NSM) (SSM)	0.431	-
Year (2016-2018)	0.031	11.53 (1.26–105.71)
Age (< 45 years)	0.322	-
Node (+)	0.375	-
Hormone Receptor (-)	0.218	-
HER2 (+)	0.998	-
Radiotherapy (Yes)	0.874	-
Axillary dissection (No)	0.994	-
Chemotherapy (Yes)	0.938	-
Hormone therapy (No)	0.655	-
Death (No)	1.000	-

* $p < 0.05$; OR: odds ratio; 95%CI: 95% confidence interval for the adjusted OR; SSM: skin-sparing mastectomy; NSM: nipple-sparing mastectomy.

establishment of guidelines. Nevertheless, further studies are required to increase understanding of this phenomenon and the impact it produces in the country.

AUTHORS' CONTRIBUTION

F.P.: Conceptualization, data curation, formal analysis, investigation, methodology, project administration, resources, supervision,

validation, visualization, writing — original draft, writing — review & editing.

M.V.: Conceptualization, data curation, formal analysis, investigation, methodology, project administration, resources, supervision, validation, visualization, writing — original draft, writing — review & editing.

P.G.: Data curation, formal analysis, methodology, resources, software, validation, visualization, writing — review & editing.

REFERENCES

1. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. *N Engl J Med*. 2002;347(16):1233-41. <https://doi.org/10.1056/nejmoa022152>
2. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. *N Engl J Med*. 2002;347(16):1227-32. <https://doi.org/10.1056/nejmoa020989>
3. Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. *J Natl Cancer Inst*. 2000;92(14):1143-50. <https://doi.org/10.1093/jnci/92.14.1143>
4. Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. *Cancer*. 2003;98(4):697-702. <https://doi.org/10.1002/cncr.11580>
5. Blichert-Toft M, Rose C, Andersen JA, Overgaard M, Axelsson CK, Andersen KW, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. *J Natl Cancer Inst Monogr*. 1992;(11):19-25.
6. Arriagada R, Lê MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. *J Clin Oncol*. 1996;14(5):1558-64. <https://doi.org/10.1200/jco.1996.14.5.1558>
7. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. *J Natl Cancer Inst*. 1996;88(21):1529-42. <https://doi.org/10.1093/jnci/88.21.1529>
8. Lanitis S, Tekkis PP, Sgourakis G, Dimopoulos N, Al Mufti RA, Hadjiminas DJ. Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies. *Ann Surg*. 2010;251(4):632-9. <https://doi.org/10.1097/sla.0b013e3181d35bf8>
9. Galimberti V, Morigi C, Bagnardi V, Corso G, Vicini E, Fontana SK, et al. Oncological outcomes of nipple-sparing mastectomy: a single-center experience of 1989 patients. *Ann Surg Oncol*. 2018;25(13):3849-57. <https://doi.org/10.1245/s10434-018-6759-0>
10. Neuburger J, Macneill F, Jeevan R, van der Meulen JH, Cromwell DA. Trends in the use of bilateral mastectomy in England from 2002 to 2011: retrospective analysis of hospital episode statistics. *BMJ Open*. 2013;3(8):e003179. <https://doi.org/10.1136/bmjopen-2013-003179>
11. Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. *BMJ*. 2014;348:g226. <https://doi.org/10.1136/bmj.g226>
12. Albornoz CR, Matros E, Lee CN, Hudis CA, Pusic AL, Elkin E, et al. Bilateral Mastectomy versus breast-conserving surgery for early-stage breast cancer: the role of breast reconstruction. *Plast Reconstr Surg*. 2015;135(6):1518-26. <https://doi.org/10.1097/prs.0000000000001276>
13. Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. *J Clin Oncol*. 2007;25(33):5203-9. <https://doi.org/10.1200/jco.2007.12.3141>
14. Habermann EB, Abbott A, Parsons HM, Virnig BA, Al-Refaie WB, Tuttle TM. Are mastectomy rates really increasing in the United States? *J Clin Oncol*. 2010;28(21):3437-41. <https://doi.org/10.1200/jco.2009.27.6774>
15. Cavalcante FP, Lima MV. Nipple-sparing mastectomy with periareolar incision and two-stage reconstruction: initial analysis of 31 cases. *Breast J*. 2018;24(6):940-3. <https://doi.org/10.1111/tbj.13114>
16. Kummerow KL, DuL, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. *JAMA Surg*. 2015;150(1):9-16. <https://doi.org/10.1001/jamasurg.2014.2895>
17. Nichols HB, González AB, Lacey Jr. JV, Rosenberg PS, Anderson WF. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. *J Clin Oncol*. 2011;29(12):1564-9. <https://doi.org/10.1200/jco.2010.32.7395>
18. Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. *Breast Cancer Res Treat*. 2014;144(3):443-55. <https://doi.org/10.1007/s10549-014-2890-1>
19. Reiner AS, Sisti J, John EM, Lynch CF, Brooks JD, Mellemkjaer L, et al. Breast cancer family history and contralateral breast cancer risk in young women: an update from the Women's Environmental Cancer and Radiation Epidemiology Study. *J Clin Oncol*. 2018;36(15):1513-20. <https://doi.org/10.1200/jco.2017.77.3424>

20. Wright FC, Hong NJ, Quan ML, Beyfuss K, Temple S, Covelli A, et al. Indications for contralateral prophylactic mastectomy: a consensus statement using modified delphi methodology. *Ann Surg.* 2018;267(2):271-9. <https://doi.org/10.1097/sla.0000000000002309>
21. Jagsi R, Hawley ST, Griffith KA, Janz NK, Kurian AW, Ward KC, et al. Contralateral prophylactic mastectomy decisions in a population-based sample of patients with early-stage breast cancer. *JAMA Surg.* 2017;152(3):274-82. <https://dx.doi.org/10.1001%2Fjamasurg.2016.4749>
22. Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA, Gomez SL. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. *JAMA.* 2014;312(9):902-14. <https://dx.doi.org/10.1001%2Fjama.2014.10707>
23. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. *J Natl Cancer Inst Monogr.* 2001;(30):96-102. <https://doi.org/10.1093/oxfordjournals.jncimonographs.a003469>
24. Pollom EL, Qian Y, Chin AL, Dirbas FM, Asch SM, Kurian AW, et al. Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy. *Int J Cancer.* 2018;143(12):3262-72. <https://doi.org/10.1002/ijc.31747>
25. Huang J, Chagpar A. Complications in patients with unilateral breast cancer who undergo contralateral prophylactic mastectomy versus unilateral mastectomy. *Surgery.* 2018;164(6):1347-50. <https://doi.org/10.1016/j.surg.2018.05.044>
26. Marks LB, Gupta GP, Muss HB, Ollila DW. Mastectomy may be an inferior oncologic approach compared to breast preservation. *Int J Radiat Oncol Biol Phys.* 2019;103(1):78-80. <https://doi.org/10.1016/j.ijrobp.2018.07.2021>
27. Massenburg BB, Sanati-Mehrziy P, Ingargiola MJ, Rosa JH, Taub PJ. Flap failure and wound complications in autologous breast reconstruction: a national perspective. *Aesthetic Plast Surg.* 2015;39(6):902-9. <https://doi.org/10.1007/s00266-015-0575-8>



Patient navigation: fighting for the rights of breast cancer patients in Brazil

Sandra Gioia^{1,2,3*} , Lucia Brigagão¹ , Maicon Rocha¹ , Paul Goss³ 

ABSTRACT

Introduction: The content of this article deals with the experience of the navigation program for patients in a breast cancer diagnosis center of the State Health Department of Rio de Janeiro. The objective was to show how the patient navigation program can allow the proper application of the 60-day Law, being a topic of interest for the planning and evaluation of actions to control this cancer in Brazil. **Methodology:** The patient navigator accompanied women from the Unified Health System (*Sistema Único de Saúde* — SUS) with a diagnosis of breast cancer to start treatment at a specialized center within 60 days. Information on the clinical characteristics of the patients, clinical dates and barriers encountered were collected. Univariate logistic regression was used to assess factors associated with starting treatment within 60 days. **Results:** From January to July 2020, 301 breast biopsies were performed, 126 (42%) of breast cancer. The mean age was 54 years (26–88). 75% of the lesions were diagnosed in advanced stages (IIB to IV). The mean time to start treatment was 39 days (11–108). The main barriers found were: fear (93%), difficulty in communicating with the medical team (81%), uncoordinated health care (37%). Being treated outside the city of Rio de Janeiro (RJ) was the main factor associated with treatment within 60 days (79.5% vs. 20.5%, $p < 0.001$). **Conclusion:** The integration of the patient browser into work processes contributed to compliance with the 60-day Law in 86% of cases. In the context of a complex and fragmented healthcare system for a population in a situation of socioeconomic vulnerability, the patient navigation program proves to be a tool to increase the rate of law enforcement in Brazil.

KEYWORDS: breast neoplasms; patient navigation; barriers to access of health services; patient rights.

INTRODUCTION

Although there is a trajectory of actions for the prevention and control of breast cancer (BC) in Brazil, the scenario of its high incidence, diagnosis at an advanced stage, and high mortality continues to be constant due to barriers regarding access to health care¹. The estimate for the 2020-2022 triennium is of about 66,280 new cases per year, with an incidence of 61.61 per 100,000 inhabitants². The crude death rate was 15.4 per 100,000 inhabitants, with 16,069 deaths in 2016. There was an increase of 33.6% in the mortality rate from BC in the period from 1980 to 2016².

Approximately 75% of Brazilians are covered exclusively by the Unified Health System (*Sistema Único de Saúde* — SUS), and although progress toward universal health coverage has been made across the country, large disparities that affect cancer care remain³. Women treated in SUS have more advanced disease and worse disease-free and overall survival when compared to women treated in private health care

facilities (which can be partially attributed to longer delays and advanced stages in diagnosis)³.

The average time for diagnosis is up to 31 days in the private health care system, with 18% of cases diagnosed in stages III and IV, while in SUS the average is 93 days, and in some cases it can reach up to 180 days, with 40% of cases diagnosed in these advanced stages⁴. In addition, the average age of BC diagnosis in Brazil is 53 years, and 30% to 40% of women are under 50 years of age. This significant portion of women is outside the Ministry of Health's screening recommendation and has more aggressive and faster growing tumors (HER-2 positive and triple negative subtypes)^{4,5}.

Providing quality cancer care to all patients presents numerous challenges, including difficulties in coordination of and access to care. It is "a community-based service delivery intervention designed to promote access to timely diagnosis and treatment of cancer and other chronic diseases, removing barriers to care"⁶. Patient navigation has been frequently proposed

¹Secretaria de Estado de Saúde do Rio de Janeiro – Rio de Janeiro (RJ), Brazil.

²Global Cancer Institute – Boston (MA), United States.

³Massachusetts General Hospital Cancer Center and Harvard Medical School – Boston (MA), United States.

*Corresponding author: sandra.gioia@gmail.com

Conflict of interests: nothing to declare.

Received on: 03/09/2020. Accepted on: 06/09/2021.

and implemented to face the challenges of access to cancer care in high-income countries⁷. There are still few studies on patient navigation interventions in cancer treatment in low- and middle-income countries in Asia, South America, and Africa, but all suggest that the provision of navigation services can improve access to cancer care in these countries⁷. All barriers to accessing healthcare resources affect health, overall survival, and mortality rates, which is why a patient navigation program (PNP) is so important. This can ensure that patients receive the help they need on the cancer journey in low- and middle-income countries, particularly in areas where access to health care is fragmented and health systems may be fragile and underfunded⁸.

Recognizing the negative impact of the delay in cancer diagnosis and treatment, in 2012 the Brazilian government issued Law No. 12.732/12 of the Ministry of Health, or the 60-day Law (*Lei dos 60 Dias*). This law establishes that treatment for any type of cancer for patients in the public health system must start within 60 days of the definitive diagnosis⁹. In a recent initiative in Rio de Janeiro (RJ), the effectiveness of patient navigation in the public health system from a diagnostic center was proven through an increase in the rate of compliance with the 60-day Law from 10% to 52%¹⁰. This study showed the main factors that contribute to compliance with the Law in Rio de Janeiro¹¹:

- improvement in the structure and processes of diagnostic services (histopathological report with the identification of the molecular subtype, delivery of the report in a medical consultation, direct insertion into the system regulation, performance of staging exams);
- patient navigator acting on the main barriers (fear and fatalistic thoughts and uncoordinated health care);
- treatment outside the capital of Rio de Janeiro.

The content of this article deals with the experience of navigating patients in a BC diagnosis center of the State Health Department of Rio de Janeiro within a women's hospital, *Hospital da Mulher Heloneida Studart* (HM), in the city of São João de Meriti (RJ). This diagnostic center serves mainly the Baixada Fluminense (part of the population in Metropolitan Health Region I)¹². The objective was to offer those interested in the topic, especially managers and health professionals, subsidies to understand, plan and evaluate the actions to control this cancer throughout the continuum of care in which patient navigation intends to allow the proper application of the 60-day Law.

The PNP at HM aims to help women diagnosed with BC start treatment at a specialized center within 60 days. Its target population is women from the SUS with a diagnosis of BC, who need to start treatment at a specialized center. Its main goals are:

- To be successful if at least 70% of women start treatment within 60 days of histopathological confirmation
- To use the results to inform hospitals and health policy makers about the positive results of patient navigation.

METHODS

This is an intervention in a diagnostic service in which a social worker was trained to be a patient navigator (PN) with the responsibility of monitoring patients recruited from the day of the breast biopsy at the HM Imaging Center to the start of treatment at the Reference Center determined by the regulation of the State Health Department of Rio de Janeiro. Inclusion criteria were: women with a diagnosis of BC over 18 years old and attending a public service for consultation regarding a confirmed BC. Exclusion criteria were: no personal documents; patients with private health care insurance; investigation or diagnosis of second primary tumor; patients in the terminal phase of some other disease (prognosis of survival of less than 6 months); uncontrolled comorbidities; history of drug abuse or alcoholism; patients suffering from major psychotic disorders or uncontrolled psychiatric disorders; mentally handicapped patients; incarcerated patients; loss of follow-up.

Contact with the patient took place at least once a week by phone, e-mail, text message or in person. After three consecutive unsuccessful contacts with the patient, navigation was interrupted, this being called loss to follow-up.

Information was collected on the patients' clinical characteristics, clinical dates, barriers encountered, a satisfaction questionnaire, and the Functional Assessment of Cancer Therapy — Breast¹³ questionnaire was applied, which includes a list of statements that other patients with BC judged to be important. Descriptive analysis of population characteristics was performed using measures of central tendency and dispersion (continuous variables) and measures of absolute and relative frequency (categorical variables). To assess factors associated with starting treatment within 60 days, a univariate logistic regression was performed.

RESULTS

From January to July 2020, 301 breast biopsies were performed, with 126 (42%) positive cases for malignancy. Twenty-three patients were excluded (6 died before the biopsy result, 7 were not located, and 10 had private health insurance). Table 1 shows the clinical characteristics of the 103 patients enrolled in the PNP of HM and of the 85 patients followed up to the start of treatment after additional exclusions (14 due to loss of follow-up, 3 due to investigation of a second primary tumor, and 1 due to uncontrolled comorbidities).

Mean age was 54 years (26–88 years). Forty percent of patients were under 50 years of age, and 84% reside in *Baixada Fluminense*. Seventy-five percent of the lesions were diagnosed at an advanced stage (clinical stage IIB to IV). As for the biological profile, 59% were classified as luminal, 21% as HER-2 positive, and 20% as triple negative. Women under 50 years of age were more frequently diagnosed at an advanced stage than women over 50 years (81% vs. 77%, $p = 0.655$). HER-2 and triple negative

Table 1. Clinical and treatment characteristics of women with breast cancer (n = 103).

Characteristics	n	%
Age range, in years		
< 50	42	40
≥ 50	61	60
Municipality of residence		
Belford Roxo	12	12
Cabo Frio	05	5
Duque de Caxias	07	7
Japeri	01	1
Mesquita	05	5
Nilópolis	07	7
Nova Iguaçu	25	24
Rio de Janeiro	19	18
São João de Meriti	22	21
Clinical staging at diagnosis		
<i>in situ</i>	00	0
I	03	3
IIA	23	22
IIB	29	28
IIIA	03	3
IIIB	36	35
IIIC	01	1
IV	08	8
Clinical staging at diagnosis		
Initial	26	25
Advanced	77	75
Histological type		
Invasive ductal carcinoma	89	86
Invasive lobular carcinoma	10	10
Ductal carcinoma <i>in situ</i>	03	3
Invasive papillary carcinoma	01	1
Grade		
1	06	6
2	78	76
3	19	18
Biological profile		
Luminal A	25	25
Luminal B	35	34
HER-2 positive	22	21
Triple negative	21	20
Family history for breast cancer		
Yes	29	28
No	74	72
Related death		
Yes	01	1
No	102	99
Additional exclusions		
Loss of follow-up	14	14
Second primary tumor	03	3
Uncontrolled comorbidities	01	1
Type of initial treatment*		
Surgery	16	19
Chemotherapy	64	75
Hormone therapy	5	6
Location of referral center for initial treatment*		
Duque de Caxias	28	33
Nova Iguaçu	26	31
Rio de Janeiro	24	28
Cabo Frio	06	7
Espírito Santo	01	1

Initial staging = *in situ* to IIA, advanced = IIB to IV; Family history for breast cancer = at least one first-degree relative diagnosed with: breast cancer before age 50; bilateral breast cancer or ovarian cancer in any age group; women with a family history of male breast cancer; women with a histopathological diagnosis of proliferative breast lesion with atypia or lobular neoplasm *in situ*; women with a personal history of breast cancer; *after additional exclusions n=85.


subtypes were also more frequent in young women (22% and 32% vs. 21% and 17%, $p=0.197$). Twenty-eight percent of patients had a family history of BC. In the 9-month follow-up, 1 death related to BC was observed.

The mean times of the main clinical dates were: 59 days (3–179 days) between the mammography report and the biopsy; 20 days (15–30 days) between the biopsy and the histopathological report; 8 days (0–18 days) between the histopathological report and insertion into the regulatory system (SER/RJ); 32 days (0–90 days) between insertion in the regulation and the first consultation with a breast cancer specialist at the referral center. Eighty-one percent of patients started treatment with systemic therapy, and 66% started treatment in Baixada Fluminense (*Instituto Oncológico de Nova Iguaçu, Hospital Geral de Nova Iguaçu and Hospital Jardim Amália de Duque de Caxias*).

The average time to start treatment was 39 days (11–108 days), with an 86% compliance rate. Figure 1 shows the number of cases (%) of BC, according to the time to start treatment.

Table 2 shows the factors associated with treatment within 60 days. Patients who were referred for initial treatment outside the municipality of Rio de Janeiro (Baixada Fluminense, Cabo Frio, and Espírito Santo) were more likely to be treated within 60 days when compared to patients referred for treatment in the municipality of Rio de Janeiro (79.5% x 20.5%, $p < 0.001$).

The main barriers reported by patients are shown in Figure 2. Fear and fatalistic thoughts were reported by 93% of patients (fear of breast removal, hair loss, chemotherapy side effects, and death and suicidal thoughts). There was a suicide attempt in which the patient reported that, given the possibility of imminent death, she preferred to take her own life as soon as possible. The other barriers identified are attributed to the health system, such as difficulty in communicating with the health team (81%), uncoordinated health care (37%), waiting to start treatment (25%), and the need to redo staging exams (14%).

**Figure 1.** Number of cases (%) of breast cancer according to time to start treatment.

Patients' experience was assessed throughout the entire navigation process. With a score of 1 as a very poor experience and a score of 10 as an excellent experience, patients gave scores of 10, 9, and 8 to their overall experience (95%, 1%, and 4%, respectively). This characterized an excellent performance of the PNP.

Figure 3 shows the patient perception survey with the number (%) of agreement regarding the PN's relationship and services. Gratitude and nurturing and welcoming reception were the prevalent feelings among the patients, as shown by some statements: "I appreciate the reception with a lot of empathy, clearing up doubts, clarifying what was confusing in my head, offering psychological support"; "This awareness and support work is very important in a place that would only be for the delivery of test results"; "Despite the diagnosis, I feel welcomed and confident in the success of my treatment".

Figure 4 shows the responses to the Functional Assessment of Cancer Therapy-Breast questionnaire. This is a multidimensional questionnaire already well validated and used internationally as an instrument to measure quality of life in patients with BC.

Table 2. Factors associated with treatment within 60 days.

Characteristics	Time to start treatment ≤ 60 days (%)	p-value*
Age range (years)		
< 50	42 (57.5)	0.626
≥ 50	31 (42.5)	
Place of residence		
Baixada Fluminense	61 (84)	0.624
Cabo Frio	04 (5)	
Rio de Janeiro	08 (11)	
Clinical staging at diagnosis		
Initial	14 (19)	0.266
Advanced	59 (81)	
Biological profile		
Luminal	42 (57.5)	0.567
HER-2 positive	15 (20.5)	
Triple negative	16 (22)	
Type of initial treatment		
Surgery	11 (19)	0.837
Systemic	59 (81)	
Location of referral center for initial treatment		
Outside the municipality of Rio de Janeiro	58 (79.5)	<0.001
Municipality of Rio de Janeiro	15 (20.5)	

*Pearson's χ^2 .

DISCUSSION

To achieve the goals of the PNP at the HM, changes in work processes were necessary, from scheduling the breast biopsy to the start of treatment. The central pillar was to recognize the importance of understanding patients' experiences regarding patient-centered care¹⁴. The PNP performance was considered excellent by the patients, and the feeling of gratitude and positive experience prevailed.

Cancer is a disease that significantly affects people's lives, both patients and their families. It entails changes in the routine, from the initial commotion in search of an understanding of the diagnosis, after the first symptoms, through the performing of confirmation tests, referral to a specialist, the various visits to care facilities, the costs involved, the interruption of occupational activities, the concern with subsistence, the waiting time for the start of treatment, fears in the face of uncertainty regarding the response to the proposed treatment and, above all, the stigma associated with the diagnosis¹⁵.

The help of the navigator was important to reduce the barriers encountered by patients. The solutions found include: explaining the health system, educating patients about the diagnosis and medical procedures, and showing the importance of attending appointments and taking exams (educational barrier); providing more details about the treatment of the disease and referring patients to support groups or individual psychological support (emotional barrier); explaining about the diagnosis and treatment and advising patients about not being alone in this process and communicating the individual needs of each patient with




Figure 2. Proportion of barriers reported by patients to start treatment.




Figure 3. Patient perception survey.

the medical staff (cultural barrier); coordinating appointments for treatment services and ensuring that the tests needed to start treatment are available to doctors (health system barrier)¹⁰.

Historically, cancer is perceived as an intractable and devastating disease, with an outcome directly associated with death. This fact is particularly relevant and can be a source of stress and anxiety for patients¹⁵. In this study, 52% of patients were stressed with the disease and 72% were concerned that other family members would one day have the same disease. Hence the importance of focusing and listening to patients, seeking to understand the senses and meanings they attribute to experiencing this illness¹⁵.

Seventy-six percent of the patients said they felt little, more or less or not sexually attractive, and 58% managed to feel little, more or less like a woman. It is a process that can be experienced with intense psychological distress in view of the expectations of bodily changes, modification of self-image, impairment of functionality and independence that arise as effects resulting from the indicated treatment, which may involve surgery, chemotherapy, radiotherapy, among other indications. The prevalent issues raised by oncology patients point to the fact that the diagnosis of cancer stimulates emotions and entails a degree of uncertainty and insecurity that include the struggle for dignity and a marked fear for their lifetime¹⁶.

The main barrier reported by patients was fear and fatalistic thoughts (93%), as seen in the pioneer study in *Rio Imagem* in 2018¹⁰ and of Latino populations in the United States¹⁷. In this sense, the feeling of hope must be encouraged to be part of the patients' trajectory. Despite the fears associated with the disease, it is very important to

highlight the current chances of curing and controlling the disease. Maintaining a sense of hope contributes to engaging in possible achievements and positive experiences, despite the changes brought about by the illness. Keeping the routine planning, focusing on achievable activities, preserving the sense of spiritual and/or religious connection, and practicing relaxation activities can contribute to a more hopeful perspective on the scenario that can be disorganizing¹⁸.

In addition, correct, transparent information, transmitted by respectful and careful communication that must be carried out by the health team, facilitates the understanding of the reality of the disease, helping patients in the search for adequate treatment and favoring a more active posture in the process, whilst the lack of information can lead patients to misunderstand their disease, leading them to seek unconventional therapies, often reinforced by the stigma and consequent prejudice against cancer. It is very important that patients find a safe space for care, and the health team involved must be able to offer an active and empathetic approach to emotional issues¹⁸.

Seventy-five percent of the patients had advanced disease at diagnosis, 40% of the patients were considered young, that is, under 50 years of age, and 28% of the patients had a family history of BC, indicating the importance of expanding patient navigation for primary health care¹⁹. All patients with family risk reported that they were never instructed about the risks of the disease and how to protect their family members (change in lifestyle, screening for high-risk population, genetic counseling, genetic testing, and prophylactic interventions).




Figure 4. Responses to the Functional Assessment of Cancer Therapy-Breast questionnaire.

Effective actions in the management of care and acting on the main barriers to early detection of BC can favor adherence to personalized mammographic screening, timely investigation, and access to treatment. The PN experience in the Andaraí community, in the municipality of Rio de Janeiro, showed an increase in the tracking rate from 14% to 84%, and 100% of the lesions in 2018 were diagnosed in initial staging⁹.

The compliance rate with the 60-day Law was 86%. Medical records and active search of patients diagnosed in HM in 2019 show that the rate of compliance with the law was 27% (Sandra Gioia, HM, personal information, 2020). Thus, the introduction of PN was important to increase compliance with the law, reaching the level considered desirable (above 70%). PN intervention favored the journey of the patients, who, in their majority, needed neoadjuvant chemotherapy and were referred for treatment at the reference centers in Nova Iguaçu (RJ) and Duque de Caxias (RJ) via regulation. And patients with indication for surgical treatment were referred to the General Hospital of Nova Iguaçu. These services do not have waiting lines to start treatment, as seen in services in the city of Rio de Janeiro, which worsened during the COVID-19 pandemic.

Only 20.5% of patients treated in the city of Rio de Janeiro were able to comply with the law, due to the scarcity of places to start treatment. According to a 2017 report by the State Plan for Oncology Care of the State Health Department of Rio de Janeiro, there is a deficit of 14 units in oncology in Rio de Janeiro, 11 of which are in Metropolitan Region I¹². Most states had a worse rate of compliance with the 60-day Law for cases of BC diagnosed in an out-of-hospital environment, with Rio de Janeiro having the worst performance in all of Brazil (6%)²⁰. Compliance with the 60-day law in oncology is an acquired right, and all Brazilians must strive to ensure that it is properly complied with in accordance with current ethics. Given the inability to comply with the law in Rio de Janeiro, the PNP appears as a promising intervention to reverse this situation. And decision-making intends to be within ethical limits and its dilemmas, especially in the approach to the common good, which is based on the connections of all involved, particularly for those who are considered vulnerable²¹.

Data observed in the real world with the intervention of navigation show the importance of disseminating good results to the medical community and the population. It is expected that the PNP with BC will become a public health policy in Brazil with exclusive browsers for its area of performance in continuous care¹. It is also necessary to develop the school and the digital platform for patient navigation to create work organizations based on arrangements of people (health professionals), work processes, and digital technologies to deliver health care with value for the patient, that is, delivering the best outcomes for the patient at a lower cost.

CONCLUSIONS

The introduction of the PNP for BC was considered successful, with an 86% compliance rate for the 60-day Law, but with reservations about the difficulty of complying with the law in the municipality of Rio de Janeiro due to the shortage of human resources and medical supplies.

In the Brazilian context, the PNP can represent an opportunity to properly implement the existing legislation and, as such, it would have a great potential to favor the functioning of the health system in a health care network.

ACKNOWLEDGEMENTS

Thanks to Instituto Avon and Instituto Gnosis.

AUTHORS' CONTRIBUTIONS

S.G.: Formal Analysis, Project administration, Validation, Writing — original draft, Writing — review & editing.

L.B.: Supervision.

M.R.: Data curation.

P.G.: Conceptualization, Methodology, Resources, Funding acquisition, Investigation, Writing — review & editing.










REFERENCES

1. Gioia SM, Silva SF. Implementation strategies for the guidelines for the early detection of breast cancer in Brazil. *Mastology*. 2019;29(4):224-35. <https://doi.org/10.29289/25945394201920190007>
2. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de câncer no Brasil [Internet]. Rio de Janeiro: INCA, 2019 [cited on Sept 1, 2020]. Available at: <https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2020-incidencia-de-cancer-no-brasil.pdf>
3. Câncer no Brasil: A jornada do paciente no sistema de saúde e seus impactos sociais e financeiros. Interfarma [Internet]. 2018 [cited on Sept 1, 2020]. Available at: https://edisciplinas.usp.br/pluginfile.php/6231212/mod_resource/content/3/cancer-no-brasil-n-a-jornada-do-paciente-no-sistema-de-saude-e-seus-impactos-sociais-e-financeiros-interfarma.pdf
4. Rosa DD, Bines J, Werutsky G, Barrios CH, Cronemberger E, Queiroz GS, et al. The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115). *Breast Cancer Res Treat*. 2020;183(3):749-57. <https://doi.org/10.1007/s10549-020-05831-y>
5. Franzoi MA, Rosa D, Zafaroni F, Werutsky G, Simon S, Bines J, et al. Advanced Stage at Diagnosis and Worse Clinicopathologic Features in Young Women with Breast Cancer in Brazil: A Subanalysis of the AMAZONA III Study (GBECAM 0115). *J Glob Oncol*. 2019;5:1-10. <https://doi.org/10.1200/jgo.19.00263>
6. Freeman H, Rodriguez R. History and principles of patient navigation. *Cancer*. 2011;117(150):3539-42. <https://dx.doi.org/10.1002%2Fncr.26262>

7. Dalton M, Holzman E, Erwin E, Michelen E, Rositch AF, Kumar S, et al. Cancer patient navigation in low-and middle-income countries: A scoping review. *Plos One*. 2019;14(10):e0223537. <https://dx.doi.org/10.1371%2Fjournal.pone.0223537>
8. Calhoun E, Esparza A. *Patient Navigation: overcoming barriers care*. New York: Springer; 2018.
9. Brasil. Presidência da República. Lei N. 12.732, de 22 de novembro de 2012 [Internet]. Brasil; 2012 [cited on Sept 1, 2020]. Available at: http://www.planalto.gov.br/ccivil_03/_ato2011-2014/2012/lei/112732.htm.
10. Marsillac ML, Gioia S, Silva F, Torres c, Brigadão L, San Miguel S, et al. Improvement of the "Law of 60 Days" by Implementing Patient Navigation within the Breast Cancer Program: Pilot Project in Rio de Janeiro. *Acta Sci Cancer Biol*. 2020;4(3):42-7. <https://dx.doi.org/10.31080/ASCB.2020.04.0203>
11. Gioia S, Galdino R, Brigagão L, Valadares A, Seol F, San Miguel S, et al. Prediction of Attendance to the "Law of 60 Days" in Breast Cancer Patients using Machine Learning Classifiers. *Acta Sci Cancer Biol*. 2020;4(3):1628. <https://dx.doi.org/10.31080/ASCB.2020.04.0209>
12. Rio de Janeiro. Secretaria de Estado de Saúde do Rio de Janeiro. Plano Estadual de Atenção Oncológica [Internet]. Rio de Janeiro: Secretaria de Estado de Saúde do Rio de Janeiro; 2017 [cited on Sept 1, 2020]. Available at: <http://www.cib.rj.gov.br/arquivos-para-baixar/boletins-cib/2228-planoatencaooncologicafinal-centrosregionaisdiagnostico-052017/file.html>.
13. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulskey DS, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. *J Clin Oncol*. 1997;15(3):974-86. <https://doi.org/10.1200/jco.1997.15.3.974>
14. Ahmed F, Burt J, Roland M. Measuring patient experience: concepts and methods. *Patient*. 2014;7(3):235-41. <https://doi.org/10.1007/s40271-014-0060-5>
15. Oliveira D, Cavalcante L, Carvalho R. Sentimentos de Pacientes em Cuidados Paliativos sobre modificações corporais ocasionadas pelo câncer. *Psicol Ciênc Prof*. 2019;39:e176879. <https://doi.org/10.1590/1982-3703003176879>
16. Silva K, Barreto F, Carvalho F, Carvalho PRS. Estratégias de enfrentamento após o diagnóstico de câncer de mama. *Rev Bras Prom Saúde*. 2020;33:10022. <https://doi.org/10.5020/18061230.2020.10022>
17. Tejeda S, Darnell JS, Cho YI, Stolley MR, Markossian TW, Calhoun EA. Patient barriers to follow-up care for breast and cervical cancer abnormalities. *J Womens Health*. 2013;22(6):507-17. <https://dx.doi.org/10.1089%2Fjwh.2012.3590>
18. Tamagawa R, Garland S, Vaska M, Carlson LE. Who benefits from psychosocial interventions in oncology: a systematic review of psychological moderators of treatment outcomes. *J Behav Med*. 2012;35(6):658-73. <https://doi.org/10.1007/s10865-012-9398-0>
19. Gioia S, Brigagão L, Torres C, Lima A, Medeiros M. The implementation of patient navigation to improve mammography coverage and access to breast cancer care in Rio de Janeiro. *Mastology*. 2019;29(4):186-92. <https://doi.org/10.29289/25945394201920190006>
20. Brasil. Ministério da Saúde. Relatório de Intervalo de Tempo. Integrador RHC [Internet]. Brasil: Ministério da Saúde; 2020 [cited on Sept 1, 2020]. Available at: <https://irhc.inca.gov.br/RHCNet/visualizaTabNetExterno.action>
21. Buzaid A, Achatz M, Amorim G, Barrios CH, Carvalho FM, Cavalcante FP, et al. Challenges in the journey of breast cancer patients in Brazil. *Braz J Oncol*. 2020;16:e-20200021. <https://doi.org/10.5935/2526-8732.20200021>



Impact of the immunohistochemical panel on patients with breast cancer diagnosis cared for in a referral hospital in the state of Amazonas

Hilka Flávia Barra Espírito Santo Alves Pereira^{1,2,3*} , Roberto Alves Pereira² ,
Thais Cristina Fonseca da Silva² , Henrique Vieira Pereira² , Lucas Barbosa Arruda⁴ ,
Valbécia Tavares de Aguiar⁴ , Maiara Magri Pereira Olenchi⁴ ,
Moyra Marquez Serruya⁴ , Valéria Santos da Costa⁴ 

ABSTRACT

Objective: To demonstrate the time between the diagnosis of the disease, the result of the immunohistochemical panel and the beginning of specialized treatment in patients diagnosed with breast cancer seen at the Foundation Center of Oncology of the State of Amazonas, from June to November 2018 and in the same period of 2019. **Methods:** The study was part retrospective, based on data from medical records, and part prospective, based on data from patients, and we evaluated the time between diagnosis from the immunohistochemical panel and the beginning of specialized treatment in breast cancer patients. **Results:** 170 patients diagnosed with breast cancer were included, 71 from June to November 2018 and 99 breast cancer patients seen from June to November 2019. The median time between diagnosis and immunohistochemistry results of all patients was 36 days, and comparing the two groups of patients, it was observed that for half of the 2018 patients, the time was less than 105 days, while for half of the 2019 patients, it was less than 27 days. If the times between the result of the immunohistochemical panel and the start of personalized treatment in both groups were compared, it was seen that the median time until the start of treatment was longer for patients in 2018, 94.5 days versus 79 days for patients in 2019. **Conclusion:** There was a decrease in the time between the diagnosis and the result of the molecular panel in 2019 compared to 2018. Achieving this result more quickly provided the choice of personalized treatment for each patient, having an important impact on survival in that population.

KEYWORDS: prognosis; survival; breast cancer; immunohistochemistry; time-to-treatment.

INTRODUCTION

Breast cancer is the most common cancer in women worldwide, accounting for 24.2% of all cases in 2018, with 2.1 million new cases¹. It is estimated for each year of the 2020/2022 triennium, the diagnosis of 66,280 new cases of breast cancer, with an estimated risk of 61.61 cases per 100,000 women².

The increased incidence of cancer is related to the increase in life expectancy, improvement of diagnostic methods and the expansion of screening programs³. Most tumors have a slow progression and, if diagnosed early, show a considerable increase in the possibility of cure or improvement in survival⁴.

The immunohistochemical study has been used in different situations of breast pathology. Hormone receptors, namely estrogen receptors (ER) and progesterone receptors (PR) and the over-expression or amplification of human epidermal growth factor receptor-2 (HER2), are predictive factors among breast cancer patients⁵ and are used to define the treatment and establishment of the disease prognosis associated with clinical and pathological variables, as well as lymph node involvement, tumor size, histological type, tumor grade and surgical margins⁶.

The time interval between diagnosis and the start of treatment is important to guide resolving measures⁷, since delay can worsen prognosis in breast cancer. There is an association

¹Post-graduation in Obstetrics and Gynecology, Botucatu School of Medicine, Universidade Estadual Paulista "Júlio de Mesquita Filho" – São Paulo (SP), Brazil.

²Universidade Federal do Amazonas – Manaus (AM), Brazil.

³Fundação Centro de Oncologia do Estado do Amazonas – Manaus (AM), Brazil.

⁴Universidade Nilton Lins – Manaus (AM), Brazil.

*Corresponding author: hilkaespirit Santo@me.com

Conflict of interests: nothing to declare.

Received on: 02/18/2021. Accepted on: 06/28/2021.

between delayed diagnosis and treatment with worse disease-free survival, occurrence of lymph node metastasis, tumor size and late staging, but early detection is related to higher cure rates⁸.

Therefore, in Brazil, Law No. 12.732, of November 2012 guarantees cancer patients the right to start treatment within 60 days or less after confirmed diagnosis⁹.

Accordingly, the aim of our study was to demonstrate the time between the diagnosis of the disease, result of the immunohistochemical panel and beginning of personalized treatment in patients treated at the Foundation Center of Oncology of the State of Amazonas (FCECON) with a diagnosis of breast cancer, in the period from June to November 2018 and in the same period during 2019.

METHODS

This was an observational, cross-sectional and epidemiological study, composed of a retrospective part based on data from medical records, and a prospective part based on patient data, evaluating the time between the diagnosis according to the immunohistochemical panel and the beginning of specialized treatment in patients diagnosed with breast cancer. General data such as age, clinical stage at diagnosis, histological type, immunohistochemical panel, time between diagnosis and the start of treatment and time between diagnosis and the definitive result of the immunohistochemical panel were evaluated.

The 2017 FCECON management report was used as the basis to define a sample, which says that in one year, 131 patients were diagnosed with breast cancer. Therefore, our sample includes information collected from the medical records of patients diagnosed with breast cancer in the period from June to November 2018. Only records with complete information were entered in the study. In the prospective part, data were collected from patients diagnosed with breast cancer in the period from June to November 2019, with a questionnaire being filled out at the time of the consultation at the start of treatment. A total of 169 patients were evaluated, part retrospective, part prospective, referring to the period from June to November 2018 and 2019.

In 2019, FCECON became part of Roche Laboratory's Roche Testing program, enabling the complete and rapid assessment of the immunohistochemical panel for breast cancer. Previously, the examination was performed in a laboratory outside the city of Manaus, which involved a delay that sometimes exceeded 90 days, so there was an important gain for the institution. Thus, the study aimed to determine whether there was a change in the time between the diagnosis of the disease, the result of the immunohistochemical panel and the start of specialized treatment, comparing the 2018 part and 2019 part, since the institution did not yet have this support in 2018.

The immunohistochemical study was based on the identification of markers: ER, PR, HER2 and ki-67 protein. The classification

is performed according to: luminal A (ER- and/or PR-positive, HER2-negative and ki-67 index less than 14%), luminal B (ER- and/or PR-positive, HER2-negative and ki-67 index greater than 14%), overexpressed HER2 (HER2-positive, regardless of the presence of PR and ER), triple-negative (ER-, PR- and HER2-negative) and hybrid luminal (luminal B and HER2 overexpression).

The study was approved by the Research Ethics Committee on June 30, 2019, under No. 3.477.033 and CAAE 16400519.2.0000.0004. In the prospective evaluation, all patients signed an informed consent form.

RESULTS

A total of 170 breast cancer patients were included, 71 from June to November 2018 and 99 from June to November 2019. Most patients were between 40 and 69 years old, accounting for 80% of the women included in the study.

Regarding the histological type of patients, the ductal type was the most frequent among those interviewed in both periods. In assessing the immunohistochemical panel, luminal type A was the most common among patients, while the hybrid luminal type was the least frequent.

Regarding the initial treatment chosen in both periods, surgery was the most frequent; however, there was a significant increase in the percentage of patients who had chemotherapy as initial therapy in 2019, that is, 49.5% of patients in 2019 versus 28.2% in 2018.

The data for all variables listed above are presented in Table 1.

Regarding clinical staging, stage IIA was the most frequent in both periods. The most frequent Breast Imaging Reporting and Data System (BIRADS) classification was class IV, also in the two periods studied (Table 2).

In addition to the clinical characteristics of these patients, the time interval between diagnosis and the immunohistochemical results was analyzed. The median time between diagnosis and immunohistochemistry for all patients was 36 days (median absolute deviation or MAD of 28.9 days). Comparing the two groups of patients, it was observed that for half of the patients in 2018 the time was below 105 days (median), while for half of the patients in 2019 it was below 27 days (Figure 1). According to the non-parametric Mann-Whitney test, it can be concluded that there was a significant difference in time interval from diagnosis to immunohistochemical panel results between the two groups ($P \leq 0.05$).

Regarding the time between the result of the immunohistochemical panel and the beginning of personalized treatment, the median time was 86 days (MAD=74.1). When comparing the times in the two groups, the median time to start of treatment was longer for the 2018 patients – 94.5 days versus 79 days for the 2019 patients. The non-parametric Mann-Whitney test was not statistically significant; however, in the exploratory analysis,

Table 1. Profile of patients according to age, histological type, initial treatment and immunohistochemical panel.

Variable	Total n = 170 (%)	Group	
		Patients from 2018 n = 71 (%)	Patients from 2019 n = 99 (%)
Age (years)			
< 40	19 (11.2)	7 (9.9)	12 (12.1)
40–69	136 (80.0)	59 (83.1)	77 (77.8)
≥ 70	15 (8.8)	5 (7.0)	10 (10.1)
Histological type			
Ductal	149 (87.6)	57 (80.3)	92 (92.9)
<i>In situ</i>	7 (4.1)	7 (9.9)	0
Lobular	7 (4.1)	5 (7.0)	2 (2.0)
Medullary	2 (1.2)	0	2 (2.0)
Other	2 (1.2)	1 (1.4)	1 (1.0)
Papillary	3 (1.8)	1 (1.4)	2 (2.0)
Initial treatment			
Surgery	101 (59.4)	51 (71.8)	50 (50.5)
Chemotherapy	69 (40.6)	20 (28.2)	49 (49.5)
Immunohistochemical panel			
HER2 overexpression	36 (21.2)	8 (11.3)	28 (28.3)
Luminal A	72 (42.4)	36 (50.7)	36 (36.4)
Luminal B	38 (22.4)	15 (21.1)	23 (23.2)
Hybrid luminal	4 (2.4)	4 (5.6)	0
Triple-negative	20 (11.8)	8 (11.3)	12 (12.1)

Table 2. Profile of patients according to clinical staging and Breast Imaging Reporting and Data System classification.



Variable	Total n = 170 (%)	Group	
		Patients from 2018 n = 71 (%)	Patients from 2019 n = 99 (%)
Stage			
IA	8 (4.7)	5 (7.0)	3 (3.0)
IB	14 (8.2)	4 (5.6)	10 (10.1)
IIA	56 (32.9)	26 (36.6)	30 (30.3)
IIB	38 (22.4)	15 (21.1)	23 (23.2)
IIIA	25 (15.3)	10 (15.5)	15 (15.2)
IIIB	25 (14.7)	10 (14.1)	15 (15.2)
IV	3 (1.8)	0	3 (3.0)
BIRADS			
I	1 (0.6)	0	1 (1.0)
II	6 (3.5)	3 (4.2)	3 (3.0)
III	9 (5.3)	6 (8.5)	3 (3.0)
IV	105 (61.8)	46 (64.8)	59 (59.6)
V	49 (28.8)	16 (22.5)	33 (33.3)

BIRADS: Breast Imaging Reporting and Data System.

there was a difference in the interval between the result of the molecular panel and the start of personalized treatment in the 2018 compared to 2019 period (Figure 2).

DISCUSSION

The average age of the women analyzed in the study was close to that reported in other studies with Brazilian patients diagnosed with breast cancer, demonstrating an average age of 51.8 and higher frequency between 41 and 60 years¹⁰. In the present study, most patients were between 40 and 69, totaling about 80% of the women included.

**Figure 1.** Distribution of time between diagnosis and immunohistochemical results, in days.**Figure 2.** Distribution of time between immunohistochemical results and start of treatment, in days.

Regarding the clinical staging of patients, our data agree with an earlier study that showed a prevalence of clinical stage II in patients¹¹, as seen in both periods analyzed in our study.

In the BIRADS classification of patients, there was a prevalence of classification IV in both periods, data that agree with what was described in a study in which 34.7% of patients were classified as having BIRADS IV¹².

Regarding the histological type, our finding is similar to that published in another study that demonstrated that 76.9% of the patients analyzed had the invasive ductal histological type¹³. In the present study, 87.6% had this same histological type. Data referring to the immunohistochemical panel of the patients analyzed are in agreement with a study that demonstrated that most of the patients analyzed had luminal A¹⁴.

The prevalent elapsed time interval between diagnosis and immunohistochemical results in the 2018 period agreed with an earlier finding that most of the patients analyzed had a time interval between diagnosis and immunohistochemical examination greater than 90 days¹⁵. In the 2019 period, most patients obtained their immunohistochemical results within 27 days after diagnosis, a reflection of the integration of FCECON in the Roche Laboratory Roche Testing program, enabling the complete evaluation of the immunohistochemical panel for breast cancer.

In 2019, most patients started treatment within an average interval of 85.8 days after the immunohistochemical results. These data agree with a study that demonstrated that most patients started treatment more than 60 days after immunohistochemical diagnosis¹⁵.

This decrease in the time interval between diagnosis and the result of the immunohistochemical panel in 2019 compared to what was observed in 2018 contributed to the choice of personalized treatment for each patient, which before was often not possible. In 2018, obtaining the immunohistochemical panel was

greatly delayed, exceeding the 90-day interval, so treatment was based on the staging of each patient.

In 2018, most patients underwent initial surgical treatment (71.8%), because of this large time interval to obtain the molecular panel results. Thus, many patients who had a triple-negative panel or overexpressed HER2, for example, did not benefit from the appropriate initial treatment for their molecular types. In 2019, with the possibility of obtaining immunohistochemical information sooner, there was a significant increase in patients who received chemotherapy as initial therapy (49.5%), a result of the molecular evaluation that enabled the identification of patients who would benefit from this initial therapy and thereby receive personalized treatment.

CONCLUSION

Immunohistochemical diagnosis is a very important factor in the appropriate choice of initial treatment for breast cancer patients, ensuring personalized treatment for these women. The present study demonstrates the importance of the public-private partnership in improving the times for the diagnosis and treatment of breast cancer.

AUTHORS' CONTRIBUTIONS

H.P.: Writing — original article.

R.P.: Writing — original article.

T.S.: Writing — original article.

H.P.: Writing — original article.

L.A.: Writing — original article.

V.A.: Writing — original article.

M.O.: Writing — original article.

M.S.: Writing — original article.

V.C.: Writing — original article.

REFERENCES

1. World Health Organization. International Agency for Research on Cancer. Globocan. Estimated age-standardized incidence rates (World) in 2020, breast, females, all ages [Internet]. Geneva: World Health Organization [cited on Jan 20, 2021]. Available at: <https://gco.iarc.fr/today/online-analysis-map?projection=globe>
2. Instituto Nacional de Câncer José Alencar Gomes da Silva. Coordenação de Prevenção e Vigilância. Estatísticas para Câncer de Mama [Internet]. Rio de Janeiro: INCA; 2020 [cited on Jan 20, 2021]. Available at: <http://www.oncoguia.org.br/conteudo/estatisticas-para-cancer-de-mama>
3. Vieira SC. Câncer de mama: Consenso da Sociedade Brasileira de Mastologia - Regional Piauí [Internet]. Teresina: EDUFPI, 2017 [cited on Jan 20, 2021]. Available at: <https://www.sbmastologia.com.br/medicos>
4. Instituto Nacional do Câncer (INCA). Atlas de Mortalidade por câncer [Internet]. Brasil: INCA [cited on Jan 20, 2021]. Available at: <http://mortalidade.inca.gov.br/Mortalidade/prepararModelo05.action>
5. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2020;144(5):545-63. <https://doi.org/10.5858/arpa.2019-0904-sa>
6. Weaver O, Leung JWT. Biomarkers and Imaging of Breast Cancer. Am J Roentgenol. 2018;210(2):271-8. <https://doi.org/10.2214/ajr.17.18708>

7. Huo Q, Cai C, Zhang Y, Kong X, Jiang L, Ma T, et al. Delay in Diagnosis and Treatment of Symptomatic Breast Cancer in China. *Ann Surg Oncol*. 2015;22(3):883-8. <https://doi.org/10.1245/s10434-014-4076-9>
8. Instituto Nacional de Câncer José Alencar Gomes da Silva. Diretrizes para a detecção precoce do câncer de mama no Brasil [Internet]. Rio de Janeiro: INCA; 2015 [cited on Jan 20, 2021]. Available at: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//diretrizes_deteccao_precoce_cancer_mama_brasil.pdf
9. Brasil. Presidência da República. Lei nº 12.732, de novembro de 2012. Dispõe sobre o primeiro tratamento de pacientes com neoplasia maligna comprovada e estabelece prazo para seu início. *Diário Oficial da União* [Internet]. 2012 [cited on Jan 20, 2021]. Available at: http://www.planalto.gov.br/ccivil_03/_ato2011-2014/2012/lei/l12732.htm
10. Farina A, Almeida LLR, Paula LEJ, Medeiros RV, Silva MR, Somavilla SB. Perfil epidemiológico, clínico, anátomo patológico e imunohistoquímico das pacientes com câncer de mama em Cuiabá (MT). *Rev Bras Mastologia*. 2017;27(1):74-9. <https://doi.org/10.5327/Z201700010017RBM>
11. Dantas GG, Machado DE, Francisco SC, Moraes TR, Leite RB, Resende HM, et al. Perfil epidemiológico de pacientes com câncer de mama atendidas em hospital no Sudeste do Brasil: análise de prontuários. *Cad UniFOA*. 2019;14(41):137-46. <https://doi.org/10.47385/cadunifoa.v14i41.2843>
12. Torres DM, Valente PV, Feitosa GP, Matos CFP, Mota FSX, Machado JR. Análise de dados epidemiológicos de pacientes acompanhadas por neoplasia mamária em um hospital de Fortaleza (CE). *Rev Bras Mastologia*. 2016;26(2):39-44. <https://doi.org/10.5327/Z201600020002RBM>
13. Pereira HFBESA. Perfil epidemiológico e clínico de mulheres jovens com câncer de mama no Amazonas: estudo de onze anos [tese online]. Manaus: Universidade Federal do Amazonas; 2016 [cited on Jan 20, 2021]. Available at: <https://tede.ufam.edu.br/handle/tede/5818>
14. Raffo CC, Hubie DP, Zanini GL, Abdul-Hak LP, Botogowski SH. Perfil histológico e imuno-histoquímico das pacientes com câncer de mama operadas no Hospital Santa Casa de Curitiba no período de 2014 e 2015. *Arq Méd Hosp Fac Cienc Med Santa Casa São Paulo*. 2017;62(3):139-45. <https://doi.org/10.26432/1809-3019.2017.62.3.139>
15. Monteiro SO. Atrasos no tratamento do câncer de mama: fatores associados em uma coorte de mulheres admitidas em um centro de referência do Rio de Janeiro [dissertação online]. Rio de Janeiro: Escola Nacional de Saúde Pública Sergio Arouca; 2016 [cited on Jan 20, 2021]. Available at: https://www.arca.fiocruz.br/bitstream/icict/20618/2/ve_Sergio_de_Oliveira_ENSP_2016.pdf



Evaluation of breast cancer in women under 50 in a Mastology service in the Federal District, Brazil

Ana Cláudia Leite Vilela^{1*} , Lucimara Priscila Campos Veras¹ ,
Sérgio Eduardo Paiva Ramos¹ , Sádía Martins de Paula Souza¹ 

ABSTRACT

Introduction: Breast cancer is a relevant public health issue, and its incidence has increased in patients aged less than 50 years. This population usually receives a late diagnosis, which contributes with the poor prognosis of the condition. **Objective:** To assess the percentage of patients diagnosed with breast cancer before the age of 50 and compare them with the group that was diagnosed after the age of 50. **Results:** The general mean age was 54 years; 75.68% of the patients were younger than 50 years, aged between 40 and 49 years. Among the ones who were younger than 50, 35.14% were in stage T4; 55.41% underwent neoadjuvant chemotherapy; 16.22% presented distant metastasis; and 10.81%, locoregional metastasis. On the other hand, among those aged more than 50, 22.71% were in stage T4; 30.68% underwent neoadjuvant chemotherapy; 11.36% presented distant metastasis; and 6.82%, locoregional metastasis. **Conclusion:** Breast cancer in women aged less than 50 years in a Mastology service in the Federal District has been a matter of concern, for presenting more advanced tumors at the time of diagnosis; screening is still debatable.

KEYWORDS: breast neoplasms; mammography; mass screening; early cancer detection.

INTRODUCTION

Nowadays, breast cancer is a relevant public health problem. It is the most common malignant neoplasm among women in Brazil and in most of the world, after non-melanoma skin cancer. According to the last global statistics from the Global Cancer Observatory (GLOBOCAN), 2.1 million new cases of breast cancer and 627 thousand deaths caused by the disease have been estimated¹. Breast cancer screening aims at detecting small asymptomatic tumors, thus contributing with the reduction of mortality. The ultrasound is limited to evaluate microcalcifications; therefore, it is not adequate for the screening of the general population^{2,3}.

Mammography is the only test whose efficiency is proven for the reduction of breast cancer mortality^{4,5}. The Ministry of Health recommends screening mammography for women without signs and symptoms of breast cancer, in the age group between 50 and 69 years, every two years^{6,7}. This does not consider an important part of the population (women aged from 40 to 49 years), which responds for about 15%-20% of the breast cancer cases⁸. The Brazilian Society of Mastology (SBM) recommends that breast cancer screening of women with usual population risk be performed through an annual mammography, including women aged from 40 to 75 years, aiming at the early diagnosis

and the reduction of mortality^{1,8}. After the age of 75, screening mammography is recommended for women whose life expectancy is higher than seven years based on other comorbidities^{1,9,10}.

Women aged more than 50 years are more prone to developing breast cancer; however, among young women, the clinical, pathological and immunohistochemical characteristics are more aggressive, staging is more advanced, tumor diameter is larger and there are more chances of developing metastasis¹¹⁻¹³. Since breast cancer is considered as infrequent, younger women should be addressed special attention. A study from 2015 that aimed at understanding the experience of younger women diagnosed with breast cancer, who underwent a mastectomy, pointed out that systemic metastases can occur in 55.3% of the cases in these patients; on the other hand, for systemic metastasis in elderly women, the percentage is 39.2%. The same study also showed that the mortality rate among younger women is 5% higher than among the elderly women¹⁴⁻¹⁶.

Based on the exposed, and considering that breast cancer is the most frequent type of cancer among women around the world, with high mortality rates, being a relevant public health issue, the main objective of this study was to assess the percentage of patients assisted in the Mastology service of Hospital Regional

¹Hospital Regional da Ceilândia – Ceilândia (DF), Brazil.

*Corresponding author: anaclaudia_lv@hotmail.com

Conflict of interests: nothing to declare.

Received on: 03/04/2021. Accepted on: 07/12/2021.

de Ceilândia, diagnosed with breast cancer before the age of 50. Finally, it intends to provide subsidies so that public policies can be developed to favor a more efficient and earlier diagnosis, including the coverage and screening of younger women beyond specialized treatment, therefore increasing the chances of cure for these patients.

METHOD

This is a retrospective, cross-sectional, descriptive and observational study carried out to assess the percentage of breast cancer in women, aged less than 50 years, assisted at the Mastology service of Hospital Regional da Ceilândia, from January 2015 to April 2020. The data were collected from the charts of the selected patients, inserted in Excel spreadsheets and statistically evaluated by the Statistical Package for the Social Sciences (SPSS), version 25. Significance level was $p \leq 0.05$. Both the Student's t-test and the χ^2 test were used. This analysis was approved by the Research Ethics Committee, CAAE: 35587420.3.0000.8101.

RESULTS

Our study included 162 patients who met the inclusion criteria, of which 45.70% were younger than 50 years. The general mean age was 54 ± 13.11 ; the mean of patients younger than 50 years was 42.6 ± 5 , and the mean of patients aged 50 years or more was 63.3 ± 9.5 .

Of the included patients, 9.80% had family history of breast or ovarian cancer; 84.57% had normal menarche (8-16 years of age); 75.93% were multiparous. For 32.10%, the diagnosed histological

type was luminal-B invasive ductal carcinoma (IDC); for 22.22%, it was luminal-A IDC; and for 14.20%, it was triple negative IDC. In 34.57% of the patients, the initial tumor size was T2 (> 2 and ≤ 5 cm); in 28.40%, it was T4; and in 20.99%, it was T3 (> 5 cm). Axillary impairment at physical examination was observed in 38.27% of the patients. For 59.26% of them, a core needle biopsy was performed. Axillary dissection was performed in 50% of them. Neoadjuvant chemotherapy (CT) was performed in 41.98% of the patients, and 37.65% underwent adjuvant CT; 11.11% obtained complete post-neoadjuvant CT response, and 37.65% had partial response. Distant metastasis was observed in 13.58% of the patients, and locoregional metastasis, in 8.64%.

By correlating the patients aged less than 50 years and those aged 50 years or older, we observed that 8.11% of the former had family history of breast/ovarian cancer; 83.7% had normal menarche (8-16 years of age); and 70.27% were multiparous. Of the patients aged 50 years or older, 11.36% had family history of breast/ovarian cancer; 85.23% had normal menarche (8-16 years of age); and 75.93% were multiparous (Table 1).

Patients aged less than 50 years were prevalent in the age group between 40 and 49 years (75.68%). The histological type luminal-B IDC was diagnosed in 33.68% of the patients; luminal-A IDC, in 20.27%; and triple negative IDC, in 16.22%. The initial tumor size was T4 for 35.14% of them; T2, for 27.03% of them; and T3, for 27.03% of them. Of the patients aged more than 50 years, 30.68% were diagnosed with histological type luminal-B IDC; 23.86%, with luminal-A IDC; and 12.50%, with triple negative IDC. The initial tumor size was T2 in 40.91% of them; T4, in 22.73%; and T1, in 20.45% (Table 2).

Table 1. Epidemiological characteristics of women assisted for breast cancer treatment from January, 2015, to April, 2020.

Variables	Group				Total		p-value
	< 50 years		≥ 50 years				
	N	%	N	%	N	%	
Family history of breast/ovarian cancer							
Yes (breast/ovarian)	6	8.11	10	11.36	16	9.88	0.364
No	67	90.54	78	88.64	145	89.51	
Not informed	1	1.35	0	0.00	1	0.62	
Menarcche							
Not informed	11	14.86	10	11.36	21	12.96	0.132
Normal (8–16 years of age)	62	83.78	75	85.23	137	84.57	
Early (< 8 years of age)	1	1.35	0	0.00	1	0.62	
Late (> 16 years of age)	0	0.00	3	3.41	3	1.85	
Parity							
Nulliparous	11	14.86	6	6.82	17	10.49	0.067
Primiparous	10	13.51	6	6.82	16	9.88	
Multiparous	52	70.27	71	80.68	123	75.93	
Not informed	1	1.35	5	5.68	6	3.70	

Of the patients aged less than 50 years, 41.89% presented with axillary impairment at physical examination. Sentinel lymph node biopsy was performed in 60.23% of them, and 44.32% underwent axillary dissection (Table 3).

Of the patients aged less than 50 years, 55.41% underwent neoadjuvant CT, and 35.14% underwent adjuvant CT. There was partial post-neoadjuvant CT response in 47.30% of them, and complete response in 14.86%. Of the patients aged 50 years or older, 30.68% underwent neoadjuvant CT, and 37.65% were submitted to adjuvant CT. There was partial post-neoadjuvant CT response in 37.64% of them, and complete response in 11.11% (Table 4).

Distant metastasis was observed in 16.22%, and locoregional metastasis, in 10.81% of the patients aged less than 50 years. Of those aged 50 years or more, 11.36% presented with distant metastasis, and 6.82%, with locoregional metastasis (Table 5).

DISCUSSION

Family history of breast or ovarian cancer was observed in 3.7% of the patients aged less than 50 years. In relation to those aged more than 50 years, these presented 8.05% more nulliparity and 3.72% more triple negative IDC results; also, 12.41% more initial tumor sizes T4, and 11.12% more initial sizes T3. Younger patients are diagnosed with initial tumor size above T3, which contributes with a poor prognosis. There was axillary impairment (at physical examination) in 6.7% more patients than among those aged more than 50; however, the percentage of 6.76% more axillary dissection procedures was observed among patients aged less than 50. The frequency of neoadjuvant CT was higher than 24.72% among patients aged less than 50 years, who also presented 17.75% more partial post-neoadjuvant CT response and 6.91% more complete response.

In a study carried out by Franzoi et al.¹⁷, the authors identified that 17% of the patients with breast cancer were aged less

Table 2. Clinical and pathological characteristics of patients assisted at Hospital Regional da Ceilândia from January 2015 to April 2020.

Variables	Group				Total		p-value
	< 50 years		≥ 50 years				
	N	%	N	%	N	%	
Age group (years old)							
< 30	1	1.35	0	0.00	1	0.62	0,002
30–39	17	22.97	0	0.00	17	10.49	
40–49	56	75.68	0	0.00	56	34.57	
≥ 50	0	0.00	88	100.00	88	54.32	
Histological type							
HER-2 luminal B IDC	5	6.76	5	5.68	10	6.17	0,656
HER-2 OVEREXPRESSION IDC	4	5.41	10	11.36	14	8.64	
Luminal-A IDC	15	20.27	21	23.86	36	22.22	
Luminal-B IDC	25	33.78	27	30.68	52	32.10	
Luminal HER-2 IDC	4	5.41	4	4.55	8	4.94	
Triple negative IDC	12	16.22	11	12.50	23	14.20	
CDIS HER 2 SUPEREXPRESSO	1	1.35	0	0.00	1	0.62	
Luminal-A ISDC	1	1.35	0	0.00	1	0.62	
Luminal-B ISDC	1	1.35	2	2.27	3	1.85	
Luminal A ILC	1	1.35	2	2.27	3	1.85	
Luminal B ILC	1	1.35	4	4.55	5	3.09	
Triple negative ILC	1	1.35	0	0.00	1	0.62	
Others	3	4.05	2	2.27	5	3.09	
Initial tumor size							
T1 ≤ 2 cm	8	10.81	18	20.45	26	16.05	0,026
T2 > 2 and ≤ 5 cm	20	27.03	36	40.91	56	34.57	
T3 > 5 cm	20	27.03	14	15.91	34	20.99	
T4	26	35.14	20	22.73	46	28.40	

T: size. ISDC: In situ ductal carcinoma; IDC: invasive ductal carcinoma; ILC: infiltrating lobular carcinoma.

than 50 years. In our study, the frequency of patients aged less than 50 years with breast cancer was lower; however, the findings of the authors corroborate ours regarding the fact that younger patients are more symptomatic at diagnosis, often

presenting stage III, T3/T4, grade 3, HER-2 positive, luminal-B and triple negative cancer subtypes.

In a study carried out by Laila et al.¹⁸ including 349 women aged between 24 and 90 years, the authors observed that 8.3%

Table 3. Axillary status of women with breast cancer from January 2015 to April 2020.

Variables	Group				Total		p-value
	< 50 years		≥ 50 years				
	N	%	N	%	N	%	
Axillary impairment (at physical examination)							
Yes	31	41.89	31	35.23	62	38.27	0.385
No	43	58.11	57	64.77	100	61.73	
Sentinel lymph node biopsy							
Yes	30	40.54	53	60.23	83	51.23	0.060
No	43	58.11	33	37.50	76	46.91	
Not informed	1	1.35	2	2.27	3	1.85	
Axillary dissection							
Yes	42	56.76	39	44.32	81	50.00	0.274
No	31	41.89	48	54.55	79	48.77	
Not informed	1	1.35	1	1.14	2	1.23	

Table 4. Systemic treatment of women with breast cancer from January 2015 to April 2020.

Table 1: Systemic treatment of women with breast cancer from January 2015 to April 2020.

Variables	Group				Total		p-value
	< 50 years		≥50 years				
	N	%	N	%	N	%	
Neoadjuvant CT							
Yes	41	55.41	27	30.68	68	41.98	0.002
No	33	44.59	61	69.32	94	58.02	
Adjuvant CT							
Yes	26	35.14	35	39.77	61	37.65	0.544
No	48	64.86	53	60.23	101	62.35	
Post-neo CT response							
Complete	11	14.86	7	7.95	18	11.11	0.013
Partial	35	47.30	26	29.55	61	37.65	
Did not undergo it	28	37.84	54	61.36	82	50.62	
Total	0	0.00	1	1.14	1	0.62	

Neo CT: neoadjuvant chemotherapy; CT: chemotherapy.

Table 5. Characterization of the presence of metastasis in women with breast cancer from January 2015 to April 2020.

Variables	Group				Total		p-value
	< 50 years		≥ 50 years				
	N	%	N	%	N	%	
Metastasis							
Yes/distant	12	16.22	10	11.36	22	13.58	0.106
Yes/locoregional	8	10.81	6	6.82	14	8.64	
No	54	72.97	72	81.82	126	77.78	

were aged less than 40 years, and most were diagnosed at early stages; invasive ductal carcinoma was the most common type regarding immunohistochemical characteristics. Most cancers were smaller than 2 cm. In our study, the findings were different: patients aged less than 40 years represented 11.1% of the sample, and less than 50 years, 45.7%. The prevalence of tumor sizes was between 2 and 5 cm, however, in patients aged less than 50 years, they were larger than 5 cm. The prevalent histological type, regardless of age, was luminal-B IDC.

Pereira et al.¹⁹ observed that the age group of 35 to 40 years was the most affected one. In our study, it was 40 to 49 years of age. In an analysis carried out by Magalhães et al.²⁰, distant metastasis was observed in 3.1% of the sample, and locoregional metastasis, in 0.6%, corroborating the findings of our study, in which distant metastasis was found in 13.58% of the patients, and rates of 4.8% more chances of this type of metastasis in patients aged less than 50, and 4% among patients with locoregional metastasis.

CONCLUSION

Considering the presented study, we can conclude that breast cancer in women aged less than 50 years in a Mastology service of the Federal District has been a reason of concern among these patients, since they present with more advanced tumors at

diagnosis, more need for neoadjuvant CT and higher occurrence of metastasis, which reinforces the hypothesis that the reduction in late diagnosis may increase the chances of cure. The highest prevalence among those aged less than 50 years was in the age group of 40 to 49 years, which brings up more discussions about the need for screening.

The review of the official current recommendations of the Ministry of Health for the beginning of breast cancer screening should be a base for public health policies, in order to recruit young women and generate higher rates of diagnosis, better care for the patient and the possibility of an earlier treatment for the disease.

It is important to mention that the lack of access of the population to health also leads to a later diagnosis, and this fact illustrates the urgency for improvements in public health, from the approach of the patient in primary care, providing access to information, until the proper referral to a tertiary service in search for better health indicators.

AUTHORS' CONTRIBUTIONS

A.C.L.V.: Concept, Visualization, Writing – original draft.

L.V.: Project administration, Supervision, Writing – review & editing.

S.P.R.: Data curation, Formal Analysis, Software, Supervision.

S.M.: Investigation, Methodology.



REFERENCES

1. Organização Mundial da Saúde. Globocan 2020 (Breast). The Global Cancer Observatory. Organização Mundial da Saúde; 2020.
2. Urban LAB, Chala LF, Bauab SP, Schaefer MB, Santos RP, Maranhão NMA, et al. Recomendações do Colégio Brasileiro de Radiologia e Diagnóstico por Imagem, da Sociedade Brasileira de Mastologia e da Federação Brasileira das Associações de Ginecologia e Obstetrícia para rastreamento do câncer de mama por métodos de imagem. *Radiol Bras*. 2017;50(4):244-9. <http://dx.doi.org/10.1590/0100-3984.2017-0069>
3. Dias ADA, Mauro MN, Puy TC, Oliveira CM, Fecury AA, Dias CAGM, et al. Atualização sobre os principais aspectos relacionados ao câncer de mama. *Rev Cient Multidiscipl Núcleo Conhecim*. 2017;8(11):5-17. <http://dx.doi.org/10.32749/nucleodoconhecimento.com.br/saude/cancer-de-mama>
4. Instituto Nacional de Câncer. Detecção precoce do câncer de mama. Brasil: Instituto Nacional de Câncer, Ministério da Saúde; 2020.
5. Instituto Nacional de Câncer. Confira as recomendações do Ministério da Saúde para o rastreamento do câncer de mama. Instituto Nacional de Câncer, Ministério da Saúde; 2019.
6. Instituto Nacional de Câncer. Fatores de risco para o câncer de mama. Instituto Nacional de Câncer, Ministério da Saúde; 2019.
7. Instituto Nacional de Câncer. Estatísticas de câncer. Instituto Nacional de Câncer, Ministério da Saúde; 2020.
8. Sociedade Brasileira de Mastologia. Sociedades brasileiras recomendam mamografia a partir dos 40 anos. Sociedade Brasileira de Mastologia; 2021.
9. Migowski A, Silva GA, Dias MBK, Diz MPE, Sant'Ana DR, Nadevsky P. Diretrizes para detecção precoce do câncer de mama no Brasil. II - Novas recomendações nacionais, principais evidências e controvérsias. *Cad Saúde Pública*. 2018;34(6):1-16. <https://doi.org/10.1590/0102-311X00074817>
10. Figueiredo MB, Silva DND, Costa MCS. Câncer de mama em mulheres com idade inferior a 40 anos em Rio Branco-Acre: percepção e aceitação. *DêCiência em Foco*. 2020;4(1):29-44.
11. Dutra MC, Rezende MA, Andrade VP, Soares FA, Ribeiro MV, Paula EC, et al. Imunofenótipo e evolução de câncer de mama: comparação entre mulheres muito jovens e mulheres na pós-menopausa. *Rev Bras Ginecol Obstet*. 2009;31(2):54-60. <https://doi.org/10.1590/S0100-72032009000200002>

12. Monteiro DLM, Nunes CL, Rodrigues NCP, Antunes CA, Almeida EM, Barmpas DBS, et al. Fatores associados ao câncer de mama gestacional: estudo caso-controle. *Ciênc Saúde Colet*. 2019;24(6):2361-9. <https://doi.org/10.1590/1413-81232018245.18392017>
13. Cardoso MDPC. Associação entre câncer de mama e uso de contraceptivos orais de mulheres em idade fértil [thesis]. Fortaleza: Universidade Federal do Ceará; 2020.
14. Silva DA, Silva LK, Fonseca CSM. Câncer de mama em mulheres jovens: uma avaliação do perfil clínico-epidemiológico e molecular em um centro de tratamento especializado. *Braz J Health Rev*. 2019;2(6):6076-87. <https://doi.org/10.34119/bjhrv2n6-102>
15. Almeida TGD, Comassetto I, Alves KMC, Santos AAP, Silva JMO, Trezza MCSF. Vivência da mulher jovem com câncer de mama e mastectomizada. *Esc Anna Nery*. 2015;19(3):432-8. <https://doi.org/10.5935/1414-8145.20150057>
16. Lemos NADF, Freitas-Júnior R, Moreira MAR, Silva TC, Oliveira JC, Silva CMB. Difficulties in collecting data on ductal carcinoma in situ at a population-based cancer registry. *Mastology*. 2019;29(2):86-9. <https://doi.org/10.29289/2594539420190000421>
17. Franzoi MA, Rosa DD, Zaffaroni F, Werutsky G, Simon S, Bines J, et al. Advanced stage at diagnosis and worse clinicopathologic features in young women with breast cancer in brazil: a subanalysis of the AMAZONA III Study (GBECAM 0115). *J Glob Oncol*. 2019;5:1-10. <https://doi.org/10.1200/jgo.19.00263>
18. Laila HJEA, Zenkner JRG, Araújo MC, Becker JDL, Pereira AD. Characterization of prognostic factors of breast cancer among women with this condition attended by the Brazilian unified health system in the municipality of Bagé, Rio Grande do Sul, Brazil. *Mastology*. 2019;29(2):64-70. <https://doi.org/10.29289/2594539420190000438>
19. Pereira HFB, Nunes GPS, Viapiana PS, Silva KLT. Profile of care in young women with breast cancer in Amazonas: 11 years study. *Mastology*. 2019;29(1):20-4. <https://doi.org/10.29289/2594539420190000426>
20. Magalhães GDF, Cavalcanti FP, Lima MVA, Castro RB. Evaluation of local recurrence of breast conservation surgery at the Ceará institute of cancer. *Mastology*. 2019;29(1):10-3. <https://doi.org/10.29289/2594539420190000371>



Breast-conserving treatment in oncoplastic times: indications, cosmesis, and quality of life

Idam de Oliveira-Junior^{1,2} , Raphael Luiz Haikel¹ , René Aloísio da Costa Vieira^{2,3*} 

ABSTRACT

Breast-conserving treatment was established as an oncologically safe procedure for breast cancer. However, the cosmetic outcomes of breast-conserving treatments are often unsatisfactory. In this scenario, oncoplastic breast-conserving surgery incorporated plastic surgery concepts and techniques into the oncological treatment in order to ensure better cosmesis, thus increasing the indications for breast-conserving treatment. At the same time, oncoplastic breast-conserving surgery is usually presented as a generic term, which should be evaluated taking many aspects into account: indication, patient selection, the surgery itself, cosmetic quality, and quality of life — data that are still scarce in the literature.

KEYWORDS: breast neoplasms; mastectomy, segmental; conservative treatment; surgery, plastic; cosmetic techniques.

INTRODUCTION

The surgical treatment of breast cancer is one of the only oncological areas in which other people besides the patient will judge the cosmetic outcome in the same way the oncologic result is assessed. The woman will have her breasts evaluated by radiotherapists, radiologists, gynecologists, mammography technicians, among others. Thus, we cannot address breast cancer surgery without its associated esthetic criterion¹.

For many years, radical mastectomy was the only surgical treatment offered for breast cancer. However, when Fisher et al. compared mastectomy, lumpectomy, and lumpectomy followed by breast radiotherapy in a randomized trial, they found no significant differences regarding disease-free survival, distant-disease-free survival, or overall survival among the 3 groups, even after 20 years of follow-up². Likewise, between 1973 and 1980, Umberto Veronesi compared quadrantectomy associated with radiotherapy and mastectomy, and, once again, the results overlapped³.

With the establishment of breast-conserving treatment (BCT) associated with the increase in early diagnosis, the advance in systemic therapies, and the consequent increase in patient survival, the analysis of surgical treatment transcended purely oncologic issues⁴.

Surgeons started to look into improving the cosmetic quality of the procedure. After all, up to 30% of patients submitted to quadrantectomy need late reconstruction due to unsatisfactory esthetic

outcomes⁵. Thus, oncoplastic breast-conserving surgery (OBCS) emerges to improve the cosmetic results of breast cancer surgeries. OBCS is usually presented as a generic term, involving procedures associated with both BCT and reconstruction after mastectomy. Nonetheless, it should be contextualized in each analysis and evaluated based on many aspects: indication, patient selection, the surgery itself, cosmetic quality, and quality of life (QoL) (Figure 1)⁶.

Figure 2 illustrates the results between symmetry (Figures 2A and 2C) and bilateral surgery (Figures 2C and 2D), traditional surgery (Figure 2A and 2B) and OBCS (Figures 2C–2D), in addition to important breast tissue changes after radiotherapy, such as skin edema and fibrosis (Figure 2B), justifying the discussion on the subject.

ONCOPLASTIC BREAST-CONSERVING SURGERY

From an oncological point of view, OBCS allows initial candidates for radical treatment to receive conservative treatment. It enables large resections, with possible wider margins, which could lead to lower rates of positive margins without compromising esthetic results⁶. Many initial contraindications for BCT have become relative after OBCS, such as tumors larger than 5 cm and local skin infiltration, provided the margins are satisfactory and the breast volume allows the procedure.

¹Department of Mastology and Breast Reconstruction, Hospital de Câncer de Barretos – São Paulo, Brazil

²Postgraduate Program in Obstetrics and Gynecology, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista “Júlio de Mesquita Filho” – Botucatu (SP), Brazil.

³Department of Oncological Surgery, Mastology Division, Hospital de Câncer de Muriaé – Minas Gerais, Brazil.

*Corresponding author: reneacv@terra.com.br

Conflict of interests: nothing to declare.

Received on: 06/17/2020. Accepted on: 08/28/2020.

However, long-term follow-up data on recurrence, cosmetic results, or QoL are scarce⁴.

Most published series evaluates the OBCS applicability to tumors that require a small surgical resection due to their reduced size. Silverstein et al. described the term “extreme oncoplasty” for cases with an initial indication for mastectomy, but that were submitted to OBCS. After assessing 66 patients with tumors whose mean size was 77 mm, they found similar recurrence to that of patients with small tumors⁷.

Another factor contributing to a higher indication of BCT was the neoadjuvant chemotherapy for breast cancer, even in the presence of locally advanced tumors. Nevertheless, a good cosmetic result after surgery is expected by this group of patients. Thus, OBCS has achieved good cosmetic results even in more

extensive resections of locally advanced carcinomas, representing a satisfactory option to avoid radical surgery, whose morbidity is higher⁸. Vieira et al. conducted a matched case-control study with a mean follow-up of 67.1 months, revealing that patients with locally advanced tumors submitted to neoadjuvant chemotherapy and OBCS showed no difference regarding local and locoregional recurrence and overall survival compared to BCT⁴.

Any patient eligible for breast-conserving surgery, with appropriate size and ptosis in relation to tumor size, should be considered a candidate for OBCS^{9,10}. However, the selection of patients submitted to these procedures shows an important bias. They tend to be performed in young¹¹ and more educated patients, who might demand a better cosmetic result⁴.


Several observational studies have evidenced the association between OBCS and lower rates of positive surgical margins. A recent meta-analysis by Losken et al. indicated that OBCS could halve the rate of positive margins (12% vs. 21%, $p < 0.0001$)¹². Consequently, it might reduce the rate of surgical re-excision, as shown by Down et al. (5.4% vs. 28.9%, $p = 0.002$)¹³. Another meta-analysis involving 18 studies found no significant difference concerning reoperation between the OBCS and BCT groups after adjustment for publication bias¹¹.

Based on the assumption that the oncological safety of OBCS should be similar to that of standard treatment¹⁴, Rietjens et al., in 74 months of follow-up, detected 8.4% recurrence in patients with pT2-3 tumors submitted to OBCS, whereas pT1 patients had no recurrence¹⁵. Another study identified local recurrence of 4.3% in OBCS and 3.7% in BCT¹⁶. Clough et al. found a 5-year cumulative incidence of 2.2%, 1.1%, and 12.4% for local, locoregional, and distant recurrence, respectively¹⁷. We emphasize that tumors are approximately 3 cm in size in most series that evaluate OBCS^{4,17}.

A meta-analysis including 11 studies compared the oncologic results between BCT and OBCS, with a total of 3,789 cases (2,691 patients in the BCT group and 1,098 in the OBCS group) without significant difference between pathological staging, and found that local and distant recurrence rates were similar in both groups. Overall survival data also revealed non-inferior effects of OBCS compared to BCT¹⁸.

In a meta-analysis involving 18,103 patients with mean follow-up time ranging from 1.5 to 9.2 years, Kosasih et al. found no significant difference between BCT, OBCS, and mastectomy (relative risk — $RR = 0.861$; 95% confidence interval — 95%CI 0.640–1.160; $p = 0.296$) regarding recurrence¹¹.

The comparison between BCT and OBCS in 8,659 patients (3,165 in the OBCS group and 5,494 in the BCT group) showed that the surgical specimen weight and the tumor size were higher in the oncoplastic group (2.7 vs. 1.2 cm), which also presented significantly lower positive margins and re-excision rates. Nonetheless, local recurrence was 4.2% in the OBCS group and 7% in the BCT group ($p < 0.0001$), although follow-up was longer in the BCT group (64 vs. 37 months)¹².



OBCS: oncoplastic breast-conserving surgery; BCT: breast-conserving treatment. Source: adapted from Oliveira-Junior et al. with authorization⁶.

Figure 1. Outcomes involved in oncoplastic breast-conserving surgery.

SURGICAL TECHNIQUES AND STRATEGIES

OBCS incorporated plastic surgery concepts and techniques into the surgical treatment of breast cancer, becoming associated with the excision of breast parenchyma and the simultaneous reconstruction/reshaping of the defect in order to avoid local deformities. Therefore, a variety of techniques can be performed in BCT, extending its indications. In addition, by reducing the parenchyma, oncoplastic techniques promote the effectiveness of radiotherapy in the remaining tissue, with dose homogeneity and acceptably low complication rates^{19,20}.

In our field, Andrade Urban developed a classification based on technical skills to improve the training of surgeons. It consists of three distinct skills:

- Class I covers glandular mobilization and reshaping, without requiring specific surgical training;
- Class II demands specific training because it involves skills related to breast reconstruction with implants, mastopexy, and mastopexy, usually bilateral for symmetrization;

- Class III encompasses autologous flaps or a combination of techniques, requiring specific training²¹.

Other classifications for oncoplastic procedures have been proposed. The one by Clough et al. divides the technique into two levels, based on the complexity of the procedure. “Level 1” techniques are based on glandular mobilization and repositioning of the nipple-areola complex, with less than 20% of the breast volume resected. Those classified as “level 2” involve resections ranging from 20% to 50% of the breast volume and are divided into volume repositioning techniques (therapeutic mammaplasty) and volume replacement techniques (fascia or myocutaneous flaps), associated or not with contralateral mammaplasty^{8,22}. The American Society of Breast Surgeons, in consensus, also opted for this definition and classification system of OBCS based on anatomy and volume, as it applies to most techniques described in the literature. However, the classification should act as a practical guideline for surgeons rather than a strict rule, as underlined by the committee²³.




Figure 2. Breast-conserving treatment. (A) Symmetry and conservative treatment on the right breast; (B) asymmetry and conservative treatment on the left breast; (C) good symmetry in conservative treatment and symmetrization (D) asymmetry in conservative treatment with oncoplastic technique — plug flap — and symmetrization.

Training schools have divergences as to OBCS classification. In the “First International Consensus Conference on Standardization of Oncoplastic Breast Conserving Surgery”, experts, mostly Europeans, voted to adopt the Clough classification as the standard for clinical practice (indication, planning, and performance of the procedure)²⁴. Nonetheless, for billing purposes, the consensus was to use the classification by Hoffmann et al.²⁵, which is based on the complexity of the breast surgical procedure, whether oncologic, oncoplastic, or reconstructive. Still, they disagreed on which classification should be recommended as the best standard for clinical research²⁴.

Weber et al. proposed nomenclature and algorithms to help surgeons standardize the ideal OBCS procedure. The procedures were classified as conventional tumorectomy (glandular reapproximation and direct closure of the surgical wound), mastopexy (non-oncological skin resection and nipple repositioning, with or without pedicles), oncoplastic tumorectomy (glandular reshaping and volume replacement), and oncoplastic reduction mammoplasty (non-oncological breast reduction, with repositioning of the nipple-areola complex through pedicles). The two proposed algorithms — indication and reconstruction — are targeted at surgical planning according to breast size and shape, tumor size and location, vascular supply to suggest flaps, glandular reshaping, and specific pedicles to replace the resected volume²⁶.

Regardless of the classification adopted, conservative treatment involves class I and II procedures, favoring the training of mastologists and the development of centers directed at this training in Brazil²⁷.

Whether OBCS falls within the competence of the mastologist, surgical oncologist, or plastic surgeon is debatable. In Brazil, similar to other countries, professionals participate cooperatively in most cases. Nonetheless, this scenario can differ significantly: most women undergoing surgical treatment of breast cancer do not have access to reconstruction. Each surgical specialty has its usual advantages, but training should be required for OBCS to ensure oncological safety and superior cosmetic outcomes²¹.

The surgeon must choose the surgical technique taking into account the tumor characteristics and the breast morphology, besides the developed expertise, not forgetting the patient's cosmetic expectations, considering the lack of a single formula for the surgery. Breasts vary considerably, resulting in several possibilities to solve the challenges posed by the tumor⁴.

Regarding BCT, given the diversity of procedures, several authors have attempted to exemplify them based on breast volume²⁸, quadrant location^{22,29}, technique selected according to algorithms²⁴, variety of techniques³⁰, development of new techniques^{10,31}, and application to extensive surgeries⁷. Thus, the large number of techniques, ranging from small local parenchyma reshaping to elaborate resections, made the term OBCS very generic, combining various possible surgical outcomes, with different levels of complexity, into a single category. In this respect,

several techniques are grouped, and given the lack of a standard, the literature has room for analyses and comparisons. Moreover, the theoretical-practical concept of oncological safety associated with the cosmetic result is recent and needs improvement^{4,10}.

Therefore, in BCT, oncoplasty involves care related to oncological treatment versus adequacy of the volume in the affected breast associated with the secondary adequacy of the volume in the contralateral breast¹. Breast-conserving surgery often results in breast asymmetry, which is related to worse post-operative QoL and worse psychosocial functions; after all, the cosmetic result has become an important factor in the surgical treatment of breast cancer³². Women with significant breast asymmetry are more prone to a poorer psychosocial status than those with small asymmetry³³. In order to maintain symmetry, many patients are submitted to oncological treatment involving OBCS and contralateral symmetrization in the same procedure; however, the literature on the subject is scarce, precluding any conclusions regarding its actual impact on women.

The ideal timing for contralateral breast surgery is after the end of radiotherapy in the index breast, considering the different degrees of volume and elasticity loss and of fibrosis. The index breast volume will continue to change progressively over the years due to the persistent radiation injury. Therefore, the asymmetry assessment should also consider the treatment duration and the moment of symmetrization³⁴.

After learning the long-term effects of radiotherapy and the varying degrees of asymmetry, many patients choose to undergo symmetrization and oncological treatment simultaneously; however, the need for symmetrization lacks criteria. In general, the literature has no objective data on the subject, and several authors do not describe the symmetrization rate, which should be part of studies related to BCT and OBCS³⁴.

COSMESIS ASSESSMENT

The main objective of breast-conserving surgeries is to have local control from an oncological perspective, preserving cosmesis. Nevertheless, surgical resection without adequate reshaping of the remaining parenchyma allows scarring and fibrosis to reveal, after radiotherapy, the unreconstructed cavity, the distortion of the nipple-areola complex, and the uniformity of the parenchyma distribution, which are factors OBCS has overcome^{34,35}.

Radiotherapy can cause immediate-to-late alterations, including skin depigmentation, telangiectasias, edema, fibrosis, and changes in breast sensitivity, varying according to dose, irradiated volume, and individual radiosensitivity. In general, combining these changes leads to a progressive reduction in breast volume, affecting the “time” aspect when evaluating breast cosmesis³⁶.

OBCS paradigms (oncologic principles associated with plastic improvement) are widely adopted; however, the lack of randomized data makes breast surgeons accept an increasing number

of series²⁶. Tenofsky et al., *apud* Kosasih et al., when analyzing cosmetic satisfaction among patients submitted to OBCS and BCT, noted that 13.8% (OBCS group) and 7.1% (BCT group) were dissatisfied, although without statistical significance ($p=0.191$)¹¹. In other evaluations, satisfaction with the cosmetic result is higher in the OBCS group than in the BCT one (89.5% vs. 82.9%, $p<0.001$)¹².

The main factors associated with breast asymmetry after BCT are age over 60 years, high body mass index, large tumor size, tumors located in the central, inner, or lower quadrants, small breast volume, need for re-excision, breast parenchyma resection greater than 100 cm³, and radiation dose heterogeneity^{34,35}. However, in a cohort of 1,035 patients, these factors did not negatively influence the esthetic result. The study showed that wound infection, pain, scar expansion, scars perceptible on palpation, and keloids were associated with a lower cosmetic classification³⁷.

Motivated by asymmetry, many patients undergo reconstructive procedures. After this procedure, for example, 94.5% of patients were satisfied after 1 year and 88.8% after 5 years, while 19.1% and 6.4% required a second and third surgery, respectively³⁸. Of note, the cosmetic result may vary during the post-treatment follow-up since the late effects of radiotherapy mentioned above and the change in body mass may directly affect the satisfaction with cosmesis and breast symmetry.

Given the diversity of the procedures available, many cosmetic outcomes can be expected after BCT and OBCS. Thus, the cosmetic evaluation after breast-conserving procedures is relative, with poor rater agreement, which can be minimized after consensus among them. Nonetheless, this scenario hardly occurs in clinical practice³⁹.

Cosmetic results can be assessed with objective and subjective tools. Subjective methods take into account the analysis of professionals involved in the treatment, the patient's evaluation, or domains of QoL questionnaires³⁹⁻⁴¹. In turn, objective methods consider the measurement of asymmetry between the treated and untreated breast, but there is no universal reference measure. In this scenario, the Breast Cancer Conservative Treatment Cosmetic Results (BCCT.core) software was created to evaluate patients submitted to BCT, using symmetry algorithms, with results calibrated by European experts, showing a great correlation between them. The results are divided into 4 categories (1-excellent, 2-good, 3-fair, 4-poor). This methodology is reproducible and widely used in research⁴². Nevertheless, the software is not available to the general public, with use only in research.

Regarding the effects of radiotherapy in BCT, the Radiation Therapy Oncology Group and the European Organisation for Research and Treatment of Cancer (RTOG/EORTC) scale evaluates cutaneous and subcutaneous changes, while the Late Effects Normal Tissue Task Force/Subjective, Objective, Management, Analytic (LENT/SOMA) scale quantifies telangiectasia, fibrosis, edema, ulceration, breast pigmentation changes, lymphedema, and breast pain, with scores ranging from 0 to 4⁴³.

The cosmetic results of breast surgery have other forms of evaluation⁴⁴. The Harvard scale, proposed by Harris, initially aimed at evaluating cosmesis after radiotherapy, assessing three main points: skin changes, breast fibrosis/retraction, and radiation-induced alterations, as well as cosmetic evaluation (excellent, good, fair, and poor)⁴⁵. The Garbay scale, which evaluates the results of patients submitted to breast reconstruction⁴⁶ and was later used for patients undergoing BCT³², analyzes breast volume, shape, and height, the inframammary fold, and scarring. It is grouped into four classes and assessed by the numerical sum of the results. The scale by Fitoussi et al. categorizes breast asymmetry and defines a reconstruction classification for contralateral symmetrization³⁸.

Despite the different classifications, no consensus has been reached on how to evaluate breast cosmesis after BCT. When comparing BCCT.core with the Harris scale, the results showed a poor association ($Kappa=0.34$)⁴². In turn, OBCS showed excellent results both in the Harris classification and the BCCT.core. Conversely, several series presented poor agreement between objective and subjective methods and the patient's self-report (usually the patient has a better self-evaluation compared to other methods)³².

QUALITY OF LIFE

Compared to mastectomy, the benefits of breast-conserving surgery are indisputable, particularly because it ensures feminine fulfillment by preserving the normal breast sensation and limiting morbidity in relation to reconstruction by autologous implants or flaps. These benefits increase when adjuvant radiotherapy is administered after mastectomy with reconstruction⁹. Several studies have shown the advantages of OBCS when it comes to better cosmetic results and patients' satisfaction, although contradictory results have also been reported¹².

For the vast majority of surgeons, OBCS is strongly associated with improved QoL, but combining the cosmetic result and its benefits from the patient's perspective is quite complex^{12,24}.

With the increase in survival, concern with QoL has become routine in oncological treatment for both professionals and patients. Some questionnaires assess the general conditions of oncological treatment (e.g., European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire – EORTC QLQ C30, Functional Assessment of Cancer Therapy-General – FACT-G), others are specific for breast cancer (e.g., EORTC QLQ BR23, Functional Assessment of Cancer Therapy-Breast – FACT-B), mastectomy and breast reconstruction (MAS, Michigan Breast Reconstruction Outcome Study – MBROS, BREAST-Q), and BCT (Breast Cancer Treatment Outcome Scale – BCTOS, BREAST-Q)⁴⁰.

EORTC QLQ-C30 is a general questionnaire for cancer patients. It consists of 30 questions divided into 3 dimensions: functional scale, symptom scale associated with 6 unique items (dyspnea, insomnia, loss of appetite, constipation, diarrhea, and financial

difficulties), and overall QoL. Like QLQ-C30, QLQ-BR23 scores are converted from 0–100 and follow the same reasoning for interpretation. EORTC QLQ-BR23 is a QoL questionnaire specific to breast cancer patients. Validated in Portuguese, it has 23 questions divided into 2 dimensions — functional scale and symptom scale — and uses a 4-point scale to obtain the score (not at all, a little, quite a bit, and very much)⁴⁷.

Comparing the QoL of 485 patients submitted to BCT, 46 to mastectomy with immediate reconstruction, and 87 to mastectomy without reconstruction 1 year after treatment using the QLQ-C30 and QLQ-BR23 questionnaires, those who underwent BCT and immediate reconstruction showed better scores as to social function, general function, and body image. At the same time, the comparison of these two groups (BCT and reconstruction) presented no difference regarding objective cosmetic effects, except for body image in QLQ-BR23⁴⁸. Another study used the QLQ-C30 and QLQ-BR23 questionnaires to assess the QoL of patients submitted to BCT (n=76) and to mastectomy without (n=20) and with (n=16) reconstruction. The authors identified that those who underwent BCT had better body image and were more satisfied than the other groups⁴⁹.

BCTOS⁵⁰, aimed at the subjective evaluation of esthetic and functional results after BCT, has questions about functional status, cosmetic status, breast-specific pain, and edema. It comprises 22 items — 8 questions related to breast shape and volume, 7 to shoulder/arm movement, 4 to arm volume, and 3 to breast pain and sensitivity³³. These questions are scored from 1 to 4 points — 1 point meaning no difference between the treated and untreated breast or area and 4 points corresponding to a great difference between the treated and untreated breast or area. This questionnaire was translated into Brazilian Portuguese and validated⁴¹.

BCTOS has proven to be effective in patients submitted to conservative treatment associated with radiotherapy⁵⁰. BCTOS cosmetic results were compared with those of BCCT.core with high agreement, but patients presented higher rates of cosmetic satisfaction in BCTOS than in the software⁵¹.

Another questionnaire developed is the Breast-Q, initially designed to evaluate breast surgery⁵² and used in both plastic and reconstructive surgery. It is divided into six domains: satisfaction with breasts, general outcomes, care experience, psychosocial, physical, and sexual well-being. The second version of this questionnaire, created to evaluate BCT, has not been translated into Brazilian Portuguese yet, with few studies using it⁵³. The literature has validation studies of the electronic version⁵⁴ and for the Japanese population, but not for a Brazilian version.

International study administering Breast-Q to patients submitted to mastectomy with and without reconstruction and to BCT revealed that the mastectomy with reconstruction group had better scores in the sexual well-being domain than the BCT and mastectomy without reconstruction groups. However, no difference was found in the psychosocial domain⁵⁵; therefore, immediate reconstruction is related to better Breast-Q scores⁵⁶.

In the literature, comparing objective results evaluated by objective and reproducible QoL instruments has proven to be difficult. Exner et al.⁵⁷ used the Breast Analyzing Tool (BAT) to objectively evaluate the breast symmetry of 101 patients submitted to BCT, correlating the results with the QoL measured by the Breast Image Scale (BIS) and the EORTC QLQ-BR23. They found no direct association between symmetry and the patients' QoL.

The level of satisfaction does not necessarily reflect the degree of symmetry: women with normal breasts may be dissatisfied with them⁵⁸. In general, QoL studies are not associated with objective results, and selection bias might occur when evaluating patients submitted to OBCS. Despite the apparent similarity between groups, previous choices have been made, leading to the selection of younger, better educated, and more inquisitive patients for OBCS.

By comprising a wide range of oncological and reconstructive surgical procedures, oncoplastic surgery — with or without symmetrization — allows the reduction of both the affected and the contralateral breast, which can be performed immediately, in stages, or later, with no differences in QoL between groups⁵⁹. We underline that the patient's analysis of these results requires a gold standard, and the current methods can vary considerably in both cosmetic and functional evaluation⁶⁰.

CONCLUSION

Oncoplastic surgery increased the indications for breast-conserving treatment while maintaining oncological safety. As a result, OBCS favors breast preservation, increasing female satisfaction, which can positively impact cosmetic and QoL results.

Research ethics

As a literature review, this study does not require evaluation by the Research Ethics Committee, according to Resolution 466/2012.

The patients authorized the use of their images in scientific publications by signing the Informed Consent Form of a study approved by the Research Ethics Committee of the Hospital de Câncer de Barretos, under number 782/2014.

ACKNOWLEDGMENTS

To Fabiola Cristina Brandini da Silva for taking the pictures.

AUTHORS' CONTRIBUTIONS

I.O.J.: conceptualization, data curation, formal analysis, investigation, methodology, writing – original draft, writing – review & editing. R.L.H.: conceptualization, writing – original draft, writing – review & editing. R.A.C.V.: conceptualization, data curation, formal analysis, investigation, methodology, writing – original draft, writing – review & editing.

REFERENCES

- Kopkash K, Clark P. Basic Oncoplastic Surgery for Breast Conservation: Tips and Techniques. *Ann Surg Oncol*. 2018;25(10):2823-8. <https://doi.org/10.1245/s10434-018-6604-5>
- Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. *New Engl J Med*. 2002;347(16):1233-41. <https://doi.org/10.1056/nejmoa022152>
- Mora LD. History of Surgical Treatment of Breast Cancer - Empiricism and Science. *Rev Port Cir*. 2013;(27):41-58.
- Vieira RA, Carrara GF, Scapulatempo Neto C, Morini MA, Brentani MM, Figueira MA. The role of oncoplastic breast conserving treatment for locally advanced breast tumors. A matching case-control study. *Ann Med Surg (Lond)*. 2016;10:61-8. <https://dx.doi.org/10.1016/j.amsu.2016.08.001>
- Clough KB, Cuminet J, Fitoussi A, Nos C, Mosseri V. Cosmetic sequelae after conservative treatment for breast cancer: classification and results of surgical correction. *Ann Plast Surg*. 1998;41(5):471-81. <https://doi.org/10.1097/0000637-199811000-00004>
- Oliveira-Junior I, Silva IA, Silva FCB, Silva JJ, Sarri AJ, Paiva CE, et al. Oncoplastic Surgery in Breast-Conserving Treatment. Patient Profile and impact on quality of life. *Breast Care*. 2020. <https://doi.org/10.1159/000507240>
- Silverstein MJ, Savalia N, Khan S, Ryan J. Extreme oncoplasty: breast conservation for patients who need mastectomy. *Breast J*. 2015;21(1):52-9. <https://doi.org/10.1111/tbj.12356>
- Clough KB, Benyahi D, Nos C, Charles C, Sarfati I. Oncoplastic surgery: pushing the limits of breast-conserving surgery. *Breast J*. 2015;21(2):140-6. <https://doi.org/10.1111/tbj.12372>
- Patel K, Bloom J, Nardello S, Cohen S, Reiland J, Chatterjee A. An Oncoplastic Surgery Primer: Common Indications, Techniques, and Complications in Level 1 and 2 Volume Displacement Oncoplastic Surgery. *Ann Surg Oncol*. 2019;26(10):3063-70. <https://doi.org/10.1245/s10434-019-07592-5>
- Paulinelli RR, Oliveira VM, Bagnoli F, Chade MC, Alves KL, Freitas-Junior R. Oncoplastic mammaplasty with geometric compensation--a technique for breast conservation. *J Surg Oncol*. 2014;110(8):912-8. <https://doi.org/10.1002/jso.23751>
- Kosasih S, Tayeh S, Mokbel K, Kasem A. Is oncoplastic breast conserving surgery oncologically safe? A meta-analysis of 18,103 patients. *Am J Surg*. 2020;220(2):385-92. <https://doi.org/10.1016/j.amjsurg.2019.12.019>
- Losken A, Dugal CS, Styblo TM, Carlson GW. A meta-analysis comparing breast conservation therapy alone to the oncoplastic technique. *Ann Plast Surg*. 2014;72(2):145-9. <https://doi.org/10.1097/sap.0b013e3182605598>
- Down SK, Jha PK, Burger A, Hussien MI. Oncological advantages of oncoplastic breast-conserving surgery in treatment of early breast cancer. *Breast J*. 2013;19(1):56-63. <https://doi.org/10.1111/tbj.12047>
- Cutress RI, Summerhayes C, Rainsbury R. Guidelines for oncoplastic breast reconstruction. *Ann R Coll Surg Engl*. 2013;95(3):161-2. <https://doi.org/10.1308/003588413x13511609957696>
- Rietjens M, Urban CA, Rey PC, Mazzarol G, Maisonneuve P, Garusi C, et al. Long-term oncological results of breast conservative treatment with oncoplastic surgery. *Breast*. 2007;16(4):387-95. <https://doi.org/10.1016/j.breast.2007.01.008>
- Chakravorty A, Shrestha AK, Sanmugalingam N, Rapisarda F, Roche N, Querci Della Rovere G, et al. How safe is oncoplastic breast conservation? Comparative analysis with standard breast conserving surgery. *Eur J Surg Oncol*. 2012;38(5):395-8. <https://doi.org/10.1016/j.ejso.2012.02.186>
- Clough KB, van la Parra RFD, Thygesen HH, Levy E, Russ E, Halabi NM, et al. Long-term Results After Oncoplastic Surgery for Breast Cancer: A 10-year Follow-up. *Ann Surg*. 2018;268(1):165-71. <https://doi.org/10.1097/sla.0000000000002255>
- Chen JY, Huang YJ, Zhang LL, Yang CQ, Wang K. Comparison of Oncoplastic Breast-Conserving Surgery and Breast-Conserving Surgery Alone: A Meta-Analysis. *J Breast Cancer*. 2018;21(3):321-9. <https://doi.org/10.4048/jbc.2018.21.e36>
- Munhoz AM, Montag E, Gemperli R. Current aspects of therapeutic reduction mammaplasty for immediate early breast cancer management: An update. *World J Clin Oncol*. 2014;5(1):1-18. <https://doi.org/10.5306/wjco.v5.i1.1>
- Borm KJ, Schonknecht C, Nestler A, Oechsner M, Waschulzik B, Combs SE, et al. Outcomes of immediate oncoplastic surgery and adjuvant radiotherapy in breast cancer patients. *BMC Cancer*. 2019;19(1):907. <https://doi.org/10.1186/s12885-019-6104-4>
- Andrade Urban C. New classification for oncoplastic procedures in surgical practice. *Breast*. 2008;17(4):321-2. <https://doi.org/10.1016/j.breast.2007.11.032>
- Clough KB, Kaufman GJ, Nos C, Buccimazza I, Sarfati IM. Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery. *Ann Surg Oncol*. 2010;17(5):1375-91. <https://doi.org/10.1245/s10434-009-0792-y>
- Chatterjee A, Gass J, Patel K, Holmes D, Kopkash K, Peiris L, et al. A Consensus Definition and Classification System of Oncoplastic Surgery Developed by the American Society of Breast Surgeons. *Ann Surg Oncol*. 2019;26(11):3436-44. <https://doi.org/10.1245/s10434-019-07345-4>
- Weber WP, Soysal SD, El-Tamer M, Sacchini V, Knauer M, Tausch C, et al. First international consensus conference on standardization of oncoplastic breast conserving surgery. *Breast Cancer Res Treat*. 2017;165(1):139-49. <https://doi.org/10.1007/s10549-017-4314-5>
- Hoffmann J, Wallwiener D. Classifying breast cancer surgery: a novel, complexity-based system for oncological, oncoplastic and reconstructive procedures, and proof of principle by analysis of 1225 operations in 1166 patients. *BMC Cancer*. 2009;9:108. <https://doi.org/10.1186/1471-2407-9-108>
- Weber WP, Soysal SD, Fulco I, Barandun M, Babst D, Kalbermatten D, et al. Standardization of oncoplastic breast conserving surgery. *Eur J Surg Oncol*. 2017;43(7):1236-43. <https://doi.org/10.1016/j.ejso.2017.01.006>
- Zucca Matthes AG, Viera RA, Michelli RA, Ribeiro GH, Bailao A, Jr., Haikel RL, et al. The development of an Oncoplastic Training Center - OTC. *Int J Surg*. 2012;10(5):265-9. <https://doi.org/10.1016/j.ijsu.2012.03.009>

28. Munhoz AM, Montag E, Gemperli R. Oncoplastic breast surgery: indications, techniques and perspectives. *Gland Surg*. 2013;2(3):143-57. <https://doi.org/10.3978/j.issn.2227-684x.2013.08.02>
29. Clough KB, Ihrai T, Oden S, Kaufman G, Massey E, Nos C. Oncoplastic surgery for breast cancer based on tumour location and a quadrant-per-quadrant atlas. *Br J Surg*. 2012;99(10):1389-95. <https://doi.org/10.1002/bjs.8877>
30. Silverstein MJ, Mai T, Savalia N, Vaince F, Guerra L. Oncoplastic breast conservation surgery: the new paradigm. *J Surg Oncol*. 2014;110(1):82-9. <https://doi.org/10.1002/jso.23641>
31. Silverstein MJ, Savalia NB, Khan S, Ryan J, Epstein M, DeLeon C, et al. Oncoplastic Split Reduction with Intraoperative Radiation Therapy. *Ann Surg Oncol*. 2015;22(10):3405-6. <https://doi.org/10.1245/s10434-015-4671-4>
32. Santos G, Urban C, Edelweiss MI, Zucca-Matthes G, de Oliveira VM, Arana GH, et al. Long-Term Comparison of Aesthetical Outcomes After Oncoplastic Surgery and Lumpectomy in Breast Cancer Patients. *Ann Surg Oncol*. 2015;22(8):2500-8. <https://doi.org/10.1245/s10434-014-4301-6>
33. Stanton AL, Krishnan L, Collins CA. Form or function? Part 1. Subjective cosmetic and functional correlates of quality of life in women treated with breast-conserving surgical procedures and radiotherapy. *Cancer*. 2001;91(12):2273-81.
34. Savalia NB, Silverstein MJ. Oncoplastic breast reconstruction: Patient selection and surgical techniques. *J Surg Oncol*. 2016;113(8):875-82. <https://doi.org/10.1002/jso.24212>
35. Hennigs A, Hartmann B, Rauch G, Golatta M, Tabatabai P, Domschke C, et al. Long-term objective esthetic outcome after breast-conserving therapy. *Breast Cancer Res Treat*. 2015;153(2):345-51. <https://doi.org/10.1007/s10549-015-3540-y>
36. Wazer DE, DiPetrillo T, Schmidt-Ullrich R, Weld L, Smith TJ, Marchant DJ, et al. Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. *J Clin Oncol*. 1992;10(3):356-63. <https://doi.org/10.1200/jco.1992.10.3.356>
37. Rezai M, Knispel S, Kellersmann S, Lax H, Kimmig R, Kern P. Systematization of Oncoplastic Surgery: Selection of Surgical Techniques and Patient-Reported Outcome in a Cohort of 1,035 Patients. *Ann Surg Oncol*. 2015;22(11):3730-7. <https://doi.org/10.1245/s10434-015-4396-4>
38. Fitoussi AD, Berry MG, Couturaud B, Falcou MC, Salmon RJ. Management of the post-breast-conserving therapy defect: extended follow-up and reclassification. *Plast Reconstr Surg*. 2010;125(3):783-91. <https://doi.org/10.1097/prs.0b013e3181ccda68>
39. Cardoso MJ, Cardoso J, Santos AC, Barros H, Cardoso de Oliveira M. Interobserver agreement and consensus over the esthetic evaluation of conservative treatment for breast cancer. *Breast*. 2006;15(1):52-7. <https://doi.org/10.1016/j.breast.2005.04.013>
40. Chen CM, Cano SJ, Klassen AF, King T, McCarthy C, Cordeiro PG, et al. Measuring quality of life in oncologic breast surgery: a systematic review of patient-reported outcome measures. *Breast J*. 2010;16(6):587-97. <https://doi.org/10.1111/j.1524-4741.2010.00983.x>
41. Brandini da Silva FC, Jose da Silva J, Sarri AJ, Paiva CE, Aloisio da Costa Vieira R. Comprehensive Validation Study of Quality-of-Life Questionnaire Using Objective Clinical Measures: Breast Cancer Treatment Outcome Scale (BCTOS), Brazilian Portuguese Version. *Clin Breast Cancer*. 2019;19(1):e85-e100. <https://doi.org/10.1016/j.clbc.2018.10.004>
42. Cardoso MJ, Cardoso J, Amaral N, Azevedo I, Barreau L, Bernardo M, et al. Turning subjective into objective: the BCCT. core software for evaluation of cosmetic results in breast cancer conservative treatment. *Breast*. 2007;16(5):456-61. <https://doi.org/10.1016/j.breast.2007.05.002>
43. Hoeller U, Tribius S, Kuhlmeier A, Grader K, Fehlauer F, Alberti W. Increasing the rate of late toxicity by changing the score? A comparison of RTOG/EORTC and LENT/SOMA scores. *Int J Radiat Oncol Biol Phys*. 2003;55(4):1013-8. [https://doi.org/10.1016/s0360-3016\(02\)04202-5](https://doi.org/10.1016/s0360-3016(02)04202-5)
44. Santos G, Urban C, Edelweiss MI, Kuroda F, Capp E. Evaluation of the aesthetical and quality of life results after breast cancer surgery. *Rev Bras Mastol*. 2013;23(3):60-8.
45. Harris JR, Levene MB, Svensson G, Hellman S. Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. *Int J Radiat Oncol Biol Phys*. 1979;5(2):257-61. [https://doi.org/10.1016/0360-3016\(79\)90729-6](https://doi.org/10.1016/0360-3016(79)90729-6)
46. Garbay JR, Rietjens M, Petit JY. [Esthetic results of breast reconstruction after amputation for cancer. 323 cases]. *J Gynecol Obstet Biol Reprod (Paris)*. 1992;21(4):405-12.
47. Michels FA, Latorre M do R, Maciel M do S. Validity, reliability and understanding of the EORTC-C30 and EORTC-Br23, quality of life questionnaires specific for breast cancer. *Rev Bras Epidemiol*. 2013;16(2):352-63. <https://doi.org/10.1590/S1415-790X2013000200011>
48. Kim MK, Kim T, Moon HG, Jin US, Kim K, Kim J, et al. Effect of cosmetic outcome on quality of life after breast cancer surgery. *Eur J Surg Oncol*. 2015;41(3):426-32. <https://doi.org/10.1016/j.ejso.2014.12.002>
49. Han J, Grothuesmann D, Neises M, Hille U, Hillemanns P. Quality of life and satisfaction after breast cancer operation. *Arch Gynecol Obstet*. 2010;282(1):75-82. <https://doi.org/10.1007/s00404-009-1302-y>
50. Krishnan L, Stanton AL, Collins CA, Liston VE, Jewell WR. Form or function? Part 2. Objective cosmetic and functional correlates of quality of life in women treated with breast-conserving surgical procedures and radiotherapy. *Cancer*. 2001;91(12):2282-7.
51. Heil J, Dahlkamp J, Golatta M, Rom J, Domschke C, Rauch G, et al. Aesthetics in breast conserving therapy: do objectively measured results match patients' evaluations? *Ann Surg Oncol*. 2011;18(1):134-8. <https://doi.org/10.1245/s10434-010-1252-4>
52. Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. *Plast Reconstr Surg*. 2009;124(2):345-53. <https://doi.org/10.1097/prs.0b013e3181ae807>
53. O'Connell RL, DiMicco R, Khabra K, O'Flynn EA, de Souza N, Roche N, et al. Initial experience of the BREAST-Q breast-conserving therapy module. *Breast Cancer Res Treat*. 2016;160(1):79-89. <https://doi.org/10.1007/s10549-016-3966-x>
54. Fuzesi S, Cano SJ, Klassen AF, Atisha D, Pusic AL. Validation of the electronic version of the BREAST-Q in the army of women study. *Breast*. 2017;33:44-9. <https://doi.org/10.1016/j.breast.2017.02.015>

55. Howes BH, Watson DI, Xu C, Fosh B, Canepa M, Dean NR. Quality of life following total mastectomy with and without reconstruction versus breast-conserving surgery for breast cancer: A case-controlled cohort study. *J Plast Reconstr Aesthet Surg.* 2016;69(9):1184-91. <https://doi.org/10.1016/j.bjps.2016.06.004>
56. Rosson GD, Shridharani SM, Magarakis M, Manahan MA, Basdag B, Gilson MM, et al. Quality of life before reconstructive breast surgery: A preoperative comparison of patients with immediate, delayed, and major revision reconstruction. *Microsurgery.* 2013;33(4):253-8. <https://doi.org/10.1002/micr.22081>
57. Exner R, Krois W, Mittlbock M, Dubsky P, Jakesz R, Gnant M, et al. Objectively measured breast symmetry has no influence on quality of life in breast cancer patients. *Eur J Surg Oncol.* 2012;38(2):130-6. <https://doi.org/10.1016/j.ejso.2011.10.012>
58. Matthes A do C, Sgrignoli RB. Definition of mammary eutrophy for women in the menopause. *Rev Latino-Am Enfermagem.* 2009;17(1):108-12. <http://dx.doi.org/10.1590/S0104-11692009000100017>
59. Patel KM, Hannan CM, Gatti ME, Nahabedian MY. A head-to-head comparison of quality of life and aesthetic outcomes following immediate, staged-immediate, and delayed oncoplastic reduction mammoplasty. *Plast Reconstr Surg.* 2011;127(6):2167-75. <https://doi.org/10.1097/prs.0b013e3182131c1c>
60. Heil J, Czink E, Golatta M, Schott S, Hof H, Jenetzky E, et al. Change of aesthetic and functional outcome over time and their relationship to quality of life after breast conserving therapy. *Eur J Surg Oncol.* 2011;37(2):116-21. <https://doi.org/10.1016/j.ejso.2010.11.007>



The impact of anesthetic techniques on breast cancer recurrence: a systematic review of clinical evidence

Aline Tenório Dourado^{1*} , Amanda Vasconcelos de Albuquerque¹ ,
Dayse Figueiredo Ribeiro de Sena¹ , José Lamartine de Andrade Aguiar¹ 

ABSTRACT

Introduction: Surgery is the most effective treatment for breast cancer; however, several factors can impair the immune system during the perioperative period, including the anesthetic technique. Since metastasis is the leading cause of death, one of the treatment pillars is to prevent cancer progression. This systematic review will focus on the prospective clinical evidence available on anesthesia's role in favoring breast cancer recurrence. **Methods:** The Cochrane Library, Medline, Embase, LILACs, and Web of Science were electronically searched from inception through December 2020 for randomized controlled trials assessing the association of postoperative recurrence and survival with the use of regional anesthesia, opioids, anesthetic adjuncts, and general anesthesia during surgical resection of breast cancer. In total, 711 articles were retrieved. After title and abstract screening and full-text reviews, five randomized controlled trials were selected. **Results:** Two studies compared inhalation anesthesia with total intravenous anesthesia, while three compared general anesthesia with regional anesthesia and analgesia. There was no significant association between the anesthetic technique and local recurrence, metastasis, or survival. **Conclusion:** This systematic review did not find an association between the type of anesthesia performed and a higher breast cancer recurrence rate. Up to this time, there is no clinical evidence to support a specific anesthetic technique for malignant breast tumor resection surgeries.

KEYWORDS: breast neoplasms; recurrence; anesthesia.

INTRODUCTION

Breast cancer is the most commonly diagnosed cancer among women globally, with 1.7 million diagnoses every year¹ and second in line for the most common cause of cancer-related death². Surgery resection treats a large number of malignant tumors; breast cancer is no exception. Early detection of localized or regional breast cancer can procure a 99%4-85% 5-year survival rate³, with 97% of women in stages I or II experiencing surgery⁴. Therefore, perioperative management may interfere with oncological outcomes.

Several risk factors impair the immune system during the perioperative period⁵. Pain, blood transfusion, hypothermia, and anesthetic technique cause immunosuppression, allowing cancerous cells to migrate to distant organs⁶ — even surgical manipulation can release micrometastasis into the circulation, along with the acute inflammatory response that extensive surgery entails⁷.

Metastasis is the major cause of death in breast cancer patients, with a 30% incidence rate⁸; therefore, preventing recurrence is of paramount importance. A new era of research has emerged in the anesthesia field. Each anesthetic technique affects cancer cells in a particular way. Regional anesthesia reduces surgical stress, inflammatory response, and opioid consumption⁹⁻¹¹. Local anesthetics (LAs) have shown antiproliferative and cytotoxic effects against *in vitro*¹² tumor cells. Sevoflurane suppresses the immune system by decreasing Natural Killer (NK) cells' activity, promoting T-lymphocyte apoptosis and increasing pro-inflammatory cytokines¹³⁻¹⁵. Opioids have a more complex role on cancer recurrence¹⁶: a low dose can elicit tumor growth via angiogenesis and down-regulation of the immune response, while high concentrations may curb tumor growth. The opioid receptors κ and μ act divergently, with the former promoting and the latter inducing a pro-inflammatory response¹⁷.

¹Universidade Federal de Pernambuco – Recife (PE), Brazil.

*Corresponding author: aline.dourado@ufpe.br

Conflict of interests: nothing to declare.

Funding: Coordenação Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

Received on: 03/18/2021. Accepted on: 06/09/2021.

A myriad of retrospective studies suggests that volatile anesthetics and opioid anesthesia promote breast cancer recurrence compared to propofol-based and regional anesthesia¹⁸⁻²⁰. Exadaktylos et al.¹⁸ reported that women had a significantly lower risk of cancer recurrence if submitted to a combination of propofol and thoracic paravertebral block (TPVB) compared to balanced general anesthesia (GA) with sevoflurane and opioids. However, the anesthetic technique of choice for mastectomies is still debatable.

This systematic review focused on the clinical evidence available on the role of anesthesia regarding breast cancer recurrence. To the extent of our knowledge, it was the first to compare only prospective randomized control trials. We described the data and critically analyzed randomized clinical trials on the use of regional anesthesia, opioids, anesthetics adjuncts, and GA in patients undergoing breast cancer resection.

METHODS

This systematic review was conducted according to the Cochrane Handbook for Systematic Reviews and Interventions²¹ and the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)²². The study protocol was published on Open Science Framework,

Search strategy

We conducted an electronic search of the following databases (from inception through December 2, 2020): Cochrane Library and Cochrane Trials Register, Medline, Embase, LILACs, and Web of Science; no language limitation was enforced. Search terms included: “Breast Cancer”, “Anesthetic Technique” or “Regional Anesthesia” or “General Anesthesia”, “Propofol” or “Sevoflurane”, “Disease Free Survival” or “Recurrence” or “Metastasis”. The complete list of search terms is attached in the online [Appendix 1](#). Manually, we performed a thorough search within oncological and anesthesia society websites, annals of congresses, and articles’ reference lists. Ongoing clinical trials were also assembled by searching the combination “breast neoplasms” at <https://clinicaltrials.gov/>²³.

Study selection and data extraction

The inclusion criteria were threefold: randomized controlled clinical trials (RCT), surgery for resection of malignant breast tumor in female over 18 years old, and three possible interventions’ scenarios — comparing the use of regional anesthesia, either isolated or combined to general anesthesia, with general anesthesia; comparing volatile anesthesia with total intravenous anesthesia; comparing opioid-free anesthesia with opioids. Studies depicting metastatic disease were excluded. The primary outcome was postoperative cancer recurrence, defined as locoregional recurrence and distant metastasis.

The secondary outcomes were overall survival and recurrence-free survival.

Two of the authors (A.D., D.S.) independently assessed titles and abstracts for admittance into this review. If any divergence of judgment were manifested, a third author (A.A.) would settle. The data were extracted in a standardized way through an electronic form. Apart from measured outcomes and types of interventions, other extracted data included study-related information, such as author, year of publication, sample, follow-up time, and conclusions. Given methodological diversity and statistical heterogeneity, a meta-analysis was not conducted. Instead, a systematic review of the applicable clinical evidence was completed.

Risk of bias

We covered six domains for assessing the risk of individual bias²⁴: selection bias, performance bias, detection bias, attrition bias, reporting bias, and others. A high risk of bias is considered when the studies fall out of these criteria. Two authors independently appraised these risks for the breast cancer recurrence outcome, which are summarized in Figure 1.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Cho et al. 2017							
Yan et al. 2019							
Karmakar et al. 2017							
Finn et al. 2017							
Sessler et al. 2019							

Source: Higgins et al.²⁴.

Figure 1. Risk of bias summary.


RESULTS

The electronic and manual search found 899 studies, 711 of them eligible for title and abstract review. Six hundred and seventy-two studies were deemed irrelevant, while 39 were singled out for full-text reading and quality assessment. Lastly, five clinical trials were selected for data extraction (Figure 2).

Two studies compared the association of inhalation anesthesia and total intravenous anesthesia (TIVA) (Table 1) on cancer

recurrence rates, metastasis, recurrence-free survival (RFS), and overall survival (OS). Both included patients with breast cancer stage 0-III, and the type of surgery performed varied from breast-conserving surgery to radical mastectomy, with no significant difference between the groups. Cho et al.²⁵ followed 48 women for two years to find that only one patient in the sevoflurane-fentanyl (SEVO) group had a recurrence in the contralateral breast without statistical significance. Yan et al.²⁶ also investigated short-term cancer recurrence in 80 women for the same amount of time. The two-year RFS rate in the SEVO and TIVA groups for the first and second studies, respectively, averaged 89.5% and 97.6% ($p = 0.138$) while the two-year OS rate did 92.8% and 100% ($p = 0.182$).

The other three studies investigated cancer recurrence by comparing general anesthesia with regional anesthesia and analgesia (Table 2). Finn et al.²⁷ followed 54 women for five years — all underwent mastectomy with balanced GA and thoracic paravertebral block (TPVB), but, for 72 hours after surgery, one group received a perineural infusion of ropivacaine while the other received saline (placebo). No significant association between the anesthesia technique and cancer recurrence was observed. Karmakar et al.²⁸ followed 173 women for five years after a modified radical mastectomy and used a similar method of a continuous TPVB. The women were randomized into three groups: control, perineural infusion with saline (placebo), and perineural infusion with ropivacaine; all of them received total intravenous GA with propofol. Each group incidences of local cancer recurrence, metastasis, and all-cause mortality were 2.3% (95%CI 0.7–5.4%), 7.9% (95%CI 4.6–12.6%), and 6.8% (95%CI 3.6–11.2%), respectively. These studies did not discriminate in which breast cancer stage the patients were admitted.



Source: Shamseer et al.²².

Figure 2. PRISMA flow diagram.

Table 1. Summary of trials comparing total intravenous general anesthesia versus balanced general anesthesia.

Author	Year	Study design	Tumor stage	Type of surgery	Intervention	Groups		Outcome	Follow-up time	Conclusion	Observations
						TIVA (n = 24)	SEVO (n = 24)				
Cho et al. ²⁵	2017	RCT	0-III	Partial mastectomy, total mastectomy, radical mastectomy	TIVA vs GA with volatile anesthetic	Propofol (TCI) + Ketorolac (60 mg)	Sevoflurane (according to BIS) + Fentanyl (50 mcg)	Incidence of cancer recurrence and metastasis	2 years	No significant association between anesthesia technique and recurrence was observed.	Both groups used remifentanyl and tramadol.
Yan et al. ²⁶	2019	RCT	0-III	BCS, mastectomy with or without axillary lymph node dissection	TIVA vs GA with volatile anesthetic	Propofol 3-6 mg/kg/h	Sevoflurane 1.5-2% (according to BIS)	Incidence of cancer recurrence, RFS and OS	2 years	No significant association between anesthesia technique and recurrence was observed.	Both groups used fentanyl and flurbiprofen.

RCT: randomized controlled trial; TCI: target control infusion; TIVA: total intravenous anesthesia; SEVO: Sevoflurane; BIS: Bispectral index; RFS: recurrence free survival; OS: overall survival; BCS: breast conserving surgery.

Table 2. Summary of trials comparing general anesthesia versus regional anesthesia.

Author	Year	Study design	Tumor stage	Type of surgery	Intervention	Groups		Outcome	Follow-up time	Conclusion	Observations
Finn et al. ²⁷	2017	RCT	N/A	Unilateral or bilateral mastectomy with or without axillary lymph node dissection	General anesthesia + single dose RA vs GA + continuous dose RA	Control (n = 28)	LA (n = 26)	Incidence of cancer recurrence and OS	5 years	No significant association between anesthesia technique and recurrence was observed.	All patients received nitrous oxide, acetaminophen and intravenous opioid (fentanyl or hydromorphone or morphine)
						GA (sevoflurane) + TPVBs (ropivacaine 0,5% 15 ml + saline 72h)					
Karmakar et al. ²⁸	2017	RCT	N/A	Radical mastectomy	General anesthesia vs GA + single dose RA vs GA + continuous dose RA	Control (n = 58)	Saline (n = 56)	Incidence of cancer recurrence, metastasis and OS	5 years	No significant association between anesthesia technique and recurrence was observed.	All patients received a propofol-based anesthesia
						TIVA (propofol)	TIVA (propofol) + TPVBs (ropivacaine 2 mg/kg + saline 72h)				
Sessler et al. ²⁹	2019	RCT	0-III	Simple mastectomy, modified mastectomy, wide local excision with node dissection	General anesthesia vs regional anesthesia	Control (n = 1,065)	LA (n = 1,043)	Incidence of cancer recurrence	36 months	No significant association between anesthesia technique and recurrence was observed.	Both groups used propofol, fentanyl and morphine
						GA (sevoflurane)					

RCT: randomized controlled trial; GA: general anesthesia; RA: regional anesthesia; TIVA: total intravenous anesthesia; LA: local anesthetic; TPVB: thoracic paravertebral block (s: single; c: continuous); TEB: thoracic epidural block; OS: overall survival; N/A: not available.

The third study is a multicenter, prospective, randomized trial conducted by Sessler et al.²⁹. Over two thousand women, initially classified as breast cancer stage 0-III, were accompanied for a median follow-up of 36 (IQR 24–49) months and divided into two groups: regional anesthesia-analgesia (n = 1,043) and general anesthesia and opioid analgesia (n = 1,065). The first group received a thoracic epidural or a paravertebral block with a continuous catheter infusion of local anesthetic for postoperative analgesia. In the second group, anesthesia was maintained with sevoflurane, and the patients received morphine sulfate at the end of the surgery. The groups reported 102 (10%) against 111 (10%) recurrences, respectively (HR = 0.97, 95%CI 0.74–1.28; P = 0.84), indicating that regional anesthesia did not reduce breast cancer recurrence.

A meta-analysis was not conducted due to the diverseness in general anesthesia techniques, local anesthetics used for TPVB, and tumor staging permeating each study.

DISCUSSION

Our research showed no significant statistical association between anesthetic technique and higher breast cancer recurrence rate. Since our review was limited to randomized clinical trials, only five studies could be considered, although a few ongoing clinical trials may publish results in the following years (Table 3).

We divided our findings into two groups: intravenous anesthesia versus volatile anesthesia and general anesthesia (GA) versus GA combined with regional techniques (Table 1). In the first group, neither study reported intervention-related benefits.

Table 3. Summary of ongoing clinical trials registered on Clinicaltrials.gov.

Trial number	Study Title	Interventions
NCT03109990	Impact of Dexmedetomidine on Breast Cancer Recurrence After Surgery	<ul style="list-style-type: none"> •Drug: Dexmedetomidine •Drug: Saline
NCT03941223	Regional Anesthesia for Breast Surgery	<ul style="list-style-type: none"> •Procedure: PECSII and paravertebral blocks
NCT01204242	IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: Effects on Postoperative Recovery and Cancer Recurrence	<ul style="list-style-type: none"> •Drug: Lidocaine •Drug: Saline
NCT03117894	PECS-2 for Breast Surgery	<ul style="list-style-type: none"> •Procedure: PECS-2

PECS2: pectoral nerve block type 2.

This finding contradicts Wigmore et al.³⁰, who, in a 2016 retrospective study with over 7,000 cancer patients, reported an approximately 50% higher mortality rate for volatile anesthesia against intravenous anesthesia, with an adjusted hazard ratio of 1.46 (1.29 to 1.66).

Cho et al.²⁵ compared two groups with different anesthetic techniques and analgesia: a propofol-ketorolac group (TIVA) and a sevoflurane-fentanyl group (SEVO), investigating the effect of these techniques in the cytotoxicity of natural killer cells and tumor recurrence up to two years after surgery. Cancer metastasis did not occur in either group, in spite of different drug properties. Propofol has cyclooxygenase (COX-2) inhibiting activity, which reduces the production of prostaglandin E2 (PGE2), a mediator of pain and inflammation³¹. Ketorolac also impedes prostaglandin synthesis via the inhibition of the COX enzyme, above its antitumor and anti-angiogenic properties³². Volatile anesthetics and fentanyl, though, suppress NK cells and T lymphocytes^{33,34}.

Pain causes immunosuppression³⁵; however, since both groups had a similar analgesic efficacy, the authors could eliminate it as a contributing factor. Pain scores were assessed using an 11-point numerical rating scale (NRS) at 30 minutes, 6 hours, 24h, and 48h postoperatively. If the patients complained of an NRS ≥ 4 pain, ketorolac and propacetamol were given to the TIVA group and fentanyl to the SEVO group. Since both groups received different analgesic drugs, the authors could not discriminate each drug's effects on inflammatory response. Another limitation of the study was that all patients received remifentanyl intraoperatively and tramadol for postoperative pain control — even though they are not considered immunosuppressive drugs and the doses were equivalent between the groups^{36,37}, we cannot exclude their opioid effect.

Yan et al.²⁶ had a short-term recurrence rate of breast cancer in five (6.3%) patients, four SEVO and one TIVA, during 28 months of follow-up. Two deaths were observed, both in the volatile group. No difference was found between RFS (p = 0.953) and OS (p = 0.281) between the two anesthetic techniques. Propofol was used for anesthetic induction in both groups, and fentanyl and flurbiprofen were given to all patients to provide postoperative analgesia. Those interventions could make it difficult to differentiate the individual properties of sevoflurane and propofol in the immune response. However, the study aimed to compare different anesthetic techniques rather than just different drugs.

In both Cho's and Yan's studies, we found puzzling elements and could not observe benefits from either anesthetic technique. Besides, the short-term RFS of breast cancer was elevated³⁸, which would require a large sample and a longer follow-up to detect any significant difference.

Forget et al.³⁹ had already suggested that non-steroidal anti-inflammatory drugs (NSAIDs) given shortly before surgery produce antitumor effects. Fentanyl has also demonstrated antitumor properties by inhibiting cancer cell migration and invasion⁴⁰;

however, in a large Danish cohort population study, opioid use showed no clinically significant association with breast cancer recurrence⁴¹. Thus, the effects of opioids on tumor growth and metastasis are complex and controversial: they may play a beneficial role, but it depends on drug concentration, duration of exposure, and even cancer type^{16,42}.

In 2006, the first study to describe a positive relationship between regional anesthesia and breast tumor propagation, by Exadaktylos et al.¹⁸, showed the recurrence rate for the sevoflurane-fentanyl group as four times higher than the propofol-paravertebral block group. On the other hand, Kairaluoma et al.⁴³, in 2016, published a similar retrospective study following 86 women for 12 years; the results did not demonstrate any anti-metastatic effect of perioperative regional anesthesia.

Our second group of studies, which analyzed regional techniques, culminated in findings analogous to Kairaluoma et al.'s. Karmakar et al.²⁸ compared TIVA with GA combined with TPVB and a third group that used postoperative transcatheter analgesia. There was no difference in the risk of local cancer recurrence, metastasis, or all-cause mortality between the groups ($p = 0.79$, $p = 0.91$, and $p = 0.13$, respectively). When compared to the group which received only GA, the risk of local recurrence or metastasis agreed with that for patients in the GA plus single-TPVB group (HR = 1.11, 95%CI 0.32–3.83) or the GA plus continuous-TPVB group (HR = 0.79, 95%CI 0.21–2.96).

Since all patients received total intravenous anesthesia with propofol, it is questioned whether this could camouflage the regional anesthesia technique's anti-inflammatory perk. As explained earlier, propofol has numerous documented positive effects on the immune system function^{14,31,44}, so that the TIVA components may have conferred this immunoprotective benefit. In contrast, using a single general anesthesia technique helped to evaluate how regional anesthesia affected the recurrence rate.

Finn et al.²⁷ concluded that adding a continuous ropivacaine infusion to a single-injection paravertebral block in the immediate postoperative period did not decrease the post-mastectomy cancer recurrence risk. Five out of 54 (9.3%) patients suffered from recurrence: three among those in the ropivacaine group (11.5%) and two in the saline group (7.1%; $p = 0.92$). Nevertheless, we should also consider that single-injection ropivacaine was administered to all patients, which might have decreased surgical stress in both treatment groups — ropivacaine can provide 8-16 hours of analgesia. Therefore, albeit not always an obvious choice, regional anesthesia is a technique with proven benefits; with the TPVB comes less chronic pain and better postoperative physical and mental performance⁴⁵.

Sessler et al.²⁹ was a much-expected multicenter trial. A large sample and well-designed study, it proved the irrelevance of the regional anesthetic technique in attaining less tumoral occurrence. Nonetheless, there is space for reservations, as has already

been discussed^{46–49}. Firstly, anesthetic techniques overlapped, with the concurrent use of fentanyl, propofol, and morphine in all patients and the supplementation of sevoflurane in 17% of the patients from the paravertebral block group. This combined use of opioids and volatile anesthetic with the regional technique might have interfered with its benefit. Secondly, the average follow-up of 36 months can be considered a short time to assess tumor recurrence. Finally, better screening and superior protocol regimens have decreased breast cancer mortality rates over the last decade⁵⁰, meaning the clinical treatment of the disease itself has evolved⁵¹ during the total general study period of 12 years.

The temporary immune changes caused by anesthetic drugs do not seem to bring long-term repercussions. Despite the paucity of relevant randomized controlled trials, where just one avails a high level of evidence, our qualitative analyses did not find an association between the type of anesthesia performed and the prognosis in breast cancer patients. Neither regional nor total intravenous anesthetic techniques showed significantly superior outcomes when compared to general anesthesia.

Our research's primary limitations were the narrow set of applicable studies, the significant heterogeneity, the small sample size and short follow-up time from some trials, and the high or unclear risk of bias from most included studies. This type of review suffers from difficulty to standardize in order to reduce bias. It is impossible to blind the anesthesiologist who will administer distinct techniques. Besides, each trial adopted different doses and concentrations, and the disease itself bears multiple stages. The stage and grade of the tumors and the surgical management variables presented a good distribution among the study groups, but most women were diagnosed in the early stages, which naturally translates to fewer recurrence rates³. Due to this low incidence of recurrence, the validation of the findings might prove difficult, even with significant statistical differences. There are yet other questions that may raise bias for this type of controlled trial: does breast cancer surgery stress is enough to cause immunosuppression? Does the natural evolution of anti-cancer therapies inhibit the *in-vitro*-proved^{52,53} harmful effects of anesthetics? Therefore, we suggest choosing the best available technique, considering patient comorbidities and particularities.

CONCLUSION

This review did not find an association between the type of anesthesia performed and the long-term prognosis in patients with breast cancer. It points out to no clinical evidence currently supporting a specific anesthetic technique for malignant breast tumor resection surgeries. However, the scarcity of high-quality randomized clinical trials on the subject, with larger samples and longer follow-up times demands further research.

AUTHORS' CONTRIBUTION

A.D.: conceptualization, investigation, methodology, data acquisition, formal analysis, writing – first draft, writing – review & editing; A.A.: conceptualization, investigation, methodology, data

acquisition, formal analysis, writing – first draft; D.S.: conceptualization, investigation, methodology, data acquisition, formal analysis, writing – review & editing; J.L.A.: conceptualization, methodology, formal analysis, writing – review & editing.

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359-86. <https://doi.org/10.1002/ijc.29210>
2. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and Mortality and Epidemiology of Breast Cancer in the World. *Asian Pac J Cancer Prev*. 2016;17(S3):43-6. <https://doi.org/10.7314/apjcp.2016.17.s3.43>
3. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. (eds.). *Cancer Statistics Review, 1975-2015 - SEER Statistics*. Bethesda: National Cancer Institute; 2018.
4. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. *CA Cancer J Clin*. 2016;66(4):271-89. <https://doi.org/10.3322/caac.21349>
5. Eden C, Esses G, Katz D, DeMaria Jr. S. Effects of anesthetic interventions on breast cancer behavior, cancer-related patient outcomes, and postoperative recovery. *Surg Oncol*. 2018;27(2):266-74. <https://dx.doi.org/10.1016%2Fj.suronc.2018.05.001>
6. Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. *Nat Rev Clin Oncol*. 2015;12(4):213-26. <https://doi.org/10.1038/nrclinonc.2014.224>
7. Neeman E, Ben-Eliyahu S. Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. *Brain Behav Immun*. 2013;30(Suppl.):S32-40. <https://doi.org/10.1016/j.bbi.2012.03.006>
8. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. *Oncologist*. 2005;10(Suppl. 3):20-9. <https://doi.org/10.1634/theoncologist.10-90003-20>
9. Weng M, Chen W, Hou W, Li L, Ding M, Miao C. The effect of neuraxial anesthesia on cancer recurrence and survival after cancer surgery: an updated meta-analysis. *Oncotarget*. 2016;7(12):15262-73. <https://doi.org/10.18632/oncotarget.7683>
10. Deegan CA, Murray D, Doran P, Moriarty DC, Sessler DI, Mascha E, et al. Anesthetic Technique and the Cytokine and Matrix Metalloproteinase Response to Primary Breast Cancer Surgery. *Reg Anesth Pain Med*. 2010;35(6):490-5. <https://doi.org/10.1097/aap.0b013e3181ef4d05>
11. Wu J, Buggy D, Fleischmann E, Parra-Sanchez I, Treschan T, Kurz A, et al. Thoracic paravertebral regional anesthesia improves analgesia after breast cancer surgery: a randomized controlled multicentre clinical trial. *Can J Anaesth*. 2015;62(3):241-51. <https://doi.org/10.1007/s12630-014-0285-8>
12. Li R, Xiao C, Liu H, Huang Y, Dilger JP, Lin J. Effects of local anesthetics on breast cancer cell viability and migration. *BMC Cancer*. 2018;18(1):666. <https://doi.org/10.1186/s12885-018-4576-2>
13. Ecimovic P, McHugh B, Murray D, Doran P, Buggy DJ. Effects of Sevoflurane on Breast Cancer Cell Function In Vitro. *Anticancer Res*. 2013;33(10):4255-60.
14. Melamed R, Bar-Yosef S, Shakhar G, Shakhar K, Ben-Eliyahu S. Suppression of Natural Killer Cell Activity and Promotion of Tumor Metastasis by Ketamine, Thiopental, and Halothane, but Not by Propofol: Mediating Mechanisms and Prophylactic Measures. *Anesth Analg*. 2003;97(5):1331-9. <https://doi.org/10.1213/01.ane.0000082995.44040.07>
15. Yuki K, Astrof NS, Bracken C, Sulpicio GS, Shimaoka M. Sevoflurane binds and allosterically blocks integrin lymphocyte function-associated antigen-1. *Anesthesiology*. 2010;113(3):600-9. <https://doi.org/10.1097/aln.0b013e3181e89a77>
16. Juneja R. Opioids and cancer recurrence. *Curr Opin Support Palliat Care*. 2014;8(2):91-101. <https://doi.org/10.1097/spc.0000000000000056>
17. Lin X, Wang YJ, Li Q, Hou YY, Hong MH, Cao YL, et al. Chronic high-dose morphine treatment promotes SH-SY5Y cell apoptosis via c-Jun N-terminal kinase-mediated activation of mitochondria-dependent pathway. *FEBS J*. 2009;276(7):2022-36. <https://doi.org/10.1111/j.1742-4658.2009.06938.x>
18. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? *Anesthesiology*. 2006;105(4):660-4. <https://doi.org/10.1097/00000542-200610000-00008>
19. Lee JH, Kang SH, Kim Y, Kim HA, Kim BS. Effects of propofol-based total intravenous anesthesia on recurrence and overall survival in patients after modified radical mastectomy: A retrospective study. *Korean J Anesthesiol*. 2016;69(2):126-32. <https://doi.org/10.4097/kjae.2016.69.2.126>
20. Koonce SL, McLaughlin SA, Eck DL, Porter S, Bagaria S, Clendenen SR, et al. Breast cancer recurrence in patients receiving epidural and paravertebral anesthesia: a retrospective, case-control study. *Middle East J Anaesthesiol*. 2014;22(6):567-71.
21. Higgins J, Green S. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. The Cochrane Collaboration; 2011.
22. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation. *BMJ*. 2015;350:g7647. <https://doi.org/10.1136/bmj.g7647>

23. National Library of Medicine (US). Clinical Trials [Internet]. Bethesda: National Library of Medicine [cited on Dec. 30, 2020]. Available from: <https://clinicaltrials.gov>
24. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928. <https://doi.org/10.1136/bmj.d5928>
25. Cho JS, Lee MH, Kim SI, Park S, Park HS, Oh E, et al. The Effects of Perioperative Anesthesia and Analgesia on Immune Function in Patients Undergoing Breast Cancer Resection: a Prospective Randomized Study. *Int J Med Sci*. 2017;14(10):970-6. <https://doi.org/10.7150/ijms.20064>
26. Yan T, Zhang G-H, Cheng Y-Z, Wu L-X, Liu X-Y, Sun Y-L, et al. Effects of anesthetic technique and surgery on myeloid-derived suppressor cells and prognosis in women who underwent breast cancer surgery: a prospective study. *Cancer Manag Res*. 2019;11:5513-22. <https://doi.org/10.2147/cmar.s183519>
27. Finn DM, Ilfeld BM, Unkart JT, Madison SJ, Suresh PJ, Sandhu NPS, et al. Post-mastectomy cancer recurrence with and without a continuous paravertebral block in the immediate postoperative period: a prospective multi-year follow-up pilot study of a randomized, triple-masked, placebo-controlled investigation. *J Anesth*. 2017;31(3):374-9. <https://dx.doi.org/10.1007%2Fs00540-017-2345-z>
28. Karmakar MK, Samy W, Lee A, Li JW, Chan WC, Chen PP, et al. Survival Analysis of Patients with Breast Cancer Undergoing a Modified Radical Mastectomy With or Without a Thoracic Paravertebral Block: a 5-Year Follow-up of a Randomized Controlled Trial. *Anticancer Res*. 2017;37(10):5813-20. <https://doi.org/10.21873/anticancer.12024>
29. Sessler DI, Pei L, Huang Y, Fleischmann E, Marhofer P, Kurz A, et al. Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. *Lancet*. 2019;394(10211):1807-15. [https://doi.org/10.1016/S0140-6736\(19\)32313-X](https://doi.org/10.1016/S0140-6736(19)32313-X)
30. Wigmore TJ, Mohammed K, Jhanji S. Long-term Survival for Patients Undergoing Volatile versus IV Anesthesia for Cancer Surgery: A Retrospective Analysis. *Anesthesiology*. 2016;124(1):69-79. <https://doi.org/10.1097/aln.0000000000000936>
31. Inada T, Kubo K, Shingu K. Possible link between cyclooxygenase-inhibiting and antitumor properties of propofol. *J Anesth*. 2011;25(4):569-75. <https://doi.org/10.1007/s00540-011-1163-y>
32. Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. *Br J Cancer*. 2007;97(11):1523-31. <https://dx.doi.org/10.1038%2Fsj.bjc.6604057>
33. Pirbudak Cocelli L, Ugur MG, Karadasli H. Comparison of effects of low-flow sevoflurane and desflurane anesthesia on neutrophil and T-cell populations. *Curr Ther Res Clin Exp*. 2012;73(1-2):41-51. <https://doi.org/10.1016/j.curtheres.2012.02.005>
34. Plein LM, Rittner HL. Opioids and the immune system - friend or foe. *Br J Pharmacol*. 2018;175(14):2717-25. <https://doi.org/10.1111/bph.13750>
35. Snyder GL, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. *Br J Anaesth*. 2010;105(2):106-15. <https://doi.org/10.1093/bja/aeq164>
36. Cronin AJ, Aucutt-Walter NM, Budinetz T, Bonafide CP, DiVittore NA, Gordin V, et al. Low-dose remifentanyl infusion does not impair natural killer cell function in healthy volunteers. *Br J Anaesth*. 2003;91(6):805-9. <https://doi.org/10.1093/bja/aeg273>
37. Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. *Br J Pharmacol*. 1997;121(4):834-40. <https://doi.org/10.1038/sj.bjp.0701138>
38. Houze de l'Aulnoit A, Rogoz B, Pincon C, Houze de l'Aulnoit D. Metastasis-free interval in breast cancer patients: Thirty-year trends and time dependency of prognostic factors. A retrospective analysis based on a single institution experience. *Breast*. 2018;37:80-8. <https://doi.org/10.1016/j.breast.2017.10.008>
39. Forget P, Vandenhende J, Berliere M, Machiels J-P, Nussbaum B, Legrand C, et al. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. *Anesth Analg*. 2010;110(6):1630-5. <https://doi.org/10.1213/ane.0b013e3181d2ad07>
40. Li A, Xin W, Ma C. Fentanyl inhibits the invasion and migration of colorectal cancer cells via inhibiting the negative regulation of Ets-1 on BANCER. *Biochem Biophys Res Commun*. 2015;465(3):594-600. <https://doi.org/10.1016/j.bbrc.2015.08.068>
41. Cronin-Fenton DP, Heide-Jørgensen U, Ahern TP, Lash TL, Christiansen PM, Ejlersen B, et al. Opioids and breast cancer recurrence: A Danish population-based cohort study. *Cancer*. 2015;121(19):3507-14. <https://doi.org/10.1002/cncr.29532>
42. Yardeni IZ, Beilin B, Mayburd E, Alcalay Y, Bessler H. Relationship between fentanyl dosage and immune function in the postoperative period. *J Opioid Manag*. 2008;4(1):27-33. <https://doi.org/10.5055/jom.2008.0005>
43. Kairaluoma P, Mattson J, Heikkilä P, Pere P, Leidenius M. Perioperative Paravertebral Regional Anaesthesia and Breast Cancer Recurrence. *Anticancer Res*. 2016;36(1):415-8.
44. Deegan CA, Murray D, Doran P, Ecimovic P, Moriarty DC, Buggy DJ. Effect of anaesthetic technique on oestrogen receptor-negative breast cancer cell function in vitro. *Br J Anaesth*. 2009;103(5):685-90. <https://doi.org/10.1093/bja/aep261>
45. Karmakar MK, Samy W, Li JW, Lee A, Chan WC, Chen PP, et al. Thoracic paravertebral block and its effects on chronic pain and health-related quality of life after modified radical mastectomy. *Reg Anesth Pain Med*. 2014;39(4):289-98. <https://doi.org/10.1097/aap.0000000000000113>
46. Cata JP, Forget P. Paravertebral block with propofol anaesthesia does not improve survival compared with sevoflurane anaesthesia for breast cancer surgery: independent discussion of a randomised controlled trial. *Br J Anaesth*. 2020;124(1):19-24. <https://doi.org/10.1016/j.bja.2019.09.039>
47. Ishikawa M, Sakamoto A, Ma D. Recurrence of breast cancer after anaesthesia. *Lancet*. 2020;396(10248):375-6. [https://doi.org/10.1016/S0140-6736\(20\)30488-8](https://doi.org/10.1016/S0140-6736(20)30488-8)

48. Moris D, Kontos M. Recurrence of breast cancer after anaesthesia. *Lancet*. 2020;396(10248):376-7. [https://doi.org/10.1016/S0140-6736\(20\)30489-X](https://doi.org/10.1016/S0140-6736(20)30489-X)
49. Nielsen KC, Melton MS, Gebhard RE, Greengrass RA. Recurrence of breast cancer after anaesthesia. *Lancet*. 2020;396(10248):376. [https://doi.org/10.1016/S0140-6736\(20\)30487-6](https://doi.org/10.1016/S0140-6736(20)30487-6)
50. Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. *Breast Cancer (Auckl)*. 2015;9(Suppl. 2):17-34. <https://doi.org/10.4137/bcbcr.s29420>
51. Hennigs A, Riedel F, Marmé F, Sinn P, Lindel K, Gondos A, et al. Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. *Breast Cancer Res Treat*. 2016;160(3):491-9. <https://doi.org/10.1007/s10549-016-4016-4>
52. Forget P, Aguirre JA, Bencic I, Borgeat A, Cama A, Condron C, et al. How anesthetic, analgesic and other non-surgical techniques during cancer surgery might affect postoperative oncologic outcomes: A summary of current state of evidence. *Cancers (Basel)*. 2019;11(5):592. <https://doi.org/10.3390/cancers11050592>
53. Buckley A, McQuaid S, Johnson P, Buggy D. Effect of anaesthetic technique on ER positive breast cancer cell apoptosis in the presence of CD56+ NK cells. *Ir J Med Sci*. 2013;182:S60. Available from: <https://www.embase.com/search/results?subaction=viewrecord&id=L71326324&from=export>



Molecular breast imaging and background uptake of fibroglandular tissue as tools to predict neoplasms in dense breasts

Carla Lima Santos Viviani^{1*} , Lucimara Priscila Veras² , Dionísio Nepomuceno Viviani¹ ,
Amanda Sofia Silva Mascarenhas¹ , Rivadávio Fernandes Batista de Amorim³ 

ABSTRACT

The sensitivity of mammography as a screening method is low in dense breasts, which are associated with a high risk of developing tumors. Thus, molecular breast imaging (MBI) with background uptake (BPU) of fibroglandular tissue can be used as a complementary method. The aim of this review was to synthesize the existing evidence on these important diagnostic imaging tools. Three electronic databases were searched to identify original articles, including publications dating from September 2010 and September 2020, in English, conducted in any location, and addressing at least one aspect related to dense breasts and Breast-specific gamma-imaging (BSGI). In total, 22 studies were reviewed. Several advantages of MBI and BPU as complementary methods of screening for dense breasts were found. Among them, we can mention the increase in breast cancer detection rate, easy implementation in clinical practice, high patient satisfaction, low cost and good reproducibility. In view of the good results found in our review, we can conclude that the implementation of MBI, especially with BPU, can be a promising complementary tool for screening of dense breasts.

KEYWORDS: molecular imaging; breast neoplasms; radionuclide imaging; breast density.

INTRODUCTION

Breast cancer is the type of cancer with the highest incidence among women around the world, with 2,088,849 new cases reported worldwide in 2018, which corresponds to 11.6% of all cases of cancer detected in that year¹.

Mammography is the standard screening method to detect breast cancer due to its high sensitivity in most cases, enabling diagnoses at the earliest stages and, therefore, reducing mortality rates. However, this method has some relevant limitations. One of them is the use in dense breasts, since the sensitivity of the mammogram decreases as the breast density increases.

Dense breasts are strongly associated with the risk of developing tumors. However, as this is a highly prevalent condition, it is impractical for physicians to consider that all women with this type of breast constitution are at high risk, as this would justify additional tests or preventive options in almost half of the female population. To identify the subset of women with dense breasts who are most at risk for breast cancer and who is most

likely to benefit from these strategies, improved risk stratification tools are needed².

Molecular Breast Imaging (MBI), also known as Breast-specific gamma-imaging (BSGI), which is a nuclear medicine scan performed with the Sestamibi-99mTc radiotracer and a dedicated gamma camera, can be one of these tools. New technologies, including cadmium-zinc-telluride (CZT) detectors, silicon photodiodes, and small detectors placed in the configuration of a mammograph, allow to reduce so drastically the radiation dose to obtain images in this type of study that it has become acceptable as a screening exam.

In the assessment of dense breasts by magnetic resonance imaging (MRI), the level of gadolinium contrast enhancement within the fibroglandular tissue, termed Background Parenchymal Enhancement (BPE), has been associated with both prevalent and incident breast cancer. Similarly, the background uptake (BPU) of fibroglandular tissue in MBI depicts the level of Sestamibi-99mTc uptake in that tissue, and is also strongly associated with the risk of breast cancer³.

¹Brasília Medical Images, SHLS Nuclear Medicine – Brasília (DF), Brazil.

²School of Health Sciences – Brasília (DF), Brazil.

³Department of Pathology, Medical School, Universidade de Brasília – Brasília (DF), Brazil.

*Corresponding author: carlalimasantos@hotmail.com

Conflict of interests: nothing to declare.

Received on: 02/03/2021. Accepted on: 09/06/2021

Given the current importance of BPU as a tool for screening cancer in dense breasts and the lack of studies on the subject, we decided to carry out an integrative literature review aiming to better guide the scientific community on the subject.

METHOD

The decision to carry out an integrative review was aimed at a potential view of studies carried out with different designs.

Data sources and research strategy:

To find articles in the literature, a search was carried out in the following databases: Web of Science, PubMed and Medical Literature Analysis and Retrieval System Online (Medline). The following strategy was used in both researched bases: (("molecular breast imaging" OR "MBI" OR "breast specific gamma imaging" OR "breast-specific gamma imaging" OR "BSGI") AND ("dense breast" OR "background parenchymal uptake" OR "BPU")).

Inclusion, exclusion and eligibility criteria

All studies included in this review met the following inclusion criteria:

- papers written in English and published between September 2010 and September 2020;
- studies conducted in any location;
- papers exploring at least one aspect related to dense breasts and scintigraphy performed in specific mammary gamma-camera.

Since the number of publications found on the topic was not large, quantitative, qualitative and mixed studies were included in the review. The exclusion criteria were:

- journal publications with impact factor less than 2;
- review or case report formats.

The following eligibility criteria were defined:

- papers that were specifically relevant to the topic addressed;
- publications that did not primarily address technical tools.

Selection and screening of articles

First, the title and abstract of the papers were evaluated by two authors as to the adequacy to the theme, using the inclusion and exclusion criteria. Then, articles selected for evaluation of the full text were independently reviewed by two authors, and then jointly in case of any discrepancies. A third author was consulted to resolve divergences and to assist in the final decision on whether to include or exclude the article.

Quality assessment

The critical evaluation of selected articles was made by two independent reviewers on the methodological quality. For quality assessment, two distinct checklists were used: the Critical

Appraisal Skills Program (CASP) checklist for qualitative studies⁴, and the Joanna Briggs Institute (JBI) checklist for quantitative studies⁵. A third reviewer was consulted to reconcile any discrepancies in quality assessments.

Data extraction and synthesis

Data extraction tables were created independently by two authors, and then modified as necessary (Tables 1 and 2). Information on these tables included author, year of publication, country, study characteristics, and main results. Data were extracted by one author and verified by two other authors for accuracy. A meta-analysis of quantitative studies was not feasible due to the heterogeneity of the studies' approaches to measure and report knowledge.

RESULTS

Summary of study selection

The search in databases identified 117 records. Of these, 24 were duplicates and were later removed. The initial screening process based on title and abstract resulted in the exclusion of 55 articles, leaving 38 for full-text reading. Then, another 16 articles were excluded, 14 for not focusing specifically on the topic and 2 for being technical tools. The search and selection process is shown in Figure 1.

Studies' characteristics

The 22 studies included in this review were published between 2011 and 2020 and conducted in 3 countries: the United States of America (n = 18), China (n = 2) and South Korea (n = 2). Table 1 shows their outstanding characteristics.

Quality of studies included

Study quality was rated as good (score ≥ 80), regular (score 50–79%), and poor (score $< 50\%$). Due to the limited literature available in this area, all studies were included in this review, regardless of their quality. However, none of them had a bad qualification.

Studies' results

The breast cancer detection rate is increased when MBI is associated with mammography^{6,7}, especially in cases of dense breasts⁶. In the study by Rhodes et al., when associating MBI with mammography, there was the detection of 8.8 cases of breast cancer per 1,000 women with dense breasts on mammography⁶.

Other studies have shown that MBI was useful to predict whether breast lesions are malignant or benign, and found a high overall sensitivity in this type of study when it comes to detecting breast cancer (95.4%), with no significant difference considering non-dense and dense breasts, regardless of breast density assessed by mammography^{8,9}.

Table 1. Characteristics of the studies.

Author and year of publication	Location	Methodology	Sample
Hruska et al., 2018 ²	MayoClinic, USA	Case-control study Survey questionnaires Review of medical data	239 individuals
Hruska et al., 2021 ³	MayoClinic, USA	Retrospective cohort study Analyses of MBI studies with BPU assessment and medical data review	2,992 women
Rhodes et al., 2015 ⁶	MayoClinic, USA	Prospective study MBI Image Analysis	1,585 women
Brem et al., 2016 ⁷	The George Washington University Medical Faculty, USA	Retrospective study MBI and mammography image analysis	849 women
Choi et al., 2018 ⁸	Incheon St. Mary's Hospital, College of Medicine, South Korea	Retrospective study MBI image analysis Breast Biopsy Results	231 women
Rechtman et al., 2014 ⁹	The George Washington University, USA	Retrospective evaluation MBI image analysis Breast Biopsy Results	341 women (347 breast assessed)
Connors et al., 2012 ¹⁰	MayoClinic, USA	Observational study Observing MBI results	50 MBI exams
Rhodes et al., 2020 ¹¹	MayoClinic, USA 2019	Qualitative study	NR
Shermis et al., 2016 ¹²	ProMedicaBreastCare Center, USA	Retrospective study MBI, mammography and MRI image analysis Breast Biopsy Results	1,696 patients
Shermis et al., 2017 ¹³	ProMedica Breast Care Center, USA	Qualitative study	NR
Zhang et al., 2020 ¹⁴	Hospital of Zhejiang University School of Medicine, China	Retrospective study Analysis of ultrasound, mammography and BSGI images	364 women
Yu et al., 2016 ¹⁵	Zhejiang University School of Medicine, Hangzhou, China	Retrospective study Analysis of MBI, mammography, ultrasound and MRI images	357 women
Rhodes et al., 2011 ¹⁶	MayoClinic, USA	Prospective study MBI and mammography image analysis Breast Biopsy Results	936 women
Hendrick et al., 2016 ¹⁷	Universidade do Colorado, USA	Retrospective study Use of data from Rhodes et al., 2015 Analysis of mammography, MBI and mammography associated with MBI.	1,595 women
Hruska et al., 2015 ¹⁸	MayoClinic, USA	Prospective single-institution study Review of mammography and MBI studies Determining the costs of breast exams	1,585 women
Hruska et al., 2016 ¹⁹	MayoClinic, USA	Retrospective case-control study Review of medical data and MBI images	241 women
Hruska et al., 2019 ²⁰	MayoClinic, USA	Prospective study, pilot Review of medical data, application of questionnaires and analysis of MBI studies	21 women
Yoon et al., 2015 ²¹	EwaWomansUniversity Seoul, South Korea	Retrospective study MBI, MRI and mammography image analysis Medical data collection	145 women
Ching et al., 2018 ²²	The George Washington University, USA	Retrospective study MBI image analysis Breast biopsy results	153 women
Hruska et al., 2015 ²³	MayoClinic, USA	Retrospective study Review of medical data, questionnaires MBI and mammography analysis	1,149 women
Hruska et al., 2015 ²⁴	MayoClinic, USA	Cohort study Collection of medical data, measurement of hormone levels and analysis of MBI studies	42 women
Dibble 2021 ²⁵	Alpert Medical School of Brown University, USA	Editorial comment	NR

NR: not reported; MBI: molecular breast imaging; MRI: magnetic resonance.

Table 2. Findings of the studies.

Author, year of publication, study design	Objectives	Interventions/ methods	Results/Conclusions
Hruska et al., 2018 ² Case-control study	To develop and evaluate a new quantitative method that assesses BPU, to compare quantification to qualitative categorization, and to determine the association of BPU with the risk of developing breast cancer.	The association of quantitative BPU with breast cancer was examined.	BPU quantification is a reproducible method that can predict the risk of breast cancer, as well as a qualitative method, regardless of the density seen on mammography and hormonal factors.
Hruska et al., 2021 ³ Retrospective cohort study	To examine the association of BPU with breast cancer and estimate the absolute risk and discriminatory accuracy of BPU by means of a cohort study.	Categorization of patients according to BPU in MBI exams	BPU in MBI is an independent risk factor for breast cancer, with a strongest association among postmenopausal women with dense breasts.
Rhodes et al., 2015 ⁶ Prospective study	To evaluate the diagnostic performance of MBI in the evaluation of women with dense breasts after alterations that reduced the radiation dose.	Decrease in radiation dose in MBI study.	The addition of low-dose radiation MBI to routine mammographic evaluation pointed to a 67% increase in sensitivity to detect neoplasms.
Brem et al., 2016 ⁷ Retrospective study	To determine the increase in breast cancer detection when using MBI in conjunction with mammography to assess women at high risk for breast cancer.	NA	MBI increased breast cancer detection by 1.7% in the study, suggesting that it is beneficial for the detection breast cancer in high-risk women, particularly those with dense breasts.
Choi et al., 2018 ⁸ Retrospective study	To investigate which feature of BSGI uptake in women who were recently diagnosed with breast cancer was associated with malignancy.	NA	Analysis of radiotracer uptake characteristics in BSGI is useful to predict whether breast lesions are malignant or benign.
Rechtman et al., 2014 ⁹ Retrospective study	To evaluate the sensitivity of MBI for detecting breast cancer in dense and non-dense breasts.	NA	BSGI has high sensitivity for detecting breast cancer in women with dense and non-dense breasts and is an effective complementary imaging method for the assessment of breasts.
Conners et al., 2012 ¹⁰ Observational study	To determine the diagnostic agreement and accuracy in the use of a lexical pattern of description in the interpretation of the MBI.	NA	Newly trained radiologists assessing MBI with the proposed lexical pattern achieved a high rate of agreement and diagnostic accuracy.
Rhodes et al., 2020 ¹¹ Qualitative study	To investigate whether the MBI exam has a route to supplemental screening for dense breasts.	NA	There is currently no consensus among specialists or imaging societies as to the need to use BPI or additional screening. Therefore, patients should be guided on the balance between benefits and harms.
Shermis et al., 2016 ¹² Retrospective study	To retrospectively assess the clinical performance of molecular breast imaging as a complementary screening tool for women with dense breast tissue.	NA	Molecular breast imaging linked to a high incremental cancer detection rate of 7.7% at an acceptable radiation dose.
Shermis et al., 2017 ¹³ Qualitative study	To describe how MBI is used in conjunction with recent technological advances in other imaging methods for breast cancer screening and problem solving.	NA	The integration of MBI into clinical practice was proven simple, easy to implement, with high patient satisfaction and easy reimbursement.
Zhang et al., 2020 ¹⁴ Retrospective study	To investigate the adjuvant efficacy of US and BSGI for dense breasts.	NA	For women with dense breasts, mammography plus BSGI or US may improve diagnostic accuracy. Furthermore, BSGI has high specificity and can reduce invasive biopsies.

Continue...

Table 2. Continuation.

Author, year of publication, study design	Objectives	Interventions/ methods	Results/Conclusions
Yu et al., 2016 ¹⁵ Retrospective study	To analyze the diagnostic value of BSGI for Chinese women.	NA	BSGI may help improve the ability to diagnose early-stage breast cancer among Chinese women, particularly for ductal carcinoma in situ (DCIS), mammographically dense breasts, and non-luminal breast cancer A.
Rhodes et al., 2011 ¹⁶ Prospective study	To compare the performance of dedicated gamma camera and mammography in screening women with dense breasts.	NA	The addition of gamma-camera imaging to mammography increased significantly the detection of node-negative breast cancer in dense breasts.
Hendrick et al., 2016 ¹⁷ Retrospective study	To estimate radiation-induced cancer mortality for mammography and MBI based on the biological effects of reporting ionizing radiation VII in asymptomatic women with dense breasts aged 40 to 79 years.	NA	The radiation benefit-risk ratio is estimated at 13 for 40 to 49 years with mammography, and the value doubles for each subsequent age range, from 10 years to 70–79 years. For BSGI, this ratio is estimated at 5 for women aged 40–49 years and doubles at 70–79 years.
Hruska et al., 2015 ¹⁸ Prospective study	To investigate the diagnostic gain and costs generated by adding MBI to screening mammography in women with dense breasts.	Adding MBI to mammography for screening of dense breasts	There was an increase in the overall costs and rate of benign biopsies, but also an increase in the rate of cancer detection, which resulted in a lower cost per case detected.
Hruska et al., 2016 ¹⁹ Case-control study	To investigate whether BPU in MBI is a risk factor for breast cancer.	Associations between categories of BPU and risk of developing breast cancer	This study provided the first evidence of BPU as a risk factor for breast cancer.
Hruska et al., 2019 ²⁰ Prospective study	To explore the feasibility of offering a short-term low-dose oral tamoxifen intervention for women with high BPU and examine whether this intervention would reduce BPU.	Women with high BPU had an MBI exam, followed by another after 30 days of oral tamoxifen.	Short-term intervention with low-dose tamoxifen may reduce high BPU in MBI for some patients. Preliminary findings have suggested that 10 mg of tamoxifen per day may be more effective than 5 mg to induce BPU decline in 30 days.
Yoon et al., 2015 ²¹ Retrospective study	To investigate factors that may affect MBI uptake in normal breasts and the impact of uptake on MBI diagnostic performance.	NA	BPE in RNM was the most important uptake factor in the MBI. High background uptake or marked background parenchyma enhancement can diminish MBI diagnostic performance.
Ching et al., 2018 ²² Retrospective study	To evaluate the correlation between the characteristics described in the MBI and the positive predictive value in the detection of breast cancer.	NA	Neither mass or non-mass variation nor the assessment of background uptake in MBI were significant determinants of probability of malignancy. Dense breasts were associated with low predictability and heterogeneous background uptake in MBI.
Hruska et al., 2015 ²³ Retrospective study	To describe the prevalence of the BPU categories observed in MBI screening and to examine its association with mammographic density and other clinical factors.	NA	Among women with similar mammographic density, BPU ranged from photopenic to marked. The highest BPU occurred in young, non-menopausal patients on hormone therapy.
Hruska et al., 2015 ²⁴ Cohort study	To assess the impact of the menstrual cycle phase on the aspect of BPU.	MBI study in different phases of the menstrual cycle.	When high BPU was present, it was more often seen during the luteal phase compared to the follicular phase, and in women with dense breasts compared to non-dense breasts.
Dibble 2021 ²⁵ Qualitative study	Editorial comment regarding ARTICLE 20 [3]	NA	The results of the article in question add to the growing literature that supports personalized breast cancer screening and risk assessment incorporating imaging biomarkers.

NA: not applicable; MBI: molecular breast imaging; BPU: background uptake of fibroglandular tissue; BPE: background enhancement of fibroglandular tissue; US: ultrasound.

Among the advantages of MBI studies, we can highlight a high incremental rate of cancer detection at an acceptable radiation dose, easy integration to implement in clinical practice, with high patient satisfaction, low cost, good tolerance and high reproducibility¹⁰⁻¹³.

Two studies^{14,15} compared other imaging methods with MBI to assess dense breasts. These studies selected Chinese women with dense breasts upon mammography and submitted them to other investigation methods, such as ultrasonography (US), magnetic resonance imaging (MRI) and MBI. In both studies, the sensitivity and specificity of each method were investigated. Yu et al.¹⁵ concluded that the isolated sensitivity and specificity of MBI were, respectively, 80.35% and 83.19% for the detection of breast cancer. The MBI, however, has low sensitivity to detect axillary lymph nodes (32%). Zhang et al.¹⁴ evaluated the sensitivity, specificity and diagnostic accuracy of the combination of mammography and MBI versus mammography and US. The increased diagnostic specificity of MBI was 30.8% versus 20.6% of US (10.3% difference, $p = 0.003$). There was no difference between MBI or US in increasing the sensitivity of diagnosis in mammography (increased sensitivity 25.2% versus 22.1%, difference 3.2%, $p = 0.23$).

The study by Rhodes et al.⁶ showed the performance characteristics of MBI and mammography for screening cancer in

women with dense breasts. Combined mammography and MBI were significantly more sensitive than mammography alone (91% versus 27%, $p = 0.016$). MBI and mammography specificities were similar (93% and 91%, respectively). The positive predictive value (PPV) of a screening test with abnormal results was significantly higher for MBI compared to mammography (12% versus 3%, $p = 0.01$). Although recall rates for mammography and MBI did not differ significantly, there was a trend towards a lower recall rate for MBI¹⁶. However, Hendrick and Tredennick reported that, while the lowest dose of MBI has benefit-risk estimates greater than 1 for women with dense breasts and age 40 years or older, this estimate is not outweighed by the benefit-risk related to screening mammography¹⁷.

Several techniques can be used to further screen women with dense breasts. Low radiation dose MBI can be one of these¹⁸. BPU of fibroglandular tissue, which refers to the level of Sestamibi-^{99m}Tc uptake within fibroglandular tissue on molecular breast imaging (MBI), has been identified as a strong risk factor for breast cancer, regardless of mammographic density^{2,19,20}.

Yoon et al. investigated factors that could affect MBI background uptake in normal breasts and the impact of MBI background uptake on the diagnostic performance of MBI. Background parenchyma enhancement (BPE) on MRI was the most important factor. A high background uptake or marked BPE can decrease the diagnostic performance of MBI²¹.

Some studies used subjective categories to classify BPU into four groups: photopenic aspect (lower uptake than that observed in subcutaneous fat), minimal to mild (equal to or a little higher than fat), moderate (greater than mild, but less than twice the uptake in fat) and accentuated (at least twice greater than seen in fat)^{2,3,19,22}. Due to possible variations between different observers, a quantitative method was proposed for a more accurate reproducibility of this classification².

A retrospective study carried out in 2015 with more than 1,100 women reported some clinical factors as associated with higher levels of BPU. Young, non-menopausal patients on hormone replacement therapy (HRT) were rated in the moderate to severe category²³. Another study showed effects of menstrual cycle phase on BPU. When high BPU values were seen, they were more frequent in the luteal phase and in women with dense breasts²⁴. Hruska et al. stated that short-term intervention with low-dose tamoxifen can reduce BPU in MBI for some patients. Preliminary findings suggested that tamoxifen at 10 mg per day was more effective than 5 mg to induce BPU decay in 30 days²⁰.

A study from 2018 with 153 women associated the MBI PPV in relation to the character of the lesions, BPU and breast density. Mass or non-mass variability in the character of lesions was not a good determinant of malignancy likelihood. Furthermore, it was concluded that BPU heterogeneity did not significantly affect the prediction of positivity. However, dense breasts had more findings than non-dense breasts²².




Figure 1. Article search and selection process.

The association of BPU with predicting the development of breast cancer in post- and pre-menopausal women in five years was evaluated in a 2020 cohort. Increased BPU was shown to be associated with an increased risk of breast cancer in post-menopausal women. However, a non-significant association was seen in premenopausal women. In postmenopausal women, BPU provides discriminatory accuracy to predict breast cancer risk when combined with the Gail or BCSC models (which include risk factors in the assessment). The group of postmenopausal women, with low BPU and on hormone replacement therapy was reported as having the lowest risk for breast cancer^{3,25}.

DISCUSSION

MBI in clinical practice, as a complement to mammography in the detection of breast cancer, has been reported by several studies^{6,7,22}. The pros of this imaging method are: easy interpretation, high rate of inter-observer agreement, high diagnostic accuracy and not being operator-dependent, like ultrasonography. However, the method does have some disadvantages, including the use of radiation and low sensitivity in detecting axillary lymph nodes¹⁵.

When compared to MRI, MBI has similar sensitivity and specificity for breast cancer, except in women who are at high risk of developing the disease, in which the sensitivity of MBI is slightly higher than that of MRI⁷. However, further studies are needed to better characterize this difference.

The cost of MBI is comparable to the cost of 3D mammography and approximately one-tenth of the cost of MRI¹¹. The addition of MBI to screening mammography in women with dense breasts was already proven to increase the overall cost and rate of benign biopsies. However, there is an increase in cancer detection when compared to mammography alone, which represents a great advantage, as it results in a lower cost per case detected¹⁸.

Although concerns about exposure to MBI radiation have limited its acceptance in the past, low doses have enabled the use of this method for routine screening³. This allowed an effective supplemental imaging technique for subgroups of women in which the sensitivity of mammography is limited. However, further studies are needed to assess whether MBI could replace mammography in certain populations or whether the two modalities could be used together¹⁶.

MBI images are known to have high sensitivity in detecting breast cancer, both in patients with dense breast tissue and in patients with non-dense breast tissue. Choi et al. showed that the accuracy of predicting malignancy in breast lesions could be improved by analyzing uptake characteristics rather than diagnosing malignancy based solely on the presence of radiotracer uptake. The results also associate higher uptake intensity with a higher frequency of malignancy⁸.

With regard to patients with dense breasts, studies suggest that MBI is a very useful imaging modality for the detection of tumors^{12,13}.

The increase in MBI as an adjuvant method can promote early detection of breast cancer, offer more treatment options and reduce morbidity and mortality among these patients^{14,15}. Furthermore, considering the supplementary assessment of dense breasts through MBI, the recall rate to reassess the exam varies from 7% to 13%, which is lower than that reported for breast ultrasound and MRI¹¹.

BPU assessed in the MBI of women with dense breast tissue can function as an additional risk factor that can help identify the subgroup of patients that would most benefit from screening or primary prevention options¹⁹. BPU was shown to be strongly associated with the risk of developing breast cancer, regardless of mammographic density and hormonal factors².

However, a study by Hruska et al. showed higher BPU values during the luteal phase in non-menopausal women, compared to the follicular phase of the menstrual cycle, and in women with dense breasts compared to women with non-dense breasts²⁴. Another study showed that postmenopausal women with dense breasts and high BPU were identified as being at particularly high absolute risk, while the lowest risk subgroup were postmenopausal women on hormone therapy with low BPU. This finding suggests that low BPU may identify a subset of women with hormone-unresponsive breast tissue and therefore no increased risk of breast cancer due to hormone therapy³.

Short-term administration of low-dose tamoxifen has shown a reduction in BPU in some women, which could suggest that this medication reduces the risk of breast cancer. However, given the variability of BPU response to tamoxifen among the study participants, a future study is needed²⁰.

CONCLUSIONS

We can conclude, after a careful review of the studies selected, that the use of MBI as a complementary screening method for dense breasts would be of great value in clinical practice, as it can increase the diagnostic sensitivity and specificity at low cost and good tolerance by patients.

The use of BPU along with MBI should be considered in these patients, since the level of fibroglandular tissue uptake was associated with risk of developing breast cancer, regardless of mammographic density and hormonal factors, which allows for the identification of a subset of women with dense breasts upon mammography and at high risk of developing neoplasia.

AUTHORS' CONTRIBUTION

C.L.S.V.: Conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, software, supervision, validation, visualization, writing – original draft, writing – review & editing.

LPCVG: Conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration,

resources, software, validation, visualization, writing – original draft, writing – review & editing.

DNP: Data curation, formal analysis, funding acquisition, investigation, project administration, resources, software, supervision, validation, visualization, writing – original draft, writing – review & editing.

ASM: Data curation, formal analysis, funding acquisition, investigation, resources, software, visualization, writing – original draft.

RFBA: Conceptualization, formal analysis, methodology, project administration, resources, supervision, validation, visualization, writing – review & editing.

REFERENCES

- World Health Organization. International Agency for Research on Cancer. Globocan 2018 [Internet]. World Health Organization [cited on Set 14, 2020]. Available from: <https://gco.iarc.fr>
- Hruska CB, Geske JR, Swanson TN, Mammal AN, Lake DS, Manduca A, et al. Quantitative background parenchymal uptake on molecular breast imaging and breast cancer risk: a case-control study. *Breast Cancer Res.* 2018;20(1):46. <https://doi.org/10.1186/s13058-018-0973-3>
- Hruska CB, Geske JR, Connors AL, Whaley DH, Rhodes DJ, O'Connor MK, et al. Background Parenchymal Uptake on Molecular Breast Imaging and Breast Cancer Risk: A Cohort Study. *Am J Roentgenol.* 2021;216(5):1193-204. <https://doi.org/10.2214/AJR.20.23854>
- Critical Appraisal Skills Programme (CASP). [Internet]. Oxford Centre for Triple Value Healthcare; 2019 [cited on Oct 26, 2020]. Available from <https://casp-uk.net/casp-tools-checklists>
- Checklist for Systematic Reviews and Research Syntheses. Critical Appraisal tools for use in JBI Systematic Reviews [Internet]. 2020 [cited on Oct 26, 2020]. Available from: <https://joannabriggs.org/critical-appraisal-tools>
- Rhodes DJ, Hruska CB, Connors AL, Tortorelli CL, Maxwell RW, Jones KN, et al. Molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts. *Am J Roentgenol.* 2015;204(2):241-51. <https://dx.doi.org/10.2214%2FAJR.14.13357>
- Brem RF, Ruda RC, Yang JL, Coffey CM, Rapelyea JA. Breast-specific γ -imaging for the detection of mammographically occult breast cancer in women at increased risk. *J Nucl Med.* 2016;57(5):678-84. <https://doi.org/10.2967/jnumed.115.168385>
- Choi EK, Im JJ, Park CS, Chung YA, Kim K, Oh JK. Usefulness of feature analysis of breast-specific gamma imaging for predicting malignancy. *Eur Radiol.* 2018;28(12):5195-202. <https://doi.org/10.1007/s00330-018-5563-3>
- Rechtman LR, Lenihan MJ, Lieberman JH, Teal CB, Torrente J, Rapelyea JA, et al. Breast-specific gamma imaging for the detection of breast cancer in dense versus nondense breasts. *Am J Roentgenol.* 2014;202(2):293-8. <https://doi.org/10.2214/ajr.13.11585>
- Connors AL, Hruska CB, Tortorelli CL, Maxwell RW, Rhodes DJ, Boughey JC, et al. Lexicon for standardized interpretation of gamma camera molecular breast imaging: Observer agreement and diagnostic accuracy. *Eur J Nucl Med Mol Imaging.* 2012;39(6):971-82. <https://doi.org/10.1007/s00259-011-2054-z>
- Rhodes DJ. Supplemental screening in the dense breast: Does molecular breast imaging have a role? *Menopause.* 2020;27(1):110-2. <https://doi.org/10.1097/gme.0000000000001471>
- Shermis RB, Wilson KD, Doyle MT, Martin TS, Merryman D, Kudrolli H, et al. Supplemental breast cancer screening with molecular breast imaging for women with dense breast tissue. *Am J Roentgenol.* 2016;207(2):450-7. <https://doi.org/10.2214/ajr.15.15924>
- Shermis RB, Redfern RE, Burns J, Kudrolli H. Molecular breast imaging in breast cancer screening and problem solving. *Radiographics.* 2017;37(5):1309-606. <https://doi.org/10.1148/rg.2017160204>
- Zhang Z, Wang W, Wang X, Yu X, Zhu Y, Zhan H, et al. Breast-specific gamma imaging or ultrasonography as adjunct imaging diagnostics in women with mammographically dense breasts. *Eur Radiol.* 2020;30(11):6062-71. <https://doi.org/10.1007/s00330-020-06950-2>
- Yu X, Hu G, Zhang Z, Qiu F, Shao X, Wang X, et al. Retrospective and comparative analysis of 99mTc-Sestamibi breast specific gamma imaging versus mammography, ultrasound, and magnetic resonance imaging for the detection of breast cancer in Chinese women. *BMC Cancer.* 2016;16(1):1-10. <https://doi.org/10.1186/s12885-016-2537-1>
- Rhodes DJ, Hruska CB, Phillips SW, Whaley DH, O'Connor MK. Dedicated dual-head gamma imaging for breast cancer screening in women with mammographically dense breasts. *Radiology.* 2011;258(1):106-18. <https://doi.org/10.1148/radiol.10100625>
- Hendrick RE, Tredennick T. Benefit to radiation risk of breast-specific gamma imaging compared with mammography in screening asymptomatic women with dense breasts. *Radiology.* 2016;281(2):583-8. <https://doi.org/10.1148/radiol.2016151581>
- Hruska CB, Connors AL, Jones KN, O'Connor MK, Moriarty JP, Boughey JC, et al. Diagnostic workup and costs of a single supplemental molecular breast imaging screen of mammographically dense breasts. *Am J Roentgenol.* 2015;204(6):1345-53. <https://doi.org/10.2214/ajr.14.13306>
- Hruska CB, Scott CG, Connors AL, Whaley DH, Rhodes DJ, Carter RE, et al. Background parenchymal uptake on molecular breast imaging as a breast cancer risk factor: A case-control study. *Breast Cancer Res.* 2016;18(1):42. <https://doi.org/10.1186/s13058-016-0704-6>

20. Hruska CB, Hunt KN, Conners AL, Geske JR, Brandt KR, Degnim AC, et al. Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: A pilot study. *Breast Cancer Res.* 2019;21(1):38. <https://doi.org/10.1186/s13058-019-1120-5>
21. Yoon HJ, Kim Y, Lee JE, Kim BS. Background ^{99m}Tc-methoxyisobutylisonitrile uptake of breast-specific gamma imaging in relation to background parenchymal enhancement in magnetic resonance imaging. *Eur Radiol.* 2015;25(1):32-40. <https://doi.org/10.1007/s00330-014-3400-x>
22. Ching JG, Brem RF. Breast Lesions Detected via Molecular Breast Imaging: Physiological Parameters Affecting Interpretation. *Acad Radiol.* 2018;25(12):1568-76. <https://doi.org/10.1016/j.acra.2018.03.004>
23. Hruska CB, Rhodes DJ, Conners AL, Jones KN, Carter RE, Lingineni RK, et al. Background parenchymal uptake during molecular breast imaging and associated clinical factors. *Am J Roentgenol.* 2015;204(3):W363-70. <https://doi.org/10.2214/ajr.14.12979>
24. Hruska CB, Conners AL, Vachon CM, O'Connor MK, Shuster LT, Bartley AC, et al. Effect of Menstrual Cycle Phase on Background Parenchymal Uptake at Molecular Breast Imaging. *Acad Radiol.* 2015;22(9):1147-56. <https://dx.doi.org/10.1016%2Fj.acra.2015.04.003>
25. Dibble EH. Editorial Comment on "Background Parenchymal Uptake on Molecular Breast Imaging and Breast Cancer Risk: A Cohort Study." *Am J Roentgenol.* 2021;216(5):1204. <https://doi.org/10.2214/AJR.20.24456>



Pleomorphic adenoma of the breast

Marina Sonagli^{1*}, Georgia Terra Lustre di Flora¹, Tábata Alves Domingos¹,
Vinicius Felipe Cardona¹, Solange Maria Torchia de Carvalho¹,
Cynthia Aparecida Bueno de Toledo Osório¹, Fabiana Baroni Alves Makdissi¹

ABSTRACT

Pleomorphic adenoma (PA) is a common tumor of the salivary gland, but rarely occurs in the breast. PA of the breast is a benign tumor that usually presents as a periareolar nodule. Core-needle biopsies may yield misdiagnosis with complex fibroadenoma, phyllodes tumor and metaplastic breast cancer due to the mixture of stromal and epithelial elements. We present a case of PA of the breast suspected after core-needle biopsy, but confirmed after surgical excision. The importance to make a correct diagnosis consists in avoid extensive unnecessary surgery, such as mastectomy, since PA can be treated with local surgical resection.

KEYWORDS: adenoma, pleomorphic; breast neoplasms; neoplasms, glandular and epithelial.

INTRODUCTION

Pleomorphic adenoma (PA) is a benign tumor commonly found in the parotid gland, but rarely described in breasts¹. PA is a mixed tumor, composed of epithelial and myoepithelial elements, which can occur in either breast or parotid tissues due to its common embryological ectodermal origin². Accurate identification is important to avoid misdiagnosis such as a primary sarcoma, an adenomyoepithelioma, a Phyllodes tumor or metaplastic breast carcinoma that may lead to unnecessary extensive surgery³⁻⁵. Thus, we report a case of a PA suspected after core needle biopsy and confirmed after surgical excision.

CASE REPORT

An asymptomatic 71-year-old woman presented a lump in her right breast during breast cancer screening. Mammography and breast ultrasound showed a periareolar, irregular and hypoechoic lump in the lower internal quadrant of the right breast, measuring 9 mm (Figure 1). Core-needle biopsy demonstrated a benign biphasic neoplasm, composed of a mixture of epithelial and myoepithelial cells, with a focus of apocrine metaplasia, sclerosing adenosis, and chondromyxoid stroma (Figure 2). Immunohistochemistry revealed p63 and calponin expression in myoepithelial cells, in addition to a low Ki67 proliferation index (Figure 2). Based on histopathological findings, it was not possible to differentiate between complex fibroadenoma and PA of the breast. Consequently, the patient underwent surgical excision of the nodule. Examination

of the surgical specimen showed a well-defined lesion with clear margins, and characteristic epithelial and myoepithelial elements without atypia, embedded into a chondromyxoid stroma, with foci of chondroid metaplasia (Figure 3). Final pathological report confirmed PA of the breast.

This study was approved by the Ethics and Research Committee of the A.C. Camargo Cancer Center (number 4.213.207) and was conducted following the Helsinki Declaration principles. All information and images were de-identified.

DISCUSSION

PA of the breast was first reported in 1906⁶. Since then, less than a hundred cases have been reported worldwide, including one from Brazil^{3,7-12}. PA typically occurs in females between 23 to 85 years of age⁷ and is usually located in the periareolar region and in the right breast¹³. PA presents clinically as a breast nodule with an average size of 2 cm, which can be palpable and difficult to differentiate from breast cancer^{11,14}.

There are no specific imaging findings of PA¹¹. Although PA is often reported as a well-circumscribed lump, it may demonstrate irregular contours on breast ultrasound and can appear as a lump without microcalcifications on mammography³. On pathological examination, PA appears as a circumscribed lesion that is clearly demarcated from the surrounding tissue, and is characterized by a mixture of epithelial and mesenchymal components such as glandular ducts, myoepithelial cells, myxomatous stroma, and cartilaginous

¹A.C. Camargo Cancer Center – São Paulo (SP), Brazil.

*Corresponding author: marina.sonagli@accamargo.org.br

Conflict of interests: nothing to declare.

Received on: 10/05/2020. Accepted on: 11/26/2020




Figure 1. Mammography (left) and ultrasound (right) demonstrating a 9 mm hypoechoic and irregular nodule in the lower internal quadrant of the right breast.




Figure 2. Hematoxylin-eosin stain (100x) of core-needle biopsy specimen of (A) the right breast lump showing glands surrounded by epithelial and myoepithelial cells and (B) focus of chondromyxoid stroma. Immunohistochemical (100x) of core-needle biopsy specimen of the right breast lump showing positivity for p63 (nuclear) and (C) calponin (cytoplasmatic) expression in myoepithelial cells and (D) low Ki67 proliferation rate.




Figure 3. (A) Hematoxylin-eosin stain of surgical specimen showing a well-defined lesion under low-power magnification (40x) and (B) a high-power magnification (200x) of pleomorphic adenoma with glandular elements in chondromyxoid stroma with cartilaginous and osseous metaplasia.

components. PA diagnosis can be difficult in core biopsy specimens because it must be differentiated from complex fibroadenoma or phyllodes tumor^{1,3,4,15}. In addition, two case reports have described misdiagnoses of breast PA identified as matrix-producing metaplastic breast cancer in core-needle biopsy specimens^{4,15}.

Recommended treatment is local resection with 3 mm of clear margins to avoid disruption of the tumor capsule^{2,4}. PA is an indolent tumor, but recurrences have been reported^{2,13}. Recurrence is usually in the adjacent subareolar area, with an average postoperative recurrence interval of 4 years^{2,4}.

CONCLUSIONS

Breast PA is a rare tumor that presents clinically as a periareolar nodule. Despite its being a benign tumor, the diagnosis from core-needle biopsy specimens is difficult due to the mixture of stromal and epithelial elements that can raise a differential diagnosis of complex fibroadenoma, phyllodes tumor, and metaplastic breast cancer. This case illustrates a presentation of a breast lump in an elderly patient for whom breast

cancer was the primary diagnostic consideration. Diagnostic accuracy is essential to avoid extensive surgical overtreatment such as mastectomy, as PA can be cured by local surgical resection.

ACKNOWLEDGMENTS

We thank the A.C. Camargo Cancer Center research department for all the support during the writing of this case report.

AUTHORS' CONTRIBUTIONS

M.S.: Conceptualization, Project administration, Writing — original draft, Writing — review & editing.

G.T.L.F.: Writing — original draft.

T.A.D.: Writing — original draft, Writing — review & editing.

V.F.C.: Writing — original draft, Writing — review & editing.

S.M.T.C.: Writing — review & editing.

C.A.B.T.O.: Writing — review & editing.



F.B.A.M.: Supervision, Writing — review & editing.

REFERENCES

- Reid-Nicholson M, Bleiweiss I, Pace B, Azueta V, Jaffer S. Pleomorphic adenoma of the breast: A case report and distinction from mucinous carcinoma. *Arch Pathol Lab Med*. 2003;127(4):474-7. [https://doi.org/10.1043/0003-9985\(2003\)127%3C0474:paotb%3E2.0.co;2](https://doi.org/10.1043/0003-9985(2003)127%3C0474:paotb%3E2.0.co;2)
- John BJ, Griffiths C, Ebbs SR. Pleomorphic adenoma of the breast should be excised with a cuff of normal tissue. *Breast J*. 2007;13(4):418-20. <https://doi.org/10.1111/j.1524-4741.2007.00452.x>
- Takahashi K. Diagnosis of an extremely rare pleomorphic adenoma of the breast with core needle biopsy: A case report. *Ann Med Surg*. 2018;36:242-5. <https://doi.org/10.1016/j.amsu.2018.10.037>
- Djakovic A, Engel JB, Geisinger E, Honig A, Tschammler A, Dietl J. Pleomorphic adenoma of the breast initially misdiagnosed as metaplastic carcinoma in preoperative stereotactic biopsy: a case report and review of the literature. *Eur J Gynaecol Oncol*. 2011;32(4):427-30.
- Foschini MP, Krausz T. WHO Classification of Tumours. Breast Tumours. In: WHO Classification of Tumours Editorial Board, editor. WHO Classification of tumour series. 5th ed. Lyon: International Agency for Research on Cancer; 2019. p. 40-2.
- Lecène AL. Observation d'un cas de tumeur "mixte" du sein. *Rev Chir*. 1906;33:434-68.
- Khamechian T, Alizargar J, Mazoochi T. Reporting a Rare Case of Pleomorphic Adenoma of the Breast. *Case Rep Med*. 2014;2014:387183. <https://doi.org/10.1155/2014/387183>
- Di Bonito M, Cantile M, Cerrone M, Liguori G, Botti G. Synchronous Pleomorphic Adenoma and Invasive Ductal Carcinoma in Distinct Breasts. *Breast J*. 2015;21(4):428-30. <https://doi.org/10.1111/tbj.12426>
- Srinivasamurthy BC, Bhat RV, Gopal SV. A rare benign tumor of breast masquerading on fine needle aspiration cytology: A case report. *Breast Dis*. 2017;37(2):105-7. <https://doi.org/10.3233/bd-170270>
- Nestarez JE, Corrêa MAC, Simões AB, Cominotti MLM, Barreto E, Rosa JAV. Adenoma pleomórfico da mama. *Rev Bras Mastol*. 1998;8(3):164-6.
- Leekha N, Muralee M, Mathews A, Preethi TR, Ahamed MI. Pleomorphic Adenoma of Breast-A Case Report and Review of Literature. *Indian J Surg Oncol*. 2014;5(2):152-4. <https://doi.org/10.1007/s13193-014-0310-y>
- Arsilan A, Göldoğan N, Kapucuoğlu N, Esen G, Kara H, Uras C. A rare case of pleomorphic adenoma of the breast: Ultrasonography and pathology findings. *Breast J*. 2018;24(6):1069-70. <https://doi.org/10.1111/tbj.13133>
- Diaz NM, McDivitt RW, Wick MR. Pleomorphic adenoma of the breast: A clinicopathologic and immunohistochemical study of 10 cases. *Hum Pathol*. 1991;22(12):1206-14. [https://doi.org/10.1016/0046-8177\(91\)90102-u](https://doi.org/10.1016/0046-8177(91)90102-u)
- Sato K, Ueda Y, Shimasaki M, Ozaki M, Nitta N, Chada K, et al. Pleomorphic adenoma (benign mixed tumor) of the breast: A case report and review of the literature. *Pathol Res Pract*. 2005;201(4):333-9. <https://doi.org/10.1016/j.prp.2005.03.004>
- Rakha EA, Aleskandarany MA, Samaka RM, Hodi Z, Lee AHS, Ellis IO. Pleomorphic adenoma-like tumour of the breast. *Histopathology*. 2016;68(3):405-10. <https://doi.org/10.1111/his.12757>



Minimally invasive treatment of gynecomastia by ultrasound-guided vacuum-assisted excision: report of a case series

Henrique Lima Couto^{1,2} , Carolina Nazareth Valadares^{1,2,3*} , Osmar Pellegrini Junior⁴ ,
Tereza Cristina Ferreira de Oliveira¹ , Patricia Martins Gomes El Bacha¹ , Shirley das Graças Ferreira¹ 

ABSTRACT

Introduction: Gynecomastia (GM) is a benign proliferation of glandular breast tissue in men. Some cases need surgical intervention. Traditional open surgery by semicircular inferior periareolar incision is the most common surgical approach. In order to obtain better esthetic results, some alternatives to open surgery have been proposed, such as liposuction, endoscopic mastectomy, and vacuum-assisted excision (VAE). **Objective:** To describe the technical surgical approach of ultrasound-guided VAE of GM and its results from a case series. **Method:** This is an evaluation of seven GM cases submitted to ultrasound-guided VAE with a 10G needle using the ENCOR® BD whole circumference automated breast biopsy system in Redimasto – Redimama, a Brazilian breast center. The result was considered good or satisfactory when it showed minimal remaining gland, good symmetry, no retraction, necrosis, hypertrophic scar, or displacement of the nipple-areola complex. All patients answered a questionnaire to evaluate their satisfaction and perception of the procedure. **Results:** Seven (7) patients with Simon grade 1 and 2 bilateral GM underwent ultrasound-guided VAE. No case of displacement, necrosis, or retraction of the nipple-areola complex, post-procedure bleeding, infection, skin necrosis, or asymmetry was detected. No patient reported decrease or change in nipple sensation or erection. All patients had bruises and hematomas that spontaneously resolved within 30 days. All results were considered good or excellent by patients and surgeons. **Conclusion:** Minimally invasive ultrasound-guided VAE is an excellent alternative for the treatment of GM. It is better indicated for Simon grade 1 and 2 GM, with good and excellent esthetic results, small scar, and low rates of nipple and areolar complications. It allows an outpatient procedure with low morbidity (local anesthesia) and fast recovery.

KEYWORDS: gynecomastia; mammary ultrasonography; interventional ultrasound; needle biopsy.

INTRODUCTION

Gynecomastia (GM) is a benign proliferation of glandular breast tissue in men¹. It is the most common male breast disorder, accounting for nearly 60% of them. It can be unilateral or, most often, bilateral. GM is a common condition with a prevalence of 32% to 65%, depending on age, and can affect up to 70% of all pubescent boys². A man's lifespan has three peaks: the first occurs during infancy, the second during puberty, and the third in middle-aged and older men^{1,2}. GM in infancy and puberty resolves spontaneously in most cases. Proper investigation is highly recommended among adults and older adults to exclude underlying diseases¹.

GM typically results from an absolute or relative deficiency of androgen action or excessive estrogen action in the breast tissue². No treatment is necessary for asymptomatic adolescents or men, but it is required when GM is progressive, painful, or causes cosmetic discomfort. It usually resolves by itself or by removing the underlying cause, such as medication, anabolic-androgenic steroid abuse, or treatment of systemic diseases³. Medical therapy can also be prescribed for patients with a recent diagnosis — within two years —, but is less effective for long-standing GM. Some cases need surgical intervention. According to Simon, GM can be classified into grades⁴ (Table 1).

Traditional open surgery by semicircular inferior periareolar incision is the most common surgical approach, but it may cause

¹Redimasto, Redimama – Belo Horizonte (MG), Brazil.

²Universidade Federal de Minas Gerais – Belo Horizonte (MG), Brazil.

³Santa Casa de Belo Horizonte – Belo Horizonte (MG), Brazil.

⁴Hospital da Força Aérea – Brasília (DF), Brazil.

*Corresponding author: carolinanvaladares@gmail.com

Conflict of interests: nothing to declare.

Received on: 11/03/2020. Accepted on: 11/18/2020

significant morbidities, such as asymmetry, poor scarring, and nipple-areola complex retraction or necrosis⁵⁻⁷. In order to obtain better esthetic results, some alternatives to open surgery have been proposed, such as liposuction, endoscopic mastectomy, and vacuum-assisted excision (VAE)⁷⁻⁹.

In the last few years, the use of vacuum-assisted devices, originally created to diagnose breast lesions by radiologically-guided procedures, has shown to be promising in the surgical management of GM⁸⁻¹².

OBJECTIVE

To describe the technical surgical approach of ultrasound-guided VAE of GM and its results from a case series.

METHOD

The study consists of seven GM cases evaluated from December 1, 2018, to December 1, 2019. The patients underwent ultrasound-guided VAE with a 10G needle using the ENCOR® BD whole circumference automated breast biopsy system in Redimasto — Redimama, a Brazilian breast center. Before the procedure, all patients were submitted to a clinical evaluation with full history and physical examination by a breast surgeon, as well as mammography, breast ultrasound, and blood tests. All patients signed an informed consent form for the VAE procedure. All procedures were performed by breast surgeons experts in ultrasound-guided VAE. The procedures took place in the breast center, in an outpatient approach, through a 3 mm incision in each breast, with local anesthesia, using 2% lidocaine and bupivacaine when necessary, according to the maximum dose

for the patient's weight. No sedation was necessary. After the 10G needle was introduced and positioned via ultrasound, the automated vacuum device was activated (Figures 1 and 2). The number of fragments extracted from each breast varied according to the surgeon's judgment of each case, taking into account the amount of breast tissue during clinical examination, mammography, and breast ultrasound before surgery, as well as the real-time breast ultrasound evaluation during the procedure. The vacuum method for dense breasts with fine precision was used for all cases. The resection performed left a 1-cm thick gland behind the nipple, just like the standard surgical procedure. At the end of the VAE of the GM, vacuum and manual suction of the residual cavity were performed to avoid or reduce the incidence of postoperative hematomas and bruises. Only one patient had the surgical cavity marked with a metal clip. Mammographic images were obtained one and six months after VAE to evaluate the removal of the glandular tissue (Figure 3). Patients wore a thoracic compression belt for at least 30 days. Follow-up was scheduled at 7 days, 14 days, 1 month, 2 months, and 6 months after the procedure, and consisted of clinical examination, pictures, and survey of the patient's and breast surgeon's satisfaction. The result was considered good or satisfactory when it showed minimal remaining gland, good symmetry, no retraction, necrosis, hypertrophic scar, or displacement of the nipple-areola complex. All patients answered a questionnaire to evaluate their satisfaction and perception of the procedure.

RESULTS

Seven patients with Simon grade 1 and 2 bilateral GM underwent ultrasound-guided VAE. One of them had undergone previous traditional open surgical treatment of GM with unsatisfactory results, and all patients expressed their wish to have an excision with less morbidity, small scars, and good esthetic outcome. The mean age was 27.5 years (ranging from 19 to 34 years). The average procedure time was 28 minutes (ranging from 23 to 54 minutes). The main complaint and indication for the procedure was the esthetic appearance of GM, followed by physical deformity. One patient had an areola fissure caused by the vacuum suction during the procedure, which was promptly sutured and did not affect the final esthetic result. At follow-up, all patients and breast surgeons reported excellent or good satisfaction (Figures 4 and 5), and at the six-month review, no patient presented recurrence or asked for another intervention or open surgery. No patient had postoperative seroma, bleeding, or hemorrhage or needed to be taken to the operating room at any time, during or after the surgical procedure and follow-up. All procedures were performed in an outpatient setting, with local anesthesia and no sedation. Histological evaluation revealed benign GM in all patients. No case of displacement, necrosis, or

Table 1. Simon grade of gynecomastia.

Grade 1	small breast without excess skin
Grade 2	moderate breast without excess skin
Grade 3	moderate breast with excess skin
Grade 4	large breast with excess skin



Figure 1. Ultrasound-guided vacuum-assisted excision of gynecomastia: surgical approach.



Figure 2. Ultrasound-guided vacuum-assisted excision of gynecomastia: surgical specimen.




Figure 3. Mammograms before and six months after ultrasound-guided vacuum-assisted excision of gynecomastia.

retraction of the nipple-areola complex was detected. None of the individuals investigated presented postoperative bleeding, infection, skin necrosis, or asymmetry. No patient reported decrease or change in nipple sensation or erection. All patients had bruises and hematomas that spontaneously resolved within 30 days of VAE, with excellent or good cosmetic results and no skin sequelae. The individuals investigated were able to return to their life activities in 2 days and to physical work in 14 days. Physical activities were allowed two weeks after the procedure. All results were considered good or excellent by patients and surgeons (Table 2¹³ and Figure 3).

DISCUSSION

The main goal of treating GM is to remove the excess of breast tissue, achieving the best symmetry with minimal scarring and good or excellent esthetic results. Different from subcutaneous mastectomy for cancer treatment, the purpose of GM surgery is not to excise all breast tissue in an oncologic fashion. GM surgery aims to remove enough breast tissue to obtain a good cosmetic result and avoid clinical recurrence. The open surgical approach is still the standard procedure for persistent GM after one or two years, especially when associated with psychological distress, unsatisfactory body image, and avoidance of activities in which the chest is exposed (sports and swimming)⁴. For years, subcutaneous mastectomy through a semicircular inferior areolar incision, associated or not with liposuction, has been the gold-standard surgical

procedure for this condition. The results are usually satisfactory, but postoperative complications are common, including areola deformity or retraction; “saucer-shaped defect” (from over-resection of breast tissue); seroma; poor scarring, such as retraction, hypertrophic scar, or keloid formation; wound dehiscence; and nipple retraction, necrosis, or altered sensation. The side effects of standard surgery have been a long-standing concern. In 1987, Courtiss et al. published an article reporting that 101 out of 159 patients presented high complication rates after traditional excision for the treatment of GM, including under-resection (21.9%), “saucer-shaped defect” (18.7%), poor scarring (18.7%), hematoma (16.1%), and seroma (9.4%)⁶. In order to decrease morbidity and improve esthetic results, the GM treatment should improve with new surgical techniques and minimally invasive procedures.

More recently, some groups have described an endoscope-assisted subcutaneous mastectomy⁵, with a smaller incision. However, this technique did not eliminate the potential complication of having a scar on a visible part of the chest or axillae, and the risk of nipple-areola complex complications remains⁸.

In 2010, the Royal College of Surgeons of England published the first article about a vacuum-assisted biopsy device associated with liposuction to provide a minimally invasive approach for GM, with excellent results⁸. The group suggested that ultrasound guidance could be positive in those cases. One year later, the Chinese experience with a vacuum-assisted biopsy device was also published⁹. Recently, the indications




Figure 4. 34-year-old man with Simon grade 2 gynecomastia.

for VAE have expanded to more severe Simon grades of GM, with the procedure performed in the operating room under general anesthesia¹⁰.

A recent prospective series compared VAE of GM with open traditional surgery. The VAE group had significantly smaller scar sizes (0.40 ± 0.08 cm vs. 5.34 ± 0.38 cm, $p < 0.01$), shorter healing time (3.67 ± 0.71 days vs. 7.90 ± 0.92 days, $p < 0.01$) and hospitalization (2.60 ± 0.62 vs. 7.17 ± 0.83 days, $p < 0.01$), as well as higher postoperative satisfaction (4.70 ± 0.60 scores vs. 3.20 ± 0.55 scores, $p < 0.01$). The incidence rate of bruises was significantly higher in the VAE group compared to the open surgical group (47% vs. 17%, $p = 0.013$ and 54% vs. 20%, $p = 0.007$), respectively¹¹.

The benefits of VAE are similar to those of minimally invasive procedures in general — reduced morbidity, better esthetic results, fewer recovery days, and no hospitalization time or cost⁸. The results from this series corroborate the findings of other series and studies. Depending on the GM grade, the VAE can be performed with local anesthesia, with or without sedation. With the evolution of vacuum-assisted devices, better vacuum aspiration, and multiple fragments collected in an automated circular approach with one-step needle insertion, it is possible to remove a considerable amount of breast tissue in a few minutes, reducing the odds of infection or complication. A study reported a median time of 50




Figure 5. Same patient six months after ultrasound-guided vacuum-assisted excision of gynecomastia.

Table 2. Satisfaction evaluation: adaptation of the consultation satisfaction questionnaire.

n = 7	Esthetic discomfort	Physical deformity	Medical indication	
Patient complaint	5	2	0	
n = 7	Excellent	Good	Regular	Bad
Final esthetic result (6 months) – patient	5	2	0	0
Final esthetic result (6 months) – surgeon	4	3	0	0
n = 7	yes	no		
Would the patient repeat or recommend the procedure for someone?	7	0		
Was the procedure well tolerated?	7	0		
Complications n = 7				
Seroma	0			
Bruises	7			
Anesthesia scar	0			
Bleeding	0			
Areola fissure	1			
Displacement, necrosis, or retraction of the nipple-areola complex.	0			
Decrease or change in nipple sensation or erection	0			

Source: Mazzarone¹³.

minutes using an 8G needle with a semi-automated device⁸, while in this series, the median time was 25 minutes using a 10G needle with a whole circumference automated device. The patients' procedure tolerance was high, even with just local anesthesia. Automated devices allow faster, safe, and outpatient procedures that preclude hospitalization and have the potential of saving costs.

Doubts related to long-time recurrence remain and require more studies for clarification. Longer follow-up will be necessary to evaluate this issue better. Nevertheless, the amount of breast tissue excised described by the literature and this series is not different from the traditional open surgical specimen. Mammographic images gradually change over time. After six months, it is possible to estimate the amount of tissue resected, but, like in benign surgeries, the degree of architectural distortion is high, especially due to large hematomas and bruises, which fade with time. This finding indicates that the best moment for a mammographic evaluation of the amount of breast resected should probably be after one year of the procedure.

CONCLUSION

Minimally invasive ultrasound-guided VAE is an excellent alternative for the treatment of GM. It is better indicated for Simon

grade 1 and 2 GM, with good and excellent esthetic results and low rates of nipple and areolar complications. It allows an outpatient procedure with low morbidity (local anesthesia) and fast recovery. Hematomas and bruises are always present due to the nature of the approach. Breast surgeons can obtain satisfactory cosmetic results with little morbidity and postoperative complications, such as nipple retraction or necrosis. Ultrasound-guided VAE has become a valuable approach for the surgical management of Simon grade 1 and 2 GM, with or without liposuction according to necessity. Trials comparing VAE of GM with open surgery should also evaluate clinically relevant recurrence throughout the years to establish the safety of these surgical approaches over time.

AUTHORS' CONTRIBUTION

C.V.: Investigation, Methodology, Project Administration, Writing — Review and Editing.

H.L.: Investigation, Methodology, Project Administration, Supervision, Validation, Writing — Review and Editing.

T.O.: Writing — Review and Editing, Formal Analysis.

P.B.: Methodology, Writing — Review and Editing.

S.F.: Data Curation, Validation, Writing — Review and Editing.

O.J.: Investigation, Visualization, Writing — Original Draft, Validation.

REFERENCES

1. Kanakis GA, Nordkap L, Bang AK, Calogero AE, Bártfai G, Corona G, et al. EAA clinical practice guidelines-gynecomastia evaluation and management. *Andrology*. 2019;7(6):778-93. <https://doi.org/10.1111/andr.12636>
2. Narula HS, Carlson HE. Gynaecomastia: pathophysiology, diagnosis and treatment. *Nat Rev Endocrinol*. 2014;10(11):684-98. <https://doi.org/10.1038/nrendo.2014.139>
3. Vojvodic M, Xu FZ, Cai R, Roy M, Fielding JC. Anabolic-androgenic Steroid Use Among Gynecomastia Patients: Prevalence and RelevancetoSurgicalManagement. *AnnPlastSurg*. 2019;83(3):258-63. <https://doi.org/10.1097/SAP.0000000000001850>
4. Simon BE, Hoffman S, Kahn S. Classification and surgical correction of gynecomastia. *Plast Reconstr Surg*. 1973;51(1):48-52. <https://doi.org/10.1097/00006534-197301000-00009>
5. Varlet F, Raia-Barjat T, Bustangi N, Vermersch S, Scalabre A. Treatment of Gynecomastia by Endoscopic Subcutaneous Mastectomy in Adolescents. *J Laparoendosc Adv Surg Tech A*. 2019;29(8):1073-6. <https://doi.org/10.1089/lap.2019.0256>
6. Courtiss EH. Gynecomastia: analysis of 159 patients and current recommendations for treatment. *Plast Reconstr Surg*. 1987;79(5):740-53. <https://doi.org/10.1097/00006534-198705000-00010>
7. Colombo-Benkman M, Buse B, Stern J, Herfarth C. Indications for and results of surgical therapy for male gynecomastia. *Am J Surg*. 1999;178(1):60-3. [https://doi.org/10.1016/s0002-9610\(99\)00108-7](https://doi.org/10.1016/s0002-9610(99)00108-7)
8. Qutob O, Elahi B, Garimella V, Ihsan N, Drew PJ. Minimally invasive excision of gynaecomastia—a novel and effective surgical technique. *Ann R Coll Surg Engl*. 2010;92(3):198-200. <https://doi.org/10.1308/003588410x12628812458815>
9. He Q, Zheng L, Zhuang D, Fan Z, Xi C, Zhou P. Surgical treatment of gynecomastia by vacuum-assisted biopsy device. *J Laparoendosc Adv Surg Tech A*. 2011;21(5):431-4. <https://doi.org/10.1089/lap.2011.0019>
10. Yao Y, Yang Y, Liu J, Wang Y, Zhao Y. Vacuum-assisted minimally invasive surgery. An innovative method for the operative treatment of gynecomastia. *Surgery*. 2019;166(5):934-9. <https://doi.org/10.1016/j.surg.2019.04.032>
11. Wang Y, Wang J, Liu L, Liang W, Qin Y, Zheng Z, et al. Comparison of curative effects between mammotome-assisted minimally invasive resection (MAMIR) and traditional open surgery for gynecomastia in Chinese patients: A prospective clinical study. *Breast J*. 2019;25(6):1084-9. <https://doi.org/10.1111/tbj.13424>
12. Iwuagwu O, Drew P. Vacuum-assisted biopsy device-diagnostic and therapeutic applications in breast surgery. *Breast*. 2004;13(6):483-7. <https://doi.org/10.1016/j.breast.2004.06.004>
13. Mazzarone F. Avaliação da satisfação do resultado de cirurgia plástica [dissertation]. Rio de Janeiro: Fundação Cesgranrio; 2013.



Silicone granuloma mimicking lymphatic metastases in a patient with breast cancer

Márcia Marinho^{1*}, Luís Castro², Maria José Rocha², Arlindo Ferreira²

ABSTRACT

Silicone breast implants are commonly used, even for reconstruction after mastectomy in malignant disease. In this setting, the presence of suspicious lymphadenopathy should be investigated, because it could represent disease progression. A case of a woman with left breast cancer (more than 20 years ago) and prosthetic reconstruction is reported. She developed a second breast cancer on the opposite side. During follow up, a suspicious lymphadenopathy was seen in the computed tomography scan, but the final diagnosis corresponded to a siliconoma. Silicone granuloma is a difficult diagnosis in these cases, but must be considered.

KEYWORDS: breast implants; adverse effects; breast neoplasm; surgery; granuloma; diagnostic imaging; woman.

INTRODUCTION

Silicone breast implants are commonly used for breast augmentation and also in reconstruction procedures, including those after mastectomy for oncologic purposes¹.

Leakage from either ruptured or intact implants can occur, stimulating granulomatous foreign body reaction. The resulting silicone granuloma, also known as siliconoma, corresponds to the inflammatory response to the free liquid silicone but could be misinterpreted as a malignant situation²⁻⁴.

Siliconomas can occur locally (manifesting as lymphadenopathy) or present at distant sites (rare cases in lower limbs and vulva have been already described) because the silicone polymer is a lipid soluble and therefore its migration in fatty tissue can easily take place^{5,6}.

In patients with breast cancer submitted to reconstruction with silicone implants after mastectomy, the presence of siliconomas could mimic a progression of the disease. Careful evaluation is needed and the differential diagnosis must take into consideration this benign pathology.

CASE REPORT

A 66-year-old female patient with a previous left mastectomy in 1995 for neuroendocrine carcinoma (T2N0M0) was now referred to our institution for abnormal mammography of the right breast.

The neuroendocrine carcinoma was treated with chemotherapy and hormone therapy with tamoxifen. A breast reconstruction with silicone implant on the left side and a symmetrizing surgery on the right breast were performed.

In 2012, corrective surgery was done due to fibrous encapsulation of the implant.

In February 2018, the patient was referred for polymorphic microcalcifications in the upper external periareolar region of the right breast causing a dystrophic aspect on the mammogram. These alterations were not present in the previous exams.

On clinical examination, no alterations in inspection nor solid mass were palpable in both breasts. The ultrasound showed no abnormalities.

A stereotactic biopsy was performed and the histological exam revealed ductal carcinoma in situ (DCIS), nuclear grade 2 with >90% of estrogen receptors positivity. A tumor-ectomy was conducted with the neoplasia adjacent to the lower surgical margin and one millimeter (mm) apart from the medial one. The microcalcifications were present in the histological exam.

The case, pTis (DCIS) Nx, was discussed by a multidisciplinary team and it was decided to proceed with radiotherapy (RT) and hormone therapy.

In the planning computed tomography (CT) scan prior to the RT session, a suspicious lymphadenopathy of the internal mammary

¹Centro Hospitalar de Vila Nova de Gaia/Espinho – Porto, Portugal.

²Hospital de Braga – Braga, Portugal

*Corresponding author: marciasilvamarinho@gmail.com

Conflict of interests: nothing to declare.

Received on: 03/14/2020. Accepted on: 06/11/2020.

lymph nodes was identified (Figure 1). To confirm the findings, a CT scan with contrast was performed and showed an apparent intact silicone implant, as well as lymph nodes in both internal mammary chains (Figure 2), with 15 mm maximum diameter on the left side.

A core needle biopsy was performed (Figure 3) and the histological exam revealed “vacuolated histiocytes with little birefringent



Figure 1. Planning computed tomography scan prior to radiotherapy (coronal plan): lymphadenopathy of the internal mammary lymph nodes on the left side.




Figure 2. Contrast computed tomography scan (coronal plan): lymph nodes in both internal mammary chains, the biggest one on the left side with 15 mm.




Figure 3. Core needle biopsy of the suspicious lymphadenopathy.

material in polarized light and multinucleated giant cells with vacuoles of different sizes and asteroid bodies; compatible with silicone granuloma”.

The patient underwent successful RT treatment. Currently, under hormone therapy, the patient is being followed up (two years) without complications.

The presence of suspicious lymph nodes in a breast cancer case could change the staging and consequently, the strategic therapy. In a patient with silicone breast implants, silicon granulomas must be considered in the differential diagnosis of suspicious lymphadenopathy.

DISCUSSION

Silicone granulomas are benign lesions that could have a similar presentation to malignancy.

In patients with breast cancer and silicone implants, the presence of lymphadenopathy might not always correspond to a progression of the disease, but instead to a siliconoma. Therefore, clinicians must be aware of this condition and consider it in the differential diagnosis^{3,6}.

Silicone material could migrate even without clear evidence of implant rupture. The migration mechanism is still unknown, but it has been suggested that absorbed silicone molecules may follow vascular spread or travel with lymphatic flow⁵.

Magnetic resonance imaging (MRI) findings could include evidence of implant collapse and also free silicone particles outside the prosthetic shell⁷. Sonographic evaluation may reveal echogenic lesions with a “snowstorm” appearance, but there are no specific findings. Positron emission/ computed tomography (PET CT) in patients with siliconomas may be falsely positive⁷.

Pathological tissue specimens remain the gold standard for diagnosis of siliconomas. Histological findings include foamy macrophages and refractile droplets of clear material⁷.

In conclusion, silicone granulomas are benign lesions rarely reported in the literature, which could nonetheless occur in patients with silicone implants, either for breast augmentation or reconstruction in oncologic patients. These lesions could be easily misinterpreted as a malignancy progression in breast cancer patients with silicone implants. Although this pathology demands a high grade of suspicion, clinicians should consider it in the differential diagnosis for proper staging and treatment of oncologic patients.

AUTHORS' CONTRIBUTIONS

M.M.: conceptualization, data curation, formal analysis, investigation, methodology, writing – original draft, writing – review & editing.

L.C.: data curation, visualization, validation, review & editing. M.J.R.: visualization, validation.





A.F.: visualization, validation.

REFERENCES

1. Chuangsuwanich A, Warnnissorn M, Lohsiriwat V. Siliconoma of the breasts. *Gland Surg.* 2013;2(1):46-9. <https://doi.org/10.3978/j.issn.2227-684X.2013.02.05>
2. Brown SL, Silverman BG, Berg WA. Rupture of silicone-gel breast implants: causes, sequelae, and diagnosis. *Lancet.* 1997;350(9090):1531-7. [https://doi.org/10.1016/S0140-6736\(97\)03164-4](https://doi.org/10.1016/S0140-6736(97)03164-4)
3. Carson B, Cox S, Ismael H. Giant siliconoma mimicking locally advanced breast cancer: a case report and review of literature. *Int J Surg Case Rep.* 2018;48:54-60. <https://doi.org/10.1016/j.ijscr.2018.05.001>
4. Lee Y, Song SE, Yoon E-S, Bae JW, Jung SP. Extensive silicone lymphadenopathy after breast implant insertion mimicking malignant lymphadenopathy. *Ann Surg Treat Res.* 2017;93(6):331-5. <https://doi.org/10.4174/astr.2017.93.6.331>
5. Oh JH, Song SY, Lew DH, Lee DW. Distant migration of multiple siliconomas in lower extremities following breast implant rupture: case report. *Plast Reconstr Surg Glob Open.* 2016;4(10):e1011. <https://doi.org/10.1097/GOX.0000000000001011>
6. Jeng C-J, Ko M-L, Wang T-H, Huang S-H. Vulvar siliconoma migrating from injected silicone breast augmentation. *BJOG.* 2005;112(12):1659-60. <https://doi.org/10.1111/j.1471-0528.2005.00761.x>
7. Grubstein A, Cohen M, Steinmetz A, Cohen D. Siliconomas mimicking cancer. *Clin Imaging.* 2011;35(3):228-31. <https://doi.org/10.1016/j.clinimag.2010.07.006>



VRAM flap for locally advanced breast cancer

René Aloisio da Costa Vieira^{1,2,3*} , Raphael Luiz Haikel⁴ ,
Luciano Ipólito Branquinho⁴ , Idam de Oliveira-Junior^{1,4} 

ABSTRACT

The authors presented a case of a patient with locally advanced breast cancer, with mammary and axillary localization, initially considered non-resectable, with good response after neoadjuvant chemotherapy. Due to the location of the lesion and the need for extensive resection, radical mastectomy was performed, associated with reconstruction with myocutaneous flap of the vertical rectus abdominis muscle. Different therapeutic options, the reasons that determine this choice, and local long-term control were discussed.

KEYWORDS: breast neoplasms; myocutaneous flap; surgical flaps; neoadjuvant therapy.

INTRODUCTION

Vertical Rectus Abdominis Myocutaneous (VRAM) is a versatile flap¹, generally used in pelvic reconstruction² and, to a lesser extent, in the reconstruction of the chest wall after extensive resection in locally advanced breast carcinoma. It has a lower rate of necrosis compared to the Transverse Abdominal Muscle Flap (TRAM), but it is associated with the presence of visible abdominal incision^{1,3}, with a small cosmetic input⁴.

In the case of reconstruction of defects after mastectomy in locally advanced tumors, with the need to use myocutaneous flaps, the latissimus dorsi flap is the option⁵. However, there is space for the use of the abdominal external oblique muscle flap⁶, TRAM or VRAM⁷. A case in which VRAM was used was presented here, along with a discussion on the factors related to its choice and results.

CASE REPORT

A 63-year-old patient was admitted with a palpable complaint in her right breast six months ago. Upon examination, an ulcerated tumor mass with a foul odor was noted, measuring 15 × 13 cm, occupying external quadrants of the right breast, with extension to the axillary and dorsal regions (Figure 1A). In the right axillary region, lymph node conglomerate adhered to deep planes, cT4b cN2 M0, was palpated. Core biopsy was performed with anatomopathological (AP) analysis, identifying invasive ductal

carcinoma, histological grade 3. Immunohistochemical study found a triple negative tumor. The patient underwent neoadjuvant chemotherapy (AC-T), with disappearance of ulceration, stability of the mammary lesion and satellite skin lesions, compromising the axillary and dorsal regions (Figures 1B and 1C). Subsequently, surgical treatment was performed using the Madden modified radical mastectomy technique (Figure 1D) with rotation of VRAM to close the defect in the chest wall (Figure 2), with good postoperative evolution (Figure 3). The AP analysis of the surgical specimen found metaplastic infiltrative carcinoma of the adenosquamous type, histological grade 3, measuring 8 cm in the longest axis, with cutaneous involvement, free surgical margins and 0/12 axillary lymph nodes compromised by neoplasia. Adjuvant was performed with radiotherapy (plastron + axilla + supraclavicular fossa – 28 X 180 cGY). During the follow-up, 14 months after the end of treatment, the disease progressed with distant disease (lung) and, later, bone and plastron. Local recurrence (plastron) and death occurred at 37 months and 44 months after surgical treatment, respectively.

DISCUSSION

In choosing the flap to close the defect after mastectomy, several factors were involved: the surgeon's experience, the size of the defect, training in microsurgical techniques, and the potential complications involved. In general, the microsurgical and

¹Postgraduate Program in Tocogynecology, School of Medicine of Botucatu – Botucatu (SP), Brazil.

²Postgraduate Program in Oncology, Hospital de Câncer de Barretos – Barretos (SP), Brazil.

³Department of Surgery, Mastology Division, Hospital de Câncer de Muriaé – Muriaé (MG), Brazil.

⁴Department of Mastology and Breast Reconstruction, Hospital de Câncer de Barretos – Barretos (SP), Brazil.

*Corresponding author: reneacv@terra.com.br

Conflict of interests: nothing to declare.

Received on: 12/24/2020. Accepted on: 03/03/2021

myocutaneous flaps allow the closure of areas superior to the fasciocutaneous or dermo-fat flaps, except for the ipsilateral thoracoabdominal dermofat (ITADE) flap, which, despite covering

an extensive area, is associated with a higher rate of complication and cutaneous necrosis, being the necrosis greater than 4.3% and smaller than 34.7%^{6,8,9}.




Figure 1. (A) Schematic representation prior to treatment; (B) control after neoadjuvant chemotherapy; (C) resection area; (D) resected area.




Figure 2. Vertical rectus abdominis flap. (A) Fabrication of the flap and transposition to the axillary region. Observe the use of zone I of the flap only. (B) Surgical result.




Figure 3. Vertical rectus abdominis flap: flap coverage area, with local healing and final result. (A) Intra-operative; (B and C) postoperative.

It is known that few services have professionals qualified in micro-surgical techniques, and the breast surgeon must have knowledge of the different reconstruction possibilities and their strengths and weaknesses, allowing the best choice of the myocutaneous flaps to be used. The latissimus dorsal flap is the one of choice. Despite disadvantages such as the incision on the back and the limitation of the skin donor area for very extensive defects⁵, it is the flap with a low rate of surgical complication and greater ease of execution.

The flap of the oblique abdominal muscle, little found in the literature, does not determine important fragility of the abdominal wall and is associated with an extensive scar, although it has a higher necrosis rate (less than 10%)¹⁰. The modification of the myocutaneous flap of the abdominal oblique, despite allowing coverage of an upper area, is associated with a high rate of necrosis (70.6%)⁶, representing a good option for use in extreme cases.

VRAM, in turn, is a versatile flap, associated with a low rate of complications, but it generates fragility in the abdominal wall, as well as the presence of a vertical scar^{7,11}, with less necrosis compared to TRAM¹².

In the present case, the reconstruction was performed by mastologists and oncologic surgeons with knowledge of different flaps. The tumor was found in the breast and in the lateral region of the chest, which influenced the choice of the flap. The resection of an extensive lateral chest area, determined by tumor involvement, reduced the donor area of the latissimus dorsi, limiting the choice of this flap. Thus, the contralateral

rectus abdominis muscle was considered as a choice, facilitated by the patient's body mass index and the availability of adipose tissue. In its manufacture, only the irrigation zone I³ was used, with a good donor area for coverage. In extreme cases, however, the skin donor area can be enlarged, with increased flap size and greater coverage, using tissue from zones II and III¹³.

The patient evolved well, and the surgery associated with the reconstruction allowed local control of the disease for 37 months, which positively influenced the quality of life².

CONCLUSION

VRAM is an excellent flap that allows coverage of large skin defects in the chest wall. It constitutes yet another option to be considered after resection of locally advanced breast tumors.

AUTHORS' CONTRIBUTION

R.A.C.V: Conceptualization, formal analysis, investigation, methodology, project administration, supervision, writing — original draft, writing — review & editing.

R.L.H.: Conceptualization, formal analysis, writing — review & editing.

L.I.B.: Data curation, writing — review & editing.

I.O.-J.: Investigation, methodology, supervision, writing — original draft, writing — review & editing.

REFERENCES

- Daigeler A, Simidjiiska-Belyaeva M, Drücke D, Goertz O, Hirsch T, Soimaru C, et al. The versatility of the pedicled vertical rectus abdominis myocutaneous flap in oncologic patients. *Langenbecks Arch Surg*. 2011;396(8):1271-9. <https://doi.org/10.1007/s00423-011-0823-6>
- O'Dowd V, Burke JP, Condon E, Waldron D, Ajmal N, Deasy J, et al. Vertical rectus abdominis myocutaneous flap and quality of life following abdominoperineal excision for rectal cancer: a multi-institutional study. *Tech Coloproctol*. 2014;18(10):901-6. <https://doi.org/10.1007/s10151-014-1156-6>
- Kotti B. Optimizing the pedicled rectus abdominis flap: revised designs and vascular classification for safer procedures. *Aesthetic Plast Surg*. 2014;38(2):387-94. <https://doi.org/10.1007/s00266-014-0273-y>
- Fujiwara M, Nakamura Y, Sano A, Nakayama E, Nagasawa M, Shindo T. Delayed vertical rectus abdominis myocutaneous flap for anterior chest wall reconstruction. *Aesthetic Plast Surg*. 2006;30(1):120-4. <https://doi.org/10.1007/s00266-005-0145-6>
- Munhoz AM, Montag E, Arruda E, Okada A, Brasil JA, Gemperli R, et al. Immediate locally advanced breast cancer and chest wall reconstruction: surgical planning and reconstruction strategies with extended V-Y latissimus dorsi myocutaneous flap. *Plast Reconstr Surg*. 2011;127(6):2186-97. <https://doi.org/10.1097/prs.0b013e318213a038>
- Costa Vieira RA, Oliveira-Junior I, Branquinho LI, Haikel RL, Ching AW. Modified External Oblique Myocutaneous Flap for Repair of Postmastectomy Defects in Locally Advanced Breast Tumors: A Cohort Series Associated with a Systematic Review of Literature. *Ann Surg Oncol*. 2020. <https://doi.org/10.1245/s10434-020-09205-y>
- Mir M, Shahdhar M, Ganaie K, Syed Q. Oncological safety of immediate rectus abdominis myocutaneous breast reconstruction in patients with locally advanced disease (stage IIB and III). *South Asian J Cancer*. 2013;2(4):239-42. <https://doi.org/10.4103/2278-330x.119921>
- Vieira R, Silva KMT, Oliveira-Junior I, Lima MA. ITADE flap after mastectomy for locally advanced breast cancer: A good choice for mid-sized defects of the chest wall, based on a systematic review of thoracoabdominal flaps. *J Surg Oncol*. 2017;115(8):949-58. <https://doi.org/10.1002/jso.24619>
- Vieira RAC, Boni R, Silva VD. Reply: ITADE flap after mastectomy for locally advanced breast cancer: A good choice for mid-sized defects of the chest wall based on a systematic review of thoracoabdominal flaps. *J Surg Oncol*. 2019;119(8):1182-3. <https://doi.org/10.1002/jso.25436>

10. Lee S, Jung Y, Bae Y. Immediate chest wall reconstruction using an external oblique myocutaneous flap for large skin defects after mastectomy in advanced or recurrent breast cancer patients: A single center experience. *J Surg Oncol.* 2018;117(2):124-9. <https://doi.org/10.1002/jso.24830>
11. Bassiouny MM, Maamoun SI, El-Shazly Sel D, Youssef OZ. TRAM flap for immediate post mastectomy reconstruction: comparison between pedicled and free transfer. *J Egypt Natl Canc Inst.* 2005;17(4):231-8.
12. Behnam AB, Nguyen D, Moran SL, Serletti JM. TRAM flap breast reconstruction for patients with advanced breast disease. *Ann Plast Surg.* 2003;50(6):567-71. <https://doi.org/10.1097/01.sap.0000069075.27321.bc>
13. Lin YN, Ou-Yang F, Hsieh MC, Lee SS, Huang SH, Chuang CH, et al. Use of Extended Pedicled Transverse Rectus Abdominis Myocutaneous Flap for Extensive Chest Wall Defect Reconstruction After Mastectomy for Locally Advanced Breast Cancer. *Ann Plast Surg.* 2020;84(1S Suppl. 1):S34-S39. <https://doi.org/10.1097/sap.0000000000002188>



Myeloid sarcoma in the breast in a patient with acute myeloid leukemia: a case report

Ana Lucia Kefalas Oliveira¹ , July Helen Marinho de Almeida^{1*} ,
João Henrique do Amaral e Silva¹ , Jessé Marcos de Oliveira¹ 

ABSTRACT

Myeloid sarcoma infiltration into the breast of patients with acute myeloid leukemia is rare. The present study reports the case of a 56-year-old woman diagnosed with AML and an incidental finding of a breast tumor. The nodule biopsy raised the suspicion of invasive lobular carcinoma and poorly differentiated angiosarcoma. Subsequent immunohistochemical study concluded the diagnosis of myeloid sarcoma. The varied image presentations, the lack of knowledge of clinical data and complementary propaedeutics, and the histopathological similarity with certain primary breast lesions make it difficult to discover secondary infiltration by myeloid sarcoma in this unusual site.

KEYWORDS: breast neoplasms; sarcoma, myeloid; leukemia.

INTRODUCTION

Myeloid sarcoma (MS) is the tumor form of acute myeloid leukemia (AML), consisting of a collection of myeloid blasts in an anatomical site other than the bone marrow. It is addressed by several names, including myeloblastoma, monocytic sarcoma and chloroma. Other synonyms are granulocytic sarcoma and extramedullary myeloid tumor¹. Although it can affect any region of the body, its presentation in the breast is extremely uncommon, having been, until 2005, only 67 cases recorded in the literature², with additional episodes reported sporadically until recently³. Skin, lymph nodes, gastrointestinal tract, bone, soft tissues and testicles are the most frequent sites of involvement⁴. MS can be found isolated in about a quarter of cases, or during the course of AML, chronic myeloid leukemia, myelodysplastic syndrome or other myeloproliferative disorders³. MS occurs with an incidence of 2% to 14% in AML⁵. The age of onset varies from 29 to 72 years, mean age of 42 years¹. It is difficult to define typical characteristics of the affected patients, so the diagnosis can only be confirmed through pathological examination with immunohistochemistry.

CASE REPORT

A 56-year-old female patient presented at the emergency unit complaining of adynamia, moderate dyspnea, hyporexia, and weight

loss within the past two months, with symptomatic worsening in the last 15 days. She carried recent tests that revealed significant anemia, thrombocytopenia, and leukocytosis, and was admitted to our institution for investigation. On physical examination, she was pale, sarcopenic, dehydrated, and had multiple lymph node enlargements. She was diagnosed with AML subtype M4, using bone marrow aspirate, and induction chemotherapy with cytarabine was started six days after admission.

Chest tomography performed to assess respiratory distress revealed an incidental finding of a nodule in the right breast and axillary lymph node enlargement. Mammography (Figure 1) revealed a nodule in the right breast measuring 2 cm, located at the junction of the lateral quadrants, oval, with indistinct margins, being categorized as a suspected lesion of malignancy. Complementary ultrasonography (Figure 2) confirmed the suspicious findings, identifying an oval nodule parallel to the skin, circumscribed, heterogeneous, with slight posterior acoustic reinforcement, without flow to the color Doppler study, at the union of the lateral quadrants on the right, at 9 o'clock, 4 cm from the papilla, and measuring 2 × 1.4 × 1.8 cm. A thick needle biopsy revealed breast tissue infiltrated by round, diseased cells, with a high nucleus-cytoplasm ratio. In the absence of clinical and laboratory information, and due to the probabilities, the hypotheses of invasive lobular carcinoma and poorly differentiated angiosarcoma were raised. However, an immunohistochemical

¹Hospital das Clínicas da Universidade Federal do Triângulo Mineiro – Uberaba (MG), Brazil.

*Corresponding author: july_helen3@hotmail.com

Conflict of interests: nothing to declare.

Received on: 11/29/2020. Accepted on: 03/03/2021

study ruled out these hypotheses by revealing a negative result for cytokeratins 7 and AE1/AE2.

The patient's clinical weakness postponed the surgical approach to breast injury, which was followed up with imaging tests until conditions favored invasive treatment. A new mammogram (Figure 3), performed seven months following the first, after three complete chemotherapy cycles, no longer showed the nodule, which on ultrasound showed a significant reduction in tumor mass. Leukemic infiltration in the breast became the main clinical

suspicion, considering the behavior of the tumor in the face of chemotherapy directed at leukemia and the inconsistent diagnoses between anatomopathological and immunohistochemical studies.

Nine months after the diagnosis, the patient underwent an open excisional biopsy, and the examination of the surgical specimen showed sparse foci of remaining neoplasia. A new immunohistochemical study, in the light of clinical information, resulted in positive tumor cells for the CD34, CD45, lysozyme, CD15, and myeloperoxidase markers. Thus, the diagnosis of breast infiltration by MS was confirmed. Ten months after diagnosis, and after four cycles of chemotherapy, the patient died as a result of complications from the underlying disease.

DISCUSSION

MS can occur in three clinical contexts: simultaneously with blood and bone marrow involvement, as in the case of our patient; as isolated recurrence of AML; and prior to the manifestations of systemic leukemia⁶. Even in patients with bone marrow invasion, breast MS is quite uncommon. Patients with breast MS have mainly a painless mass, without inversion or nipple secretion⁷. In the case studied, the patient did not present evident symptoms. However, previous studies report both asymptomatic presentation and presentation of painful palpable nodulation⁷. Therefore,




Figure 1. Mammography in oblique mediolateral view showing a nodule in the right breast, measuring 2 cm, at the junction of the lateral quadrants, oval, with indistinct margins (BI-RADS 4A).




Figure 2. Ultrasonography showing an oval nodule, parallel to the skin, circumscribed, heterogeneous, without flow to the color Doppler study, at the union of the lateral quadrants, at 9 am, 4 cm apart from the papilla, measuring 2 × 1.4 × 1.8 cm.




Figure 3. Mammography performed after 3 cycles of chemotherapy no longer demonstrated the nodule.

it is difficult to define typical clinical presentations of the tumor. The morphological, imaging, and histological characteristics are as variable as the clinical presentation, of difficult diagnosis, especially if it is of low suspicion. Mammography shows that breast leukemias have three mammographic patterns: breast masses, architectural distortions, and no abnormalities. Most breast masses are hyperdense, have a rounded shape and microlobulated margins, and occasionally accompany internal microcalcifications. On ultrasound, they usually present as solitary or multiple masses that tend to be homogeneously hypoechoic with microlobulated or indistinct margins². The immunohistochemical study is extremely useful in recognizing MS, the most specific markers of myeloid differentiation being myeloperoxidase and lysozyme, both positive in this case. The levels of myeloperoxidase positive cell expression in MS tend to be between 66 and 83.6%⁶. The most common differential diagnoses include invasive lobular carcinoma, non-Hodgkin's lymphoma or even non-neoplastic conditions, such as inflammation and extramedullary hematopoiesis⁸. In the reported case, the diagnosis of invasive lobular carcinoma was the first to be considered.

The treatment modalities recorded in the literature include surgical excision, radiotherapy, and chemotherapy and depend on the patient's clinical conditions, the size of the tumor, and the systemic response. However, most studies have concluded that all patients with MS should receive mastectomy or breast sectorectomy combined with standard systemic chemotherapy, and overall survival appears to be longer in patients treated with chemotherapy compared to those who do not receive it. Although the patient in the case presented has died, due to previous clinical

weakness, it is important to note that the response of the breast tumor to chemotherapy was quite significant, since it was no longer identified in the follow-up mammography and had a significant reduction demonstrated on ultrasound.

CONCLUSION

The case presented here shows the importance of the clinical-pathological correlation and maintenance of high diagnostic suspicion for MS in patients with AML, although morphological or histological characteristics suggest other conditions. In the case of the presented patient, the diagnosis of AML helped to consider the diagnostic possibility of MS and, consequently, contributed to a satisfactory mammary tumor regression. The rarity of breast involvement by this type of tumor means that most of the information available on its behavior and its manifestations is obtained from case reports and small retrospective studies. Its extremely variable presentation makes diagnosis difficult through imaging exams, requiring the use of all the resources necessary for anatomopathological and immunohistochemical diagnosis.

AUTHORS' CONTRIBUTION

A.L.K.O.: conceptualization, investigation, methodology, project administration, supervision, validation.

J.H.M.A.: methodology, research, writing – original draft, writing – review & editing).

J.H.A.S.: writing – review & editing, validation.

J.M.O.: writing – review & editing.

REFERENCES

1. Nalwa A, Nath D, Suri V, Jamaluddin MA, Srivastava A. Myeloid sarcoma of the breast in an aleukemic patient: a rare entity in an uncommon location. *Malays J Pathol*. 2015;37(1):63-6.
2. Kim SJ, Kim WG. Sonographic Features of a Myeloid Sarcoma of the Breast as a Relapse of Acute Myeloid Leukemia After Stem-Cell Transplantation: A Case Report. *Am J Case Rep*. 2019;20:612-9. <https://doi.org/10.12659/AJCR.915453>
3. Zhai J, Kong X, Yang X, Gao J, Xuan L, Wang X, et al. An uncommon granulocytic sarcoma of the breast: a case report and literature review. *Onco Targets Ther*. 2018;11:3685-90. <https://doi.org/10.2147/OTT.S149149>
4. Gomaa W, Ghanim A, Emam E, Bayoumi K, Ghanim A. Primary Myeloid Sarcoma of the Breast: A Case Report and Review of Literature. *J Microsc Ultrastruct*. 2018;6(4):212-4. https://doi.org/10.4103/2FJMAU.JMAU_15_18
5. Huang XE, Li YJ, Zhou XD. Granulocytic sarcoma of the breast: A case report. *Oncol Lett*. 2015;10(4):2447-9. <https://doi.org/10.3892/ol.2015.3532>
6. Wu HY, Liu L, Gu L, Luo YH. Clinical characteristics and management of primary granulocytic sarcoma of the breast: A case report. *Medicine (Baltimore)*. 2019;98(35):e16648. <https://doi.org/10.1097/MD.00000000000016648>
7. Sharma A, Das AK, Pal S, Bhattacharyya S. Fine-needle aspiration cytology of granulocytic sarcoma presenting as a breast lump - Report of a rare case with a comprehensive literature search. *J Lab Physicians*. 2018;10(1):113-5. https://doi.org/10.4103/JLPJLP_114_17
8. Fernandes Vieira V, Vo QD, Bouquet de la Jolinière J, Khomsi F, Feki A, Hoogewoud HM. Granulocytic Sarcoma Presenting as a Palpable Breast Lump. *Front Surg*. 2017;3:67. <https://doi.org/10.3389/fsurg.2016.00067>



Adenoid cystic carcinoma of the breast: case report

Matheus Lavigne Marinho^{1*} , Alexandre Tafuri² , Carlos Alberto da Silva Ramos² ,
Antônio Alexandre Lisboa Ladeia² , Luciana de Carvalho Azevedo³ 

ABSTRACT

Adenoid cystic carcinoma (AdCC) of the breast is an uncommon invasive lobular neoplasm whose morphology is similar to the homonymous tumor of salivary glands and with a peculiar behavior toward the “triple-negative” (TN) profile. Tumors belonging to this family do not immunohistochemically express three of the main prognostic biomarkers and tend to show a more aggressive behavior. However, this rare histological pattern of breast cancer is generally associated with good prognosis. In this study, the authors describe the case of a 49-year-old woman diagnosed with this rare malignant tumor and who underwent breast-conserving surgery. Recent studies have aimed to understand the genes, genetic alterations, and etiological aspects related to the still obscure etiopathogenesis of AdCC. Thus, morphological and molecular aspects relevant to AdCC and reported in the literature will be discussed.

KEYWORDS: adenoid cystic carcinoma; breast neoplasms; triple-negative breast neoplasms.

INTRODUCTION

Currently, breast cancer stands out in prevalence among women, associated with increasing longevity, new lifestyle habits, and early menopause¹. Accurate anatomopathological diagnosis of tumors is essential to adopt an adequate and effective therapeutic approach, enabling satisfactory patients' survival^{1,2}. Among the different histological types of breast cancer, adenoid cystic carcinoma (AdCC) stands out for being uncommon and presenting peculiar morphological and immunohistochemical characteristics, which provide a paradoxically favorable prognosis². Due to the rare incidence, many cases of AdCC are not properly recognized or recorded in epidemiological databases, hindering the elucidation of AdCC etiopathogenic correlations^{2,3}. In a recent publication on breast neoplasms, the World Health Organization (WHO) histologically subclassifies AdCC into classic, solid-basoloid, or with high-grade transformation². These definitions are essentially based on architectural, cytological, and immunohistochemical characteristics, but they can also be objectified by genomic profiling^{2,4,5}. Genomic studies performed by *in situ* hybridization (FISH) or by polymerase chain reaction (PCR) have gained prominence in the characterization and understanding of the AdCC etiopathogenesis⁴. The present case report addresses the diagnosis of an uncommon malignant breast tumor compatible with classic AdCC of the breast after histological and immunohistochemical evaluation.

CASE REPORT

A 49-year-old woman sought a mastology service due to the presence of a mass in the left breast. Despite apparently normal nipples and breasts, absence of bulging or skin retraction, a medium-radiodensity nodule with partially defined contours was observed at 2 o'clock in the left upper lateral quadrant, measuring 1.1 cm (Figure 1A). As no suspicious microcalcifications and alterations in the lymph nodes of the left axillary region were evidenced, it was classified as BI-RADS 0. According to ultrasonography exam, there was a lesion suggestive of a BI-RADS 4 solid nodule, described as a nodular image, solid, rounded, hypoechoic, heterogeneous, with regular contours, with no flow capture on Doppler, 30 mm from the nipple, 12.8 mm from the skin, and measuring 9.6 x 8.1 mm (Figures 1B and 1C). All identified lymph nodes were echographically normal.

For anatomopathological analysis, core biopsy products and a sectionectomy surgical specimen of the upper lateral quadrant of the left breast were obtained, in addition to a biopsy of the patient's sentinel lymph node. According to macroscopic inspection, the tumor was a white nodule, measuring 2.5 cm, located deep to the breast (Figure 1D), whereas the lymph nodes, sentinel or non-sentinel, were soft to the cut with light-brown color and approximate size of 1.0 cm. Histological analysis showed a neoplasm consisting of epithelial cells in a tubular and cribriform pattern, with few solid elements [score 1], similarly to the salivary gland tumor, diffusely infiltrating the breast parenchyma and adipose tissue. In addition, round and elongated

¹Faculdade de Medicina, Universidade Federal de Minas Gerais – Belo Horizonte (MG), Brazil.

²Laboratório Tafuri de Patologia – Belo Horizonte (MG), Brazil.

³Hospital Alberto Cavalcanti, Rede Fundação Hospitalar do Estado de Minas Gerais – Belo Horizonte (MG), Brazil.

*Corresponding author: matheuslavignepato@gmail.com

Conflict of interests: nothing to declare.

Received on: 02/05/2021. Accepted on: 06/09/2021

cells with moderate nuclear atypia [score 2], low mitotic index [score 1] as well as substance in the gland lumens (sometimes basophilic, sometimes eosinophilic) were verified. In special Alcian Blue staining, myxoid materials were observed in the basal lamina and gland content, confirming mucopolysaccharide composition (Figure 2).

The immunohistochemical study showed negativity for estrogen, progesterone, and HER2 receptors, dual cell population, epithelial and myoepithelial, as well as positivity for Ki-67 and CD117 (c-KIT) (Table 1).

Considering all the characteristics of the neoplasm, the following diagnosis was concluded: adenoid cystic carcinoma of the breast, with the following pathological staging: *pT2pN0pMX*. Taking into account the known favorable prognosis of this carcinoma and the absence of metastases, the propaedeutic and curative approach of sectionectomy dispensed with chemotherapy or radiotherapy. Furthermore, regular mastology follow-up was adopted with the patient for active surveillance of tumor recurrence.

DISCUSSION

Adenoid cystic carcinoma of the breast (AdCC), a rare and important variant of invasive carcinoma, is worthy of attention of pathologists who routinely deal with breast biopsies^{6,7}. Ghabach et al. estimated an age-adjusted incidence rate of 0.92 for every 1 million people/year, predominantly verified in postmenopausal women with a median age of 60 years⁸. This epidemiological finding is corroborated by studies showing an incidence rate ranging between 0.1% and 3.5% among all breast carcinomas and age ranging between 33 and 74 years^{2,4,6,8,9}. With a histological aspect resembling the homonymous tumor of salivary glands, in the breast, for classic types of AdCC, it requires a differential diagnosis with collagenous spherulosis, intraductal carcinoma with cribriform pattern^{5,6,10}. As for the solid variant of AdCC, it requires differentiating it from neuroendocrine carcinoma, solid papillary carcinoma, metaplastic carcinoma, and malignant lymphoma^{4,6,9,11}. Although the etiopathogenic relationship has not yet been confirmed, some authors suggest an association of




Figure 1. Macroscopic aspects of adenoid cystic carcinoma of the breast in imaging and anatomopathological tests.

AdCC with benign lesions such as microglandular adenosis, tubular adenosis, adenomyoepithelioma and fibroadenoma^{2,4,5,12}.

The tumor is histologically composed of a dual cell population (epithelial and myoepithelial), with a triple-negative molecular profile for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)^{2,4,7,13}. Furthermore, it presents basophilic secretions, formed by materials from the basal membrane, in the pseudoglandular lumens, which are better observed in the special Alcian Blue or PAS (Periodic acid-reactive Schiff) stains^{2,8,9,12}. Other findings that support the AdCC hypothesis are potential immunohistochemical markers, such as CD117 and Ki-67, as well as the evaluation of MYB-NIFB gene fusion or mutated genes BRAF, FGFR1/2, ERBB2, and NOTCH1, through molecular cytogenetic techniques as PCR or FISH^{2,4,6,9,12}.

Among these mutations, the activation of NOTCH1, simultaneously considered oncogene and tumor suppressor gene, is identified in solid and triple-negative (TN) tumors, such as AdCC, influencing resistance to chemotherapy drugs^{2,14}. *In vitro* and *in vivo* studies performed by Stoeck et al. showed that, unlike NOTCH2 and HES4 biomarkers, the increasing expression of NOTCH1 induces

sensitivity to the gamma-secretase inhibitor MRK-003, as monotherapy or combined with the antineoplastic drug Paclitaxel¹⁴. The transcription product of this mutated gene is significantly

Table 1. Immunohistochemical profile of the tumor based on the sectionectomy product.

Antibody	Clone	Result (neoplastic cells, %)
Estrogen Receptor	ER1	Negative (0)
Progesterone Receptor	PgR636	Negative (0)
HER2 oncogene product	SP3	Negative (score 0)
Ki-67: Cell proliferation antigen	MIB1	Positive (15)
Calponin (muscle and myoepithelial cells)	Calp	Focally positive
Tumor Protein p63 (squamous/transitional epithelium; myoepithelial cells)	DAK-p63	Positive (myoepithelial cells)
CD117 – KIT gene product	YR145	Positive

KIT: Proto-Oncogene Receptor Tyrosine Kinase; HER2: Human epidermal growth factor receptor 2.




Figure 2. Microscopic aspects of adenoid cystic carcinoma of the breast.

higher in basal-like and mesenchymal TN tumors^{13,14}. These basal-like tumors are subclassified into types 1 and 2, according to genetic expression, influencing sensitivity to chemotherapeutics^{14,15}. Despite sharing morphological characteristics with solid-basaloid AdCC, the differential diagnosis is enabled by investigating the tumor extension and identifying typical areas of AdCC².

On mammography, the lesion, whose size varies between 1 and 140 mm, is observed as a lobulated or irregular mass, sometimes cystic, which may have defined borders; on ultrasound, it is solid and hypoechoic, or a heterogeneous mass^{6,9,16}. According to guidelines from the American Society of Clinical Oncology/College of American Pathologists, breast tumors suspected of malignancy should be biopsied by core biopsy for immunohistochemical evaluation⁷. The expression or absence of markers is able to predict biological behavior and therapeutic response^{7,13,17}. Among them, positivity for PR and ER favorably correlates with prognosis and hormonal therapeutic effect¹³, unlike HER2, which is usually associated with aggressiveness and hormonal resistance^{7,17}.

Belonging to the family of tumors with TN immunophenotype, the combination of the absence of expression of endocrine receptors (ER and PR) and HER2 results in a favorable prognosis for patients with breast AdCC^{2,8,18}. In the last decade, studies concluded that the neoplasm is well-located, especially in the retroareolar region, with a high survival rate of approximately 95% in 10 years and, in tumors measuring less than 14 mm, there is no lymph node involvement^{2,16}. Although uncommon, there are records of cases reporting axillary lymph node involvement, metastases to lungs, bones, livers, brain, and kidneys^{2,8,16}, mainly observed in AdCCs with high-grade transformation, in which the glandular histological pattern is essentially replaced with a solid area, a subtype with worse prognosis^{2,4,9,12,18}.

Breast AdCC is not restricted to the female population; there are epidemiological studies that show this rare neoplasm in men^{2,18}. A retrospective analysis of 19 cases of AdCC treated at a Canadian hospital reported involvement in a 53-year-old man, with a tumor measuring 4.0 cm, lymph node involvement, and presence of metastasis¹⁸.

Although TN tumors have a clinical profile related to worse prognosis and resistance to hormonal therapy and trastuzumab, AdCC has an essentially favorable prognosis and can be conservatively treated^{2,14,15,18}. To date, there is no consensus on the ideal

treatment for AdCC^{8,10}. Based on the characteristics of the tumor and the patient's immunological conditions, breast-conserving surgery, mastectomy, chemotherapy, or radiotherapy are indicated^{2,10}. This adjuvant modality is prioritized when lymph node dissemination is detected^{10,16,18}. In situations similar to that of the studied patient, the breast-conserving sectionectomy surgery with subsequent follow-up was adopted, considering the reduced size of the tumor and the absence of lymph node or hematogenous dissemination^{10,16}.

CONCLUSION

Adenoid cystic carcinoma of the breast is part of the triple-negative tumor family and presents a paradoxically benign behavior when compared with its peers. As it is a rare tumor, the diagnosis can be facilitated through special histological techniques and the evaluation of the molecular or genomic profiling. Margin-free surgical excision is the standardized therapeutic approach, followed by clinical follow-up established between the mastologist and the patient. Although even rarer, there are records in the literature of recurrence and metastasis. Authors of the present article emphasize the importance of conducting further studies to elucidate the etiopathogenesis of breast AdCC, aiming to understand the natural history of this tumor and the mechanisms that allow it to behave differently.

AUTHORS' CONTRIBUTIONS

M.L.M.: conceptualization, data curation, investigation, methodology, project management, writing – original draft, writing – review & editing.

A.T.: resources, project administration, funding acquisition, data curation, methodology, writing – original draft, writing – review & editing.

A.A.L.L.: resources, conceptualization, methodology, supervision, writing – original draft, writing – review & editing.

C.A.S.R.: resources, formal analysis, methodology, writing – original draft, writing – review & editing.

L.C.A.: data curation, resources, writing – original draft, writing – review & editing.

REFERENCES

1. Instituto Nacional de Câncer José Alencar Gomes da Silva. A situação do câncer de mama no Brasil: síntese de dados dos sistemas de informação [Internet]. Brazil: Instituto Nacional de Câncer José Alencar Gomes da Silva; 2019 [accessed on November 25, 2020]. Available from: https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/a_situacao_ca_mama_brasil_2019.pdf
2. World Health Organization (WHO). WHO Classification of Tumours Editorial Board. Breast tumours [Internet]. 5th ed. Lyon: International Agency for Research on Cancer; 2019 [accessed on November 24, 2020]. v. 2. Available from: <https://publications.iarc.fr/581>
3. Brasil. Ministério da Saúde. Sistema de Informação do Colo do Útero. Sistema de Informação do câncer de mama. Datasus [Internet]. Ministério da Saúde [accessed on November 24, 2020]. Available from: <http://w3.datasus.gov.br/siscam/index.php?area=0402>
4. Vranic S, Bender R, Palazzo J, Gatalica Z. A review of adenoid cystic carcinoma of the breast with emphasis on its molecular and genetic characteristics. *Hum Pathol*. 2013;44(3):301-9. <https://doi.org/10.1016/j.humpath.2012.01.002>

5. Goldblum JR, Lamps LW, McKenney JK, Myers JL, Rosai and Ackerman's Surgical Pathology. 9^a ed. Philadelphia: Elsevier; 2004. v. 2. 1828 p.
6. Epstein J, Simpson J, Sanders M. Differential Diagnosis in Surgical Pathology: Breast. Philadelphia: Wolters Kluwer Health; 2016.
7. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/ College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018;142(11):1364-82. <https://doi.org/10.5858/arpa.2018-0902-sa>
8. Ghabach B, Anderson WF, Curtis RE, Huycke MM, Lavigne JA, Dores GM. Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study. Breast Cancer Res. 2010;12:R54. <https://doi.org/10.1186/bcr2613>
9. Cambruzzi E, Pêgas KL, Zettler CG, Zettler EW. Carcinoma adenoide cístico de mama: relato de caso de uma rara neoplasia. Rev AMRIGS. 2012;56(2):161-3.
10. Romeira D, Cardoso D, Miranda H, Martins A. Adenoid cystic carcinoma: triple negative breast cancer with good prognosis. BMJ Case Rep. 2016;2016:bcr2015213704. <https://doi.org/10.1136/bcr-2015-213704>
11. Ferlay J, Colombet M, Soerjomataram I, Mathews C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: Globocan sources and methods. Int J Cancer. 2019;144(8):1941-53. <https://doi.org/10.1002/ijc.31937>
12. Righi A, Lenzi M, Morandi L, Flamminio F, De Biase D, Farnedi A, et al. Adenoid cystic carcinoma of the breast associated with invasive duct carcinoma: a case report. Int J Surg Pathol. 2011;19(2):230-4. <https://doi.org/10.1177/1066896909332321>
13. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020;38(12):1346-66. <https://doi.org/10.1200/JCO.19.02309>
14. Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C, et al. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. Cancer Discov. 2014;4(10):1154-67. <https://doi.org/10.1158/2159-8290.CD-13-0830>
15. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. <https://doi.org/10.1186/s13058-020-01296-5>
16. Thompson K, Grabowski J, Saltzstein SL, Sadler GR, Blair SL. Adenoid cystic breast carcinoma: is axillary staging necessary in all cases? Results from the California Cancer Registry. Breast J. 2011;17(5):485-9. <https://doi.org/10.1111/j.1524-4741.2011.01117.x>
17. Veeraraghavan J, De Angelis C, Reis-Filho JS, Pascual T, Prat A, Rimawi MF, et al. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast. 2017;34(Suppl. 1):S19-S26. <https://doi.org/10.1016/j.breast.2017.06.022>
18. Millar BM, Kerba M, Youngson B, Lockwood GA, Liu F. The potential role of breast conservation surgery and adjuvant breast radiation for adenoid cystic carcinoma of the breast. Breast Cancer Res Treat. 2004;87:225-32. <https://doi.org/10.1007/s10549-004-8693-z>



Solid intracystic papillary carcinoma in male breast: case report

Vanessa Geron¹ , Evelyn Borges Queiroz¹ , Fernanda Santos Lopes¹ ,
Elisabete Lilian Dair¹ , Marcelo Ballaben Carloni¹ 

ABSTRACT

The intracystic papillary carcinoma (IPC) is one of the rarest types of breast cancer, mainly in men, representing less than 1% of the malignant diseases in the male sex. It is frequently associated with the ductal carcinoma *in situ* (DCIS), but there are also other forms such as the pure and the invasive ones. The male population breast cancer diagnosis is late and, therefore, it has a worse prognosis. The diagnosis is given by imaging tests and anatomopathological studies. The treatment consists of excisional tumor therapy, which can be carried out conservatively or through mastectomy, with or without adjuvant therapy.

KEYWORDS: breast neoplasms, male; carcinoma, papillary; carcinoma, intraductal, noninfiltrating.

INTRODUCTION

Breast cancer in men is rare, accounting for about 1% of all breast cancers and associated with less than 0.1% mortality. Its incidence, as well as in women, is also related to age, as it mainly affects men aged over 60 years. The five-year overall and event-free survival is low, mainly due to the late diagnosis. When this diagnosis is made, a neoplasm in a more advanced stage is identified^{1,2}.

Intracystic papillary carcinoma (IPC) is among the rarest forms of breast cancer, with an incidence of less than 1% of breast neoplasms. It is usually verified in older women, but it also affects men, though more uncommonly. It has a good prognosis. Its 10-year survival rate is 100% and the recurrence-free rate is 95%, which shows that, despite being a rare cancer, it has a high survival rate and a low recurrence rate¹⁻⁸. Thus, to document the occurrence of breast cancer in men is deemed very relevant to identify possible risk factors, to develop more specific therapeutic strategies and even future prevention measures.

Therefore, this study aimed to report the case of a male patient diagnosed with breast cancer, as well as his clinical history and the histological subtype of the tumor, in addition to analyzing the therapeutic approach and its follow-up.

CASE REPORT

FRS, man, 41 years old, identified the presence of a painless nodule in the left breast in the retroareolar region and sought medical care in

December 2018. On that occasion, ultrasound and bilateral screening mammogram were performed, which showed, respectively, a 1.3 cm nodulation in the left breast, well-delimited, in the retroareolar, hypoechoic and Bi-rads III region, and a well-delimited nodulation in the central region of the left breast of 1.2 cm and Bi-rads 0.

Five months after undergoing these tests, the patient sought new medical care in May 2019. During this consultation, bulging in the left areolar region was identified on the physical examination, on static inspection, and its accentuation, on dynamic inspection. On palpation of the breast, a hardened nodulation of approximately 2 cm in diameter was observed in the retroareolar region, irregular and adhered to adjacent planes. In the armpits, bilateral fibroelastic lymph nodes were detected, and breast expression was negative.

After clinical evaluation, a new ultrasound was requested and a nodular growth of 0.26 cm was observed, with a new diameter of 1.56 cm. Furthermore, irregular contours and Bi-rads IVa were found, which demonstrated significant tumor growth in the last five months. An excisional biopsy was chosen for anatomopathological study due to the location and superficiality of the nodulation.

Postoperatively, the patient developed seroma and a small area of necrosis in the areolar region (Figure 1).

The anatomopathological report of the excision of the breast nodule showed an epithelial proliferative lesion with an extensive area of tumor necrosis. The residual neoplasm sample showed cells with mild atypia arranged in solid and cribriform arrangements. Mitotic figures were not observed and the surgical margins were compromised (Figure 2A).

¹Faculdade de Medicina de Franca – Franca (SP), Brazil.

*Corresponding author: vanessa_geron@hotmail.com

Conflict of interests: nothing to declare.

Received on: 04/28/2021. Accepted on: 06/28/2021


To confirm the diagnosis, the specimen was referred to immunohistochemical study, which showed encapsulated papillary carcinoma,⁹ with an intermediate-grade ductal carcinoma *in situ* component in the adjacent parenchyma (Figure 2B). Histological sections demonstrated an extensively necrotic papillary lesion, well-delimited, consisting of fibrovascular axes covered by monotonous epithelial cells with atypia.

In the periphery of the lesion, areas of intermediate-grade solid and cribriform ductal carcinoma *in situ* were identified. No frankly-invasive carcinoma foci were identified in the sample. The presence of associated ductal carcinoma *in situ* poses greater risk of local recurrence.

The neoplasm was negative for calponin (SMMHC) and p63 protein, confirming the absence of these cells in the papillary stems and in the periphery of the lesion, negative for high molecular weight cytokeratin (CK-14), and showed strong and diffuse positivity for estrogen receptor (ER) (Figure 2B, Table 1).



Figure 1. Patient's left breast showing postoperative changes.



H&E: hematoxylin and eosin staining; ER: estrogen receptors.

Figure 2. (A) Results of the histopathological study that showed, in the periphery of the lesion, areas of intermediate-grade ductal carcinoma *in situ*, solid and cribriform types; (B) Immunohistochemical study showing strong and diffuse positivity for estrogen receptors.

The anatomopathological report also demonstrated an epithelial proliferative lesion with extensive tumor necrosis. The residual neoplasm sample showed cells with mild atypia arranged in solid and cribriform arrangements.


After diagnostic confirmation, the patient underwent simple mastectomy, with isotopic labeling of sentinel lymph node, and had good postoperative evolution. According to the anatomopathological study, a sentinel lymph node free of neoplastic infiltrate and the left breast without residual neoplasia were verified.

Clinical oncology evaluation was requested and Tamoxifen 20 mg/day was prescribed. The patient remained in clinical follow-up after surgery. He showed no signs of local recurrence and has been under outpatient follow-up since the time of diagnosis, in December 2018, with a total follow-up time of three years.

DISCUSSION

Intracystic papillary carcinoma (IPC) is a rare cancer, representing 1% of all types of cancer. It accounts for up to 2% of cases in women, whereas in men the incidence is less than 1%. The average age of its onset ranges from 68 to 84 years, and it mainly affects women, being unusual for men⁴. It is characterized as intracystic papillary growth carcinoma of the breast, mostly unilateral growth. The diagnosis is usually localized, without dissemination to lymph nodes or with distant metastases^{3,4,10}. In the reported patient, the tumor presentation was at 41 years of age, lower than the epidemiological data, and it was well-localized and without dissemination and/or metastases.

Anatomically, this tumor usually appears macroscopically as a well-defined lesion surrounded by a fibrous capsule. Microscopically, the capsule can be filled by a fibrovascular layer, and its stroma is characterized by cells distributed in clearly papillary structures. However, they can present a malignant cellular aspect, with the presence of atypia^{4,5,10}.



Histologically, IPC is divided into three subtypes: pure, IPC associated with ductal carcinoma *in situ* (DCIS), and that associated with invasive cancer^{4,5,10}. IPC in its pure form is extremely rare. The most frequent form of presentation is associated with DCIS or invasive cancer. In order to differentiate the histological type, studies claim that core biopsy has proved to be effective in differentiating papillary neoplasms from other diseases and from their benign forms⁶. Addressing the nature of the carcinoma is extremely important for the prognosis, as IPC associated with DCIS becomes an important causal factor for the development of invasive carcinoma, requiring additional treatment⁶.

Thus, IPC associated with DCIS refers to a more diffuse form of the disease, which involves several ducts, thus making the lesion more extensive and less localized, favoring the development of invasive carcinoma in addition to posing greater risk of local recurrence³.

The progression of carcinoma to the invasive form can be identified by immunohistochemical study, as the high degree of cell differentiation favors the metastatic process of the tumor. The lack of a basal layer in myoepithelial cells (SMMHC) can be identified by calponin and p63, proteins present in myoepithelial cells that, when expressed, indicate that the carcinoma is not yet invasive, i.e., that it is *in situ*^{3,11-13}. Hence, it is observed that the loss of the basal layer in the myoepithelial cells, i.e., the loss of expression of calponin and p63, assists in the tumor metastatic dissemination, making the carcinoma invasive. Nevertheless, the lack of expression of these receptors increases the chances of this tumor to be malignant. The identification, by immunohistochemistry, of calponin and p63 proteins is highly sensitive in detecting tumor invasion in malignant papillary breast lesions, being widely used in clinical practice^{3,11-13}.

Clinical, radiological and immunohistochemical findings are essential for diagnosis. Ultrasonography shows a hypoechoic area with soft tissue echoes projecting from the cyst wall and evidencing an intracystic tumor⁷. Mammography in IPC is less specific for small tumors and usually becomes inconclusive. Conversely, larger lesions can be described as dense and well-circumscribed masses. Excisional biopsy can be performed on cystic breast lesions, and the anatomopathological study associated with immunohistochemistry helps to make a definitive IPC diagnosis^{3,13}.

The differential diagnosis of intracystic papillary lesions is given by histopathological samples and immunohistological studies. Therefore, some authors have reported that differentiation of

intracystic papillary carcinoma is also related to loss of heterozygosity (LOH) on chromosome 16q. This characteristic has become a useful marker to differentiate an intracystic papillary carcinoma from an intraductal papillary carcinoma, as it does not have LOH^{7,8}. Thus, by polymerase chain reaction, it is possible to determine the malignant potential of IPC more clearly. The etiology of the lesions is paramount to verify the disease prognosis and, therefore, to analyze an additional treatment plan when feasible⁶⁻⁸.

According to the literature, the detection of ER and progesterone increases the probability that the tumor will develop in a favorable way. This is because about 90% of IPC that are positive for these markers are classified as neoplasms with good prognosis⁴. Furthermore, the presence of LOH on chromosome 16q in IPC demonstrates that this tumor has a low probability of malignancy, which is an important prognostic factor. However, the negativity expressed by calponin and p63 proteins in myoepithelial cells indicates that this tumor has a greater chance of progressing to an invasive carcinoma, favoring distant metastases. Therefore, despite presenting a worse prognostic factor due to the negativity of the expression of proteins in myoepithelial cells, other factors, such as the expression of ER and the presence of LOH on chromosome 16q, cooperate for the carcinoma of the patient in question to present a good prognosis over time¹¹⁻¹³.

Treatment, according to some studies, should be based on the associated pathology, and there are still no definitive guidelines for treatment. Surgical excision with a safety margin for resection has become the mainstay of treatment and can be conservative or not; in the later case, a mastectomy is required⁴⁻¹⁶.

Regarding the use of hormone replacement therapy, it is not recommended as a routine procedure, considering that there are no changes related to future prognosis. Nevertheless, concerning IPC associated with DCIS or microinvasive disease, patients may receive Tamoxifen therapy due to increased rates of tumor recurrence and the development of invasive carcinoma. Thus, additional treatment is needed to reduce tumor recurrence rates^{3,16,17}.

CONCLUSION

Intracystic papillary carcinoma is an extremely rare cancer, especially in men. Some immunohistochemical characteristics make this tumor associated with carcinoma *in situ* to have a better prognosis

Table 1. Result of the immunohistochemical study of the collected sample with positivity only for estrogen and androgen receptors. The remaining was negative.

Antibodies	Clone	Result	Note / Block (%)
Estrogen receptor	ER1	Positive	100; +++/+++ (A2884/19)
Cytokeratin 14	LL002	Negative	(A2884/19)
Myoepithelial cells (SMMHC)	SMMS-1	Negative, Myoep. cells	(A2884/19)
p63 protein (squamous/transitional epithelia; myoepithelial cells)	DAK-p63	Negative, Myoep. cells	(A2884/19)
Androgen receptor	F39.4.1	Positive	(A2884/19)

such as the presence of ER. Diagnostic investigation is carried out through clinical examination associated with imaging tests, which may be requested during the evaluation. In addition, anatomicopathological and immunohistochemical studies can contribute to a better characterization of the carcinoma. The mainstay of initial treatment is surgical excision of the tumor, followed by systemic adjuvant therapy, using Tamoxifen, a selective ER modulator. Therefore, this drug is the most suitable for tumors that express positivity for ER and progesterone. As for radiotherapy, it has been shown to be more effective for IPC associated with DCIS, but it is more suitable for more aggressive cases associated with lymphovascular invasion.

AUTHORS' CONTRIBUTIONS

V.G.: Conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, investigation, project

administration, supervision, validation, visualization, writing – original draft, writing – review & editing.

E.B.Q.: Conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, investigation, project administration, supervision, validation, visualization, writing – original draft, writing – review & editing.

F.S.L.: Conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, investigation, project administration, supervision, validation, visualization, writing – original draft, writing – review & editing.

E.L.D.: Conceptualization, funding acquisition, investigation, methodology, investigation, project administration, supervision, validation, visualization, writing – review & editing.





M.B.C.: Conceptualization, funding acquisition, investigation, methodology, investigation, project administration, supervision, validation, visualization, writing – review & editing.

REFERENCES

- Salomon MFB, Mendonça JV, Pasqualette HAP, Pereira PMS, Sondermman VRM, Manoel VR. Câncer de mama no homem. Rev Bras Mastologia. 2015;25(4):141-5. <https://doi.org/10.5327/Z201500040005RBM>
- Yetkin G, Celayir MF, Tanik C, Citgez B, Uludag M, Mihmanli M. Male breast cancer: A 10 year retrospective case series in a tertiary care hospital. J Pak Med Assoc. 2019;69(8):1209-12.
- Romics L Jr., O'Brien ME, Relihan N, O'Connell F, Redmond HP. Intracystic papillary carcinoma in a male as a rare presentation of breast cancer: a case report and literature review. J Med Case Rep. 2009;3:13. <https://doi.org/10.1186/1752-1947-3-13>
- Luo H, Meng K, He J, Hu Z, Yang O, Lan T, et al. Intracystic papillary carcinoma of the breast in males. Three case reports. Medicine. 2020;99(25):e20278. <https://dx.doi.org/10.1097%2FMD.00000000000020278>
- Barcelos MRB, Vereno Filho AL, Chambô Filho A, Guimarães RA, Cintra LC. Carcinoma Papilífero Intracístico de Mama: Revisão de Literatura e Relato de Dois Casos. Rev Bras Cancerol. 1999;45(3):57-63.
- Brahmi SA, El M'rabet FZ, Akesbi Y, Benbrahim Z, El Hind AF, Znati K, et al. Intracystic papillary carcinoma associated with ductal carcinoma in situ in a male breast: a case report. Cases J. 2009;2:7260. <https://dx.doi.org/10.4076%2F1757-1626-2-7260>
- Sinha S, Hughes RG, Ryley NG. Papillary carcinoma in a male breast cyst: a diagnostic challenge. Ann R Coll Surg Engl. 2006;88(5):W3-W5. <https://dx.doi.org/10.1308%2F147870806X129232>
- Kumar M, Pottipati B, Arakeri SU, Javalgi AP. Infiltrating Ductal Carcinoma Co-Existing with Intraductal Papillary Carcinoma of Male Breast: A Rare Case Report. J Clin Diag Res. 2017;11(6):ED04-ED05. <https://dx.doi.org/10.7860%2FJCDR%2F2017%2F26818.10002>
- Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de Vijver MJ. WHO Classification of Tumours of the Breast. 4th ed. Lyon: IARC; 2012.
- Ingle SB, Murdeshwar HG, Siddiqui S. Papillary carcinoma of breast: Minireview. World J Clin Cases. 2016;4(1):20-4. <https://dx.doi.org/10.12998%2Fwjcc.v4.i1.20>
- Russell TD, Jindal S, Agunbiade S, Gao D, Troxell M, Borges VF, et al. Myoepithelial cell differentiation markers in ductal carcinoma *in situ* progression. Am J Pathol. 2015;185(11):3076-89. <https://doi.org/10.1016/j.ajpath.2015.07.004>
- Li X, Pan B, Song X, Li N, Zhao D, Li M, et al. Breast cancer organoids from a patient with giant papillary carcinoma as a high-fidelity model. Cancer Cell Int. 2020;20:86. <https://doi.org/10.1186/s12935-020-01171-5>
- Hu ZI, Liu C, Fisher PR, Cohen JA. Intracystic papillary carcinoma of the breast in a male patient. Rare Tumors. 2016;8(1):6050. <https://dx.doi.org/10.4081%2Frt.2016.6050>
- Hariprasad S, Hariprasad P, Srinivas T. Intracystic Papillary Carcinoma of the Breast in Males: A Case Report and Review of the Literature. J Clin Diag Res. 2013;7(3):568-70. <https://dx.doi.org/10.7860%2FJCDR%2F2013%2F4998.2828>
- Dhebri AR, Ahmad A, Shah N, Arora PK. Intracystic papillary carcinoma of breast: report of three cases and review of the literature. BMJ Case Rep. 2012;2012:bcr2012007237. <http://dx.doi.org/10.1136/bcr-2012-007237>
- Esposito E, Bonito M, Iodice G, Avino F, Donzelli I, Fucito A, et al. Intracystic papillary breast carcinoma with DCIS in a man: a case report. Transl Cancer Res. 2019;8(Suppl. 5):S445-8. <http://dx.doi.org/10.21037/tcr.2019.09.40>
- Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen VN, et al. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Res. 2017;19(1):125. <https://doi.org/10.1186/s13058-017-0916-4>



Pathogenic variants in *BRCA1/2* genes among patients with triple-negative breast cancer: a case series

Rafael Everton Assunção Ribeiro da Costa^{1*} , Fergus Tomás Rocha de Oliveira¹ ,
Ana Lúcia Nascimento Araújo² , Sabas Carlos Vieira³ 

ABSTRACT

Triple-negative breast cancer (TNBC) is an uncommon molecular subtype (representing 15%–20% of breast cancers) characterized by the non-expression of estrogen receptor, progesterone receptor, and human epidermal growth receptor factor 2. More aggressive and lethal, TNBC is often associated with pathogenic variants in *BRCA1/2* genes. This study aimed to describe a series of seven cases of patients with TNBC and pathogenic variants in *BRCA1/2* genes. All patients were female and under 50 years of age at diagnosis. Four of them presented a family history of breast cancer and/or other neoplasms. The predominant clinical stage was IIB, and the main anatomopathological stage was pT2pN0M0. The mean tumor size in the series was 2.5 cm (1.0 to 3.2 cm). Ki-67 was > 30% in all patients. Three cases (43%) had pathological complete response, and only one presented extensive residual disease after neoadjuvant chemotherapy. Six patients showed pathogenic variants in *BRCA1* (86%) and one in *BRCA2+* (14%). After a mean follow-up of 38 months (19 to 68 months), five patients were alive and without neoplastic disease, and two progressed to metastasis.

KEYWORDS: mutation; genes, *BRCA1*; genes, *BRCA2*; triple negative breast neoplasms; case reports.

INTRODUCTION

Triple-negative breast cancer (TNBC) is a molecular subtype characterized by the non-expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth receptor factor 2 (HER2). With a worse prognosis and lower survival, TNBC represents 15% to 20% of breast cancers and is more frequent in black and Hispanic women^{1,2}.

TNBC is also associated with a higher incidence of pathogenic variants in *BRCA1/2* genes, especially in *BRCA1*³. Study conducted by Barreta et al. showed that the overall survival (OS) of patients with no pathogenic variants in *BRCA1/2* is greater than among *BRCA1/2+* patients. However, recurrence-free survival (RFS) presented no significant difference⁴.

Identifying patients with TNBC and *BRCA1/2* pathogenic variants is important because it allows defining risk-reducing surgical strategies (contralateral mastectomy and bilateral salpingo-oophorectomy) and administering systemic treatments (use of platinum agents in neoadjuvant therapies and poly [ADP-ribose] polymerase inhibitors — PARP [Olaparib] in metastatic settings)^{5,6}.

This study aimed to describe a series of seven cases of patients with TNBC and pathogenic variants in *BRCA1/2* genes.

CASE SERIES

As shown in Table 1, all patients were female. The mean age in the series was 37 years (28 to 48). Six patients (86%) had pathogenic variants in *BRCA1* and one (14%) in *BRCA2+*. The mean tumor size was 2.5 cm (1.0 to 3.2 cm). Five patients (71%) presented clinical stage IIB and anatomopathological stage pT2pN0M0. All of them received surgical treatment, neoadjuvant chemotherapy, and adjuvant radiotherapy. After a mean follow-up of 38 months (19 to 68 months), all patients were alive, but two presented metastatic neoplastic disease (case 5 since March 2020 and case 6 since February 2020).

Case 1 patient reported an extensive family history of breast cancer: four maternal cousins (one deceased), one paternal cousin, and a sister (diagnosed with breast cancer at 44 years of age). In addition, she had a maternal aunt with ovarian cancer (death at 74 years) and two paternal uncles with lung cancer. Case 3 patient declared as family history of cancer: her mother (diagnosed with breast cancer at 30 years of age in the 1980s, dying at the age of 36), father (lung cancer), paternal grandmother (pancreatic cancer), a maternal cousin (ovarian cancer), and a paternal aunt and paternal cousin (hematological neoplasms). Case 4 patient also

¹Universidade Estadual do Piauí – Teresina (PI), Brazil.

²Hospital São Marcos – Teresina (PI), Brazil.

³Oncocenter – Teresina (PI), Brazil.

*Corresponding author: rafaelearcosta@gmail.com

Conflict of interests: nothing to declare.

Received on: 06/08/2021. Accepted on: 07/12/2021

had a family history of cancer: her father, who died as a result of prostate cancer, and a maternal aunt, who had cervical cancer. Case 5 patient did not know her family history because she

is adopted and has no contact with her biological family. Case 7 patient stated that her mother was diagnosed with breast cancer at 35 years of age and died at 45.

Table 1. Description of variables associated with patients in the series.

Description	Patients	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7
Gender		Female	Female	Female	Female	Female	Female	Female
Age at diagnosis (years)		38	36	47	48	28	32	32
Previous pregnancies (number)		4	0	1	5	1	3	0
Comorbidities		None	None	None	None	None	None	None
Family history of breast cancer		Yes	No	Yes	No	Unknown	No	Yes
Family history of other neoplasms		Yes	No	Yes	Yes	Unknown	No	No
Histological type		NST	NST	NST	NST	NST	NST	NST
Tumor size (cm)		2.5	2.3	1.0	2.8	3.2	2.8	2.9
Cell differentiation grade		G3	G2	G2	G3	G3	G2	G2
Angiolymphatic invasion		No	No	No	No	No	Yes	No
Perineural invasion		No	No	No	No	No	No	No
Ki-67 (%)		60	40	40	70	90	80	40
Molecular subtype		TN	TN	TN	TN	TN	TN	TN
Axillary involvement (number of lymph nodes)		No	No	No	No	Yes (4)	No	No
Metastasis at diagnosis		No	No	No	No	No	No	No
Clinical stage		IIB	IIB	IB	IIB	IIIC	IIB	IIB
Anatomopathological stage		pT2pN0M0	pT2pN0M0	pT1pN0M0	pT2pN0M0	pT2pN2M0	pT2pN0M0	pT2pN0M0
Surgical treatment		M+SLN+AD	M+SLN	M+SLN	SR+SLN	M+SLN+AD	SR+SLN	M+SLN
Contralateral mastectomy		Yes	Yes	Yes	No	Yes	No	Yes
Salpingo-oophorectomy		No	No	Yes	Yes	No	Yes	No
Complementary treatment		NACT+ART	NACT+ART	NACT+ART	NACT+ART	NACT+ART	NACT+ART	NACT+ART
Immunotherapy		No	No	No	No	No	No	No
Olaparib		No	No	No	No	Yes	Yes	No
Sentinel lymph node		Negative	Negative	Negative	Negative	Positive	Negative	Negative
Pathological response		pCR	pCR	RCB-II	RCB-I	RCB-III	RCB-II	pCR
Pathogenic mutations (<i>BRCA1/2</i>)		<i>BRCA1</i>	<i>BRCA1</i>	<i>BRCA1</i>	<i>BRCA2</i>	<i>BRCA1</i>	<i>BRCA1</i>	<i>BRCA1</i>
Clinical course		ADF	ADF	ADF	ADF	Metastasis	Metastasis	ADF

NST: invasive carcinoma of no special type; TN: triple-negative; M: mastectomy; SR: segmental resection; SLN: sentinel lymph node; AD: axillary drainage; NACT: neoadjuvant chemotherapy; ART: adjuvant radiotherapy; pCR: pathological complete response; RCB-I: minimal residual cancer burden; RCB-II: moderate residual cancer burden; RCB-III: extensive residual cancer burden; ADF: alive and disease-free.

Table 2. Description of *BRCA1/2* pathogenic variants detected in the patients in the series.

Patient	Gene	Pathogenic variant (allele profile)	Protein	Molecular consequence	Accession number in ClinVar
Case 1	<i>BRCA1</i>	c.3331_3334del (heterozygosity)	p.Gln1111fs	Frameshift	VCV000037523.14
Case 2	<i>BRCA1</i>	c.5266dupC (heterozygosity)	p.Gln1756fs	*	VCV000017677.29
Case 3	<i>BRCA1</i>	c.3331_3334del (heterozygosity)	p.Gln1111fs	Frameshift	VCV000037523.14
Case 4	<i>BRCA2</i>	c.2167delA (heterozygosity)	*	*	New (not described in ClinVar)
Case 5	<i>BRCA1</i>	c.4675+1G>A (heterozygosity)	*	Splice donor	VCV000055256.15
Case 6	<i>BRCA1</i>	c.655G>A (heterozygosity)	p.Asp219Asn	Missense	VCV000055655.7
Case 7	<i>BRCA1</i>	c.3331_3334del (heterozygosity)	p.Gln1111fs	Frameshift	VCV000037523.14

*No associated data in ClinVar (<https://ncbi.nlm.nih.gov/clinvar/>).

Table 2 shows the *BRCA1/2* pathogenic variants found. Among the *BRCA1* pathogenic variants, three corresponded to the identical frameshift type (c.3331_3334del [p.Gln1111fs] in heterozygosity, determining a truncated protein), and these probands were not from related families.

This case series originated from a study based on medical records of patients diagnosed with breast cancer, part of a scientific project approved by the Research Ethics Committee (REC) of the Universidade Estadual do Piauí, Teresina (Piauí), Brazil, under the Certificate of Presentation for Ethical Consideration (*Certificado de Apresentação para Apreciação Ética* — CAAE) No. 30154720.0.0000.5209. All Brazilian ethical directives on research were observed (National Health Council Resolution No. 466/12).

DISCUSSION

In this study, all patients were under 50 years of age at diagnosis. Robertson et al. performed the genetic analysis of 308 patients with TNBC and found 45 cases with *BRCA1* pathogenic variants. They concluded that the chances of patients with TN tumors having *BRCA1* pathogenic variants are higher before the age of 50 years (above 10%). This finding justifies the National Comprehensive Cancer Network (NCCN) recommendation to test all patients diagnosed with TNBC before the age of 60 for *BRCA1/2*⁹.

Among the six patients who knew their family history, four presented a family history of breast cancer and/or other neoplasms. Family history is a known risk factor for the development of breast cancer, with higher frequency in patients with *BRCA1/2* pathogenic variants, which also occurred in this study¹⁰.

After univariate and multivariate analyses, Lopes et al. showed that angiolymphatic invasion and larger tumor size were factors associated with worse prognosis in TNBC¹¹. In this series, the two cases that progressed to metastasis presented tumor sizes larger than the mean of the series (2.5 cm), and case 6, who progressed to metastasis, showed angiolymphatic invasion.

Ki-67 is an important prognostic factor related to worse TNBC progression¹². However, greater knowledge about its cut-off point is needed, with some studies indicating a value of approximately 30%^{13,14}. In this series, all patients had Ki-67 values >30%.

Silva et al. revealed that TNBC is a predictive factor for pathological complete response (pCR), occurring in about 40% of these patients¹⁵. Other studies also associate TN tumors in patients with *BRCA1/2* pathogenic variants with higher chemoresponsiveness^{16,17}. In this study, three patients (43%) had pCR, and only one presented extensive residual disease (residual cancer burden — RCB-III) after neoadjuvant chemotherapy, ratifying literature data.

Six patients showed pathogenic variants in *BRCA1* and one in *BRCA2*. The literature also indicates a higher prevalence of *BRCA1* in young women diagnosed with TNBC compared to *BRCA2*^{18,19}. Case 4 presented the novel pathogenic variant c.2167delA in *BRCA2* (not yet described in ClinVar). Nonetheless, this variant has been described in the literature. In the study by Palmero et al. on *BRCA1/2* pathogenic variants in 649 probands of 28 centers from 11 Brazilian states, the authors analyzed 208 *BRCA2*+ probands and also found the pathogenic variant c.2167delA in one of them²⁰.

Literature data indicate that patients with *BRCA1* and *BRCA2* pathogenic variants have a 27% and 19% probability of developing contralateral breast cancer after primary tumor surgery in the ipsilateral breast, while this risk is only 5% in the general population. At the same time, contralateral mastectomy shows no benefits regarding OS in these patients. In turn, bilateral salpingo-oophorectomy reduces the risk of cancer recurrence in the ipsilateral and contralateral breast in *BRCA1/2*+ patients, improving their OS. Bilateral salpingo-oophorectomy also decreases the likelihood of ovarian cancer by more than 80% in *BRCA1/2*+ patients²¹. In addition, risk-reducing surgical strategies are more beneficial to younger patients with TNBC and *BRCA1/2*+ and with pCR after neoadjuvant chemotherapy⁵. In this study, all patients underwent risk-reducing contralateral mastectomy and/or bilateral salpingo-oophorectomy.

After a mean follow-up of 38 months (19 to 68 months), five patients were alive and disease-free, while two progressed to metastasis before five years from diagnosis. The literature associates TNBC with worse clinical course and lower survival. However, immunotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors have also improved the prognosis of patients with TN tumors and *BRCA1/2* pathogenic variants^{22,23}. In this series, case 5 developed metastasis to lymph nodes, lungs, adrenal glands, and bones 20 months after the initial diagnosis, and case 6 developed metastasis to lymph nodes and the central nervous system 41 months after the initial diagnosis. Olaparib (a PARP inhibitor) was administered as a therapeutic option for these two patients after metastasis. Both patients (cases 5 and 6) are still alive and on clinical follow-up 9 and 10 months after systemic recurrence, respectively.

The limitations of this study include the sample size and being performed in a single oncology center.

CONCLUSION

Among the seven patients with TNBC and *BRCA1/2* pathogenic variants in this series (all women, with a mean age of 37 years and mean tumor size of 2.5 cm), three (43%) presented pCR, and only one had RCB-III after neoadjuvant chemotherapy. The mean follow-up time was 38 months. At the end of follow-up, all patients were alive, and two presented systemic neoplastic disease before five years from diagnosis.

AUTHORS' CONTRIBUTIONS

R.E.A.R.C.: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing — original draft, Writing — review & editing.

F.T.R.O.: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing — original draft.

A.L.N.A.: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing — review & editing.

S.C.V.: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing — review & editing.

REFERENCES

1. Heimes AS, Schmidt M. Atezolizumab for the treatment of triple-negative breast cancer. *Expert Opin Investig Drugs*. 2019;28(1):1-5. <https://doi.org/10.1080/13543784.2019.1552255>
2. Gonçalves Jr. H, Guerra MR, Cintra JRD, Fayer VA, Brum IV, Teixeira MTB. Survival study of triple-negative and non-triple-negative breast cancer in a Brazilian cohort. *Clin Med Insights Oncol*. 2018;12:1179554918790563. <https://doi.org/10.1177/1179554918790563>
3. Lips EH, Mulder L, Oonk A, Van der Kolk LE, Hogervorst FBL, Imholz ALT, et al. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. *Br J Cancer*. 2013;108(10):2172-7. <https://doi.org/10.1038/bjc.2013.144>
4. Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. *Medicine (Baltimore)*. 2016;95(40):e4975. <https://doi.org/10.1097/md.0000000000004975>
5. Mau C, Untch M. Prophylactic surgery: for whom, when and how? *Breast Care (Basel)*. 2017;12(6):379-84. <https://doi.org/10.1159/000485830>
6. Azim HA, Ghosn M, Oualla K, Kassem L. Personalized treatment in metastatic triple-negative breast cancer: the outlook in 2020. *Breast J*. 2020;26(1):69-80. <https://doi.org/10.1111/tbj.13713>
7. Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. *Br J Cancer*. 2012;106(6):1234-8. <https://doi.org/10.1038/bjc.2012.31>
8. Meyer P, Landgraf K, Högel B, Eiermann W, Ataseven B. BRCA2 mutations and triple-negative breast cancer. *PLoS One*. 2012;7(5):e38361. <https://doi.org/10.1371/journal.pone.0038361>
9. Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2021;19(1):77-102. <https://doi.org/10.6004/jnccn.2021.0001>
10. Ozsoy A, Barca N, Dolek BA, Akta H, Elverici E, Araz L, et al. The relationship between breast cancer and risk factors: a single-center study. *Eur J Breast Health*. 2017;13(3):145-9. <https://doi.org/10.5152/tjbh.2017.3180>
11. Lopes CM, Montemor Netto MR, Mansani FP, Stival RSM, Cassapula MR, Oliveira TFB. Clinical, histomorphological, and therapeutic prognostic factors in patients with triple-negative invasive breast cancer. *J Bras Patol Med Lab*. 2015;51(6):397-406. <https://doi.org/10.5935/1676-2444.20150062>
12. Pan Y, Yuan Y, Liu G, Wei Y. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients. *PLoS One*. 2017;12(2):e0172324. <https://doi.org/10.1371/journal.pone.0172324>
13. Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu J, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. *Sci Rep*. 2020;10(1):225. <https://doi.org/10.1038/s41598-019-57094-3>
14. Wang W, Wu J, Zhang P, Fei X, Zong Y, Chen X, et al. Prognostic and predictive value of Ki-67 in triple-negative breast cancer. *Oncotarget*. 2016;7(21):31079-87. <https://doi.org/10.18632/oncotarget.9075>
15. Silva LCFF, Arruda LSM, David Filho WJ, Cruz FJSM, Trufelli DC, Del Giglio A. Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer. *Einstein (Sao Paulo)*. 2019;17(1):eAO3434. https://doi.org/10.31744/einstein_journal/2019AO3434
16. Wang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T, et al. Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer. *Ann Oncol*. 2015;26(3):523-8. <https://doi.org/10.1093/annonc/mdu559>
17. Jiang T, Shi W, Wali VB, Pongor LS, Li C, Lau R, et al. Predictors of chemosensitivity in triple negative breast cancer: an integrated genomic analysis. *PLoS Med*. 2016;13(12):e1002193. <https://doi.org/10.1371/journal.pmed.1002193>
18. Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. *Ann Surg Oncol*. 2013;20(10):3254-8. <https://doi.org/10.1245/s10434-013-3205-1>
19. Armstrong N, Ryder S, Forbes C, Ross J, Gw Quek R. A systematic review of the international prevalence of BRCA mutation in breast cancer. *Clin Epidemiol*. 2019;11:543-61. <https://doi.org/10.2147/clep.s206949>

20. Palmero EI, Carraro DM, Alemar B, Moreira MAM, Ribeiro-dos-Santos A, Abe-Sandes K, et al. The germline mutational landscape of BRCA1 and BRCA2 in Brazil. *Sci Rep*. 2018;8(1):9188. <https://doi.org/10.1038/s41598-018-27315-2>
21. Lee A, In Moon B, Kim TH. BRCA1/BRCA2 pathogenic variant breast cancer: treatment and prevention strategies. *Ann Lab Med*. 2020;40(2):114-21. <https://doi.org/10.3343/alm.2020.40.2.114>
22. Tarantino P, Gandini S, Trapani D, Criscitiello C, Curigliano G. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials. *Crit Rev Oncol Hematol*. 2021;159:103223. <https://doi.org/10.1016/j.critrevonc.2021.103223>
23. Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. *Ann Oncol*. 2021;32(2):240-9. <https://doi.org/10.1016/j.annonc.2020.11.009>



Breast cancer staging in population-based registries: an alert to the quality of information

Leonardo Ribeiro Soares¹ , Maria Paula Curado² , Ruffo Freitas-Junior^{1,3*} 

ABSTRACT

Objective: To discuss the practical difficulties associated with breast cancer staging, especially in the context of population-based cancer registries (PBCR). **Methods:** This is a short communication that discusses the importance and temporal evolution of breast cancer staging, as well as the limitations and new challenges associated with this process. **Results:** This study discusses the importance and temporal evolution of breast cancer staging, as well as the limitations and new challenges associated with this process. Minimal divergences in physical examination and disagreements in imaging tests can classify the patient in a higher or lower stage of the disease. In some population-based registries, up to 20% of the information regarding the clinical stage of breast cancer may be mistaken. **Conclusion:** We highlight the necessity for continuing education and constant training for all professionals involved in the breast cancer epidemiological context. The utilization of new technologies can help standardize the information and reduce the divergences related to cancer staging registry.

KEYWORDS: breast neoplasms; neoplasm staging; registries; evidence-based practice.

INTRODUCTION

Clinical staging plays an important role in the therapeutic planning and prognostic evaluation of patients with breast cancer¹. This staging usually follows the TNM (primary tumor [T], regional lymph nodes [N], distant metastases [M]) system of the American Joint Committee on Cancer (AJCC), whose classification criteria are periodically updated based on scientific evidence^{2,3}. However, only 23% of population-based cancer registries (PBCR) that participate in the Cancer Incidence in Five Continents, Volume IX (CI5-IX) have declared to collect TNM staging for all tumor sites⁴⁻⁷.

The staging process is especially important in the critical assessment of survival curves and other epidemiological variables obtained from PBCR^{2,7}. Lack of standardization hinders the epidemiological analysis of different populations and can interfere in the interpretation and development of public policies related to malignant neoplasms^{6,8}. As an example, we can underline a recent divergence observed in breast cancer survival rates in the city of Goiânia, Brazil. In the CONCORD-2 study, the net survival rate for patients diagnosed with breast cancer was

79.4% between 1995 and 1999, 63.9% between 2000 and 2004, and 59.2% between 2005 and 2009⁹. However, using data from the local cancer registry, the time trends in 5-year overall survival rates were very different: 57.0% survival rate between 1988 and 1990¹⁰, 65.4% between 1990 and 1994¹¹, and 72.1% between 1995 and 2003¹². According to the authors of the CONCORD-2 study, the estimates for breast cancer survival in Goiânia were less reliable than would be preferred¹³. This divergence should not be a true epidemiological event but a methodological limitation¹⁴.

In this context, PBCR must follow international good practice recommendations to ensure satisfactory performance quality, operationalization, and data quality^{8,15,16}. These parameters range from the percentage of cases collected through histopathological tests¹⁶ to the organization of flow diagrams for each neoplasm^{17,18}.

Each registry is responsible for the criteria employed to verify the quality of the clinical data collected, which are usually not reported adequately. In most registries, the person responsible for gathering information is a non-medical professional, advised by a multidisciplinary team of specialists. Despite the constant personnel training, some mistakes still occur due to the increasing

¹Mastology Program, Hospital das Clínicas, Universidade Federal de Goiás – Goiânia (GO), Brazil.

²A.C. Camargo Cancer Center, Fundação Antônio Prudente – São Paulo (SP), Brazil.

³Hospital Araújo Jorge, Associação de Combate ao Câncer em Goiás – Goiânia (GO), Brazil.

*Corresponding author: ruffojr@terra.com.br

Conflict of interests: nothing to declare.

Received on: 10/25/2020. Accepted on: 11/26/2020.

complexity of the tumor staging process. Medical staff can also make mistakes in the staging, particularly when they gather and enter the data. This scenario may justify the high rates of “incomplete data” regarding tumor staging in different international series, usually ranging from 5% to 20%¹⁹⁻²¹.

PRACTICAL DIFFICULTIES IN BREAST CANCER STAGING

Cancer staging estimates the extension of the neoplasm within the person's body. Despite the particularities of each tumor site, a report is usually issued after a physical examination. This report could include specific complementary tests, such as biochemical tests, computed tomography, among others²². However, in a real-world scenario, several factors can limit or hinder this staging process^{6,8}.

Concerning breast cancer staging, inter-observer variation must be highlighted in tumor measurement and clinical assessment of patients. In this context, if tumor palpation changes from 5.0 cm to 5.1 cm, cancer staging also changes, along with the prognostic classification. The assessment of lymph node status often shows divergences regarding small palpable axillary lymph nodes, which could represent a reactional inflammatory state (cN0) or one isolated axillary lymph node affected (cN1). Table 1 describes some situations that result from divergences in the staging process, with some considerations and good practice recommendations.

In most developing countries, the population can experience difficulties in accessing health services, which could extend the waiting time for complementary tests²³. In these situations, the clinical staging of the patient is only concluded after two or three medical consultations and, occasionally, after cancer treatment begins. This fact hinders the staging process, as the patient can present significant variations in physical examinations during the investigation period, generally related to the progression of the disease. Effectively, choosing the best moment to register a variable can become a subjective decision: date of the first consultation? After the completion of complementary tests? Before starting treatment? Or should we always consider the most advanced staging?

Finally, another common situation in regions with hierarchical health systems is referring patients who received treatment from other services to reference centers after a breast cancer diagnosis. In this context, the dialog between the respective assistant professionals regarding the initial physical examination of the patient can prevent the use of the terms cTx and cNx, which would render the patient's initial staging as “unknown”.

TEMPORAL VARIATIONS IN BREAST CANCER STAGING

The conceptual changes in breast cancer staging implemented over time have accompanied the evolution of scientific knowledge of the disease. The introduction of new

Table 1. Examples of divergences in the process of breast cancer clinical staging, with the respective recommendations.

TNM	Diagnostic question	Specifications	Recommendations
Evaluation of the “T” status	Tumor measurement	cT1 (≤ 2.0 cm) or cT2 (> 2.0 cm) cT2 (≤ 5.0 cm) or cT3 (> 5.0 cm)	Measurement with a caliper Two or more measurements, taken by the same observer Correlation with breast imaging tests
	Presence and extension of tissue involvement (cT4)	Localized ($< 1/3$ of breast tissue involvement, cT4b) or diffuse (inflammatory carcinoma, cT4d)	Ambient lighting and adequate breast exposure Percentage estimation of tissue involvement Correlation with tissue evaluation in imaging tests Tissue biopsy (punch), in case of doubt
	Chest wall and pectoral muscle involvement	Chest wall involvement (cT4a or cT4c)	Correlation with chest imaging tests (computed tomography and/or magnetic resonance)
Evaluation of the “N” status	Presence and extension of axillary involvement	cN0 (reactive lymph node, free axillary lines) or cN1	Correlation with imaging tests (ultrasound) Ultrasound-guided biopsy of atypical lymph node (fine-needle or core biopsy)
	Affected lymph nodes in the internal mammary, supraclavicular, or infraclavicular chain	cN2 or cN3, depending on the grade	Correlation with imaging tests (ultrasound, magnetic resonance, positron emission tomography-computed tomography – PET-CT) Ultrasound-guided biopsy of atypical lymph node (fine-needle or core biopsy)
Evaluation of the “M” status	Distant metastasis	cM0 or cM1	Correlation with laboratory and/or imaging tests (computed tomography, magnetic resonance, PET-CT) Cytological or histological evaluation (collection of material guided by imaging methods or surgically)

perspectives related to pathologic diagnoses, such as the identification of micrometastasis and isolated tumor cells in axillary lymph nodes, has also forced new concepts to be considered throughout time²⁴.

In January 2003, with the publication of the 6th edition of the cancer staging manual elaborated by AJCC, patients with affected lymph nodes in the supraclavicular chain were classified as cN3c staging and removed from the cM1 group³. Thus, statistics related to metastatic disease collected during this transition phase must be analyzed with caution due to the possibility of selection bias²⁵.

More recently, in 2018, the 8th edition of the manual removed lobular carcinoma *in situ* from the *Tis* staging^{26,27}, which should affect the incidence curves of the disease in the next years. Reducing the number of *Tis* patients might increase the proportion of diagnosed cases in stages II, III, and IV; however, this scenario could reflect an untrue epidemiological event.

Lastly, the situation of patients who achieved complete pathological response (pCR; ypT0ypN0cM0) after neoadjuvant therapies and of those with tumor cells circulating in peripheral blood [cM0(i+)] must be considered. According to the 8th edition of the cancer staging manual, the identification of circulating tumor cells does not classify the patient as cM1 in the absence of other signs of metastatic disease. Similarly, patients with pCR do not constitute a new specific group and remain in the group assigned at the moment of diagnosis. Nevertheless, with advances in the understanding of tumor biology and prognostic stratification of these patients^{27,28}, new concepts involving pCR and molecular techniques for cancer research might be incorporated into the next editions of breast cancer staging.

BREAST CANCER STAGING: 8TH EDITION

Traditionally, breast cancer staging was based on the anatomical extension of the disease and did not consider tumor biology. After 2018, the new staging (8th edition) elaborated by AJCC included biomarkers for the disease to improve the prognostic stratification of patients^{26,27}.

This inclusion was based on the retrospective evaluation of patients treated at the MD Anderson Cancer Center, in the USA, and posteriorly validated by the California Cancer Registry⁷ and the National Cancer Database²⁹. In this context, the inclusion of biomarkers resulted in better accuracy in the patient's prognostic evaluation regarding isolated anatomical staging^{7,29}.

Anatomical staging (AS) has also changed in relation to the 7th edition but maintains its practical value and remains an adequate instrument for the prognostic evaluation of patients. However, the main change was the creation of the clinical prognostic staging (CPS) and pathological prognostic staging (PPS),

with the inclusion of tumor grade, HER2, and estrogen and progesterone receptors.

Genomic signatures can also be used in PPS as a potential modifier of staging, when available and indicated. In these situations, a low-risk genomic result indicates a similar prognosis to stage IA, which can affect the decision-making related to the adjuvant treatment of these women^{30,31}.

The greatest limitation of this new staging is the wide range of categories according to the combination of different criteria, with more than 1,400 possibilities of clinical staging and prognosis. In some circumstances, the combination of clinical and pathological variables can generate up to four staging classifications for the same patient, from the moment of diagnosis to the postoperative evaluation. These categories can be consulted in several specific tables available at the AJCC website (cancerstaging.org) or other platforms.

In the context of PBCR, the new version of the AJCC makes it even more difficult to collect information regarding breast cancer staging. Therefore, new studies involving this variable should state which type of staging was employed, how and when this assessment was carried out, and lastly, which instrument was used to interpret the obtained TNM. Nevertheless, we recommend caution when comparing studies conducted in different periods and geographic regions, with different or insufficiently described methodologies.

FUTURE PERSPECTIVES

An application developed by a Brazilian mastologist (TNM8 BREAST CANCER CALCULATOR[®]) was approved and licensed by AJCC for global use and is available at the Apple Store and Google Play at a reasonable price. This application allows the individualized inclusion of variables and automatically provides the corresponding staging³². In times of globalization and wide access to information, electronic instruments can help with the data collection process for population-based registries and improve the quality of information on breast cancer staging.

Finally, we emphasize the need for continuing education, along with constant training for all professionals involved in the breast cancer epidemiological context, from assistant medical doctors to the professionals responsible for gathering and registering this information. The utilization of new technologies can help standardize the information and reduce the divergences related to cancer staging registry.

AUTHORS' CONTRIBUTIONS





L.R.S.: Conceptualization, data curation, formal analysis, writing — original draft; M.P.C.: Formal analysis, writing — original draft; R.F.-J.: Formal analysis, writing — original draft.

REFERENCES

1. Beahrs OH. Staging of cancer of the breast as a guide to therapy. *Cancer*. 1984;53(3 Suppl.):592-4. [https://doi.org/10.1002/1097-0142\(19840201\)53:3+%3C592::aid-cnrcr2820531303%3E3.0.co;2-9](https://doi.org/10.1002/1097-0142(19840201)53:3+%3C592::aid-cnrcr2820531303%3E3.0.co;2-9)
2. Chavez-MacGregor M, Mittendorf EA, Clarke CA, Lichtensztajn DY, Hunt KK, Giordano SH. Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. *Oncologist*. 2017;22(11):1292-300. <https://doi.org/10.1634/theoncologist.2017-0116>
3. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. *AJCC cancer staging manual*. 6th ed. New York: Springer-Verlag; 2002.
4. Curado MP. Techniques of registration. In: Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al., eds. *Cancer Incidence in Five Continents*. Lyon: IARC; 2007. v. 9. p. 14-39.
5. Camargo Cancela M, Chapuis F, Curado MP. Abstracting stage in population-based cancer registries: the example of oral cavity and oropharynx cancers. *Cancer Epidemiol*. 2010;34(4):501-6. <https://doi.org/10.1016/j.canep.2010.04.012>
6. Curado MP, Voti L, Sortino-Rachou AM. Cancer registration data and quality indicators in low and middle income countries: their interpretation and potential use for the improvement of cancer care. *Cancer Causes Control*. 2009;20:751-6. <https://doi.org/10.1007/s10552-008-9288-5>
7. Weiss A, Chavez-MacGregor M, Lichtensztajn DY, Yi M, Tadros A, Hortobagyi GN, et al. Validation study of the AJCC eighth edition prognostic stage compared with the anatomic stage in breast cancer. *JAMA Oncol*. 2018;4(2):203-9. <https://doi.org/10.1001/jamaoncol.2017.4298>
8. Valsecchi MG, Steliarova-Foucher E. Cancer registration in developing countries: luxury or necessity? *Lancet Oncol*. 2008;9(2):159-67. [https://doi.org/10.1016/S1470-2045\(08\)70028-7](https://doi.org/10.1016/S1470-2045(08)70028-7)
9. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet*. 2015;385(9972):977-1010. [https://doi.org/10.1016/S0140-6736\(14\)62038-9](https://doi.org/10.1016/S0140-6736(14)62038-9)
10. Abreu E, Koifman RJ, Fanqueiro AG, Land MGP, Koifman S. Sobrevida de dez anos de câncer de mama feminino em coorte populacional em Goiânia (GO), Brasil, 1988-1990. *Cad Saúde Coletiva*. 2012;20(3):305-13.
11. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). *Lancet Oncol*. 2008;9(8):730-56. [https://doi.org/10.1016/S1470-2045\(08\)70179-7](https://doi.org/10.1016/S1470-2045(08)70179-7)
12. Freitas-Junior R, Nunes RD, Martins E, Curado MP, Freitas NMA, Soares LR, et al. Prognostic factors and overall survival of breast cancer in the city of Goiania, Brazil: a population-based study. *Rev Col Bras Cir*. 2017;44(5):435-43. <https://doi.org/10.1590/0100-69912017005003>
13. Allemani C, Coleman MP. Cancer survival: [corrected] the CONCORD-2 study—Authors' reply. *Lancet*. 2015;386(9992):429-30. [https://doi.org/10.1016/S0140-6736\(15\)61443-X](https://doi.org/10.1016/S0140-6736(15)61443-X)
14. Freitas-Junior R, Soares LR, Barrios CH. Cancer survival: [corrected] the CONCORD-2 study. *Lancet*. 2015;386(9992):428-9. [https://doi.org/10.1016/S0140-6736\(15\)61441-6](https://doi.org/10.1016/S0140-6736(15)61441-6)
15. Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Instituto Nacional de Câncer. Coordenação de Prevenção e Vigilância. Manual de rotinas e procedimentos para registros de câncer de base populacional. 2nd ed. Rio de Janeiro: INCA; 2012 [accessed on 22 Jan 2019]. Available at: <https://www.inca.gov.br/publicacoes/manuais/manual-de-rotinas-e-procedimentos-para-registros-de-cancer-de-base-populacional>
16. Parkin DM, Whelan SI, Ferlay J, Teppo L, Thomas DB. *Cancer incidence in five continents*. Lyon: International Agency for Research on Cancer; 2002. v. 8.
17. Freitas NMA, Freitas-Junior R, Curado MP, Martins E, Bandeira e Silva CM, Moreira MAR, et al. Tendência da incidência e da mortalidade do câncer de mama em Goiânia: análise de 15 anos (1988-2002). *Rev Bras Mastol*. 2006;16(1):17-21.
18. Moura L, Curado MP, Simões EJ, Cezário AC, Urdaneta M. Avaliação do registro de câncer de base populacional do município de Goiânia, estado de Goiás, Brasil. *Epidemiol Serv Saúde*. 2006;15(4):7-17. <https://doi.org/10.5123/S1679-49742006000400002>
19. Miller JW, Smith JL, Ryerson AB, Tucker TC, Allemani C. Disparities in breast cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study. *Cancer*. 2017;123(Suppl. 24):5100-18. <https://doi.org/10.1002/cncr.30988>
20. Elkin EB, Hudis C, Begg CB, Schrag D. The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. *Cancer*. 2005;104(6):1149-57. <https://doi.org/10.1002/cncr.21285>
21. Lemos NAF, Freitas-Junior R, Moreira MAR, Silva TC, Oliveira JC, Silva CMB. Difficulties in collecting data on ductal carcinoma in situ at a population-based cancer registry. *Mastology*. 2019;29(2):86-9. <https://doi.org/10.29289/2594539420190000421>
22. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Fort Washington: National Comprehensive Cancer Network; 2020 [accessed on Jun. 15, 2020]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
23. Tolêdo SRS, Almeida NAM, Souza MR, Minamisava R, Freitas-Junior R. Care flow of breast cancer patients in the public health care network. *Rev Eletr Enf*. 2016;18:e1201. <https://doi.org/10.5216/ree.v18.39147>
24. McCready DR, Yong WS, Ng AK, Miller N, Done S, Youngson B. Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and false-negative rates. *J Natl Cancer Inst*. 2004;96(11):873-5. <https://doi.org/10.1093/jnci/djh142>
25. Woodward WA, Strom AS, Tucker SL, McNeese MD, Perkins GH, Schechter NR, et al. Changes in the 2003 American Joint Committee on Cancer—staging for breast cancer dramatically affects stage-specific survival. *J Clin Oncol*. 2003;21(17):3244-8. <https://doi.org/10.1200/JCO.2003.03.052>

26. Hortobagyi GN, Connolly JL, D'Orsi CJ, Edge SB, Mittendorf EA, Rugo HS, et al. Breast. In: Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. *AJCC Cancer Staging Manual*. 8th ed. New York: Springer; 2016.
27. Giuliano AE, Edge SB, Hortobagyi GN. Eighth Edition of the *AJCC Cancer Staging Manual: Breast Cancer*. *Ann Surg Oncol*. 2018;25:1783-5. <https://doi.org/10.1245/s10434-018-6486-6>
28. Luen S, Virassamy B, Savas P, Salgado R, Loi S. The genomic landscape of breast cancer and its interaction with host immunity. *Breast*. 2016;29:241-50. <https://doi.org/10.1016/j.breast.2016.07.015>
29. Li X, Zhang Y, Meisel J, Jiang R, Behera M, Peng L. Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database. *Breast Cancer Res Treat*. 2018;171:303-13. <https://doi.org/10.1007/s10549-018-4832-9>
30. Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. *N Engl J Med*. 2016;375(8):717-29. <https://doi.org/10.1056/NEJMoa1602253>
31. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. *N Engl J Med*. 2018;379(2):111-21. <https://doi.org/10.1056/NEJMoa1804710>
32. Andrade WP. TNM8 Breast Cancer Calculator [Internet]. Apple; 2018 [accessed on Jun. 15, 2020]. Available at: <https://itunes.apple.com/us/app/tnm8-breast-cancer-calculator/id1294700966?mt=8>

Recurrent diffuse large B-cell lymphoma mimicking primary breast cancer

David Caetano Bastos¹ , Eduardo Nóbrega Pereira Lima¹ ,
Almir Galvão Vieira Bitencourt^{1*} , Paula Nicole Vieira Pinto Barbosa¹ 

ABSTRACT

Breast lymphoma can represent 0.8%–2.2% of extranodal lymphomas and 0.1%–0.5% of primary breast neoplasms. Imaging findings are not specific, and its distinction from primary invasive breast carcinoma should be based on clinical data and histopathological analysis. We present the case of a 62-year-old woman who showed an unusual pattern of recurrent diffuse large B-cell lymphoma (DLBCL) mimicking primary breast cancer on imaging studies, including mammography, ultrasound, magnetic resonance imaging (MRI), and positron emission tomography-computed tomography (PET-CT).

KEYWORDS: Breast neoplasms; Lymphoma; Mammography; Ultrasonography; Magnetic resonance imaging; PET-CT.

A 62-year-old woman presented to our hospital with a left breast lump. She had a prior history of non-Hodgkin's lymphoma treated with chemotherapy, in remission for two years. Mammography (Figure 1A), ultrasound (Figure 1B), and magnetic resonance imaging (MRI) (Figure 2) showed an irregular mass in the upper quadrants of the left breast with ipsilateral axillary lymph node enlargement. Ultrasound-guided core-needle biopsy of the breast mass and axillary lymph nodes was compatible with recurrent diffuse large B-cell lymphoma (DLBCL). Immunohistochemistry showed positive expression of CD20, CD79a, CD5, Bcl-6, Bcl-2, and MUM1; negative expression of CD3, CD10, CD23, Cyclin D1, CD30, EBV, and C-MYC; and 90% expression of Ki-67. Whole-body positron emission tomography-computed tomography (PET-CT) was performed and showed no other sites of disease (Figure 3).

Breast lymphoma can represent 0.8%–2.2% of extranodal lymphomas and 0.1%–0.5% of primary breast neoplasms. The most common subtypes of breast lymphoma originate from B-cells, including DLBCL, marginal zone lymphoma (MALT lymphoma), and follicular lymphoma. Age at diagnosis usually ranges from 55 to 65 years, and the most frequent clinical presentation is a breast lump that may be associated with pain in 25% of cases. Ipsilateral axillary lymph node involvement can occur in more than 40% of cases.^{1,2} Imaging findings are not specific, and its distinction from primary invasive breast carcinoma should be based on clinical data and histopathological analysis.^{3,4} At mammography, they usually present as single or multiple masses, which may be bilateral in about 28% of cases; spiculated margins,




Figure 1. Bilateral mammography on mediolateral oblique (MLO) view (A) showed an irregular hyperdense mass in the upper quadrants of the left breast, near the metallic marker in the left breast lump, and left axillary lymph node enlargement. Ultrasound (B) revealed an irregular hypoechoic mass in the left breast with posterior acoustic enhancement.

¹A.C.Camargo Cancer Center, Department of Imaging – São Paulo (SP), Brazil.

*Corresponding author: almir.bitencourt@accamargo.org.br

Conflict of interests: nothing to declare.

Received on: 03/02/2021. Accepted on: 05/02/2021.




Figure 2. Breast magnetic resonance imaging (A: axial 3D MIP subtraction image; B, C: sagittal T1-weighted enhanced images) showed an irregular mass in the upper quadrants of the left breast (A and B) and left axillary lymph node enlargement (C).




Figure 3. Whole-body positron emission tomography-computed tomography (PET-CT) (A: coronal 3D MIP PET image; B: axial fused PET-CT images) revealed a hypermetabolic mass in the left breast (SUVmax: 19.3) and left axillary lymph node enlargement at levels I and II (SUVmax: 18.1).

calcifications, and architectural distortion are unusual and suggest primary breast cancer. At ultrasonography, they frequently present as a hypo- or anechoic mass with indistinct or circumscribed margins, posterior enhancement, or no posterior features. At MRI, breast lymphoma most often appears as an irregular or circumscribed mass with mild heterogeneous internal enhancement, usually presenting a plateau or washout kinetic curve and restricted diffusion. Breast MRI can provide greater sensitivity in detecting multifocal and/or multicentric diseases.⁵ Whole-body PET-CT can contribute to distant staging due to its high sensitivity and specificity in this entity, being also useful in evaluating the therapeutic response.⁶

This case showed an unusual pattern of recurrent DLBCL mimicking primary breast cancer. Immunohistochemical analysis revealed expression of CD5 and high expression of Ki-67, which is typically associated with aggressive clinical features and adverse outcomes. The patient presented complete response on PET-CT after treatment with rituximab and ifosfamide, carboplatin, and etoposide ICE (R-ICE) chemotherapy, in addition to autologous stem cell transplantation.

AUTHORS' CONTRIBUTION

D.C.D.: investigation, writing – original draft, writing – review & editing. E.N.P.L.: investigation, writing – review & editing. A.G.V.B.: investigation, writing – original draft, writing – review & editing. P.N.V.P.B.: conceptualization, investigation, supervision, writing – review & editing.

REFERENCES

1. Glazebrook KN, Zingula S, Jones KN, Fazzio RT. Breast imaging findings in haematological malignancies. *Insights Imaging*. 2014;5(6):715-22. <https://doi.org/10.1007/s13244-014-0344-2>
2. Kalli S, Lanfranchi M, Alexander A, Makim S, Freer PE. Spectrum of extramammary malignant neoplasms in the breast with radiologic-pathologic correlation. *Curr Probl Diagn Radiol*. 2016;45(6):392-401. <https://doi.org/10.1067/j.cpradiol.2015.07.012>

3. Bitencourt AGV, Gama RRM, Graziano L, Negrão EMS, Sabino SMPS, Watanabe AHU, et al. Breast metastases from extramammary malignancies: multimodality imaging aspects. *Br J Radiol.* 2017;90(1077):20170197. <https://doi.org/10.1259/bjr.20170197>
4. Sippo DA, Kulkarni K, Carlo PD, Lee B, Eisner D, Cimino-Mathews A, et al. Metastatic disease to the breast from extramammary malignancies: a multimodality pictorial review. *Curr Probl Diagn Radiol.* 2016;45(3):225-32. <https://doi.org/10.1067/j.cpradiol.2015.07.001>
5. Liu K, Xie P, Peng W, Zhou Z. The features of breast lymphoma on MRI. *Br J Radiol.* 2013;86(1031):20130220. <https://doi.org/10.1259/bjr.20130220>
6. Benveniste AP, Marom EM, Benveniste MF, Mawlawi OR, Miranda RN, Yang W. Metastases to the breast from extramammary malignancies - PET/CT findings. *Eur J Radiol.* 2014;83(7):1106-12. <https://doi.org/10.1016/j.ejrad.2014.04.015>

Ulcerative-vegetative Locally Advanced Breast Carcinoma Mimicking Flower Image

René Aloisio da Costa Vieira^{1,2,3} , Idam de Oliveira-Junior^{1,4} 

Ulcerated locally advanced breast carcinoma (LABC)^{1,2} is an uncommon topic in the literature. Several factors contribute to delayed diagnosis, such as the health system, factors related to the patient (lack of knowledge, fear and denial of the disease), in addition to rapid tumor growth.

Ulcerated tumors can occur in any breast location, including in areolar Paget's disease³. They are usually high histologic-grade tumors, high Ki67 index and triple negative breast cancer (TNBC) molecular subtype with lymph node involvement². There are disagreements about the simple presence of ulceration determining worsening of patient's prognosis^{1,2}.

An ulcerated lesion leads to bleeding and may be the gateway to secondary infection. In this context, surgery can be⁴⁻⁶:

- up-front hygiene (avoids bleeding and infection, but is associated with the need for local flaps);
- elective, after neoadjuvant chemotherapy treatment (leaves the patient vulnerable to infection and sepsis⁷, regardless of neutropenia);

- elective, after radiotherapy, in extreme situations⁸ (attempt to increase resectability).

Prior to surgery, a surgical wound culture can be performed to guide the choice of antibiotic therapy. During surgery, special care must be taken (covering the exposed area with compresses and administration of broad-spectrum antibiotic for therapeutic purposes)⁹.

A 52-year-old female, rural worker, complaining of a tumor in the right breast for four months. She had LABC, T4bN3 (infraclavicular – IFV on tomography) M0, “*peau d'orange*” measuring 19 x 15 cm, with a 15 x 10 cm ulcerated vegetative lesion in the right breast (Figure 1). Pathological examination revealed an invasive ductal carcinoma, nuclear and histological grade 3, Ki67 index of 50%, TNBC. We opted for primary surgical treatment, with isolation of ulcerated area (Figure 2) and antibiotic therapy, followed by modified radical mastectomy associated with rotation of the ipsilateral thoracoabdominal dermomat flap (ITADE)¹⁰. No surgical




Figure 1. Ulcerative-vegetative locally advanced breast neoplasm. (A) front view; (B) side view.

¹Postgraduate Program in Tocogynecology, Faculdade de Medicina de Botucatu – Botucatu (SP), Brazil.

²Postgraduate Program in Oncology, Barretos Cancer Hospital – Barretos (SP), Brazil.

³Department of Surgery, Division of Mastology, Cancer Hospital of Muriaé – Muriaé (MG), Brazil.

⁴Department of Mastology and Breast Reconstruction, Barretos Cancer Hospital – Barretos (SP), Brazil.

*Corresponding author: reneacv@terra.com.br

Conflict of interests: nothing to declare.

Received on: 04/10/2021. Accepted on: 06/09/2021.




Figure 2. Perioperative. (A) Spontaneous necrosis and disappearance of vegetative lesion; (B) surgical wound dressing.

complications were seen. Pathological examination showed an 18 cm tumor and 4/22 compromised lymph nodes. No postoperative complications occurred. The patient then received adjuvant chemotherapy (AC-T scheme) and radiotherapy (plastron, armpit and supraclavicular fossa). Currently, after 10 years of follow-up, she is alive and without evidence of oncological disease.

The image has different characteristics compared to other ulcerated lesions, as it assumes an ulcer-vegetative aspect, resembling a “flower”, the red gerbera with a blackened center. Symmetrical vegetative tumor tissue is observed around an ulcerated and necrotic central axis, which justifies this rare

presentation. An image of balanced symmetry that starts from a central axis is often seen in nature, but not in the presentation of breast cancer.

AUTHORS' CONTRIBUTION

R.A.C.V.: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Visualization, Writing – original draft, Writing – review & editing. I.O.J.: Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing.

REFERENCES

1. Khoury T, Gaudioso C, Fang YV, Sanati S, Opyrchal M, Desouki MM, et al. The role of skin ulceration in breast carcinoma staging and outcome. *Breast J.* 2018;24(1):41-50. <https://doi.org/10.1111/tbj.12830>
2. Staudigl C, Bartova M, Salama M, Dzagnidze G, Bago-Horvath Z, Pohlodek K, et al. Histopathological characterization of ulcerated breast cancer and comparison to their non-ulcerated counterparts. *Tumour Biol.* 2015;36(5):3423-8. <https://doi.org/10.1007/s13277-014-2977-7>
3. Seetharam S, Fentiman IS. Paget's disease of the nipple. *Womens Health (Lond).* 2009;5(4):397-402. <https://doi.org/10.2217/WHE.09.23>
4. Salemis NS. Metaplastic carcinoma of the breast with mesenchymal differentiation (carcinosarcoma). A unique presentation of an aggressive malignancy and literature review. *Breast Dis.* 2018;37(3):169-75. <https://doi.org/10.3233/bd-170313>
5. Vempati P, Knoll MA, Dharmarajan K, Green S, Tiersten A, Bakst RL. Palliation of Ulcerative Breast Lesions with Radiation. *Anticancer Res.* 2016;36(9):4701-5. <https://doi.org/10.21873/anticancer.11024>
6. Khokher S, Mahmood S, Khan SA. Response to neoadjuvant chemotherapy in patients with advanced breast cancer: a local hospital experience. *Asian Pac J Cancer Prev.* 2010;11(2):303-8.
7. Meher S, Mishra TS, Sasmal PK, Rath S, Sharma R. An Ulcerated Giant Malignant Phyllodes Tumour Presenting in Septic Shock. *J Clin Diagn Res.* 2016;10(12):PJ01-PJ02. <https://dx.doi.org/10.7860%2FJCDR%2F2016%2F20252.8945>
8. Yee C, Alayed Y, Drost L, Karam I, Vesprini D, McCann C, et al. Radiotherapy for patients with unresected locally advanced breast cancer. *Ann Palliat Med.* 2018;7(4):373-84. <https://doi.org/10.21037/apm.2018.05.13>
9. Vieira ACR, Zucca Mathes AG, Michelli RA, Ribeiro GH, Haikel RL, Viana CR, et al. Necrotizing soft tissue infection of the breast: case report and literature review. *Surg Infect (Larchmt).* 2012;13(4):270-5. <http://dx.doi.org/10.1089/sur.2011.029>
10. Vieira R, Silva KMT, Oliveira-Junior I, Lima MA. ITADE flap after mastectomy for locally advanced breast cancer: A good choice for mid-sized defects of the chest wall, based on a systematic review of thoracoabdominal flaps. *J Surg Oncol.* 2017;115(8):949-58. <https://doi.org/10.1002/jso.24619>



Nipple-sparing mastectomy in normal breast: consequence of simulation and disease anxiety

Leonardo Ribeiro Soares¹ , Savio Augusto Teixeira-Silva² , Murilo Ferreira Caetano² ,
Gustavo Amaral Modesto² , Marise Amaral Rebouças Moreira³ , Ruffo Freitas-Junior^{1*} 

ABSTRACT

Diagnosis in psychiatry is a thorough and potentially artificial process. In this letter, we discuss this diagnostic process in the context of a young patient who underwent nipple-sparing mastectomy after falsifying a breast biopsy report revealing invasive ductal carcinoma. The secondary pathology revision was also forged by the patient and confirmed the diagnosis. The patient was summoned by the Service's board and admitted the falsification of breast cancer reports. After evaluation at the Psychiatric Service, changes in vital mood, psychosis, delusional activity and obsessive-compulsive symptoms were ruled out. In view of the growing demand for prophylactic mastectomy observed worldwide, similar cases may become more frequent.

KEYWORDS: breast neoplasms; patient simulation; factitious disorders.

Dear editor,

We would like to report a case received for evaluation in our Service, relevant for its severity, rarity and for having drawn multidisciplinary attention. In addition, the present case exposes the detailed and artificial diagnostic process in psychiatry. In this case, identifying the real motivation for fraud determines the final diagnosis.

A 24-year-old woman was sent to the Mastology Service after falsifying a breast biopsy report, revealing an invasive ductal carcinoma. The patient also forged the secondary pathology revision and confirmed the diagnosis. She underwent nipple-sparing mastectomy associated with sentinel lymph node biopsy and immediate right breast reconstruction with expansive prosthesis. After extensive evaluation of the material, fibrocystic alterations and fibroadenosis areas were observed, with no evidence of neoplasm. The patient was summoned by the Service board and admitted the forgery of the reports regarding the breast cancer.

After evaluation in the Psychiatry Service, vital mood alterations, psychosis, delusional activity and obsessive-compulsive symptoms were ruled out. The patient pointed out as motivation for her actions the fact that she had lost her grandfather to prostate cancer a year before, having then acquired an excessive

fear of developing neoplasms in the future. Upon discovering the nodules, the patient aimed for the removal of the breast. For that matter, the patient admitted feeling regretful for breaking the law, but not for the surgical removal of her breast.

In the case described above, the diagnosis established was disease anxiety, by DSM-5. Nonetheless, the simulation attestation is also adequate, once there is conscious and deliberate production of the symptoms, and equally conscious motivation by the examinee¹. However, while interviewing the patient's mother, it was ascertained that the patient was recently divorced and that, at the time of the surgery, the marriage was about to end. It was observed from these factors the presence of a distinct unconscious motivation: through the production of a mammary disease, she would be able to draw more attention from her ex-husband, and even a possible way of keeping the marriage. The patient denies this hypothesis and the analysis of this possible unconscious factor would demand extensive anamnestic and therapeutic processes. Nevertheless, in case this version is true, the most adequate diagnosis by the DSM-5 would be Factitious Disorder, once there is conscious production of the act and unconscious motivation¹.

To our knowledge, this is the second case of effectively performed mastectomy after the adulterated production of reports².

¹Universidade Federal de Goiás – Goiânia (GO), Brazil.

²Mental Health and Legal Medicine Department, Hospital das Clínicas, Universidade Federal de Goiás – Goiânia (GO), Brazil.

³Department of Pathology, Hospital das Clínicas, Universidade Federal de Goiás – Goiânia (GO), Brazil.

*Corresponding author: ruffojr@terra.com.br

Conflict of interests: nothing to declare.

Received on: 06/11/2020. Accepted on: 07/02/2020.

Notwithstanding, other cases of simulation have been described involving mammary pathologies and fictitious breast cancer family history^{3,4}. Therefore, because of the increasing demand for prophylactic mastectomy observed all over the world, similar cases might become more frequent.

AUTHORS' CONTRIBUTIONS

L.R.S.: Conceptualization, Data curations, Formal analysis, Writing — original draft, Writing — review & editing.

S.A.T.S.: Conceptualization, Data curations, Formal analysis, Writing — original draft, Writing — review & editing.

M.F.C.: Conceptualization, Data curations, Formal analysis, Writing — original draft, Writing — review & editing.

G.A.M.: Data curations, Writing — original draft, Writing — review & editing.

M.A.R.M.: Data curations, Formal analysis, Writing — original draft, Writing — review & editing.

R.F.J.: Conceptualization, Data curations, Formal analysis, Writing — original draft, Writing — review & editing.

REFERENCES

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (DSM-5). 5^a ed. American Psychiatric Association; 2013.
2. Feldman MD. Prophylactic bilateral radical mastectomy resulting from factitious disorder. *Psychosomatics*. 2001;42(6):519-21. <https://doi.org/10.1176/appi.psy.42.6.519>
3. Yates GP, Feldman MD. Factitious disorder: a systematic review of 455 cases in the professional literature. *Gen Hosp Psychiatry*. 2016;41:20-8. <https://doi.org/10.1016/j.genhosppsych.2016.05.002>
4. Grenga TE, Dowden RV. Munchausen's syndrome and prophylactic mastectomy. *Plast Reconstr Surg*. 1987;80(1):119-20.



ERRATUM

<https://doi.org/10.29289/25945394202020200063ERRATUM>

In the manuscript “The first mastectomy: truth or legend?”, DOI: 10.29289/25945394202020200063, published in the Mastology 2020;30:e20200063, on page 1:

Where it reads:

In 1984, Halsted published the 50 cases that he operated with a recurrence rate of 6%, while in Europe the recurrence rate were from 51% to 82%, because they did not use the surgical technique described by Halsted.

It should read:

In 1894, Halsted published the 50 cases that he operated with a recurrence rate of 6%, while in Europe the recurrence rate were from 51% to 82%, because they did not use the surgical technique described by Halsted.

ERRATUM

<https://doi.org/10.29289/259453942020V30S1027ERRATUM>

In the abstract “Gestational Gigantomastia”, DOI: 10.29289/259453942020V30S1027, published in the Mastology 2020;30(Suppl 1):27:

Where it reads:

Letícia Augusto Garcia¹

It should read:

Letícia Augusto Garcia¹, Vicente Tarricone Júnior¹, Marco Antônio Dugatto¹, Lara Varini Soares¹, Fabiano Affonso Kimus¹



